invention other than ones featuring *E. coli*. The Office Action states that "no description is provided, for example, for tRNA genes corresponding to rarely used codons in plant cells or protozoa, two large classes of cell types embraced by the claims (i.e., rarely used codons)." The Office Action also states that the prior art does not appear to provide teachings as to which of the many known tRNA genes correspond to "rarely used" codons for the many different cell types encompassed by the claims, and that there is no evidence of record that rare codon patterns have been established for a sufficient number of cell types for one of skill in the art to be able to envision a sufficient number of specific embodiments of the invention to describe the very broadly claimed genus. Finally, with respect to Written Description, the Office Action states that there remains no evidence of record to indicate that a sufficient number of tRNA genes obtained from different cell types corresponding to rarely used codons of different cell types were known in the prior art for one of skill in the art to envision a sufficient number of embodiments of the claimed vectors and host cells to describe the broad genus of host cells and vectors encompassed by the claims. Applicants respectfully disagree.

Under the law, in order to satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563; M.P.E.P. §2163. Further, under both the written description and enablement requirements, one need not describe in detail that which is well known in the art. M.P.E.P §2163, citing Hybritech v. Monoclonal Antibodies, 802 F.2d 1367, 1384. The Office Action states that "the critical elements of applicant's invention are the tRNA genes corresponding to rarely used codons on the claimed vectors which are determined by the combination of host cell type (i.e., rarely used codons), the corresponding tRNA genes and the protein to be expressed." Applicants submit that patterns of codon usage were well known to those skilled in the art at the time of filing. For example, Nakamura et al., 1996, Nucleic Acids Res. 24: 214-215 (Exhibit A) provides codon usage tabulated from the GenBank international DNA sequence databases for 4,805 species. Applicants submit that these species include prokaryotes, protozoa and fungi, and a wide variety of higher eukaryotes, including animals and plants. The codon usage tabulation of Nakamura necessarily details low, as well as high codon usage in each of the thousands of species examined.

Further, Zhang et al., 1991, Gene 105: 61-72 (Exhibit B) details low usage codons in species as diverse as E. coli (prokaryotic), yeast (S. cerevisiae; protozoan), Drosophila and eleven species of primates. The paper describes the unique combination of least-used codons for the species examined.

In addition, Saier (1995, FEBS Lett. 362: 1-4; Exhibit C) describes rare codon usage in species including *Rhodobacter capsulatus*, *R. spheroides*, *Clostridium acetobutylicum*, *Streptomyces coelicolor* and *E. coli*. Saier relates the rare codon usage to the regulation of metabolically sensitive genes.

In view of these sources of information, particularly in view of the comprehensive nature of the Nakamura database before the filing of the subject application, Applicants submit that a sufficient number of rare codon usage patterns have been established in the prior art for a sufficient number of cell types for one of skill in the art to readily envision a sufficient number of specific embodiments of rare codon usage patterns to describe the claimed genus.

With regard to tRNA genes, Applicants submit that a wide variety of tRNA genes was also known in the art at the time of filing. For example, as early as 1984, Sprinzl & Gauss described a compilation of 353 sequences of tRNA genes including cellular and mitochondrial tRNAs from bacteria and phage, plants, yeasts and fungi, insects, amphibians and mammals, including rats, mice, cows and humans (Nucleic Acids Res. 12 Suppl.: r59-131; Exhibit D). Further, there was available on the World Wide Web as of the end of 1998 (before filing), a compilation of tRNA sequences and genes including 3279 sequences. This number is taken from documentation on the current WWW compilation at www.uni-bayreuth.de/departments/biochemie/trna (see Exhibit E). The thousands of tRNA genes described include those for rarely used tRNAs. Additional rare tRNAs are described in, for example: Kawakami et al., 1993, Genetics 135: 309-320 (Exhibit F), which describes a rare Arg-tRNA-CCU in *Saccharomyces cerevisiae*; and Clouthier et al., 1998, J. Bacteriol. 180: 840-845 (Exhibit G), which describes the rare Arg-tRNA-AGA in *Salmonella enteritidis*. Applicants therefore submit that there was known in the art, at the time of filing, a large number of tRNA genes, including those encoding rare tRNAs, from a broad cross section of species.

The Office Action states that the prior art does not appear to provide teachings as to which of the many known tRNA genes correspond to "rarely used" codons for the many different cell types encompassed by the claimed invention. Applicants submit that given the extensive data on codon usage available in the art (e.g., Exhibits A-C), one of skill in the art would know if a given tRNA gene, e.g., one described in any of Exhibits D, F or G, corresponds to a rarely used codon.

In view of the above, and given the description provided in the specification, Applicants submit that the invention of claims 1-16 and 18-44 is described in sufficient detail to enable one of skill in the art to envision a sufficient number of embodiments of the claimed vectors and host cells to describe the full scope of the claimed genus of vectors and host cells. Applicants respectfully request the withdrawal of the §112, first paragraph written description rejection of claims 1-16 and 18-44.

### Rejections under 35 U.S.C. §103:

All claims remain rejected under 35 U.S.C. §103 as obvious over Del Tito et al. in combination with one or more of Makoff et al., the 1997 Novagen catalog, and Wnendt. The Office Action rejects the evidence of commercial success as an objective indicator of non-obviousness because "there remains no meaningful background against which the sales figures presented in Paper No. 10 can be weighed to determine if the demonstrated sales are so indicative of commercial success as to make the claimed invention unobvious." The Office Action further states that there needs to be a showing that the commercial success is commensurate with the claimed invention, and that "A demonstration of commercial success for a couple of specific embodiments useful in E. coli cannot be considered as evidence of nonobviousness commensurate with the full, broadly claimed genus of host cells and vector of the instant invention." Applicants respectfully disagree.

First, Applicants submit that the law does not absolutely require evidence of market share in order for commercial sales of a product of an invention to be persuasive of nonobviousness. The Federal Circuit has held that in order to demonstrate non-obviousness, the commercial success of the product must be due to the merits of the claimed invention beyond what was readily available in the prior art. *Richdel, Inc., v. Sunspool Corp.*, 714 F.2d 1573 (Fed. Cir.

invention, in J.T. Eaton & Co., Inc. v. Atlantic Paste & Glue Co. the Federal Circuit held that a primary showing of commercial success limited to sales, coupled with a demonstration that the commercial success of the product derives from the claimed invention and is attributable to something disclosed in the patent that was not readily available in the prior art is entitled to the presumption that that the commercial success of the product is attributable to the patented invention. J.T. Eaton & Co., Inc. v. Atlantic Paste & Glue Co., 106 F.3d 1563, 1571 (Fed. Cir.1997).

Applicants submit, and the Buchanan Declarations support the conclusion, that the products sold are embodiments of the claimed invention, falling plainly within the scope of claim 1. This claim requires a host cell containing a recombinant DNA molecule which comprises an array of three of more tRNA genes, wherein the tRNA genes correspond to codons that are rarely used in the host cell. As stated in Ms. Buchanan's first Rule 132 Declaration, *each* of the competent cell products for which sales figures are reported contains three tRNA genes corresponding to rarely used codons. Applicants submit that the prior art *does not* teach cells with three or more tRNA genes corresponding to codons that are rarely used in the host cell. Further, the first Buchanan Declaration states that the commercial success of the claimed invention is not the result of heavy promotion or advertising, noting that Stratagene spent no more on promotion or advertising of this product than it did on any other competent cell product it sells. The product also sells for a considerably higher price than non-codon-enhanced cells sold by the same company. Thus, the commercial success of the product is attributable not to heavy promotion or lower price, but to something disclosed in the patent that was not readily available in the prior art.

Under J.T. Eaton, having shown the necessary correspondence between the commercial success and the claimed invention, Applicants are thus entitled to the presumption that the commercial success of the product is attributable to the claimed invention. Under these circumstances, also in accord with J.T. Eaton, Applicants submit that sales alone, in the absence of market data, are indicative of non-obviousness. In view of this, and, where, as in the instant case, there are no data regarding market share because there were no competing products at the

·time of the sales reported (itself a strong indicator of non-obviousness), Applicants submit that the sales figures provided are evidence of non-obviousness.

With regard to the assertion that "A demonstration of commercial success for a couple of specific embodiments useful in E. coli cannot be considered as evidence of nonobviousness commensurate with the full, broadly claimed genus," Applicants submit that the prior art cited is drawn to expression in E. coli, as is the evidence of commercial success of the claimed invention. Thus, the scope of the demonstrated commercial success of the claimed invention is directly relevant to the non-obviousness of the claimed invention over the cited prior art. Thus, giving proper weight to the commercial success of the embodiments sold (as discussed above), E. coli embodiments of the claimed invention are non-obvious. Further, if E. coli embodiments, for which the prior art appears to be most relevant, are not obvious, Applicants submit that there is no reason to conclude that embodiments encompassing other cell types, for which there is a lack of relevant prior art, would also be non-obvious. Applicants therefore submit that the scope of the invention encompassed by the commercial embodiments is sufficient to overcome the alleged obviousness of the claimed invention.

In view of the above, Applicants submit that the invention of claims 1-16 and 18-44 is not obvious over the combination of references cited. Applicants respectfully request that the rejection of these claims under §103 be withdrawn.

Applicants submit that in view of the preceding remarks and the Exhibits provided, all issues raised in the Office Action have been addressed herein. Applicants respectfully request reconsideration of the claims.

Respectfully submitted.

Dated: September 26, 2002

Mak J. Fitzber 12 Peg. No. 48,928 for Kathler M. William

Kathleen M. Williams, Ph.D. Registration No. 34,380

Attorney for Applicant

PALMER & DODGE LLP

111 Huntington Avenue Telephone: (617) 239-0451

Telecopier: (617) 227-4420

## Codon usage tabulated from the international DNA sequence databases

Yasukazu Nakamura, Ken-nosuke Wada<sup>1</sup>, Yoshiko Wada, Hirofumi Doi<sup>2</sup>, Shigehiko Kanaya<sup>3</sup>, Takashi Gojobori and Toshimichi Ikemura\*

National Institute of Genetics and The Graduate University for Advanced Studies, Mishima, Shizuoka 411, Japan, <sup>1</sup>ATR Limited, Seika, Kyoto 619-02, Japan, <sup>2</sup>Fujitsu Laboratories Ltd, Chiba 261, Japan and <sup>3</sup>Yamagata University, Yonezawa, Yamagata 992, Japan

Received August 31, 1995; Revised and Accepted October 4, 1995

#### **ABSTRACT**

Codon usage in 87 602 genes has been calculated using the nucleotide sequence data obtained from the GenBank Genetic Sequence Data Bank (Release 90.0; September 1995). The database is called the CUTG Database; the complete form of the database can be obtained by anonymous ftp from DDBJ and a part of the database, which lists the frequency of codon use in each organism, is made searchable through our World Wide Web server.

#### **SOURCE AND METHODS**

Codon usage in individual genes has been calculated using the nucleotide sequence data obtained from the GenBank Genetic Sequence Data Bank (Release 90.0; September 1995). The compilation of codon usage is synchronized with each major release of GenBank. The resulting database is called the CUTG database (1-5).

In selecting protein coding sequences we relied on the FEATURES tables of GenBank, and only complete genes without unambiguous bases were used in the analysis. In GenBank, a group of consecutive genes whose entire region had been sequenced were registered under one LOCUS name. To distinguish the different genes belonging to a single LOCUS, the symbol # followed by a number is added after the LOCUS name; the numbers represent the order of the CDS registered in the FEATURES table of GenBank. When introns of a gene have not been completely sequenced, some of its exons are registered in separate entries (LOCUS) in GenBank. These exons, belonging to the same gene but having different LOCUS names, were combined into one entry and the first LOCUS name is added.

For the biological significance of codon usage, see Ikemura (6) and Aota and Ikemura (7,8).

#### **FILES**

Files of the present database, containing codon usage of 87 602 CDSs of 4805 species, are available by anonymous ftp from

DDBJ. Files named as gb\*\*\*.codon list the codon use in each gene registered in the GenBank Sequence files (gb\*\*\*.seq). The LOCUS names given in GenBank were used to designate individual genes. Each LOCUS name is followed by fields of information extracted from the FEATURES of each CDS for defining each open reading frame analyzed here. The order of the codons in the table is the same as the previous compilation (see the CODON\_LABEL file or REFERENCES).

To reveal the characteristics of codon use of a wide range of organisms, as well as viruses and organella, the frequency (per 1000) of codon use in 461 organisms for which >20 genes are available was calculated by summing up numbers of codon used. World Wide Web clients, such as NCSA Mosaic and Netscape, may be used to query this file. A user can display a codon usage table by clicking an anchor for selecting species or searching with species' name (Fig. 1).

### **DISTRIBUTION AND ACCESS**

Complete form of the database is available by anonymous ftp from DDBJ:

ftp://ftp.nig.ac.jp/pub/db/codon/GB90.

The file README contains the latest information on the database in plain text format.

The frequencies of codon use in 461 organisms for which >20 genes are available can be accessed on the following WWW server:

http://tisun4a.lab.nig.ac.jp/codon/CUTG.html.

Comments on the database can be sent to cutg@lab.nig.ac.jp by e-mail.

### **ACKNOWLEDGEMENTS**

The authors wish to thank Dr Y. Ugawa at the DNA Information and Stock Center, National Institute of Agrobiological Resources, for help in constructing the database. This work was supported by a grant-in-aid for creative basic research (Human Genome Project) and for scientific research on a priority area (Genome Informatics) and by a grant-in-aid of scientific research from the Ministry of Education, Science and Culture of Japan.

<sup>\*</sup> To whom correspondence should be addressed




Figure 1. Snapshot of the CUTG home page.

### REFERENCES

- 1 Maruyama, T., Gojobori, T., Aota, S. and Ikemura, T. (1986) Nucleic Acids Res., 14, r151-r197.
- Aota, S. Gojobori, T., Ishibashi, F., Maruyama, T. and Ikemura, T. (1988) Nucleic Acids Res., 16, r315-r402.

  Wada, K., Aota, S., Tsuchiya, R., Ishibashi, F., Gojobori. and Ikemura, T.
- (1990) Nucleic Acids Res., 18, 2367-2441.
- 4 Wada, K., Wada, Y., Doi, H., Ishibashi, F., Gojobori, T. and Ikemura, T. (1991) Nucleic Acids Res., 19, 1991–1986.
- (1991) Nucleic Acias Res., 19, 1991—1900.

  5 Wada, K., Wada, Y., Ishibashi, F., Gojobori, T. and Ikemura, T. (1992)

  Nucleic Acids Res., 20, 2111–2118.

  6 Ikemura, T. (1985) Mol. Biol. Evol., 2, 13–24.
- 7 Aota, S. and Ikemura, T. (1986) Nucleic Acids Res., 14, 6345-6355.
- 8 Aota, S. and Ikemura, T. (1986) Nucleic Acids Res., 14, 8702.

**GENE 06001** 

Low-usage codons in Escherichia coli, yeast, fruit fly and primates.....

(Recombinant DNA; GenBank; codon bias; Saccharomyces cerevisiae; Drosophila melanogaster; Homo sapiens)

Shiping Zhang\*\*, Geoffrey Zubay\* and Emanuel Goldman\*

<sup>a</sup> Fairchild Center for Biological Sciences. Columbia University, New York, NY 10027 (U.S.A.) Tel. (212)854-4578; and <sup>b</sup> Department of Microbiology and Molecular Genetics, UMDNJ - New Jersey Medical School, Newark, NJ 07103 (U.S.A.)

Received by W.M. Holmes: 12 September 1990 Revised/Accepted: 17 April/31 May 1991 Received at publishers: 18 June 1991

#### **SUMMARY**

Codon usage is compared between four classes of species, with an emphasis on characterization of low-usage codons. The classes of species analyzed include the bacterium Escherichia coli (ECO), the yeast Saccharomyces cerevisiae (YSC), the fruit fly Drosophila melanogaster (DRO), and several species of primates (PRI) (taken as a group; includes eleven species for which nucleotide sequence data have been reported to GenBank, however, greater than 90% of the sequences were from Homo sapiens). The number of protein-coding sequences analyzed were 968 for ECO, 484 for YSC, 244 for DRO, and 1518 for PRI. Three methods have been used to determine low-usage codons in these species. The first and most common way of assessing codon usage is by summing the number of time codons appear in reading frames of the genome in question. The second way is to examine the distribution of usage in different genes by scoring the number of protein reading frames in which a particular codon does not appear. The third way starts with a similar notion, but instead considers combinations of codons that are missing from the maximum number of genes. These three methods give very similar results. Each species has a unique combination of eight least-used codons, but all species contain the arginine codons, CGA and CGG. The agreement between YSC and PRI is particularly striking as they share six low-usage codons. All six carry the dinucleotide sequence, CG. The eight least-used codons in PRI include all codons that contain the CG dinucleotide sequence. Low-usage codons are clearly avoided in genes encoding abundant proteins for ECO, YSC and DRO. In all species, proteins containing a high percentage of low-usage codons could be characterized as cases where an excess of the protein could be detrimental. Low codon usage is relatively insensitive to gross base composition. However, dinucleotide usage can sometimes influence codon usage. This is particularly notable in the case of CG dinucleotides in PRI.

### INTRODUCTION

Amino acids (aa) that are represented by more than one codon usually do not use synonym codons equally (e.g., Grantham et al., 1981; Gouy and Gautier, 1982). Indeed, the differential use of codons is most striking and species-

specific and raises many interesting possibilities and concerns (Andersson and Kurland, 1990). Studies on ECO and YSC have shown that high abundance proteins show a sharp avoidance of codons that are in low usage in the overall gene population (Post et al., 1979; Ikemura, 1981; 1982; Bennetzen and Hall, 1982), a finding that has led to

Correspondence to: Dr. E. Goldman, Dept. of Microbiology, New Jersey Med. School, 185 S. Orange Ave., Newark, NJ 07103 (U.S.A.) Tel. (201)456-4367; Fax (201)456-3644.

Current address: Biology Department, Brookhaven National Laboratory, Upton, NY 11973 (U.S.A.)

Abbreviations: aa (a.a. in Tables), amino acid(s); bp, base pair(s); DRO, Drosophila melanogaster; ECO, Escherichia cofi; PRI, primates; r, ribosomal; STP, stop codon; YSC, yeast Saccharomyces cerevisiae.

the suggestion that low-usage codons may be more difficultto translate (Grosjean and Fiers, 1982; Konigsberg and Godson, 1983; Kurland, 1987). This suggestion is supported by the observation that cognate tRNA abundance is roughly proportional to codon usage for most codons (Ikemura, 1985) and that rates of translation can vary with concentrations of charged tRNA, at least in ECO (Rojiani et al., 1990). Direct assays of translatability lend some support to this view (Robinson et al., 1984; Bonekamp et al., 1985; Carter et al., 1986; Hoekema et al., 1987; Sørensen et al., 1989; Curran and Yarus, 1989; Chen and Inouye, 1990). Further, expression of at least one heterologous protein in ECO required oligodeoxynucleotide synthesis of the entire gene with high usage synonym codons of ECO, since message containing the naturally occurring codons of the gene (very rich in ECO's low-usage codons) failed to support measurable translation (Abate et al., 1990; T. Curran, personal communication).

Whereas papers summarizing codon usage have appeared sporadically (e.g., Grantham et al., 1981; Ikemura, 1985; Sharp and Li, 1986; Sharp et al., 1988; Wada et al., 1990), the amount of information keeps increasing at the rate of about 2 x 106 bp per year. This necessitates periodic reevaluation and updating of codon usage. There is also the need for new ways of looking at codon usage which requires new perspectives and new computer programs. For example, Gutman and Hatfield (1989) have considered the problem from the perspective of frequency of appearance of codon pairs.

For the purpose of this study and to stay within reasonable practical limits, we will confine the information presented in this paper to ECO, YSC, DRO, and PRI. Mitochondrial genomes are not included in this analysis. Here, we shall describe different ways of estimating codon usage for these four classes of organisms. In addition to serving as an update of previous papers, a new way of evaluating codon usage is introduced and the relationship between codon usage and dinucleotide frequency is addressed. A major purpose of this paper is to give an accurate assessment (as of September 1990) of low-usage codons in different species. A second and more clusive goal is to seek explanations for the evolutionary choices that have been made.

### RESULTS AND DISCUSSION

### (a) Criteria for identifying low-usage codons

We shall define codon usage as the number of times a codon is translated per unit time. This has not been measured directly in vivo, so estimates of codon usage are obtained by indirect observations. It should be appreciated that codon usage is likely to be different under different

conditions of growth. For example, under conditions of rapid growth when there are plenty of nutrients, the overall rate of protein synthesis will be maximal and the synthesis of proteins that are needed for rapid growth should be favored. By contrast, under conditions of nutrient limitation, a new set of proteins is most likely to dominate metabolism and the overall rate of protein synthesis would be reduced (Ingraham et al., 1983). We will describe three ways of estimating codon usage. Each of them has its advantages and drawbacks. Fortunately, they all give approximately the same answer as regards the hierarchy for 'most used' and 'least used' codons within each synonymous codon family.

### (1) Sums of codon appearance

The most common way of measuring codon usage is by summing the number of times codons appear in the reading frames of the genome. This approach is summarized in Table I for four different types of organisms under discussion. This method should over-estimate codons used infrequently and under-estimate codons used frequently. The reason for this is that, when averaging over the entire genome, no weight is given to the number of times different reading frames are used, which is reflected in the variable quantities of protein products. This weighting is a complex resultant of transcriptional efficiency, message stability, and translational efficiency. In general, this weighting is not precisely known but frequently it can be roughly estimated from the amount of gene-encoded protein product.

### (2) Absence of particular codons in genes

A second way of estimating codon usage is to examine the distribution of usage in different genes. We have done this by scoring the number of protein reading frames in which a particular codon does not appear. In Table II, these data are directly compared for the four species under consideration. A large number indicates a narrow distribution for the codon in question. No attempt has been made to weight this method by scoring the number of times a codon appears in a gene. Only the presence or absence of a codon within a gene has been scored. This approach to measuring codon usage is based on the prediction that the most used codons should have the broadest distribution and the least used codons should have the narrowest distribution. The data in Table II are presented in a way that is most convenient for making comparisons of relative usage between different organisms. For this purpose, the numbers have been normalized to those actually observed for DRO. The normalization factors are given in the footnote of Table II.

### (3) Combinations of excluded codons

The third way in which we have estimated codon usage starts with a similar notion to that used in the second

TABLE I

A comparison of codon usages\* among four different species\*

A.	ECO; total co	Ous: 32	anga' re	seem Particle	HELLES. \$1	05				BB	A							
	U	٠	c		A		G		U,	DRO: tot	al codo	hs: 1255	27, tol	al prote	áns: 24	4		
tr	5089 (Phe					) 188	2 (Cys	U			U		¢		A		G	
U	5838 (Phe 3397 (Leu		8 (Ser 5 (Ser)			) 196	I (Cys	Ö		1471	(Phe)	776	(Ser	183	7 (Tyr	3 70	Ø (Cys)	
	3659 (Leu		Ser	044	4 (STP) 5 (STP)		9 (STP 9 (Trp	Å	•	J 2976	Pac)	2541	(Ser)	251	4 (Tyr	) 178	2 (Ors)	
	2004 (1				, (DIE	, 310	e (Irp)	G			(Leu) (Leu)		(Ser) (Ser)		ST		(SIP)	
C	3204 (Leu 3135 (Leu		(Pro)		Hia)		I (Arg)	U					(oer)		7 (STP	) 125	8 (Trpj	
	960 (Len	262:	(Pro)	4921	l (His) Gin)		6 (Arg) 9 (Arg)	C			(Len)		(Pro)		(Hia	126	7 (Arg)	
	17477 (Leu)	7724	(Pro)	9589	(Gin)		(Arg)	A G	•		(Leu) (Leu)	2393	(Pro)		His	321	7 (Arg)	- (
	8809 (11 a)	9.406	(Thr)								(Lea)	1992	(Pro)	4670	GIn Gin	90:	Arg)	í
A	8719 (Ile)		Thr	5268 7969	(Asn) (Asz)		) (Sar) ! (Ser)	Ü		4004	(10.						(428)	
	1274 (110)	2108	(Thr)	12104	(Lava)		(Ser)	C A	A		(lic) (lie)	1088 2984	(Thr)	2608	(Asn)		(S+r)	1
	8507 (Mat)	4050	(Thr)	3857	(Lys)		(Arg)	Ğ		882	(Ile)		(Thr)	1902	(Asa)		) (Ser)   (Arg)	1
	6716 (Val)	5770	[Ala]	10393	(Asp)			<del></del> -		2997	(Met)	1704	(The)	5323	(Lys)	777	(Arg)	-
3	4652 (Val)	7490	[Ala]	7116	(Asp)		(Gly)	U Ç		1571	(Val)	1000	[Ala)					
	\$896 (Val)	6760	(Ala)	14134	Chil			~						3280	(Asp)	1981	(Gly)	1
			J [		(Gra)	5550	(Gly)	A	G	1958	(YAI)	4797	(Ala)	3100	(Aum)	7094	(11111111111111111111111111111111111111	
YS	7972 (Val)		(Ala)	6149	(GIu)		(Gly)	G G		555	(Val) (Val) (Val)	4797 1486 1714	(Ala)	2308	(Asp) (Glu) (Glu)	345 į	(Gly) (Gly)	A
YS	SC: total codor	s: 24106 (	IV, tota	6149	(GIu) ps: 484	3110				585 3424 PRI: total	(Val) (Val)	1486 1714 : 608694	(Ala) (Ala)	2308 5773 protein	(Glu) (Glu) ss: 1518	345 t 599	(CIA)	5
_	SC: total codor U 5559 (Phe)	s: 24106 ( 5954	19, tota	6149 I protesi A 3982	(Glu) DB: 484 (Tyr)	3110	(Cly)			565 3424 PRI: total	(Val) (Val)	1486 1714 :: 608694	(Ala) (Ala)	2308 5773	(Glu) (Glu) ss: 1518	345 t 599	(Gly)	5
	SC: total codor	5954 3535	(Ser)	6149 I protess A 3962 398	(Glu) ps: 484 (Tyr) (Tyr)	3110 1842 900	(Oys)	u c	D. 1	555 3424 PRI: total	(Val) (Val) codons	1486 1714 :: 608694 C	(Ala) (Ala) I, total	2308 5773 protein	(Glu) (Glu) sr. 1518 (Trr)	745 i 599	(Cly)	0 40
	SC: total codor U 5559 (Phe) 4813 (Phe)	s: 24106 ( 5954	(Ser)	6149 I protesi A 3982 3998 256	(GIu) DB: 484 (Tyr) (Tyr) (STP)	3110 1842 900 136	(Oys) (Oys) (Oys) (STP)	U G A		9684 13718	(Val) (Val) codous (Phe) (Phe)	1486 1714 :: 608694 C S052 (	(Ala) (Ala) i, total (See) (See)	2308 5773 protein 7504 11188	(Glu) (Glu) ss. 1519 (Tyr) (Tyr)	745 i 599 5982 8522	(Cly) (Cly) (Cys)	0
	5559 (Phe) 4813 (Phe) 3837 (Leu) 7776 (Leu)	5954 3535 3722 1565	(Ser) (Ser) (Ser) (Ser) (Ser)	6149 I protein A 3962 3998 256 92	(GIu) DB: 484 (Tyr) (Tyr) (STP) (STP)	3110 1842 900 136 2490	(Cly) (Ors) (Ors) (STP) (Trp)	U C A G	D. 1	555 3424 PRI: total	(Vai) (Vai) (Vai) (Vai) (Phe) (Phe) (Phe) (Leu)	1486 1714 :: 608694 C S052 (	(Ala) (Ala) i, total (Ser) (Ser) (Ser)	2308 6773 protein 7504 11198 442	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP)	599 599 5982 8522 774	(Cly) (Cly) (Cyn) (Cyn) (Cyn) (STP)	UCA
	U 5559 (Phe) 4813 (Phe) 5887 (Leu)	5954 3535 3722 1565	(Ser) (Ser) (Ser) (Ser) (Ser)	6149 I protess A 3952 3998 258 92	(GIu) DE: 484 (Tyr) (Tyr) (STP) (SIP)	1842 900 136 2490	(Gly)  (Oys) (Oys) (STP) (Trp)	U C A G	D. 1	9684 13718 9870	(Vai) (Vai)  codous (Phe) (Phe) (Leu) (Leu)	1486 1714 : 608694 C B052 10877 5786 2448	(Ala) (Ala) I, total (Sec) (Sec) (Sec) (Sec) (Sec)	2308 5773 protein 7504 11138 442 302	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP) (STP)	5451 599 5982 8522 774 8390	(Cly) (Cly) (Cys) (Cys) (Cys) (STP) (Trp)	UCA
Ys	SC: total codor  U  \$5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu) 2297 (Leu) 981 (Leu) 2840 (Leu)	5954 3535 3722 1565 3083 1388 5162	(Ser) (Ser) (Ser) (Ser) (Pro) (Pro)	6149 I protein A 3982 3998 256 92 2977 2017 7098	(Glu) DE: 484 (Tyr) (Tyr) (STP) (His) (His)	1842 900 138 2490	(Cly) (Oys) (Oys) (Oys) (STP) (Trp) (Arg) (Arg)	U C A G U C C	D. 1	9684 13718 3279 6838	(Vai) (Vai)  codous (Phe) (Phe) (Leu) (Leu) (Leu)	1486 1714 :: 608694 C S052   10877   5768   2448	(Ala) (Ala) (Ser) (Ser) (Ser) (Ser)	2308 5773 protein 7504 11195 442 302	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP) (STP) (His)	\$451 \$99 \$6982 \$522 774 \$290	(Cly) (Cly) (Cys) (Oys) (Oys) (STP) (Trp)	U C A G U
	SC: total codor  U  5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu)  2297 (Leu) 981 (Leu)	5954 3535 3722 1565 3083 1388	(Ser) (Ser) (Ser) (Ser) (Pro) (Pro)	6149 I protess A 3952 3998 258 92	(Glu) DE: 484 (Tyr) (Tyr) (STP) (His) (His)	1842 900 136 2490	(Gly)  (Oys) (Oys) (STP) (Trp)	U C A G	D. I	9684 13718 3279 6670 6538 12177 3871	(Vai) (Vai) (Vai) (Phe) (Phe) (Leu) (Leu) (Leu) (Leu)	1485 1714 C 606694 C 5052   10577   5756   2448   12138   1218	(Ala) (Ala) (Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro)	2308 5773 protein 7504 11195 442 302 5643 8815 6861	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP) (STP) (His) (Gln)	599 599 5982 8522 774 8290 2818 6945	(Cly) (Cly) (Cly) (Cys) (Cys) (STP) (Trp) (Arg) (Arg)	UCAAG
	SC: total codor  U  5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu)  2297 (Leu) 981 (Leu) 2840 (Leu)	5954 3535 3722 1565 3093 1388 5162 988	(Ser) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro)	6149  I protein  A  3982 3998 256 92 2977 7098 2500	(Glu) DE: 484 (Tyr) (Tyr) (STP) (SIP) (His) (Gla)	1842 900 136 2490 1801 467 531 255	(Gly)  (Oys) (Oys) (Oys) (STP) (Trp)  (Arg) (Arg) (Arg)	U C A G C A G	D. I	9684 13718 3279 8870 6538 12177	(Vai) (Vai) (Vai) (Phe) (Phe) (Leu) (Leu) (Leu) (Leu)	1485 1714 :: 608694 :: 608694 :: 608694 :: 10877 ( 5786 ( 5786 ( 2448 ( 9352 ( 12138 (	(Ala) (Ala) (Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro)	2308 5773 protein 7504 11195 442 302 5843 8815	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP) (STP) (His) (Gln)	5982 5982 8522 774 8390 2818 6945 3258	(Cly) (Cly) (Cys) (Oys) (STP) (Trp) (Arg) (Arg)	U C A G U
	SC: total codor  U  \$5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu) 2297 (Leu) 981 (Leu) 2840 (Leu) 2003 (Leu)  7454 (IIe) 4494 (IIe)	5954 3335 3722 1565 3093 1388 5162 988	(Ser) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Pro)	6149  I protein  A  3982 3998 258 92 2977 2017 7098 2500	(Glu)  OS: 484  (Tyr) (Tyr) (STP) (SIP) (His) (Gla) (Gla) (Ann)	1842 900 138 2490 1801 467 531 255	(Oys) (Oys) (Oye) (STP) (Trp) (Arg) (Arg) (Arg) (Ser)	U C A G U C A G U	D. I	9684 13718 3229 6870 6538 12177 3871 26255	(Vai) (Vai)  codous  (Phe) (Phe) (Leu) (Leu) (Leu) (Leu) (Leu)	1485 1714 : 606694 : 606694 : 10577   10577   5756   2448   9352   12138   9007   3201	(Ala) (Ala) (Ser) (Ser) (Ser) (Ser) (Ser) (Ser) (Ser) (Ser) (Ser)	2308 5773 protein 7504 11138 442 302 5843 8815 6861 20956	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP) (STP) (His) (His) (Gln)	\$451 \$99 \$6982 \$6982 \$774 \$390 \$818 \$945 \$258 \$354	(Cly) (Cly) (Cys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg)	UCAG
	SC: total codor  U  5559 (Phe) 4813 (Phe) 5857 (Leu) 7778 (Leu) 2297 (Leu) 981 (Leu) 2840 (Leu) 2003 (Leu) 7454 (Ile) 3054 (Ile) 3054 (Ile)	5954 3535 3722 1565 3093 1388 5162 988 5281 3425 3703	(Ser) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Thr) Thr)	6149  I protein  A  3982 3998 256 92 2977 2017 7098 2500 7587 6235 9104	(Glu)  (Tyr) (Tyr) (STP) (STP) (His) (Gla) (Gla) (Asa) (Asa)	3110 1842 900 138 2490 1801 407 531 255 2802 1782 5791	(Gly)  (Oys) (Oys) (Oys) (Oys) (Oys) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg)	U C A G C A G	D. I	9684 13718 3279 68370 6538 12177 3871 26245 9152 9152 14619	(Vai) (Vai) (Vai)  codous (Phe) (Phe) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu)	1486 1714 c: 608694 c: 608694 c: 60877 ( 5796 ( 2448 ( 12138 ( 12138 ( 39007 ( 3901 ( 13820 ()	(Ala) (Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro)	2308 5773 protein 7504 11138 442 302 5843 8815 6861 20956	(Glu) (Glu) (Tyr) (Tyr) (Tyr) (STP) (Hia) (Hia) (Gln) (Gln)	\$451 \$99 \$982 \$692 774 8390 2818 6945 3358 6354	(Cly) (Cly) (Cly) (Cys) (Oys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Ser)	UCAG UCAG U
	SC: total codor  U  \$5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu) 2297 (Leu) 981 (Leu) 2840 (Leu) 2003 (Leu)  7454 (IIe) 4494 (IIe)	5954 3335 3722 1565 3093 1388 5162 988	(Ser) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Thr) Thr)	6149  I protein  A  3982 3998 258 92 2977 7098 2500 7587 6235	(Glu)  (Tyr) (Tyr) (STP) (STP) (His) (Gla) (Gla) (Asa) (Asa)	1842 900 138 2490 1801 467 531 255	(Gly)  (Oys) (Oys) (Oys) (Oys) (Oys) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg)	U C A G U C C A G U C C	D. i	9684 13718 3229 6870 6538 12177 3871 26245 9159 9159 14619 3805	(Vai) (Vai) (Vai) (Phe) (Phe) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu)	1486 1714 c: 608694 c: 608694 c: 608694 5786 (: 2448 (	(Ala) (Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Thr) (Thr)	2308 5773 protein 7504 11195 442 302 5643 8815 6861 20956	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP) (STP) (His) (His) (Gln) (Gln) (Asn) (Asn) (Asn)	5982 5982 8522 774 8250 2818 6945 2358 6354 5747 11285 6086	(Cly) (Cly) (Cys) (Cys) (Cys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Arg) (Ser) (Arg)	UCAG
·	SC: total codor  U  \$5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu) 2297 (Leu) 2840 (Leu) 2840 (Leu) 2003 (Leu)  7454 (IIe) 4494 (IIe) 5130 (Met)  6486 (Val)	\$954 3535 3722 1565 3083 1388 5162 988 5281 3425 3703 1587	(Ser) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Thr) (Thr)	6149  I proteix  A  3982 3998 258 92 2977 2017 7098 2500 7587 6235 9104 8536	(Glu)  (Iyr) (Tyr) (STP) (His) (Gla) (Gla) (Asa) (Lys)	1842 900 138 2490 1801 407 531 255 2802 1782 5791 1814	(Oys) (Oys) (Oys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg)	U C A G U C A G G	D. i	9684 13718 3279 68370 6538 12177 3871 26245 9152 9152 14619	(Vai) (Vai) (Vai) (Phe) (Phe) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu)	1486 1714 c: 608694 c: 608694 c: 60877 ( 5796 ( 2448 ( 12138 ( 12138 ( 39007 ( 3901 ( 13820 ()	(Ala) (Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Thr) (Thr)	2308 5773 protein 7504 11138 442 302 5843 8815 6861 20956	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP) (STP) (His) (His) (Gln) (Gln) (Asn) (Asn) (Asn)	5982 5982 8622 774 8390 2816 6945 3258 6354	(Cly) (Cly) (Cys) (Cys) (Cys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Arg) (Ser) (Arg)	UC AG UC AG UG
	SC: total codor  U  5559 (Phe) 4813 (Phe) 5857 (Leu) 7778 (Leu) 2297 (Leu) 981 (Leu) 2840 (Leu) 2003 (Leu)  7454 (Ile) 3054 (Ile) 5130 (Met) 6486 (Val) 3622 (Val)	5954 3535 3722 1565 3093 1388 5182 988 5281 3425 1587 6884 2765 (	(Ser) (Ser) (Ser) (Ser) (Ser) (Pro)	6149  A  3962 3998 258 92 2977 7098 2500 7587 6235 9104 8536 8962 65418 {	(Glu)  (Tyr) (Tyr) (STP) (SIP) (His) (Gla) (Gla) (Asa) (Lys) (Lys)	1842 900 136 2490 1801 407 531 255 2802 1782 5791 1814	(Cly)  (Oys) (Oys) (Oys) (STP) (Trp)  (Arg) (Arg) (Arg) (Arg) (Arg) (Gly)	U C A G U C A G U C A G	D. i	9684 13718 3229 6870 6538 12177 3871 26245 9159 9159 14519 14519 1452 1453 12572 1458	(Val) (Val) (Val)  codous (Phe) (Leu) (Leu	1486 1714 :: 608692 :: 608692 :: 608692 :: 10577   5788   2448   9352   12138   9007   33901   13920   8768   4064   (1788	(Ala) (Ala) (See) (See) (Ser) (Ser) (Ser) Pro) Pro) Pro) Pro) Thr) Thr) Thr)	2308 5773 protein 7504 11138 442 302 5843 8815 6881 20956 10115 13569 13636 21516	(Glu) (Glu) (Glu) (Tyr) (Tyr) (STP) (His) (Gln) (Gln) (Asn) (Asn) (Lys)	245 £ 599 5982 8522 774 8390 2818 6945 2358 6354 5747 11285 6086 6627	(Cly) (Cly) (Cly) (Cys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg)	U C A G U C A G
·	SC: total codor  U  \$5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu) 2297 (Leu) 2840 (Leu) 2840 (Leu) 2003 (Leu)  7454 (IIe) 4494 (IIe) 5130 (Met)  6486 (Val)	\$954 3535 3722 1565 3083 1388 5162 988 5281 3425 3703 1587	(Ser) (Ser) (Ser) (Ser) (Ser) (Pro)	6149  A  3982 3998 255 92 2977 7098 7500 7587 9104 8536 8962 6418	(Glu)  (Tyr) (Tyr) (STP) (His) (His) (Gla) (Gla) (Asa) (Lys) (Asp) (Asp) (Glu)	1842 900 138 2490 1801 407 531 255 2802 1782 5791 1814	(Gly)  (Oys) (Oys) (Oys) (STP) (Arg) (Arg) (Arg) (Arg) (Arg) (Gly) (Gly)	U C A G U C A G G	D. i	9684 13718 32719 6538 12177 3871 20245 ( 9159 ( 14619 ( 3005 ( 13572 (	(Vai) (Vai) (Phe) (Phe) (Phe) (Leu)	1486 1714 :: 608694 :: 608694 :: 608694 10877 ( 5766 ( 2448 ( 12138 ( 9007 ( 3901 ( 18820 ( 8768 ( 4064 (	(Ala) (Ala) (See) (See) (See) (Ser) (Pro) (Pro) (Pro) (Thr) (Thr) (Thr) (Thr)	2308 5773 protein 7504 11195 442 302 5643 8815 6861 20956	(Glu) (Glu) (Tyr) (Tyr) (STP) (STP) (His) (Gln) (Gln) (Lyr) (Lyr) (Asp)	5982 5982 8522 774 8250 2818 6945 2358 6354 5747 11285 6086	(Cly) (Cly) (Cly) (Cys) (Sys) (Sys) (Arg) (Arg) (Arg) (Arg) (Arg) (Ser) (Arg) (Gry) (Cly)	UCAG UCAG UGA

<sup>&</sup>lt;sup>a</sup> DNA sequences analyzed were from GenBank version 63 (15 March 1990). Reading frames were based on 'pept' labels (or 'CDS' labels in the current GenBank format) in the FEATURE sections. Repeating sequences were excluded. Computer programs used are written in C and run on a Sun3.

The species analyzed include the bacterium £. coli (ECO), the yeast S. cerevisias (YSC), D. melanogaster (DRO), and several species of primates (PRI) (taken as a group; includes eleven species for which DNA sequence data have been reported, however, greater than 90% of the sequences were from man).

method but instead considers combinations of codons that are missing from the maximum number of genes. The assumption here is that combinations of low-usage codons should be excluded from the most active genes, because the more low-usage codons present in a gene, the greater the potential reduction in the amount of translated product. Although this remains to be experimentally tested in a rigorous fashion, there are a number of reasons to predict this result (see INTRODUCTION). The program searches for combinations of codons (two or more) that are excluded from the maximum number of reading frames of the species in question. To make the computer calculations practical, only the 20 least used codons defined by method 2 above were used in the pool to determine combinations of least-

used codons. In Table III, results are presented for combinations of up to eight codons with the least favored incidence; the number of protein reading frames that exclude the combination is given at the left in the table. Frequently, there is little difference between first, second and third (not shown) choices, indicating a degree of uncertainty in giving priority to the choices.

For ECO, there is a stepwise addition of a new low-usage codon at each stage as the size of the combination increases. This is also true for YSC except after stage 7 (combinations containing seven codons) where GGG is eliminated and AGG and ACG are simultaneously added. For DRO, a similar stepwise pattern of addition is seen as for ECO. The situation is far more complex and intriguing for PRI. The

TABLE II

Relative numbers of proteins not using a particular codon in four species

Decoration (a.a.)   Decoration   Decoration (a.a.)   Decoration   De
UUC (Phe) 17 6 12 14 AUC (Ile) 10 8 17 14 18 38 19 10 10 4 18 18 38 19 110 AUA (Ile) 10 8 17 14 18 18 18 19 10 10 10 8 17 14 10 10 10 8 17 14 10 10 10 10 8 17 14 10 10 10 10 10 10 10 10 10 10 10 10 10
UUC (Phe) 17 6 12 14 AUC (IIe) 10 8 17 14 14 UUG (Leu) 46 8 125 110 AUA (IIe) 124 55 84 88 UUGU (Ser) 33 5 49 28 AUG (Thr) 29 6 50 28 UUGC (Ser) 42 11 14 10 AOC (Thr) 16 14 13 9 UUG (Ser) 68 50 68 49 ACA (Thr) 66 33 61 27 UUG (Ser) 80 59 12 94 AOG (Thr) 50 63 63 61 27 UAU (Tyr) 30 22 87 23 AAU (Asa) 25 19 22 32 UAA (STP) 82 115 117 173 AAA (Asa) 25 19 22 32 UAA (STP) 82 115 117 173 AAA (Lys) 4 3 33 17 UAU (STP) 298 188 177 195 AAG (Lys) 25 2 9 2 UGC (Cys) 76 89 19 33 AGC (Ser) 65 40 69 40 UGA (STP) 179 175 194 120 AGA (Arg) 151 7 25 45 UUGA (STP) 179 175 194 120 AGA (Arg) 151 7 25 45 CUU (Leu) 36 85 30 12 CUU (Val) 10 6 23 38 CUU (Leu) 127 25 69 50 GUA (Val) 19 52 69 79 CUC (Leu) 127 25 69 50 GUA (Val) 19 52 69 79 CUC (Leu) 127 25 69 50 GUA (Val) 17 43 15 7 CUU (Leu) 127 25 69 50 GUA (Val) 19 52 69 79 CUC (Leu) 9 54 15 5 GUG (Val) 17 43 15 7 CUU (Leu) 9 54 15 5 GUG (Val) 17 43 15 7 CUC (Leu) 9 54 15 5 GUG (Val) 17 43 15 7 CUC (Leu) 9 54 15 5 GUG (Val) 17 43 15 7 CUC (Leu) 9 88 65 17 16 GUC (Val) 18 16 7 24 10 CUC (Pro) 98 65 17 16 GUC (Val) 18 16 7 24 10
UUA (Leu)         46         8         125         110         AUA (IIe)         124         55         84         88           UUG (Leu)         37         4         28         35         AUG (Mst)         1         0<
UGG (Leu) 27 4 28 35 AUG (Mst) 1 0 0 0 0 0 0 UGC (Ser) 33 5 49 28 ACU (Thr) 22 6 5 50 28 UGC (Ser) 42 11 14 10 ACC (Thr) 16 14 13 9 UCG (Ser) 69 50 68 40 ACA (Thr) 66 30 61 27 UCG (Ser) 80 59 12 94 ACG (Thr) 35 63 45 50 UAC (Tyr) 30 5 19 12 74 ACG (Thr) 17 17 17 17 17 17 17 17 17 17 17 17 17
UGC (Ser)
UCU (Sar) 42 11 14 10 ACU (Thr) 16 14 13 9 UCG (Sar) 69 30 68 40 ACA (Thr) 66 30 61 27 UCG (Sar) 80 59 18 94 ACG (Thr) 35 63 45 50 UAU (Tyr) 30 12 37 12 AAU (Aau) 25 19 22 32 UAC (Tyr) 30 5 19 16 AAC (Aam) 12 4 11 9 UAG (STP) 228 118 117 173 AAA (Lys) 4 3 33 17 UAG (STP) 228 128 177 195 AAG (Lys) 25 2 9 2 UGC (Cys) 76 89 19 33 AGC (Sar) 25 40 69 40 UGC (Cys) 76 89 19 33 AGC (Sar) 20 51 18 14 UGA (STP) 179 175 194 120 AGA (Arg) 181 7 95 45 UGG (Tr) 43 31 39 28 AGG (Arg) 180 58 67 23 CUU (Leu) 36 86 20 12 CUC (Val) 23 12 CUU (Leu) 37 86 87 20 12 CUC (Val) 23 12 CUC (Leu) 9 54 15 5 CUC (Val) 19 52 69 79 CUC (Leu) 9 54 15 5 CUC (Val) 17 43 16 7 CUC (Pro) 98 65 17 18 CCC (Abb) 18 7 24 10
UAA (Sier)   68   50   68   40   ACA (Thr)   66   33   61   27     UAA (Sier)   80   59   18   94   ACG (Thr)   30   63   46   50     UAA (Tyr)   30   22   37   23   AAU (Asn)   25   19   22   32     UAA (STP)   82   115   117   173   AAA (Asn)   12   4   11   9     UAA (STP)   228   188   177   195   AAG (Asn)   12   4   11   9     UGU (Oya)   83   40   75   48   AGU (See)   65   40   69   40     UGC (Cys)   76   89   19   33   AGG (See)   65   40   69   40     UGA (STP)   179   175   194   120   AGA (Arg)   161   7   95   45     UGG (Trp)   43   31   39   28   AGG (Arg)   180   56   67   23     CUU (Leu)   41   48   48   35   GUU (Val)   10   6   23   38     CUU (Leu)   38   86   30   12   GUU (Val)   10   6   23   38     CUU (Leu)   127   25   69   59   GUA (Val)   19   52   69   79     CUU (Pro)   56   26   54   21   GUU (Val)   17   43   16   7     CUU (Pro)   56   26   54   21   GUU (Val)   17   43   16   7     CUU (Pro)   98   65   17   18   GCU (Ala)   16   7   24   10     CUU (Pro)   98   65   17   18   GCU (Ala)   16   7   24   10     CUU (Pro)   98   65   17   18   GCU (Ala)   18   18   18     CUC (Leu)   18   65   17   18   GCU (Ala)   18   18     CUC (Leu)   18   65   7   74   10     CUU (Pro)   98   65   17   18   GCU (Ala)   18   18     CUC (Inc)   18   17   18   GCU (Ala)   18   18     CUC (Inc)   18   17   18   GCU (Ala)   18   18     CUC (Inc)   18   18   17   18   GCU (Ala)   18   18     CUC (Inc)   18   18   17   18   GCU (Ala)   18   18     CUC (Inc)   18   18   17   18   GCU (Ala)   18   18     CUC (Inc)   18   18   17   18   GCU (Ala)   18   18     CUC (Inc)   18   18   17   18   18   18     CUC (Inc)   18   18   17   18   18   18     CUC (Inc)   18   18   17   18   18     CUC (Inc)   18   18   18   18   18     CUC (Inc)   18   18   18   18     CUC (Inc)   18   18   18   18     CUC (Inc)   18   18     CUC (Inc)   18   18     CUC (Inc)   18   18     CUC (Inc)   18     CUC (Inc)   18     CUC (Inc)   18
UAU (Tyr) 30 22 37 23 AAU (Asu) 25 19 22 32 UAC (Tyr) 30 5 19 16 AAC (Asu) 12 4 11 9 UAU (Tyr) 30 5 19 16 AAC (Asu) 12 4 11 9 UAU (Tyr) 228 188 177 195 AAC (Lys) 25 2 9 2 UGU (Oys) 83 -40 75 48 AGU (Sec) 65 40 69 40 UGC (Cys) 76 89 19 33 AGC (Sec) 25 5 40 69 40 UGC (Cys) 76 89 19 33 AGC (Sec) 20 51 18 14 UGG (Tyr) 43 31 38 28 AGC (Sec) 20 51 18 14 UGG (Tyr) 43 31 38 28 AGC (Arg) 181 7 95 45 CUU (Leu) 41 48 48 35 GUU (Vul) 10 6 23 38 CUU (Leu) 41 48 48 35 GUU (Vul) 10 6 23 38 CUU (Leu) 127 25 69 59 GUA (Vul) 10 6 23 38 CUU (Leu) 127 25 69 59 GUA (Vul) 19 52 69 79 CUC (Leu) 9 54 15 5 GUC (Vul) 17 43 15 7 CUU (Leu) 9 54 15 5 GUC (Vul) 17 43 15 7 CUU (Pro) 56 26 54 21 GUC (Vul) 17 43 15 7 CUU (Pro) 58 26 54 21 GUC (Vul) 18 19 52 69 79 CUC (Pro) 98 65 17 18 GUC (Vul) 18 19 52 69 79 CUC (Pro) 98 65 17 18 GUC (Vul) 18 19 52 69 79 CUC (Pro) 98 65 17 18 GUC (Vul) 18 19 52 69 79 CUC (Pro) 98 65 17 18 GUC (Vul) 18 19 52 69 79 CUC (Pro) 98 65 17 18 GUC (Vul) 18 19 52 69 79 CUC (Pro) 98 65 17 18 GUC (Vul) 19 19 52 69 79 CUC (Pro) 98 65 17 18 GUC (Vul) 19 19 19 19 19 19 19 19 19 19 19 19 19
UAU (Tyr) 30 22 87 E3 AAU (Asa) 25 19 22 32 UAA (Tyr) 30 5 19 16 AAC (Asa) 12 4 11 9 UAA (STP) 82 115 117 173 AAA (Lys) 4 5 33 17 UAU (STP) 228 128 177 195 AAC (Lys) 25 2 9 2 10 UGC (Cys) 76 89 19 33 AGC (Sec) 65 40 69 40 UGA (STP) 179 175 194 120 AGA (Arg) 181 7 95 45 UGG (Trp) 43 31 39 28 AGG (Arg) 180 58 67 23 UGG (Cys) 43 84 85 35 GUU (Val) 10 6 23 38 CUU (Leu) 41 42 48 35 GUU (Val) 10 6 23 38 CUU (Leu) 127 25 69 59 GUA (Val) 19 52 69 79 CUC (Leu) 127 25 69 59 GUA (Val) 19 52 69 79 CUC (Leu) 9 54 18 5 GUC (Val) 17 43 15 7 CUC (CYc) 58 54 21 GCU (Val) 17 43 15 7 CUC (CYc) 98 65 17 18 GCU (Ala) 16 7 24 10 CUC (CYc) 98 65 17 18 GCU (Ala) 16 7 24 10
UAA (STP) 82 11.6 11.7 17.3 AAA (Lys) 4 5 33 17  UAA (STP) 228 108 107 195 AAA (Lys) 4 5 33 17  UGU (Oys) 83 .40 75 46 AGU (Ser) 65 40 69 40  UGC (Oys) 76 89 19 33 AGU (Ser) 65 40 69 40  UGA (STP) 179 175 194 120 AGA (Arg) 181 7 25 45  UGG (Trp) 43 31 39 26 AGG (Arg) 180 56 67 23  CUU (Leu) 39 86 20 12 CUC (Val) 10 6 23 38  CUA (Leu) 127 25 69 59 GUA (Val) 19 52 63 79  CUG (Leu) 9 54 15 5 CUG (Val) 17 43 15 7  CCU (Leu) 9 54 15 5 CUG (Val) 17 43 15 7  CCUC (Pro) 98 65 17 18 CCCC (Ala) 15 7 24 10
UAG (STP) 82 115 117 173 AAA (Lys) 4 3 33 17  UAG (STP) 228 188 177 195 AAG (Lys) 25 2 9 2  UGC (Cys) 76 89 19 33 AGC (Sec) 65 40 69 40  UGC (Cys) 76 89 19 33 AGC (Sec) 20 51 18 14  UGA (STP) 179 175 194 120 AGA (Arg) 161 7 95 45  UGG (Trp) 43 31 39 28 AGG (Arg) 180 56 67 23  CUU (Leu) 41 48 48 35 GUU (Val) 10 6 23 38  CUU (Leu) 39 86 20 12 GUC (Val) 23 12 19 18  CUU (Leu) 9 54 15 5 GUG (Val) 19 52 69 79  CUC (Leu) 9 54 15 5 GUG (Val) 17 43 16 7  CCU (Pro) 98 65 17 18 GCC (Ala) 18 7 24 10
UGU (Oys)   S3   40   75   48   AGU (Sec)   65   40   69   40
UGC (C7s)
UGA (STP) 179 175 194 120 AGA (Arg) 181 7 95 45 UGG (Trp) 43 31 39 28 AGG (Ser) 180 58 67 23 CUU (Leu) 41 48 48 35 GUU (Val) 10 6 23 38 CUU (Leu) 39 85 20 12 GUC (Val) 23 12 19 18 CUG (Leu) 9 54 18 5 GUG (Val) 19 52 63 79 CUG (Leu) 9 54 18 5 GUG (Val) 17 43 16 7 CUG (Pro) 58 25 54 21 GGU (Ala) 15 7 24 10 COC (Pro) 98 65 17 18 GCG (Ala) 18 7 24 10
UGG (Trp) 43 31 39 28 AGG (Arg) 180 58 67 23 CUU (Leu) 41 42 48 35 GUU (Val) 10 6 23 38 CUU (Leu) 42 45 45 CUU (Leu) 36 86 20 12 GUC (Val) 23 12 19 18 10 10 10 10 10 10 10 10 10 10 10 10 10
CHU (Leu) 43 31 29 28 AGG (Arg) 180 56 67 23 CHU (Leu) 44 48 48 35 GUU (Val) 10 6 23 38 CHU (Leu) 127 25 69 59 GUA (Val) 23 12 19 18 CHU (Leu) 9 54 15 5 GUG (Val) 17 43 15 7 CHU (Pro) 56 26 54 21 GGU (Ala) 15 7 24 10 CHU (Pro) 98 65 17 18 GGC (Ala) 16 7 24 10
OUC (Leu) 39 86 20 12 CUC (VII) 23 12 19 16  CUA (Leu) 127 25 69 59 GUA (VII) 19 52 63 79  CUA (Leu) 9 54 15 5 GUC (VII) 17 43 15 7  CCU (Pro) 56 25 54 21 GCC (Ala) 16 7 24 10  CCC (Pro) 98 65 17 18 GCC (Ala) 18 7
OUC (Lett)         39         85         20         12         GUC (Val)         23         12         19         16           CUA (Lett)         127         25         69         59         GUA (Val)         19         52         68         79           CUG (Lett)         9         54         18         5         GUG (Val)         17         43         15         7           CCU (Pro)         58         26         54         21         GCU (Ala)         15         7         24         10           CCC (Pro)         98         65         17         18         GCC (Ala)         18         7         24         10
CUA (Leta) 127 25 69 59 GUA (Val) 19 52 63 79 CUG (Leta) 9 54 15 5 GUG (Val) 17 43 15 7 CUC (Pro) 56 26 54 21 GCU (Ala) 15 7 24 10 COC (Pro) 98 65 17 16 GCC (Ala) 15 7 24 10
COU (Pro) 56 26 54 15 5 GUC (Val) 17 43 15 7 COU (Pro) 98 65 17 18 GCC (Ala) 16 7 24 10
CCC (Pro) 98 65 17 16 CCC (Ala) 16 7 24 10
UCC (Pro)   98   65   17   18   CCC (AL)   10   10
34 GCA (Ala) 11 30 40 19
OCG [FIR] 20 87 31 73 GGG (Ala) 13 73 98 82
CAU (His) 38 25 41 46 GAU (Aso) 11 8 14 19
CAU [BIS] 41 28 25 21 GAC (Am) 18 5 19
CAA (Gin) 28 5 52 43 GAA (Giu) 7 2 05 17
CAU [Gin] 10 48 11 4 4 04C ioni 1 10 4 1 1 1 1
CGU (AUX)   (9   37   31   61   52/11/Au     -   -   -   -
CGC (Arg.) 21 129 20 47 (400 (41)
CGA (Arg)   124   144   67   58   CCA (Clark)   40   72   73
OGG (Arg) 110 167 72 45 GGG (Cly) 49 70 86 18

<sup>&</sup>lt;sup>a</sup> Normalization factor for each species is the ratio of total DRO proteins to the total proteins of the species. Total proteins used are (normalization factors in parentheses): DRO, 244 (1); ECO, 968 (0.252); YSC, 484 (0.504); PRI, 1518 (0.161). To obtain the actual (instead of relative) number of proteins in each species not using a particular codon, multiply the numbers in the table by the reciprocal of the normalization factor. For example, out of the 968 ECO proteins analyzed, the actual number of ECO proteins not using the CUA codon is 127 (from the table) times 3.968 (reciprocal of normalization factor 0.252) = 504.

four codons at stage 4 are eliminated at stage 5 never to reappear as part of the favored low-usage combination at higher stages. It should be noted that these four codons are

all of the UA type. At stage 5, all four codons ending in CG emerge along with one codon, CGU, carrying a CG in the first two positions. At all future stages, codons containing

TABLE III

Numbers of proteins not using a codon or combination of codons<sup>a</sup>

A. ECO total proteins: 968	B. YSC total proteins: 484
714 AGG	852 CGG
536 AGG AGA	743 OGG CQA
352 AGG AGA AUA	178 OGG CGA OGC
255 AGG AGA CUA AUA	
203 AGG AGA CUA ALIA OGA	186 GGF GGA CGC COG
189 AGG AGA CUA AUA OGA OGG	115 CGG CGA CGG CCG GUU
120 AGG AGA CUA AUA CGA CGG CCC	95 COG CGA CGG CCG CUC GCG
83 AGG AGA CUA AUA OGA CGG CCC UOG	80 COG CGA CGC CCG CUC GCG CGG
as year your ook your own cold coc doc	72 CGG OGA OGC GOG CUC GOG ACG ACG
C. DRO total proteins: 244	D. PRI total proteins 1518
	D. PRI total proteins 1518
128 UUA	D. PRI total proteins: 1518
128 UUA 46 UUA AGA	D. PRI total proteins: 1518 687 UUA 380 UUA AUA
125 UUA 40 UUA AGA 70 UUA AGA AUA	D. PRI total proteins 1518  587 UUA 380 UUA AUA 219 UUA AUA
125 UUA 40 UUA AGA 70 UUA AGA AUA 55 UUA AGA GCG AUA	D. PRI total proteins 1518 687 UUA 380 UUA AUA 219 UUA AUA 110 UUA AUA GUA
125 UUA AGA 40 UUA AGA 70 UUA AGA AUA 55 UUA AGA GGG AUA 40 UUA AGA GGG AUA CGG	D. PRI total proteins: 1518  687 UUA  580 UUA AUA  219 UUA AUA  116 UUA AUA GUA  116 UUA AUA GUA  80 UGG GGG GGG AGG
125 UUA 46 UUA AGA 70 UUA AGA AUA 55 UUA AGA GGG AUA 40 UUA AGA GGG AUA 55 UUA AGA GGG AUA 60 UUA AGA GGG AUA	D. PRI total proteins 1518 687 UUA 380 UUA AUA 219 UUA AUA 110 UUA AUA GUA

a The indicated codons are absent from the listed number of proteins on the same line, for each species.

a CG in either their first two or last two positions dominate. At stage 8, we find all of the codons that carry the dinucleotide sequence CG.

From the standpoint of computer programming this third method of picking low-usage codons is the most complex. However, with the program in hand it is easy to apply. For purposes of comparison, in most of the remainder of this paper we will use combinations of eight low-usage codons determined by the third method. These codons for the different species are presented together in Table IV. Each species has a unique combination of eight codons, but all species contain the Arg codons CGA and CGG. The agreement between YSC and PRI is particularly striking as they share six low-usage codons. All six carry the dinucleotide sequence CG. It is appropriate to mention at this point that CG is the dinucleotide sequence that is most avoided in PRI. This may be related to the fact that the C in a CG sequence is susceptible to methylation (e.g., see Razin and Riggs, 1980) and is therefore reserved for special situations. In YSC there is no methylation of C residues in CG sequences. Despite this we shall see below that this dinucleotide is also the most unpopular in YSC.

### (b) Large codon families are more likely to contain low-usage codons as modulators of expression

There is reason to believe that, if codon usage plays a role in modulating gene expression, it is more likely to do so in the larger codon families that contain three of more synonymous codons. Two aa, Trp and Met, are represented by

TABLE IV

Low-usage codons\*

a.a.	PRI	DRO	YSC	ECO
Arg			AGG	AGG
Arg		AGA		AGA
Ile		AUA		AUA
Len				CUA
Arg	CGA	CGA	CGA	CGA
Arg	CGG	CGG	CGG	CGG
Pro				CCC
Ser .	UCG			UCG
Arg	CGC		CGC	
Pro	COG		CCG	
Leu			CUC	
Ala	GCG	,	GCG	
Thr	ACG		AOG	
Len		UUA		
Gly		GGG		
Sez		AGU		
Сув		UGU		I
Arg	CGU			

<sup>-</sup> The eight least used codons for each species, as determined by the 'combinations of excluded codons' method (see text and Table III).

single codons. The two-codon families include Phe, Tyr, His, Gin, Asn, Lys, Asp, Gin and Cys. In most of these cases, both codons are believed to be capable of recognition by a single cognate tRNA (or anticodon) in ECO (Sprinzi et al., 1987, and references therein). This does not exclude the possibility that some of these codons are used as modulators of gene expression for example, because of the different strengths of anticodon-codon interactions (Grosjean et al., 1978; Yarus et al., 1986). In the cases of all the remaining codon families, where three, four or six codons are involved, at least two tRNAs are found for every aa. Most frequently in ECO and YSC (sufficient information is not available for DRO or PRI), as indicated above, there is a correlation between the abundance of the tRNA and the abundance of the codon (Ikemura, 1981; 1982). There are notable exceptions as in the case of the CGA codon for Arg. This codon is recognized in ECO by the same tRNA that recognizes the two high-usage codons CGU and CGC (Murao et al., 1972). It seems reasonable that we should focus our attention on the major codon families to gain an appreciation of the significance of lowusage codons.

In Table V, we have compared the three methods for assessment of codon usage for the nine major codon families. In this table, codons representing the same aa are grouped together. For each species, the % is given for codon usage determined by abundance in the genome as in Table I. In parentheses, the normalized number is given of proteins of the species that do not contain the codon as in Table II. A large number in parentheses should correspond to a small % if the two methods are consistent. Inspection of Table V indicates that the two methods are in quite good agreement for most aa. With only five exceptions (Val and Ala in ECO, Val in YSC, and Ser and Thr in DRO), the least abundant codon is excluded from the most proteins. With only five exceptions (Val, Ala and Gly in ECO, and Ser and Arg in PRI), the most abundant codon within the aa codon family is excluded from the lowest numbers of proteins; that is, it has the broadest distribution. In Table V, the % use of codons designated as low-usage codons by the combination of excluded-codons methods described above (see Tables III and IV) are underlined. Only in DRO do we have a codon designated by this latter method that does not appear in Table V (the UGU coden for Cys). Simple inspection of Table V suggests that additional codons might be designated as low-usage codons. However, we have chosen to focus our attention on eight codons from each species which we think are most likely to represent bona fide low-usage codons. If we were to attempt to expand this list we would run the risk of selecting codons that may not possess the most important properties of low-usage codons. Until such time as reliable quantitative estimates on rate of translatability can be given, we prefer to make comparisons

with a smaller subset of low-usage codons that we can be relatively sure of.

TABLE V
Synonymous codon usage for major codon families

										<u> </u>
			ECO	Γ	YSC	T		RO	T	PRI
	UUA		()		.,	1	8¢	(125)	) 6	
	UUG		(37)	. 36	, -,	-1	18	(28)	11	(35)
Leo	QUO		(41)	11	,,	1.	9	(48)	11	
	CUA		(39) (127)	1.5	- : :	-   -	15	(20)	21	1
	CUG	1 =	(9)	13	2	1.	8 14	(69) (15)	45	1
	AUU	47	(10)	50		+	33	<del>- `</del>	+-	
Пe		48	(10)	30	17	- 1	 33	(18)	33	1/
	AUA	7	(124)	20			4	(17) (84)	53 13	(14) (88)
	GUU	29	(10)	44	(6)	١,	0	(22)	15	
32.1	GUC	20	(23)	25	(12)		:6	(19)	25	(38)
Val	GUA	17	(19)	16	(52)		9	(68)	25	(16)
	CUC	34	(17)	15	(43)		8	(65)	49	(79) (7)
	UCU	18	(33)	31	(5)	1	8	(49)	18	(26)
	UCC	17	(42)	18	(11)	2	-	(14)	24	(10)
Ser	UCA	12	(68)	19	(30)		8	(88)	13	(49)
oer.	ŲCG	14	(60)	8	(69)	2		(18)	6	(94)
	AGU	13	(85)	15	(40)	1		(69)	13	(40)
	AGÇ	26	(20)	9	(51)	2		(18)	26	(14)
	CCU	15	(58)	29	(26)	Į,		(54)	27	(21)
Pro	CCC	10	(99)	13	(66)	30		(17)	35	(16)
110	CCA	19	(49)	49	(7)	23		(27)	26	(34)
	CCC	56	(20)	9	(97)	30	)	(31)	11	(73)
	ACU	20	(29)	38	(6)	16	;	(50)	23	(28)
Thr	ACC	45	(16)	24	(14)	42	)	(13)	40	(9)
	ACA.	12	(66)	26	(32)	17		(61)	25	(27)
	ACC	23	(36)	11	(63)	25	<u> </u>	(46)	12	(60)
	GCU	19	(15)	44	(7)	19		(24)	28	(10)
Ala	GCC	24	(18)	24	(10)	49		(3)	42	(4)
	GCA	22	(11)	24	(30)	15		(40)	20	(18)
	GCG	35	(13)	8	(73)	17		(28)	11	(84)
	CGU	43	(18)	17	(37)	18	1	(31)	9	(81)
	CCC	37	(21)	4	(128)	33	- (	(20)	22	(47)
Arg	CGA	5	(124)	5	(144)	1.3	(	(57)	10	(88)
٠.	CGG	8	(110)	2	(157)	14	(	(72)	20	(45)
	AGA	4	(161)	54	(7)	8	(	(95)	10	(45)
-	AGG	2	(180)	17_	(58)	12	(	67)	21	(23)
	GGU	38	(13)	60	(6)	22	(	(20)	15	(32)
Gly	GGC	40	(14)	15	(34)	43	(	11)	36	(10)
-	GGA	9	(88)	15	(47)	28	(	15)	24	(25)
	GGG	13	(49)	9	(70)	7	(	88)	25	(18)

<sup>\*</sup> Numbers in each column indicate % use of synonymous codon (derived from Table I). For example, in ECO we counted a total of 31 832 Leu codons of all types in Table I. Of these, 17477 were CUG codons; thus, the % use of CUG is  $17477 \div 31832 \times 100 = 55\%$  (in sixth line).

### (c) Low-usage codons are preferentially avoided in genes for abundant proteins in ECO, YSC and DRO

Implicit in the consideration of low-usage codons is the notion that such codons are more slowly translated and therefore avoided in genes for proteins required in large amounts. This notion is supported by a comparison of proteins containing small and large numbers of low-usage codons (e.g., Ikemura, 1985). For combinations of eight excluded codons, the distribution of proteins according to the number of low-usage codons they contain is given in Table VI.

It is informative to inspect those proteins that fall into the 'zero class', which uses none of the eight designated lowusage codons, and perhaps equally informative to inspect those proteins at the other extreme that use an abnormally high concentration of these low-usage codons. In spite of the fact that the precise molar amounts of each of these proteins are not available, the trends are unmistakable. Thus for the 93 proteins that are in the zero class for ECO, 35 r-proteins are found. Most of the remainder are major proteins involved in protein synthesis initiation and elongation, enzymes involved in intermediary aa metabolism and carbohydrate metabolism and the major outer membrane proteins, OmpR and OmpF. In YSC the zero class also abounds with r-proteins. The zero class in YSC also contains some histones, enzymes involved in aa biosynthesis and fermentation, actin, alcohol dehydrogenase and several ubiquitins. Of the 25 proteins in the DRO zero class the same trend continues with a strong representation of major proteins or at least proteins that are major in some tissues some of the time. Thus, we see some r-proteins, metallothionein, myosin, major heat-shock proteins, alcohol dehydrogenase I, cytochrome c, tropomyosin and a tubulin appearing in the zero class. Only in PRI is the trend unclear. Thus, we do not find r-proteins, histones or major enzymes in the zero class. Rather we find some globins, interferons, interleukins and metallothionein. It may be that these proteins are needed in large amounts in special situa-

TABLE VI

Distributions of proteins with respect to the percentage of low-usage codons they contain

% of low codons	ECO	YSC	DRO	PRI
0%	93 <sup>th</sup>	72	25	43
above 0% to 8%	443	168	48	307
above \$% to 6%	278	190	94	539
above 6% to 9%	102	46	48	862
above 9% to 12%	30	5	16	155
above 12% to 15%	12	2	8	73
above 15%	10	1	5	39

Numbers refer to number of proteins containing the indicated % of low usage codons.

Numbers in parentheses indicate normalized number of proteins lacking the codon (taken directly from Table II).

Ounderlined are numbers of low-usage codons determined by 'combinations of excluded codons' method (see Tables III and IV).

tions and therefore it is beneficial for their translation to avoid the designated low-usage codons. Alternately, it may be that translatability plays a smaller role in the selection of low-usage codons in PRI than it does in the other species considered here.

### (d) Proteins that contain a high percentage of low-usage codons in their genes belong to classes where an excess of the protein could be detrimental

It has been argued that only high-usage codons are selected in abundant proteins, and there is no selection for low-usage codons in low-expression-level proteins (Sharp and Li, 1986; Andersson and Kurland, 1990). Nevertheless, an examination of the trends seen in classes with high frequency of low-usage codons raises the possibility of selection for low-usage codons. For example, reading frames found on transposable elements abound in classes with high frequency of low-usage codons. Indeed, transposition of the YSC Ty1 transposon has been reported to be regulated by the concentration of the cognate tRNA for one of YSC's low-usage codons, AGG (Xu and Boeke, 1990). It seems likely that transposition would be under very tight control in most species. The remainder of the proteins found in the ECO list with greater than 9% lowusage codons include some toxins and lesser known regulatory proteins. YSC in the 6% or greater low-usage class contains several regulatory protein genes and nuclear genes that encode products for mitochondria. The DRO proteins with greater than 9% low-usage codons are most notable for the large number of transposable element genes. They also contain the Shaker genes which are believed to be essential for potassium channels in the nervous system (Pongs et al., 1988). The PRI with greater than 12% lowusage codons abound in proto-oncogenes, growth factor genes, several hormone genes and, strangely enough, several histone genes. The finding of histone genes in the class with high frequency of low-usage codons in PRI contrasts with the findings in YSC where several histone genes are found in the zero class. It may be argued that primate cells are held in check by an abundance of low codon usage genes including those likely to lead to rapid growth. Rapid uncontrolled growth often spells disaster in PRI, in contrast to unicellular organisms, and our findings can be rationalized in this way. Alternately, as noted above, low-usage codons may not play the same role in PRI as they do in the other species discussed here.

### (e) Codon usage by 'zero class' proteins is more selective than for average proteins

It has been pointed out that proteins in the abundant class have a more restricted codon usage. We have seen that for ECO, YSC and DRO, the zero class also correlates reasonably well with proteins found in the most abundant group. We have engaged in the reciprocal process of selecting the abundant proteins first and then determining their codon usage from the available information in GenBank (results not shown). This reciprocal approach is similar to that taken by Sharp and Li (1987), in which these authors used abundant proteins in ECO and YSC to determine a 'Codon Adaptation Index'. This approach gives very similar results for ECO and YSC, but is more difficult to apply in dealing with organisms that have differentiated cells. Our approach of selecting combinations of excluded codons is more systematic and subject to computer analysis with a minimum of preparation.

Codon usage for zero class proteins is compared with codon usages for all proteins in Table VII. Only data for the major codon families are presented. It can be seen that the most used codons are usually the same in both cases. Exceptions (a total of eight; marked with asterisks) are usually close calls. In many cases for ECO, YSC, and DRO but not PRI, the differences between the most used codons and other codons are more extreme. Indeed, there are more codons in the low-usage group (5% or less) in the highly restricted zero class collection: nine additional in the case of ECO, 14 additional in the case of YSC, eight additional in the case of DRO, but only one additional in the case of PRI. Many of these additional codons in the 5%, or less groupings may be low-usage codons in the sense that they may translate more slowly under some or all conditions of growth. This would be a reasonable explanation for their being more scarce in proteins that are synthesized in larger amounts. To decide this, as in all cases, actual measurements of translation rates will have to be made for each of the codons individually.

### (f) Choices of low-usage codons are relatively insensitive to gross base composition

To begin a consideration of the origin of varying lowusage codons in different species, we might first examine the relationship between codon usage and base frequencies in reading frames. This information is presented in Table VIII as the ratio of the observed number of codons vs. the expected number of codons calculated from base frequencies within reading frames on the coding strand. The most relevant relationships are for synonym codons.

A ratio greater than one indicates a codon that appears at a higher-than-expected frequency based on the observed base composition of the reading frames. Similarly, a ratio of less than one indicates a codon that appears at lower-than-expected frequency. In almost all cases, the numbers presented in Table VIII reflect the absolute numbers presented in Table I. For example, the ratios of 0.21 and 3.43 for the ECO Leu codons CUA and CUG in Table VIII reflect the much lower (960) and much higher (17477) numbers for these codons in Table I. Thus, the extreme numbers

TABLE VII

Comparison of codon usage  $^a$  for all proteins (T) $^b$  and for zero-class'-proteins (Z) $^a$  for major codon families

								<u>:</u>		
				eco		YSC	ľ	RO	1	PRI
			T	<u>z</u>	T	Z	T	Z	T	Z
472.57		UUA	,		27	17	6	0	8	8
		UUG			36	75	18	14		11
	Leu	CUU			11	2	1 8	6		8
		CUC CUA	1	_	5	٥	15	17	21	18
		CUG	3 55	•	13		8	2	7	7
			1 33	83	9	1	44	61	45	49
	_	AUU	47	26	50	51	33	30	33	25
	Пė	AUC	46	74*	30	47	53	70	53	58
		AUA	7	0	20		14	0	13	18
		GUU	29	47*	44	56	19	18	16	19
	Val	GUO	20	9	25	41	26	38	25	18
	_	GUA	17	24	16	1	9	2	8	4
		GUG	34	19	15	3	46	42	49	59
		UOU	18	86 <sup>*</sup>	31	53	8	12	18	28*
		UÇO	17	32	18	32	26	51	24	26
	Ser	UCA	12	3	19	6	8	2	13	11
		UOG	14	O	8	1	22	18	6	0
		ACU	13	4	15	4	12	0	13	11
		AGC	26	25	9	4	24	17	25	23
		CCU	15	14	29	14	LL	10	27	43*
1	Pro '	CCC	10	Q	13	2	36	65	35	40
		CCA	19	14	49	84	23	19	26	17
-		CCG	56	72	9	0	30	5	11	0
		ACU	20	38	38	51	16	13	23	32
1	br	ACC	45	52	24	45	42	80	40	35
		ACA	12	3	26	3	17	3	25	32
_		ACG	23	7	11	D	25	4	12	0
		GOU	19	40*	44	72	19	27	28	33
	Ma	GCC	24	10	24	24	40	68	42	46
		GCA	22	24	24	3	15	4	20	22
_		GCG	35	25	8	0	17	3	11	0
		CCU	45	67	17	13	19	44	9	0
		ogc	37	33	4	0	33	50	22	0
A	rg	CGA	5	0	5	0	13	0	10	0
	_	CCC	8	0	2	0	14	0	20	0
		AGA AGG	4 2	0	54	87	8	0	19	48
_				0	17	0	12	6	21	52*
		GGU	38	53*	60	93	22	31	15	16
G	lly	GGC	40	42	15	4	43	42	38	40
	-	GGA	9	8	15	2	28	26	24	38
_		CCG	13	3	8	1	_7	0	25	8_

 $<sup>^{\</sup>circ}$  Numbers are % of listed codons for the same aa. The numbers for each az add to 100%. Asterisks indicate cases where most-used codon is different in zero class proteins.

observed for these codons cannot be explained by gross base compositions of the reading frames. This does not mean that gross base compositions have no influence on differential codon usage. For example, consider the case of the Lys codons AAA and AAG in YSC. Table IB shows that there are more AAA than AAG codons (9104 vs.

8536). Nevertheless, AAA codons are closer to the expected ratio than AAG codons (1.18 vs. 1.66), raising the possibility that the more favored base composition of the AAA codon influences the higher frequency of usage of this codon. YSC probably have more examples like this than the other species we are considering here because the base frequencies for YSC differ most from the equimolar value (cf. top of Table VIII, A through D). Analyses of species with more extreme base compositions would be interesting in this regard. Our main conclusion from Table VIII is that low-usage codon choices are only influenced in a minor way by the gross base composition. Other workers have reported analyses indicating that overall codon usage patterns are influenced by gross base compositions (e.g., Bibb et al., 1984; Osawa and Jukes, 1988); however, these analyses primarily reflect codon usage patterns of average and high-usage codons.

### (g) Low codon usage appears to be influenced by dinucleotide usage in some cases

In the previous section we saw that the choice of lowusage codons in the four groups of organisms we chose to consider is not influenced to any appreciable extent by the gross base composition. In this section we consider a related possibility that the choice of low-usage codons is influenced by dinucleotide preferences. It has been argued that dinucleotide preferences govern to a large extent codon choices in eukaryotes (Nussinov, 1981; Alff-Steinberger, 1987). Dinucleotide frequencies for the different species are presented in Table IX, together with the ratio of the observed-to-expected frequencies based on gross base composition. If there is a strong bias against the use of certain dinucleotide sequences it should show up in this ratio. Inspection of Table IX shows seven cases (underlined) where this ratio is 0.73 or less. The UA dinucleotide ratio is low for all species (0.71 ECO; 0.69 YSC; 0.58 DRO; 0.53 PRI), the CG ratio is low for both YSC (0.72) and PRI (0.48) and the AG ratio is low for ECO (0.73). As was seen in Table IV, ECO contains two low-usage codons, AGG and AGA, with the AG sequence, and two low-usage codons, CUA and AUA, with the UA sequence. YSC contains six low-usage codons, CGA, CGG, CGC, CCG, GCG, ACG, with the CG sequence. DRO contains two low-usage codons, AUA and UUA, with the UA sequence. Finally, all eight of the low-usage codons in PRI contain the CG sequence. On the basis of these correlations alone we must consider the proposition that there is some unknown pressure or pressures that cause certain dinucleotide sequences to be underrepresented which in turn results in an underrepresentation of the related codon or codons. However, in the process of attempting such an analysis we must be careful to distinguish cause and effect. Therefore, we must try to determine whether low dinucleotide fre-

b Values taken directly from Table V.

<sup>&</sup>quot;Zero class proteins' are those proteins that contain no residues encoded by any of the designated eight low-usage codons listed in Table IV.

TABLE VIII

Ratios of observed number of codons vs. expected number of codons \*

		U: 228989 O:	238372 A: 2:	<b>Februs:</b> 18390 G: 2654	68		DRO Gross i	base compo es U: 7	sition for . 5309 (7:	rum of reading (	Trautes; \$751 G: 103441	,
	U	0	A.	G			v		C	٨	G G	,
Ų	1.47 (Phe 1.34 (Phe	0.87 See	0.94 (Tye	0.38 /Ora	) U		1.41 (		.55 (Ser	1.04 (Tyr		
	0.78 (Leu 0.75 (Leu	) - 0.46 (Sec ) - 0.50 (Sec	) 0.14 (STP	0.05 (STP	) A	*	<sup>J</sup> 2.11 ( 0. <b>46</b> (	Leu) ().	33 (Ser 45 (Ser	1.45 (Tvr	) 0.93 (Ora)	
	0.74 (Leu)	0.48 (Pro		(44)			1.29 (		11 (Ser)			
7	0.69 (Leu) 0.21 (Leu)	0.28 (Pro)	0.72 (His	1.30 Arg	a	0	0.65 ( 0.84 {		38 (Pro) 93 (Pro)			
	3.43 (Leu)		0.88 (Gln)	0.18 (Arg 0.25 (Arg	A G		0.47	Len) O.	66 (Proj		0.88 (Arg) 0.87 (Arg)	
	2.02 (Ile)	,,	1.15 (Asn)				2.41 (1		77 (Pro)	1.99 (G)a)	0.35 (Arg)	
	1.90 (lle) 0.28 (lle)	1.64 (The) 0.44 (The)	1.64 (Ash) 2.52 (Lys)	0.90 (Ser)	O	A	1.55 (i 1.87 (i		53 (Thr) 55 (Thr)	1.85 (Ann) 1.88 (Ann)		
_	1.67 (Met)	0.76 (Thr)	0.72 (Lys)	0.13 (Arg) 0.07 (Arg)	A. G		0.56 () 1.72 ()	lle) 6.	57 (Thri	0.98 (Lys)	0.29 (Arg)	
	1.38 (Val) 0.80 (Val)	1.12 (Ala)	2.04 (Asp)	1.62 (Gly)	U	<del></del>	D.97 (V		3 (Thr)	2.49 (Lys)	0.48 (Arg)	
	0.76 (VEL)	1.40 (Ala) 1.25 (Ala)	1.33 (Asp) 3.54 (Glu)	1.55 (Gly) 0.38 (Gly)	C A	G	1.02 ČV	%1) 1.8	9 (Ala) 8 (Ala)	1.95 (Asp) 1.35 (Asp)	1.03 [Gly] 1.47 [Gly]	1
	1.40 (Val)	1.79 (Ala)	1.03 (Glu)	0.47 (Gly)	Ĝ		0.87 (V		I (Ala)	1.08 (G) u	1.04 (Gly)	- 7
50	Gross base co	mposition for su	m of reading fra		<del></del> _	-	1.78 (V		6 (Ala)	2.45 (Clu)	0.23 (Cny)	Ğ
SC	Gross base co numbers U:	mposition for su 200820 C: 1	m of reading fra 140370 A: 3298	mes; 177 G: 152556	<del></del> _	D. PI	l Gross bes	Se composit	ion for au	m of souding &	0.23 (Cny)	
50	U 1.08 (Phs)	C 1.65 (Sar)	A	mes: 177 G: 152556 G		D. PI	di Gross bar numbers	se composit U: 3914	ion for au 31 C: 4	m of souding &	0.23 (Cny)	
SC	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leq)	C 1.65 (Sar) 1.40 (Ser)	A 0.67 (Tyr) 0.97 (Tyr)	G .47 (Cys) 0.33 (Cys)	U C	D. PI	U Gross bar	se composit U: 3914	ion for au 31 C: 4 C	m of reading fra 90849 A: 4611 A 1.06 (Tyr)	0-23 (G)y) mes: (O3 G: 492738. G	U
50	U 1.08 (Phs)	C 1.65 (Sar)	A 0.67 (Tyr)	mes: 177 G: 152556 G	<u>u</u>		U Gross base numbers U 1.52 [Ph 1.86 [Ph 0.46 [Le	Se composite U: 3914  Le	ion for sur S1 C: 4 C (Ser) (Ser) (Ser)	n of reading fra 80849 A: 4611 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP)	0.23 (Gry) mes: (G3 G: 492735. G 0.73 (Cys) 0.92 (Cys) 0.00 (STP)	UCA
SC	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.84 (Leu)	1.65 (Sar) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser) 1.92 (Pro)	A  0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His)	G .47 (Cys) 0.33 (Cys) 0.03 (SIP) 0.84 (Trp) 0.66 (Arg)	U C A		U 1.82 (Ph 1.88 (Ph 0.46 (Le 0.88 (Le	Se compusite U: 3914  Le) 1.04  Le) 1.18  n) 0.68  n) 0.26	ion for sur S1 C: 4 C (Ser) (Ser) (Ser) (Ser)	m of reading fra 90849 A: 4611 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP)	0.23 (Gry)  mes:  G  0.74 (Oys)  0.92 (Cys)  0.09 (STP)  0.88 (Trp)	U
SC	U  1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.64 (Leu) 0.39 (Leu) 0.59 (Leu)	C 1.65 (Sar) 1.40 (Ser) 0.57 (Ser) 0.57 (Ser) 1.92 (Pro) 0.79 (Pro) 1.78 (Pro)	A  0.67 (Tyr) 0.97 (Tyr) 0.94 (STP) 0.02 (STP)  0.72 (His) 0.70 (His)	G G 152556 G G 1.47 (Cys) 0.33 (Cys) 0.03 (SIP) 0.84 (Trp) 0.06 (Arg) 0.24 (Arg)	U C A G		U 1.52 (Ph 1.88 (Ph 0.46 (Le 0.88 (Le 0.89 (Le 1.85 (Le)	u) 1.03 u) 1.03 u) 1.03 u) 1.03	(Ser) (Ser) (Ser) (Ser) (Ser) (Ser) (Pro)	n of reading fra 80849 A: 4611 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP)	0.23 (Gry) mes: 103 G: 492738. G 0.74 (Cys) 0.92 (Cys) 0.09 (STP) 0.38 (Trp) 0.31 (Arg) 0.51 (Arg)	U C A G
SC	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.64 (Leu) 0.39 (Leu) 0.59 (Leu) 0.73 (Leu)	C 1.65 (Sar) 1.40 (Ser) 0.50 (Ser) 0.57 (Ser) 1.92 (Pro) 0.79 (Pro) 1.78 (Pro) 0.52 (Pro)	A  0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His)	G .47 (Cys) 0.33 (Cys) 0.03 (SIP) 0.84 (Trp) 0.66 (Arg)	U C A G	U	U 1.82 (Ph 1.86 (Ph 0.46 (Le 0.88 (Le	u) 1.03 u) 0.85 u) 0.85 u) 0.85 u) 0.85	C (Ser) (Ser) (Ser) (Ser) (Pro)	m of reading fra 80849 A: 4611 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.85 (His) 0.83 (His) 0.83 (Gin)	0.23 (G)y)  mes: (03 G: 492738.  G  0.74 (Oys) 0.09 (Oys) 0.09 (STP) 0.38 (Trp)  0.30 (Arg) 0.51 (Arg) 0.50 (Arg)	U C A G U C A
	U  1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.64 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (He)	C 1.65 (Sar) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser) 1.92 (Pro) 1.79 (Pro) 0.52 (Pro) 1.28 (Thr)	A  0.67 (Tyr) 0.97 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP)  0.72 (His) 0.70 (His) 1.51 (Gio) 0.80 (Gio)  1.12 (Ash)	G G. 47 (Cys) 0.33 (Cys) 0.03 (SIP) 0.04 (Trp) 0.06 (Arg) 0.17 (Arg) 0.12 (Arg) 0.10 (Arg)	U C A G G	U	U 1.52 (Ph 1.88 (Ph 0.46 (Le 0.88 (Le 0.89 (Le 1.85 (Le 0.45 (Le 2.83 (Le	E composit  U: 3914  Le	C (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro)	m of reading fra 80849 A: 4611 A 1.06 (Tyr) 0.08 (STP) 0.03 (STP) 0.05 (His) 0.83 (His) 0.85 (Gln) 1.92 (Gln)	0.23 (Gly)  mes:  (G3 G: 492738.  G  0.72 (Cys) 0.92 (Cys) 0.00 (STP) 0.38 (Trp)  0.30 (Arg) 0.51 (Arg) 0.54 (Arg)	U C A G G
	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.64 (Leu) 0.59 (Leu) 0.73 (Leu) 0.73 (Leu) 1.26 (Ile) 1.26 (Ile) 9.45 (Ile) 9.45 (Ile)	C  1.65 (Sar) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser) 0.79 (Pro) 1.72 (Pro) 0.52 (Pro) 1.18 (Thr) 1.19 (Thr) 0.75 (Thr)	A	0.47 (Cys.) 0.33 (Cys.) 0.03 (SIP) 0.04 (Trp.) 0.06 (Arg.) 0.17 (Arg.) 0.12 (Arg.) 0.15 (Ser.) 0.55 (Ser.) 1.13 (Arg.)	U C A G U C A A G C A	U	U Gross base numbers U 1.62 (Ph 1.88 (Ph 0.46 (Le 0.88 (Le 1.85 (Le 1.85 (Le 2.88 (Le 1.50 (III	E compusit  U: 3914  U: 3914  (c) 1.04  (d) 0.25  U) 0.25  U) 1.03  U) 0.25  U) 0.34  (e) 0.90  (e) 1.30	ion for aug S1 C: 4 C C (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Pro) (Pro) (Pro) (Pro)	m of reading fra 80849 A: 4611 A 1.05 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.85 (His) 0.85 (Gin) 1.92 (Gin) 1.22 (Asn) 1.33 (Asn)	0.23 (Giy)  mes:  (03 G: 492738.  G  0.74 (Oys) 0.92 (Oys) 0.99 (STP) 0.38 (Trp)  0.30 (Arg) 0.51 (Arg) 0.54 (Arg) 0.55 (Ser) 1.03 (Ser)	U C A G U C A G U C
	U 1.02 (Phs) 1.34 (Phe) 0.99 (Leu) 1.98 (Leu) 0.84 (Leu) 0.59 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (Ile) 1.09 (Ile) 0.45 (Ile) 1.16 (Met)	C  1.65 (Sar) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser)  1.22 (Pro) 1.79 (Pro) 0.52 (Pro) 1.28 (Thr) 1.19 (Thr) 0.79 (Thr) 0.51 (Thr)	A. 3296 A. 0.67 (Tyr) 0.97 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.70 (His) 1.51 (Gin) 0.80 (Cin) 1.12 (Asn) 1.13 (Asn) 1.18 (Lys) 1.66 (Lys)	G G .47 (Cys) 0.33 (Cys) 0.03 (Str) 0.84 (Trp) 0.04 (Arg) 0.12 (Arg) 0.12 (Arg) 0.15 (Ser) 0.55 (Ser) 0.55 (Ser)	U C A G U C C A G	U C	1.52 (Ph 1.86 (Ph 0.46 (Le 0.88 (Le 0.89 (Le 1.85 (Le 0.45 (Le 2.83 (Le	E composite U: 3914 U: 3914 U: 3914 U: 3914 U: 0.68 U: 0.85 U: 0.85 U: 0.90 U:	ion for august 1 C: 4 C C (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Pro) (Thr)	m of reading fra 80849 A: 4611 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.55 (His) 0.83 (His) 0.85 (Gln) 1.92 (Gln)	0.23 (Giy)  mes:  (03 G: 492738.  G  0.72 (Cys) 0.92 (Cys) 0.09 (STP) 0.38 (Trp)  0.30 (Arg) 0.51 (Arg) 0.54 (Arg) 0.55 (Ser)	U C A G U C A G U
	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.64 (Leu) 0.59 (Leu) 0.73 (Leu) 0.73 (Leu) 1.26 (Ile) 1.09 (Ile) 0.45 (Ile) 1.16 (Met) 1.55 (Val) 1.32 (Val)	C  1.65 (Sar) 1.40 (Ser) 0.90 (Sor) 0.57 (Sor) 1.22 (Pro) 0.79 (Pro) 1.78 (Pro) 1.28 (Thr) 1.28 (Thr) 0.51 (Thr) 2.61 (Ala) 1.97 (Ala)	A  0.67 (Tyr) 0.97 (Tyr) 0.94 (STP) 0.02 (STP)  0.72 (His) 0.70 (His) 1.51 (Gin) 0.80 (Gin)  1.12 (Ash) 1.32 (Ash) 1.18 (Lys) 1.66 (Lys)  2.00 (Asp)	G G 152556  G G 152556  G G (Cys) 0.33 (Cys) 0.03 (SIP) 0.84 (Trp) 0.94 (Arg) 0.12 (Arg) 0.12 (Arg) 0.15 (Ser) 0.55 (Ser) 1.13 (Arg) 0.55 (Arg) 2.81 (Gly)	U C A G U C A G U C A G U	C A	U Gross base numbers  1.62 (Ph 1.88 (Ph 0.46 (Le 0.88 (Le 0.89 (Le 1.35 (Le) 2.83 (Le 1.30 (II) 1.69 (II) 0.42 (II) 1.53 (Mar 0.83 (Val	E compusit  U: 3914  U: 3914  1.04  0.66  1.18  0.06  0.10  0.25  0.10  0.37  1.27	ion for au Sil C:  (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Thr) (Thr) (Thr)	m of reading fra 80849 A: 4611 A 1.06 (Tyr) 0.05 (STP) 0.03 (STP) 0.05 (His) 0.83 (His) 0.85 (GIn) 1.92 (GIn) 1.22 (Asn) 1.33 (Asn) 1.39 (Lys)	0.23 (G)y)  mes:  (03 G: 492738.  G  0.74 (Cys) 0.92 (Cys) 0.09 (STP) 0.88 (Trp)  0.30 (Arg) 0.51 (Arg) 0.54 (Arg) 0.55 (Ser) 1.03 (Ser) 0.55 (Arg) 0.59 (Arg)	U C A G U C A G
_	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.59 (Leu) 0.59 (Leu) 0.59 (Leu) 1.26 (Ile) 1.09 (Ile) 1.06 (Met) 1.55 (Val) 1.55 (Val) 1.55 (Val)	C  1.65 (Sar) 1.40 (Ser) 0.50 (Sor) 0.57 (Sor) 1.92 (Pro) 0.79 (Pro) 1.78 (Pro) 0.52 (Pro) 1.28 (Thr) 1.19 (Thr) 0.51 (Thr) 2.61 (Ala) 1.17 (Ala)	A  0.67 (Tyr) 0.97 (Tyr) 0.94 (STP) 0.02 (STP)  0.72 (His) 0.70 (His) 1.51 (Gio) 0.80 (Gio)  1.12 (Asn) 1.32 (Asn) 1.18 (Lys) 1.84 (Lys) 1.86 (Lys) 2.00 (Asp) 1.73 (Asp) 2.31 (Gio)	G G.47 (Cys) 0.33 (Cys) 0.03 (SIP) 0.04 (Trp) 0.06 (Arg) 0.17 (Arg) 0.12 (Arg) 0.15 (Ser) 1.13 (Arg) 0.55 (Ser)	U C A G U C A G G	U C	1.52 (Ph 1.88 (Ph 0.46 (Le 0.88 (Le 0.85 (Le 0.45 (Le 1.30 (He 1.53 (Mer	Se composite U: 3914 U: 1.03 U	ion for aug S1 C: 4 C C (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Thr) (Thr) (Thr)	m of reading fra 80849 A: 4611  A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.83 (His) 0.85 (Gin) 1.92 (Gin) 1.92 (Asn) 1.33 (Asn) 1.39 (Lys) 2.06 (Lys)	0.23 (Giy)  mcs: (03 G: 492738.  G  0.74 (Oys) 0.92 (Cys) 0.95 (STP) 0.38 (Trp)  0.30 (Arg) 0.51 (Arg) 0.54 (Arg) 1.03 (Ser) 1.03 (Ser) 1.03 (Ser)	U C A G G U C A A G G A

a Observed number of codons is taken from Table I; expected number of codons is calculated from base frequencies within reading frames on the coding strand, assuming bases were randomly associated to form codons. The 'gross base composition for sum of reading frames' is the actual number of each base counted in coding sequences. For example, in all surveyed reading frames of ECO, there were 226989 U, 238372 C, 238380 A and 265468 G, for a sum of 969209 total bases (the sum may not be a multiple of three because we omitted unidentified bases in some sequences). The expected number for a codon is calculated from the probability that any base will occur at a specific position of the codon. In the calculation, the base frequencies are used as the probabilities. In ECO, for example, the probability that a base occurs at a specific position of the codon is 226989 + 969209 = 0.23420 for U; 238372 + 969209 = 0.24594 for C; 238380 + 969209 = 0.24595 for A; 265468 + 969209 = 0.27390 for G. The probability at which a codon is expected to occur is the product of the probabilities of the bases in the codon. The probability of the AGG (Arg) codon of ECO, for example, is calculated as 0.24595 x 0.27390 x 0.27390 = 0.01845. This number means that approx 1.8% of all codons in ECO would be expected to be AGG (also, another approx 1.8% would be GAG and still another approx. 1.8% would be GGA). Since a total of 323059 codons were counted in ECO (Table I), the expected number of AGG codons is therefore 323059 x 0.01845 = 5960. The actual number of AGG codons counted was 428 (Table I). Thus, the ratio of observed to expected numbers of codons for AGG in ECO is 428 + 5960 = 0.07.

quency is the cause of low codon frequency or the other way around.

Let us first consider the AG case for ECO. The two Arg codons AGA and AGG are both low-usage codons in ECO. If we examine the AGX box in which they occur (Table I), we find that this box is shared by two Ser codons and two Arg codons. The Ser codons are well represented

compared to other Ser codons. Based on this comparison alone we cannot make a case for saying that these low-usage codons for Arg in ECO are the result of the avoidance of the AG sequence. Other factors must be involved.

Next let us consider the UA case for DRO. Two codons, AUA for Ile and UUA for Leu, have been designated as low-usage codons. If we look at the other codons contain-

TABLE IX

Prequencies of dinucleotides in excess

	E	<b>3</b> 0	Y	SC	Di		PI	21
VU	5687 <b>9</b> 2	(1.08) <sup>b</sup>	84400	(1.16)	16404	(1.07)	88987	(1.01)
UC	51707	(0.93)	40845	(1.04)	22614	(1.08)	103345	(1.00)
UA	39532	(0.71)	43974	(0.69)	11023	(0.58)	52063	
UG	77688	(1.25)	51154	(1.21)	25971	(1.24)	150278	(0.53)
CU	53439	(0.96)	39507	(1.02)	2070B	(0.99)	1	(1.43)
CC	50942	(0.87)	29845	• /		• •	130750	(1.27)
CA	57384	(0.98)	1	(1.10)	26884	(0.95)	143974	(1.14)
CC	76386		49444	(1.11)	30348	(1.19)	143161	(1.18)
	1	(1.17)	21381	(0.72)	25081	(0.89)	62330	(0.48)
AU	59307	(1.07)	58264	(0.92)	21265	(1.13)	91864	(0.94)
AC	54289	(0.93)	41907	(0.94)	22519	(0.88)	104960	(0.87)
AA	75435	(1.80)	81823	(1.13)	23885	(1.03)	122009	(1.06)
AG	47506	(0.78)	48775	$\{0.97\}$	25689	(1.00)	140078	(1.13)
GU	56386	(0.91)	38151	(0.90)	17688	(0.85)	83357	(0.79)
ÇC	81433	(1.25)	27873	(0.94)	31082	(1.10)	128562	(0.99)
GA	63548	(0.98)	53207	(1.10)	27902	(1.08)	140390	(L.13)
GG	83482	(0.87)	38017	(1.03)	25586	(0.94)	138971	(1.05)
nm	965833		721376		975606		1920027	

Numbers to the left refer to totals for all reading frames.

ing UA (see Table I) we see that these are low, even though they have not been designated as low-usage codons. The other box containing the UA sequence contains the two Tyr codons and two of the stop codons. Since stop codons are always underrepresented this will be a constant factor in reducing the UA frequency. The same is true for other species. If we look at the other species we find that there is a tendency for the NUA codons to be underrepresented in the family boxes (except for UUA and CUA in YSC). Whether the UA sequence is influencing the codon usage or vice versa is hard to say.

To get some further indication on this point we may turn to the dinucleotide frequencies in the intron regions. These are recorded for YSC, DRO, and PRI in Table X for the UA and CG sequences. In all cases the UA dinucleotide ratio is higher for the introns than for the exons. Thus when the coding pressure is lifted, as in the noncoding regions of the introns, the UA sequence gravitates towards the statistically most probable ratio of 1.00. This comparison clearly favors the argument that the low UA dinucleotide frequency in the coding regions is probably caused by the coding pressure.

The CG sequence is associated with six low-usage

TABLE X
Ratio of observed to expected frequences of UA and CG dinucleotides

		Exons	Introns
YSC	UA	0.69	0.80
150	CG	0.72	0.86
DRO	UA	0.58	0.86
DRO	CG	0.89	0.97
PRI	UA	0.58	0.78
LICT	CG	0.48	0.29

<sup>&</sup>lt;sup>a</sup> Exon ratios are taken from Table IX (b).

codons in YSC and all eight in PRI. Since in both of these cases most of the designated low-usage codons contain most of the dinucleotide sequences in question we must carefully scrutinize the possibility that the low value for the CG sequence results from the low frequency of codons using this sequence.

Numbers in parentheses refer to ratios of observed over expected where expected is calculated from gross base composition of the reading frames. Ratios of 0.73 or less are underlined. As an example, for the GA dinucleotide in ECO, the expected number would be calculated as follows. The probability that any position will contain a G is 0.27390, or an A is 0.24595 (see footnote to Table VIII for derivation of these values). The probability of finding this dinucleotide is the product of these two individual probabilities (0.27390 × 0.24595 = 0.06737). Thus, out of 965333 dinucleotides, the expected number of GA dinucleotides is 65034 (0.06737 × 965333). The observed number of GA dinucleotides was 63548. Therefore, the ratio of observed over expected is 63548 ÷ 65034 = 0.98.

b Intron ratios are computed from 7582 dinucleotides for YSC, 56497 dinucleotides for DRO, and 686152 dinucleotides for PRI. The calculation is similar to that of the exon ratios (see Table IX, footnote b), however, the gross base composition in this case is taken from the overall base composition, not just the base composition in reading frames.

Inspection of the intron frequencies for YSC and PRI gives different indications for the CG frequency. Thus in YSC the frequency of CG moves closer to the expected (0.72 vs. 0.85), whereas for PRI it moves even further from the expected (0.48 vs. 0.29). Similarly, in YSC the overlapping intercodon C/G dinucleotide in coding sequences also moves closer to the expected, while in PRI the intercodon C/G is found at much lower frequency than expected (data not shown). It would be hazardous to draw any firm conclusions from this comparison. However, taken at face value this would argue that the low codon usage in PRI is dominated by considerations of avoidance of the CG sequence. A possible reason for this avoidance, as already indicated, is that the CG sequence is a site for methylation in PRI (Razin and Riggs, 1980). In YSC, it remains possible that coding pressure influences the dinucleotide frequencies in the coding regions.

### (h) Other factors influencing the selection of low-usage codons

Shepherd (1981) noticed that the coding sequences of most reading frames have a bias for the sequence RNY (R = purine; Y = pyrimidine; and N = purine or pyrimidine). We have done extensive analysis of this and the results (unpublished observations) support the view of Shepherd (1981) which was based on a much smaller data base. It is notable that of the designated low-usage codons (Table IV) there is only one example of a RNY sequence. This correlates with the Shepherd view and suggests that the codons selected as low-usage codons in various species may have evolved from less popular sequence arrangements.

### (i) Conclusions

(1) We have presented new approaches to identify lowusage codons in a reliable fashion. (2) We have been able to assign with reasonable confidence (with the possible exception of PRI) up to eight of the lowest-usage codons in several organisms (Table IV). (3) Gross base composition and dinucleotide frequencies in general cannot explain choices of low-usage codons; however, dinucleotide usage does show some influence on codon usage in PRI. (4) Lowusage codons are clearly avoided in abundant proteins; those proteins containing a high % of low-usage codons are generally cases where an excess of protein could be detrimental. (5) In a subsequent paper, we shall propose a model by which low-usage codons may affect translation rates. Also, a more detailed review of our data on codon usage in primates has recently been published (Zhang and Zubay, 1991)

### ACKNOWLEDGEMENTS

We acknowledge support by the American Cancer-Society, grant No. MV-313A to G.Z., and the National Institutes of Health, grants Nos. GM27711 and 2 SO7 RR05393 to E.G.; the computer resource is supported by the National Institutes of Health, grant No. 2P41 RR00442-20.

#### REFERENCES

- Abate, C., Luk, D., Gentz, R., Rauscher III, FJ. and Curran, T.: Expression and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly. Proc. Natl. Acad. Sci. USA 87 (1990) 1032–1036.
- Alff-Steinberger, C.: Codon usage in Homo sapiens: evidence for a coding pattern on the noncoding strand and evolutionary implications of dinucleotide discrimination. J. Theor. Biol. 124 (1987) 89-95.
- Andersson, S.G.E. and Kurland, C.G.: Codon preferences in free-living microorganisms. Microbiol. Rev. 54 (1990) 198-210.
- Bibb, M.J., Findlay, P.R. and Johnson, M.W.: The relationship between base composition and codon usage in bacterial genes and its use for the simple and reliable identification of protein-coding sequences. Gene 30 (1984) 157-166.
- Beunetzen, J.L. and Hall, B.D.: Codon selection in yeast. J. Biol. Chem. 257 (1982) 3026-3031.
- Bonekamp, F., Andersen, H.D., Christensen, T. and Jensen, K.F.: Codon-defined ribosomal pausing in *Escherichia coli* detected by using the *pyrE* attenuator to probe the coupling between transcription and translation. Nucleic Acids Res. 13 (1985) 4113-4123.
- Carter, P.W., Bartkus, J.M. and Calvo, J.M.: Transcription attenuation in Salmonella typhimurium: the significance of rare leucine codons in the leu leader. Proc. Natl. Acad. Sci. USA 83 (1986) 8127-8131.
- Chen, G.-F.T. and Inouye, M.: Suppression of the negative effect of minor arginine codous on gene expression; preferential usage of minor codons within the first 25 codons of the Excherichia coli genes. Nucleic Acids Res. 18 (1990) 1465-1473.
- Curran, J.F. and Yarus, M.; Rates of an-tRNA selection at 29 sense codons in vivo. J. Mol. Biol. 209 (1989) 65-77.
- Gouy, M. and Gautier, C.: Codon usage in bacteria: correlation with gene expressivity. Nucleic Acids Res. 10 (1982) 7055-7074.
- Grantham, R., Gautier, C., Gouy, M., Jacobzone, M. and Mercier, R.: Codon catalog usage is a genome strategy modulated for gene expressivity. Nucleic Acids Res. 9 (1981) r43-r74.
- Grosjean, H.J., De Henau, S. and Crothers, D.M.; On the physical basis for ambiguity in genetic coding interactions. Proc. Natl. Acad. Sci. USA 75 (1978) 610-614.
- Grosjean, H. and Fiers, W.: Preferential codon usage in prokaryotic genes: the optimal codon-anticodon interaction energy and the selective codon usage in efficiently expressed genes. Gene 18 (1982) 199-209.
- Gutman, G.A. and Hatfield, G.W.: Nonrandom utilization of codon pairs in Escherichia coli. Proc. Natl. Acad. Sci. USA 86 (1989) 3699-3703.
- Hockema, A., Kastelein, R.A., Vasser, M. and De Boer, H.A.: Codon replacement in the PGK1 gene of Saccharomyces cerevisiae: experimental approach to study the role of biased codon usage in gene expression. Mol. Cell. Biol. 7 (1987) 2914-2924.
- Ikemura, T.: Correlation between the abundance of Escherichia coli transfer RNAs and the occurrence of the respective codons in its protein

- genes: a proposal for a synonymous codon choice that is optimal for the E. coli translational system. J. Mol. Biol. 151 (1981) 389-409.
- Ikemurs, T.: Correlation between the abundance of yeast transfer RNAs and the occurrence of the respective codons in protein genes. J. Mol. Biol. 158 (1982) 573-597.
- Ikemura, T.: Codon usage and tRNA content in unicellular and multicellular organisms. Mol. Biol. Evol. 2 (1985) 13-34.
- Ingraham, J.L., Maslæe, O. and Neidhardt, F.C.: Growth rate as a variable, In: Growth of the Bacterial Cell. Singuer Associates, Sunderland, MA, 1983, pp. 267-315.
- Konigsberg, W. and Godson, G.N.: Evidence for use of rare codons in the dnaG gene and other regulatory genes of Escherichia coli. Proc. Natl. Acad. Sci. USA 80 (1983) 687-691.
- Knrland, C.G.: Strategies for efficiency and accuracy in gene expression,
   1. The major codon preference: a growth optimization strategy.
   Trends Biochem. Sci. 12 (1987) 126-128.
- Murao, K., Tanabe, T., Ishii, F., Namiki, M. and Nishimura, S.: Primary sequence of arginine transfer RNA from Escherichia coli. Biochem. Biophys. Res. Commun. 47 (1972) 1332-1337.
- Nussinov, R.: Eukaryotic dinucleotide preference rules and their implications for degenerate codon usage. J. Mol. Biol. 149 (1981) 125-131.
- Osawa, S. and Jukes, T.H.: Evolution of the genetic code as affected by anticodon content. Trends Genet. 4 (1988) 191-198.
- Pongs, O., Kecskemethy, N., Mueller, R., Krah-Jentgens, I., Baumann, A., Kiltz, H.H., Canal, I., Llamarzares, S. and Ferrus, A.: Shaker encodes a family of putative potassium channel proteins in the nervous system of Drosophila. EMBO J. 7 (1988) 1087-1096.
- Post, L.E., Strycharz, G.D., Nomura, M., Lewis, H. and Dennis, P.P.: Nucleotide sequence of the ribosomal protein gene cluster adjacent to the gene for RNA polymerase subunit β in E. coll. Proc. Natl. Acad. Sci. USA 76 (1979) 1697-1701.
- Razin, A. and Riggs, A.D.: DNA methylation and gene function. Science 210 (1980) 504-610.
- Robinson, M., Lilley, R., Emtage, J.S., Yarranton, G., Stephens, P., Millican, A., Eaton, M. and Humphreys, G.: Codon usage can affect efficiency of translation of genes in *Escherichia coli*. Nucleic Acids Res. 12 (1984) 6663-6671.

- Rojiani, M.V., Jakubowski, H. and Goldman, E.: Relationship between protein synthesis and concentrations of charged and uncharged tRNA<sup>TO</sup> in Escherichia coll. Proc. Natl. Acad. Sci. USA 87 (1990) 1511-1515.
- Sharp, P.M. and Li, W.-H.: Codon usage in regulatory genes in Escherichia coli does not reflect selection for 'rare' codons. Nucleic Acids Res. 14 (1986) 7737-7749.
- Sharp, P.M. and Li, W.-H.: The codon adaptation index a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 15 (1987) 1281-1295.
- Sharp, P.M., Cowe, E., Higgins, D.G., Shields, D.C., Wolfe, K.H. and Wright, F.: Codon usage patterns in Escherichia coll, Bacillus subtilis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens: a review of the considerable withinspecies diversity. Nucleic Acids Res. 16 (1988) 8207-8211.
- Shepherd, J.C.W.: Method to determine the reading frame of a protein from the purine/pyrimidine genome sequence and its possible evolutionary justification. Proc. Natl. Acad. Sci. USA 78 (1981) 1596-1600.
- Sørensen, M.A., Kurland, C.G. and Federsen, S.: Codon usage determines translation rate in *Escherichia coli*. J. Mol. Biol. 207 (1989) 365-377.
- Sprinzl, M., Hartmann, T., Meissner, F., Moll, J. and Vorderwulbecke. T.: Compilation of tRNA sequences and sequences of tRNA genes. Nucleic Acids Res. 15 (1987) r53-r188.
- Wada, K.-N., Aota, S.-I., Tsuchiya, R., Ishibashi, F., Gojobori, T. and Ikemura, T.: Codoo usage tabulated from the GenBank genetic sequence data. Nucleic Acids Res. 18, Suppl. (1990) 2367-2411.
- Xu, H. and Bocke, J.D.: Host genes that influence transposition in yeast: the abundance of a rare tRNA regulates Tyl transposition frequency. Proc. Natl. Acad. Sci. USA 87 (1990) 8360-8364.
- Yarus, M., Cline, S.W., Wier, P., Breeden, L. and Thompson, R.C.: Actions of the anticodon arm in translation on the phenotypes of RNA mutants. J. Mol. Biol. 192 (1986) 235-255.
- Zhang, S. and Zubay, G.: The peculiar nature of codon usage in primates. In: Setlow, J.K. (Ed.), Genetic Engineering, Vol. 13, 1991, pp. 73-113.

Minireview

## Differential codon usage: a safeguard against inappropriate expression of specialized genes?

Milton H. Saier, Jr.\*

Department of Biology. University of California at San Diego, La Jolla, CA 92093-0116, USA
Received 2 January 1995; revised version received 14 February 1995

Abstract Recent work has suggested that rare codons are sometimes used for the regulation of specialized gene expression in bacteria. Moreover, the cellular levels of certain tRNAs may fluctuate with growth conditions. Evidence implicating such mechanisms in the control of photosynthesis in Rhodobacter, solventogenesis in Clostridium, sporulation in Streptomycea, and finitrial phase variation in E. coli is summarized. It is suggested that such mechanisms will prove applicable to the control of numerous additional specialized functions, and that the empirical tools for testing this possibility are currently available.

Key words: Codon usage; Bacterium; Translation; Gene expression; Sporulation; Photosynthesis; Solventogenesis; Fimbria

#### 1. Introduction

CON.

Ning.

dam,

razi),

pt of

mai

522

In 1989, Brinkman et al. noted that eukaryotic proteins such as the human tissue type plasminogen activator, prourokinase, and the gp41 protein of HIV, which have a high content of rare codons in their respective genes, are poorly expressed in E coli [1]. Moreover, induction of the expression of any one of these beterologous, plasmid-encoded genes was found to inhibit cell division and cause plasmid instability. Most remarkably, when the bacteria were simultaneously provided with a plasmid bearing the dra Y gene, encoding a rare tRNA (tRNA\*\*GAAGO), production of the enkaryotic proteins was increased while plasmid stability and cell viability improved [1].

While these observations were of considerable practical significance to the bioengineer, they foreshadowed observations and experiments that would suggest that the use of rare codons for specialized or differentiation-specific functions in bacteria might provide a general mechanism to ensure proper temporal and spatial expression of the encoding genes. Although this hypothesis is still far from established, work in several laboratories has provided indirect evidence suggesting that rare codon usage is of functional significance in restricting or specifying appropriate gene expression. In this minireview I summarize the evidence concerned with this issue and reiterate the suggestion that the complement of tRNAs found in a particular bacterium under one set of growth conditions may differ from that found under another set of growth conditions.

\*Corresponding author. Fax: (1) (619) 534-7108. E-mail: msaier@ucsd.edu

### 2. Codon usage and gene expression

All living organisms possess characteristic GC contents and preferred sets of codons used for protein biosynthesis. GC content is a major determinant of codon usage, and codon adaptation indices (CAI values) have proven to provide a reliable, empirically determined estimate of gene expression level for specific groups of organisms [2-4]. IRNA availability during the evolution of an organism may play a significant role in determining its characteristic preferred codon usage. However, genes obtained by horizontal transmission from a phylogenetically divergent organism with GC content and codon usage different from those of the recipient bacterium approach the values characteristic of their newly acquired host only after hundreds of millions of years [5]. This fact suggests, first, that differences in codon usage must have arisen relatively early during prokaryotic evolution, and, second, that the pressure for a newly acquired gene to assume the codon usage of the host organism is minimal. The fact that certain genes exhibiting a relatively high level of specific rare codons can nevertheless be expressed at high levels when cloned behind a strong promoter (see, for example, [6]) has led some investigators to suggest that the use of rare codons does not in fact serve a regulatory function [4]. It should be pointed out in this regard that the inability to demonstrate a regulatory effect with one set of genes expressed under a given set of experimental conditions does not rule out the possibility of an analogous regulatory function for another set of genes expressed preferentially under a different set of conditions. Below I summarize evidence suggesting that various specialized functions, expressed in a variety of bacteria, may be regulated at the translational level by selective use of rare codons in relevant structural genes (see Table 1).

### 3. Rare codon usage in phototrophic vs. heterotrophic genes in Rhodobacter

In 1991, Wu and Saier noted that genes encoding proteins of the photosynthetic apparatuses (reaction center and light harvesting proteins) of the Gram-negative purple bacteria, Rhodobacter capsulatur and R. spherotdes, differed in codon usage from that of genes encoding enzymes of the fructose utilization pathway [7]. While most codons occurred with similar frequencies in these two groups of genes, a few were found to predominate, or be present exclusively in one or the other group (see Table 2 for representative examples). Moreover, other genes, such as those involved in nitrogen utilization or carotenoid biosynthesis, that were expressed under both

**电影性,电影性的影响,也是是一个** 

Section 1

Table 2

Table 1
Selective use of rare codons postulated to control specialized functions in bacteria

Function	Organism	Codon	Amino Acid
Photosynthesis	Rhodobacter capsulatus	GCU	Ala Leu
Fructose utilization	Rhodobacter capsulatus	AAU UGU	Asn Cys
Solventogenesis	Clostridium acetobutylicum	ACG	Thr
Arial mycelium development	Streptomyces coelicolor	UUA	Leu
Fimbrial production	Escherichia coli	UUG	Leu

heterotrophic and phototrophic conditions, exhibited rare codon usage frequencies that were intermediate between those found in the photosynthetic and fructose-catabolic genes (Table 2). These differences were shown to be statistically significant. It was suggested that different tRNA pools were present under phototrophic vs. heterotrophic growth conditions, and that growth conditions might influence the relative rates of transcription of the tRNA genes and their cognate amino acyl tRNA synthetases. Differences in codon usage might generally allow operation of novel post-transcriptional regulatory mechanisms. It seemed reasonable to suppose that charged tRNA availability and codon usage could provide a safeguard against expression of specialized genes under inappropriate conditions [7].

### Rare codon usage as a potential regulator of solventogenesis in Clostridium

Sauer and Dürre noted in 1992 that a mutational defect preceding the gene thrA encoding a rare tRNA, tRNA in the low GC Gram-positive bacterium, Ciostridium acetobutylicum, gave rise to the absence of solventogenesis [8]. This strict anaerobe is a spore-forming bacterium that produces acetone and butanol only during a late stage in the growth cycle. The shift to solventogenesis is accompanied by a series of morphological and physiological changes in motility, shape, and granulose content, culminating in endospore formation. Sauer and Dürre noted that the ACG codon is rarely used and is largely restricted to genes either expressed at the end of exponential growth or involved in the inducible uptake or metabolism of minor carbon and nitrogen sources [8]. Because these investigators did not conduct statistical analyses, it was not possible to state that the observed differences in codon usage reflected a

unique characteristic of specific groups of genes encoding specialized functions rather than depressed levels of expressivity, [4]. Nevertheless, the potential implications of the observations were clear. As in the case of phototrophic vs. heterotrophic gene expression in *Rhodobacter*, codon usage in *Clostridium* may provide a safeguard to insure proper expression of certain stationary phase vs. log phase genes.

### Codon usage as a determinant of the differentiated state in Streptomyces

Species of the high GC Gram-positive genus Streptomycer undergo fungal-like differentiation with the sequential formation of vegetative and aerial mycelia [9,10]. The fact that only the latter structures contain spores reflects the spatial and temporal constraints imposed upon the process of terminal differentiation within this genus. The industrial importance of these organisms is related to their capacity to produce an array of antibiotics and useful secondary metabolites during the post-exponential growth phase. Although these strict aerobes have many of the enzymatic attributes of their low GC Gram-positive cousins, their regulatory mechanisms appear to be remarkably different [11–13].

Leskiw et al. [14] and Fernández-Moreno et al. [15] first observed that, in Streptomyces coelicolor, a genetic defect in the gene bldA, encoding a rare tRNA, tRNA<sub>UUA</sub> [16,17], blocked aerial mycelium formation and prevented efficient phenotypic expression of several genes containing the rare UUA codon. bldA mutations (including deletions) did not interfere with vegetative growth but did prevent aerial mycelium formation and antibiotic production (see [18] for a review). It was suggested that this rare codon occurred preferentially in genes concerned with differentiation and antibiotic production as contrasted with those required for vegetative growth.

More recently, evidence was presented suggesting that mature tRNA accumulates in ever increasing amounts as S. coelicolor cultures age, and that the temporally regulated accumulation of this mature tRNA species correlates with an increase in efficiency of UUA-containing messenger RNA transcription and/or translation ([19]; but see also [20]). It seemed to exert regulatory effects on events occurring during late growth, including morphological differentiation and antibiotic production.

### Rare codon usage and the control of funbrial production in E. coli

A recently noted example of potential rare codon control of

Examples of differential codon usage in photosynthetic versus heterotrophic genes in Rhodobacter

	Codon	Amino acid	Fractional codon usage for each amino acid					
			fru	pho	nif	Total		
Elevated codon usage in pho genes  Elevated codon usage in fru genes	GCU CUC AAU UGU	Ala Leu Asn Cys	0.02 0.11 0.44 0.25	0.11 0.35 0.05 0.00	0.03 0.16 0.18 0.13	0.05 0.19 0.18 0.12		

Data were taken from [7]. Numerical values provide the fractional codon usage for each of the four amino acids (Ala, Asn, Cys, and Leu) in the four catagories indicated with abbreviations as follows: fru, fructose utilization (heterotrophic) genes, total of 1724 codons analyzed for R. capsulatus; nif, nitrogen utilization genes (mostly concerned with nitrogen fixation), total of 3824 codons analyzed for R. capsulatus; Total, all available sequenced genes for Rhodobacter species at the time of analysis [7].

avg

tions

aphi<sup>®</sup>

राक्षांत्री

"yœ

rma

only

tem

liffer

these

ay of

post-

have

008i

nark

i first

in the

cked

typic

aobc

1 VCg

n and

ested-

crned

asted

t ma-

1CS 25

dated

th an

tran-

amed

; inte

biotic

व्ये क

trol of

.. 12

糖肾

;

M.H. Saier, Jr. 1 FEBS Letters 362 (1995) 1-

specialized gene expression concerns the production of type 1 fimbriae in the Gram-negative enteric bacterium, Escherichia coll strain F18, which is able to colonize the mouse colon [21]. Burghoff et al. [22] isolated a 6.5 kb E coli sequence that enhanced the colonizing ability of strain F18 and simultaneously stimulated synthesis of type I fimbriae. The gene responsible for this stimulation proved to be the leuX gene, encoding a tRNA specific for the sare leucine codon UUG. This gene is in single copy at 97 min on the E coli chromosome, and the encoded tRNA species (LeuX) is apparently dispensable for growth [23]. No effect on growth rate was observed when leuX was mutated [24]. Another iRNA LeuZ, specific for the UUA leucine codon, presumably recognizes UUG by 'wobble'. and can thereby substitute adequately for LeuX, at least with respect to the expression of genes encoding functions required for vegetative growth.

The mechanism by which leuX gene expression influences type 1 fimbrial production is probably complex. The fim A gene, encoding the principal type 1 fimbrilin, lacks UUG codons altogether [25]. However, synthesis of type 1 fimbriae is subject to phase variation due to inversion of a 314 bp DNA segment that includes the find promoter ([26]; but see also [27]). The ratio of the products of two fim genes, fimB and fimE, determine the frequencies of inversion in the two opposing directions with high levels of FimB favoring the 'off' to 'on' transition. Since fimB has six UUG codons while fimE has only two [28], it has been proposed that LeuX influences type 1 fimbrial production by controlling fimB expression more stringently than that of fimE [29]. In this regard it is interesting to note that leuX expression is apparently regulated by two proteins (of 22 and 26 kDa) encoded by genes adjacent to leuX. Deletion analyses have suggested that the 22 kDa protein is a transcriptional activator while the 26 kDa protein is a repressor of leuX expression. These proteins may therefore be indirect regulators of type I fimbrial phase variation, and consequently of net fimbrial production.

Various E. coli strains are collectively capable of producing at least six distinct virulence-related fimbrize, each exhibiting specificity for and mediating adhesion to a specific mammalian cell surface macromolecule [30,31]. Expression of these fimbriae is often subject to phase variation in agreement with the belief that successful colonization of the host depends on the timely expression and subsequent silencing of specific virulence-related genes, depending on the stage of infection. A recent analysis has revealed that the leuX gene of uropathogenic E. coli strain 536 encompasses one of several sites responsible for genetic instability [32]. Internal to leuX is one of two 18nucleotide direct repeats that serve as functional sites for excision of a 190 kb DNA segment. This segment encodes, among other functions, P-related fimbrine. Excision of this DNA segment silences expression of leuX (possibly controlling type 1 fimbrial synthesis, as noted above) as well as expression of the genetic apparatus encoding P-related fimbriae. As bacterial cells lacking 'excess DNA baggage' and incapable of making fimbriae divide with increased growth rates, it may be that timely excision provides the bacterium that has already established itself in the host organism with pathogenic advantage [32]. Based on the proposed regulatory role of rare tRNAs in controlling fimbrial production, we suggest that it was not accidental that tRNA loci have come to serve as sites of virulence-associated DNA insertion/deletion phenomena.

### 7. Conclusions and perspectives

How important are the postulated regulatory mechanisms giving rise to codon-controlled phenotypic gene expression? Are they generally operative for the control of starvation-induced or stress-related vs. vegetative gene expression in E. coli and other bacteria [33]? Do they function to safeguard proper temporal expression of sporulation (spo)-specific genes at any one stage or during several different stages in the well-defined programs of differentiation of various Bacillus species [34]? Do they play a role in the control of growth phase-specific or condition-selective gene expression, e.g. expression of genes concerned with bioluminescence in Vibrio species [35,36], bacteriorhodopsin-mediated photosynthesis in archaebacteria [37], or induction of virulence-specific genes in bacterial pathogens of plants, animals and other bacteria [38-41]?

The first step towards answering these important questions would seem to be to analyze functionally related groups of bacterial genes for statistically significant differences in codon usage, as reported by Wu and Saier [7] for the photosynthetic vs. heterotrophic genes of Rhodobacter. A second step would be to measure variations in the cellular concentrations of specific rare tRNA species made under relevant but differing physiological conditions. The third step would be to establish a causal relationship between rare codon occurance, tRNA level and gene expressivity. Such studies may lead to recognition of novel codon usage-mediated mechanisms for ensuring the proper expression of temporally and spatially regulated genes in prokaryotic microorganisms. The relevance of such mechanisms to cukaryotic organisms, including protozoa, fungi, plants and animals, could then be ascertained by the application of straight-forward comparative approaches.

Acknowledgements: I thank Lisa Preble for expert assistance in the preparation of this manuscript. Work in the author's laboratory was supported by Public Health Service Grants 5RO1AI21702 and 2RO1A114176,

### References

- [1] Brinkman, U., Mattes, R.E. and Burke, P. (1989) Gene 85, 109-
- Holm., L. (1986) Nucleic Acids Res. 14, 3075-3087.
- Sharp, P.M. and Li, W.H. (1987) Nucleic Acids Res. 15, 1281-1295.
- [4] Andersson, S.V.E. and Kurland, C.G. (1990) Microbiol. Rev. 54,
- [5] Groisman, E.A., Sturmoski, M.A., Solomon, F.R., Lin, R. and Ochman, H. (1993) Proc. Natl. Acad. Sci. USA 90, 1033-1037.
- [6] Robinson, M., Lilley, R., Little, S., Emtage, J.S., Yarranton, G., Stephens, P., Millican, A., Easton, M. and Humphreys, G. (1994) Nucleic Acids Res. 12, 6663-6667.
- [7] Wu, L.-F. and Saier Jr., M.H. (1991) Res. Microbiol. 142, 943-949.
- [8] Sauer, U. and Dürre, P. (1992) FEMS Microbiol. Lett. 100, 147-154.
- [9] Chater, K.F. (1989) in: Genetics and Molecular Biology of Industrial Microorganisms (Hershberger, C.L., Queener, S.W. and Hegeman, G. eds.) pp. 99-107, American Society for Microbiology, Washington, DC.
- [10] Chater, K.F. (1993) Annu. Rev. Microbiol. 47, 668-713.
- [11] Kwakman, J.H.J.M. and Postma, P.W. (1994) J. Bacteriol. 176,
- [12] Titgemeyer, F., Walkenhorst, J., Cui, X., Reizer, J. and Saier Jr., M.H. (1994) Res. Microbiol. 145, 89-92.

in the ulatus: ation),

**集成**!

T

A!

tk

ĊП

of

ďλ 회 in O in fo I 87 čλ K 0

1.

in şţ а

S

tr dı T es se te Ь C ic ٧: al

tŀ Sİ

E

()I 5

12 JE11 NO

- [13] Titgemeyer, F., Walkenborst, J., Reizer, J., Stuiver, M.H., Cui, X.
- and Saier Jr., M.H. (1995) Microbiology 141, 51-58. [34] Leskiw, B.K., Lawlor, E.J., Fernandez-Abalos, J.M. and Chater, K.F. (1991) Proc. Natl. Acad. Sci. USA 88, 2461-2465.
- [15] Pernández-Moreno, M.A., Caballero, J.L., Hopwood, D.A. and Malpartida, F. (1991) Cell 66, 769-780.
- [16] Ribb, M.J., Findlay, P.R., and Johnson, M.W. (1984) Gene 30, 157-166.
- [17] Wright, F. and Bibb, M.J. (1992) Gene 113, 55-65.
- [18] Leskiw., B.K., Bibb, M.J. and Chater, K.F. (1991) Mol. Microbiol. 5, 2861-2867.
- [19] Leskiw, B.K., Mah, R., Lawlor, E.J. and Chater, K.F. (1993) J. Bacteriol. 175, 1995-2005.
- [20] Gramajo, H.C., Takano, E. and Bibb, M.J. (1993) Mol. Microbiol. 7, 837–845.
- [21] Cohen, P.S., Rossoll, R., Cabelli, V.J., Yang, S.L. and Laux, D.C. (1983) Infect Immun. 40, 62-69.
- [22] Burghoff, R.L., Pallesen, L., Krogfelt, K.A., Newman, J.V., Richardson, M., Bliss, J.L., Laux, D.C. and Cohen, P.C. (1993) Infect. Immun. 61, 1293-1300.
- [23] Yoshimura, M., Inokuchi, H. and Ozeki, H. (1984) J. Mol. Biol. 177, 627-644,
- [24] Komine, Y., Adachi, T., Inokuchi, H. and. Ozeki, H. (1990) J. Mol. Biol. 212, 579-598.
- [25] Klemm, P. (1984) Eur. J. Biochem. 143, 395-399.

- [26] Abraham, J.M., Freitag, C.S., Clements, J.R. and Eisenstein, B.J. (1989) Proc. Natl. Acad. Sci. USA 82, 5724-5727.
- [27] McClain, M., Blomfield, I.C., Eberhardt, K.J. and Eisenstein, B.J. (1993) J. Bacteriol. 175, 4335-4344.
- [28] Klemm, P. (1986) EMBO J. 5, 1389-1393. [29] Nowman, J.V., Burghoff, R.L., Pallesen, L., Krogfelt, K.A., Kris.
- tensen, C.S., Laux, D.C. and Cohen, P.S. (1994) FEMS Microbiol Lett. 122, 281-287.
- [30] Van Rosmalen, M. and Saier Jr., M.H. (1993) Res. Microbiol. 144 507-527.
- [31] Klemm, P. (1994) Fimbrian Adhesion, Genetics, Biogenesis, and Vaccines, CRC Press, Boca Raton, FL.
- [32] Blum, G., Ott, M., Lischewski, A., Ritter, A., Imrich, H., Tschape, H. and Hacker, J. (1994) Infect. Immun. 62, 606-614.
- [33] Matin, A. (1990) FEMS Microbiol. Eccl. 74, 185-196.
- [34] Losick, R. and Stragier, P. (1992) Nature 355, 601-604.
- [35] O'kane, D.J. and Prasher, D.C. (1992) Mol. Microbiol. 6, 443.
- [36] Meighen, B.A. (1993) FASEB J. 7, 1016-1022.
- [37] Kuan, G. and Saier Jr., M.H. (1994) Res. Microbiol. 145, 273-285. [38] Thomashow, M.F. and Cotter, T.W. (1992) J. Bacteriol. 174, 5767-5771.
- [39] Gross, R. (1993) FEMS Microbiol. Rev. 104, 301-326.
- [40] Briggs, S.P. and Johnl, G.S. (1994) Trends Genet. 10, 12-16.
- [41] Saier Jc., M.H. (1994) FEBS Lett. 337, 14-17.

**EXHIBIT D** 

Meleic Acids Research

AE2: 60 SO-BUA-6S

\*Department of Chemistry, Max-Planck-Institut für experimentelle Medizie, Hermann-Retin-Strasse 3, D-3400 Göttingen, FRO \*Department of Biochemistry, University of Bayreuth, P.O. Box 3008, D-8580 Bayreuth, and

# INTRODUCTION

In the compilation of tRNA genes the sequences have been aligned and displayed tides following nuclectide residus 73 and the intervening sequences (see Footnotes) have been excluded from the compilation. The compilation is deposited with the Nucleotide Sequence Data Library of EMBL, Heidelberg, and available compilation). The nucleotides preceding nucleotide residue 1 and the nucleoas has been done in the case of the tHMA sequences (Pig. 1 in accompanying there on magnetic tape upon request. The compilers would welcome any information regarding missing material or erroneous presentation. Acknowledgements: We thank Hedwig Gaißler, Thomas Bartmann, Werner Beubepk and Rudolf Jung for skillfull cooperation and the Fonds der Chemischen Industrie for financial support.

-4
7
- 2
Ē
ì
- 5
ž
~
α
-
٠.5
Ž
-
٩,
,
٠.
đ
-
C
-

	٠,	018	T	102	:018 (19	1CK 03	17¥	##* 6 * 4 8 Z	7¥ 316	. IN	PH	986 9.6	'я 11	2 121 D 28H	19 ·	'3') 3 '7	1383	א" נספי א" נספי	'41	22-5 CEN	٦	250	6				•		-23	N 50	J.J.	ברי	ON CO	EBATI	10134.J3(1) 8438J34	0.3.6	*am	1713 1	7891-109 30000007	T 0100
			:	l		_			1				-1	1	٠.	• • •	7								r	• •	٠.,		ı	ja sé	R E I	EMBX	<b>2</b>	# <b>#</b> #			o			
	9	-		J.	8 3	9	1	1	٦!	_		. J.	٦.	43	. 9		91	1	1	9 !	9	1	1	9	۴.	₹.	<u>, '∃</u>	9	Ħ	녆	1	는 인 보보보	ים ו שעש	פפ				NI TO LOBACI		9500
2	R	g 1	- 4	7	כש	9	1	1	վչ	d 5	) T	1	5 <b>]</b> t	1:	9	Ħ	ᄖ				Ħ	1	1	ij :	ᅥ	ı,	ĹΞ	9	Ħ	Ţ,	ı	Ų 9	9	9 9				* TRS		S <b>S00</b>
1	1	8 3	9	I I	8 3	9	1	1	<b>a</b> [:	) 9	3 1	ב ו כ	d :	:	9	Ħ	4 5	3	1	9 9	9 I	. 1	1	<b>H</b> 1	ď	ь. В.	1 1	9	н	1	**#	i s	_ R	9 9				Taten orin	790	<b>▶B00</b>
ก												3	-	Ì.			9 6			9 !					ŀ		• • •	•		HH	×××	XXX	K	KHH			O	HOTHO		
•••			1		_				١-				-1	<b>}</b> •	• •	• • •	7		-	-		•	1	9 1	٩.	٠. ا	٠,٠	.:	0	빞		## ##						32 I U. 2014 D		· E900
9		3 9	-9	5 1	9 3	9	1	1 .	43	) :	9	1 .	3 5	1:	9	ų !	<b>9</b> t	1	Ţ	9 9	3	İ	1	9 (	냭.	₽.:		.9	Ħ	ЩË	1	0 9		2 6	ירופ*	) (1800)	HN.	RITO	חפכ	2900
1	5	3 1	법	1 1	כנ	9	1	Ι.	1 1	LE	9	Э (	9 6	13	H	# 1	4	,	Ļ	9 9	9	Ŧ	כ	u į	ᅦ.	1.	Ļ	9	Ħ	ᄺ		פֿכ	9 9	9	"TODIN	ı sn.	פורו		חפכ	1500
9	<b>u</b>	9 3	9	1 (	<b>5</b> 2	9	н	1.	1	3 9	ָרָ נ	1	9 6		9	Н !	1	í	ı	9 9	3	1	н	9 (	H.	ייי בר	 בי	۱,	н			9 9		19		1347	THE M	AEHEDE	. วดษ	0500
													-ł	ŀ٠	•••	1 !	].		-	-			•			•		• - [		KSH	ĦĦ	**	#1	##				OLIH		
									-				1	ţ.	• • •	•••	١.		T	9 9	j	Ţ	1	וש	٩.	÷.:	Ţ	.٩	Ø,	<b>¬</b> -	_	9 9 ***		9 9 E##	USSUN	3 12	10.71	OB DE N	חפכ	8200
9	9 1	9 2	.9	3 t	1 )	9	T	1 ]	43	9	1	3 :	1 و	1.?	9	₽!	9 6	ı	9	9 9	)	T	3	9 1	4 ∶	ָן בָּ	בָּו	9	Ħ.	T T	3			9 9	SITII	ene	SNT	HIJUB	חפכ	0100
9	<b>u</b> :	9	9	t t	3 3	9	L.	1 :	2	בו	Đ	1:	ء ا	1 2	9	ti į		ı	9	9 9	)	1	1	9 1		נ כ	בו	9	н.			*** 3 3		i e e	"IND	910:	חבטנ	MEHITS	290	S000
			i										ı	1								_			1			-		]	_			_						
			- (						ı				l	Į.			1								ļ										3	N I	M Đ	78		
									ļ.				Ļ.	Ļ_			ļ.								L			_		1.										
S 42		D)		E 26		æ						rz LZ	120			_za			_SC	٩L	٠. ٠	4	. 6			٤_				] .	_						•			
			1	-					ı					ı	•	**	ř		6	ı	8	E	}L	P	1	21	. 1	Pt	<b>5</b> 1	9 4	8	5 7	E 2							
NG.	15	`J[.	LNU	' 0	00	1,3	Ι·Ι	Md	H	ar.	5.:	ΙIJ		l	æ	<b>S</b> (	ı			400	П	•			}	Ю	.S. (	Ιl		l M	ш	W	HO	IK	l					

E'LUMULAM' W'EMBTAKW (1685) KAGI' WELDS MEG' IG' 5092-5010 W'GKOZETGAL' W'EMBTAKW (1685) KAGI' W' 181-168	0029	M'S'YOECHEL' C'U' LYSYBNA' M'BYBUK' H'KNEMIZEL (1881) CELT 32' B'r'ebybek't C'U' LYSYBNA' M'BYBUK' H'KNEMIZEL (1881) CELT 32'	6021
(1982) HIGH, C.LARANE, G.PEPE, G.DUAGLIANIZELO, G.SACCONE, E.SBISA		TETS-1556 OTHMERMARESHEE DITMERGK' BITHMET' KINIEREMERE (1856) CEEF 18'	
P.CANTATORE, C.DE BENEBEITO, B.GADALETA, R.GALLERANI, A.G.KRODN,	0022	CHEY* 520* 5053-503+	
ULKDEN, KLEDMARDS, HARDESEL (1919) CELL 25, 203-213 S.D.BONIEN, A.TISBOLDE (1919) J. 618L, EHER. 255, 9025-9061	9900 9023	E.F. MANAGOSER, D.N. HANSER (1951) D. BIOL. CHER. 252, 291-298 F.R. GREEK, B.F. DRINK, R.R. GOEKERI, R.A.COLLING (1961) J. BIOL.	9052
CHEM. 252, tofor-11003 E.A.CHOZCC, 13, K.E.BUSHLOW, J.K.CODO, R.B.HALLICK (1920) J. BIOL.		C.J.GRECH, W.S.WOLD (1983) MUCR. ACTOS RES. 11, 5763-5774	
L-GRAF, M.EDESSEL, E.SIUTZ (1940) MATURE 736, 908-910;	2000	**CENDANET, E.LUND, J.E.DANLENS (1782) NUCL. ACIDS NES. 10.	0100

<b>36代計算 公司計算者を対する</b> まままままままま	na hacenegasal	
433T3TR1T383	วิรอคอวรก์ออบอตุว	1914 3200
ATTOOTOGOATT	grantarqaparat	A B B 8200
■		
# 3 3 7 3 R A 1 7 R 2 7	3	R R T +200
822721611382	3	T D T A 6200
おおおお		
4,33131411383	<b>1199971997</b>	T 0 1 R 2800
<b>计算机 电影 化国际的</b>		
40312AATABIS	ว่า อดอ <b>ว r ค่</b> ออดว ทำ	TRT 1800
<b>阿拉斯斯 斯斯斯特斯斯斯</b> 巴亚亚巴亚巴亚		
dooroodaa.	มีค.	1994 0900
MARK WA KANMAARARA		911 \$200
433131712172	<u> </u>	511 2000
	20142017260282	T D B H OF CO
deline and the	Tantantananga	1 2 3 4 0000
422193333		2 2 2 5 5000 B000
42272234222	42000314333143	5 5 6 6 3300
i i		вгригие:
		• * • * • •
1 !		
	· <b></b>	
84 14 24 04 99 99 19 29	1 K W O 45 25 25 25 29 89 1	9 2 3 H Sty +1+
	S ES AS ES ES EN A N 7 C	H & Q & Zb Sb
MB12 JYDRONING MB12 4	nd 90x0.J≅ri H≣rr≳ 9ri M	an restrict the particular to
	•	

TANKIJAMA 21 TANKULAM ONGODO TANKELAM ONGODO CONTRACTOR SINI ANTA NININININI SENIKANATANI SENIKANI SENIKANI SENIKANI SENIKANATANI SENIKANI 
0055/76 OBITION 1 TO 49 UAS SEQUENCED BY T.ATYALA.R.KENNO.T.ZNSWINA 1942/MULLACIOS BES. 16, 1772-1780 1943/MULLACIOS BES. 16, 1777-1780

45
esea
cids R
eic.≱
끌

	0004\\0 WILEMERI IZ WEBILEW 004\\0 WILEMERI IZ WEBILEW	00500 ALIGNENT IS ABSITEARY 0096-0 ALIGNENT IS ABSITEARY
2 8 6 8 9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	188711188811 	1
H-HHHHHHHHH	3 T T T T T T T T T T T T T T T T T T T	T D D B O 0110 D D C C D D 110
0 1 1 3 3 1 0 1 0 1 1 3 3 1 0 1	A 3 3 7 7 3 7 3 7 7 3 7 8 9 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	COS9 TGA HRGININE
<b>计算机用程序的数据数据</b>	7 3 7 7 7 7 7 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9	คอค <b>3</b> 8000 ผูอ T <b>7</b> 800
A C C T C C C C C C C C C C C C C C C C		FILANTNE CONT. 0057 A T G T 0056 T G II
87 F7 F7 E9 78	3 69 29 09 95 95 95 55 05 3+ 0 u;	44 45 G C C C C C C C C C C C C C C C C C C
HELLS STEP		няя вятка

	·
C.J.GRCEN, S.S.VURLO (1923) NUCH. ACIDG RES. 71, SVSJ-6774 C.L. MANDLEEL, J.M. MANER (1923) J. 810L. CHER. 256, 291-295 BJ. MAZZARA. G.P. LUWINETT, W.H. MECLAIR (1921) PRUC. MAPL. ACRD. SCI. R.E. SRES. A.E. SLOEL, D. VDEGIEL, H. PELDIMAN (1921) ENBO JERRHAL [, 191-207] S.S. S.S. S.S. S.S. S.S. S.S. S.S. S.S	9779-5004 A.Y.L.DERRILTM, B.R.ROE (1923) MULC. RCIOS. REG. 11, 0126 1977-5004 A.L.LERRILTM, C.R.ROEC (1921) RULC. RCIOS. REG. 11, 0130 1981) ELL ZA, 147-130 1981) ELL ZA, 147-130 1981) ELL ZA, 147-130 1982) A.L.LERRILTM, B.R.ROEC (1921) RINE 230, 437-445 1983) A.R.LOERROW, D.P.RIERLICK, B.R.ROEC, F.RANGER, P.R.SCHREIER, C.R.ROEC (1921) RINE 230, 437-445
атттаратотто деттта дено и теве атттаратотто дено дета дета дета дета дета дета дета дета	1
7 A A D T T A D D T T A A T T T T A T D A A A F T T T A B T T T A B T T A B T T A B T T A B T T B A B A	1005   1007   1008   1008   1009   1009   1009   1009   1008   1009
HEITE, DITTUR HOTTE, LOUP HEITE, DITTUR, HEITE II 1000P HEITE, STEWN HOTTE, LOUP II 1000P HEITE, LOUP HEITE, LOUP HEITE,	TI ST ST OF S B T 8 2 A E S T

Research	
sic Acids	
Nuci	l

OGENO OGENO VASTISAR ET TERRESTA OGENO		
-	THREE TRUE AT THREE WITH	
<b>被持续服务的证券的</b>	YMANTISMA SI TRISHMELIN	0/24to
ENAMENTAL DE LA LA LA LA LA LA LA LA LA LA LA LA LA		
SPS TT SPT SPN SS SS SS SS SS SS SS SS SS SS SS SS SS	1111	ESS0
33 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	. 1111	5250
TOBERT MANAGEMENT OF THE PROPERTY OF THE PROPE	TBBT	
MANAGEREMENT TO LE DILL HE TO LEGGERANDE		1520
Management 1 2 G 1 D 3 1 m 2 hearness and	T 9 9 A	0920
하다 라이크 마다 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그	явт	LYZD
A	7 5 5 7	0E20
a a star za a ta a a ta a a a a a a a a a a a a		LLZD
	1000	_
<b>美質用學是其具質問題</b>	antarangen Tari	0150
MANAGEMENT TO TO THE TOTAL PROPERTY OF THE PRO	. 2 2 9 9 5 A	
A A D D A MAN SAME SERVES TO A T T T T D D T R 11		
aa faa ta ji	មភ្ម ខ	ELO
	- M	-
0,	_	gro
94 P4 24 04 98 98 P9 29 B9 85 BB	.fnos 3WINISMA	
HEITS JYTHONING HEITS THE SEA TO BE IN MAN X	M 3 G B 74 24 M 3 G B 74 24 M 3 G B 44 44	

,						
	L 17, 629-695	An Agori (1920) cer An Agustianian (1920) cer An Agustianianian (1920)	ACIDE RES. 16, 7331-3539  A. ANDURAN, 6.5HARF, H. WAND  A. A. CANIANOS, C. DE RERECETION  C. CLANANCE, ORDER RES. 10,  C. CANIANOS, C. LANANCE, ORDER  C. CANIANOS, C. LANANCE, ORDER  C. CANIANOS, ORDER  C.	mcr vc108 25' 3782-1552 251-558 5-2556 0521	DOWN, R. WARETME, C. SEMAZDECHTO, R. W. DAVIES 4794  4	DOZI E'E'NWINDOBEN BEZOL WIELEN HE
1 A D	3388TT	1	3 3 3 9 6 1 3 3 5 1 3 3 5 1 3 3 5 1 3 3 5 1 3 5	T 2	мени мужима тими 7 т д д д т д д т д д д д д д д д д д д	IM CLD SAMPLE 4110
183 189	3 a a T T b	7 3 8 5 7 6 7 5 7 7 7 5 8 6 7 7 7 7 9 9 7 7 7 9 9 9 9 9 9 9 9 9 9	1 9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	1 0 4 2 T 3 B A T 8 T 8 T 8 T 8 T 8 T 8 T 8 T 8 T 8 T	EUGLENG GRECILIS  1 C T T P  ARRESTABLILE NIDUE  C C T T T  ARRESTABLILE NIDUE  G C C T T T  ARRESTABLILE NIDUE  G C C T T T  ARRESTABLILE NIDUE  G C C T T T  ARRESTABLILE NIDUE  G C C T T T  ARRESTABLILE NIDUE  G C C T C C	1 0241 GUU T
TT # 3	, , , , , , , , , , , , , , , , , , ,	тватя айля павтя яят:		1 A A T T T D A T A T A T A T A T A T A T	RANNANANANANANANANANANANANANANANANANANA	ULES DISO
THE TIME	THITC, LOOP IS SE SE SE SE SE SE SE SE SE SE SE SE SE	F OE BY SE ST		St 01 8 8 7 8 2	PREININE CORF.	
	1900-	-577-918	·	Matte	W.ZKONINU	

		í
	Ī	Ī
	Ġ	i
	ı	ţ
	4	q
	1	L
	4	٤
١	ſ	١
	•	Ľ
•	Ī	L
•	'	
	١	
•	¢	1
٠	į	b
•	ì	d
•	7	;
		ř

¥9185*3	C.9ACC0185, 1		3 43434 () , 157E, у убработ 1		(1981) MINCL, ACIDS RES. 9,2239-2250;	ARMINETAL CHINDLE, T SEED AND THE SEED AND T
atran	88318	111288	Лезитт	явэтя	RARTER TATABAC	OFIN CUC NOLUSE *
99939	3 9 3 7 8	1 2 2 2 2 2	i din i i i	2122 13	A1010011221221	3300H 2T2 3680
					HRITTER TIBERRANGE	* ABLUMEN ALIMENTARIO DESTA 2000
					4311381211888 *********************************	# 1040 GM CT DESCENT TO SPEC CHECKEN COSES COSES COSES COSES COSES COSES COSES CO
			3838188	199 99	TETECTIFIED NA WHENNESSEE	0387 BLC SACCHRICHYCES PONBE
91199	R R D T 8	1172288	тазатт	яютя	АТТЭВАТВТОТОВ МИМИМЕНИ В ТОТОВОВОТОВОТОВОТОВОТОВОТОВОТОВОТОВОТО	* TON DUB 2020 OTTH
33788	TRDIB	111183	антынян	TOR TR	ATTIONATOTIONS	TERSY DUE AREO NTIN
				2188 18	ATTION 1888 888888	TERBY JUB EBED
99936	3 R 3 T 8	12233	331818	a 133 T 3	q Ta i a a 1 Ta 3 T 3 3 T	OSES GUC RAT
]				•	1   1	nos GISA SITRARASA
40 45	6 9E <b>F</b> E	S9 30 35	BZ 92 ZZ	8 DS OF ST ST	EL II	
l l					SI OF E 6 78 2 4 E S I	
MGTZ.3ITM	ובירסטג ו	TKG : MGT2,31	THAIL MESTE OF	ם רמסה	INSTEAL   DISTRICT	1

VII-511 1E 1 EM	
ALLEIBS, R.A.VAN ETTEN, C.T.LRIGHT, N.B.VALGERS, D.A.CLAYTON (1981)	9420
CTIZ-13TL .11 .835 BOLDA.LDUK TEEVIDSAMAG.L.YBHDDJ.3.L	9420
+511-1533	
D.G.CLARY, D.R.WILGTERHOLME (1943) MICL. ACTOS NES. 11,	PETO
	CAEC
E.HOLSCHUM, W. ZOTTORLEY, P. A. WHITFELD (1943) NUCL. ACTOS NES. 11, 6547-8554	4516
MUCE, ACIES RES, 10, 467-500	
(\$571) B.APPEL, J.SCHAM, S.SHARP, N.YARADA, D.ZGELL (1752)	45 E O
(1885) MACP, ARIDS RES. 10, R279-3289	
PIGGEROL' PICHMANAT DILETT PARAMETIMITETON PIGMENTICALE PROPERTY	

,	O.L.GIRLER, D.R.MADARIAN, J.A.FOLSE, M.C.MARITH (1781)	)CEO
	(1980) MATURE 287, 750-752 Lienkreh, E.M. De Romentis, P. Philippes (1963) EMBQ J. 2, 583-591	
		ESEO
	T.SERITA, Y.MURHAD, S.ATEHINMAA (1921) MIRCL, ACIDG RES. 9,2039-2050; R.SHIRMA, E.MURHAD, S.ATEHINMAA (1921) MIRCL, ACIDG RES. 90,0039-2050; A. C.	SEEO

P.CANTATORE, C.DE SENEDETID, G.BADALETA, B.BALLERANI, A.M.KRGGH,	0222
O'C'EIFFER' N'C'HARLIN (1981) CURB' 8EN' 4' 132-143	
TTCO-+CTP . AES . MEND. JRIE.L	
O.L.GIELER, D.R.KAJARIAN, J.A.FOLSE, W.C.AABINK (1781)	
SECONTIZ, ALIZABOLOFF (1989) J. BIOL. CHER, 253,9015-9011	FETO
196-588 ,S .L 98H3 (East)324911H1,1,231#3#AM 30.M,3,#3#%#2,L	
SEC-OUT, TEG SAUTAN (DRPT)	
O.SEMBIRT. 1-AMO, R. GSDEM, J. PECKRANS, H. SARANG. J. ABELEDA, D. ETELL	ESEO
8777-1754	

												_																																
		1		1	B	Ţ	ij	1	<b>=</b> .	1	ر <u>د</u>	ŀ	1 E	1 1	LI	<b>4</b> (	9	0	1	ט	9	ŭ	Ţ	ㅂ	1																1	Ħ	ㅂ	9550
•	(	2	9	9	9	3	1	9	3	<u> </u>	2	1	L	L E	5 9	9 :	٠.	1	1	១	9	Ð	9	]	כ																ㅂ	9	۵	SECO
•	1	Ţ	Ţ	Ţ	Ţ	Ţ	I	1	<u> </u>	b .	1 1				1	, ا	١.	L	Ħ	Ħ	Ħ	Ţ	1	ש	1			-	۰. ،	h-1 <b>(</b>	7.	•									1	Ħ	Н	8860
t		Ţ	1	Ţ	ï	1	ij.	1	<b>H</b> 1	법 .	1 ]				t	5 t		£	Ħ	ㅂ	Ħ	1	Ţ	Ħ	1																1	ט	U	SPEO
•		5	3	Ţ	9	<u>.</u>	i	1	9	2	2	-	9	t	9 5	9 :	. כ	1	4	9	9	Ø	3	9	T															כ	9	Ħ	H	6960
9	ď	9	Ħ	9	5	<u>פ</u>	1	0 9	9 :	2	5 5	ı	t	Ŀ	1 5	) :		1.	7	9	9	9	2	2	5																9	ㅂ	2	<b>/3E</b> 0
t	1	Ĩ	Ĵ	Ţ	Ц	1	Į.	1	H 1	L	1		Ø	t	t	1	ئيا	•	2	Ħ	9	ď	1	H	Ţ																1	9	Ħ	88E0
9	נ	T.	T	T FM	9	Ü.	4	Ļ	J 5	9 .	1 3	1	. 8	ŧ	t	1 :	9	3 .	1	9	H	)	ì	9	1															¥	9	Ð	Ħ	<b>⊬</b> 9€0
9	1 -	9	Ð	٦,	9	Э.	4	]	) :	3	3 3	1	. 1	t	t	1 3	) ;	ι.	4	9	9	9	9	3	1									٠							Ħ	9	Ħ	6360
<b>≠</b> 5	ㅂ	9	9	9	5	<b>5</b> (	1	) :	) ;	3 :	בי	1	1	Ħ	<u> </u>	) :	) ,	ι.	4	9	2	9	9	7	כ																Ħ	9	Ħ	2920
	l						l																	İ									. 41	ua:	, ,	ØI.	<b>3</b> 8 :	31.	TAC	dSt	1			
	L.						ļ.					L_													L.,	<b>.</b>																		
92 72 94 E4	12	LZ	) <u>Z</u>	23 6	9,	9	¥	<u>بر</u>	9 86	25	Į.	<b>þ</b> 9	69	75	29	99	**	9-5 1		2	:S		)S E		B≯	4	0	N	H	ำ	ĸ	r	Ι,	4	1	3	. :	ַכ		2 P	<b>*</b>	,	rþ	
	ю	15	v	<b>3</b> 8	ON	IN	•				3T					<b>.</b>							41	- !				•		•		•	W	j t	MT)	Κ∋	_		_		_	-		

ALTENNENT IN ARBITRARY ALTENNENT IN ARBITRARY		OT22/22 IS HEDOMAED LO HE C IN N'OBO22FOLL' N'EETDAMMA (1881) COMM' CFM''
Wienenski is weisenen 4° 121-128	9/5920	OSSENTS IS MEDICATED TO BE C IN DIGHTARRENSIE, R. RAME, H.P. GOLDH, D. SKUKBERBER, (17, 1927) NUCL. MELDE RES, 11, 1669-8624

_
-
•
-
- 35
•
Ū
- 2
Œ
-
Œ
-
-
-
·
~
~
. 2
w
-
v

. AMBITEARY 19 AMBITEARY 15 C DT 1	O45340 ALIONGENT II O45462 ALIGHENTH II O4540 ALIGHENT II 1.653- O4640 ALIGHENT II	COST/O ALTERNENT IS ARRITHANT OSTO-O ALTERNENT IS ARRITHANT OSTO-O ALTERNENT IS ARBITHANT
**********		V-
11365681368	rad arene de seri	T 33 8 8 9 10
TIDABAATIA	1114 841	e 95 # 96>0
717866777		1
大学等等的		
13333781008	<u> </u>	D 119 65+0
111200022001	тт ваннознано	8 8 9 8 PS PS PS PS PS PS PS PS PS PS PS PS PS
ги и и и и и и и и и и и и и и и и и и		i,
		1 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
ี่ กรออลลกาวกา	тэфэтэтввавате	1 998 2500
	TILLETICERTICE	
77		T tat reso
		CARINE
###### ##############################	. 3 3 7 8 8 8 8 8 9 8 9 8 9 8	1 5 68£0
a trainig ter	эд тяяятырэятя	1 188 ∠5€0
ľ	1	FEMERAL CALLS CONT.
l	1 1	
87 - 47 - 57 - 07 - 88 - 88 - 48 - 1		44 48 B E E P I K N D 45
54 E4 14 59 49 58 E9	ralez ⊼z zz cz re e⊁	d N T C H d O E ZFSF
KELS TVÖRKNING WELL	ן זר 2002 און זר עסטדיין אדי <u>ב</u>	MARI RRING

A.TAIRA,E.YOGNIDA.R.IGHARANL,Y.TAMIRUMA.W.LYDIXE(1962) NUCL.ACIDE REG. 11. 1623-1645, 12. ALGARINA, D.P. RAR, E.R.WILSON, R.R.ROE (1962) NUCL. ACIDG REG. 11, 4777-8024 X.MAR.BENHIN, M.GOTIOMLET.P.R.WIYFELEITHED) NUCL. ACIDG REG. 11, 5367-5324 M.M.L.DG SRUITHMIANIACH P.R.WIYFELEITHED) NUCL. ACIDG REG. 11, 5457-6525 M.J.BIRB, R.A.PANH HITEN O.GCLART, D.A.UGUSTENBORRE (1933) NUCL. ACIDG REG. 11, 5457-6572 G.C.LARTE, R.A.PANH HITEN C. T. WHITEN R. M. L. AMERICK (1933) CELL 24, 147-140	### ### ##############################
rorererra	ининияния отти
	TATE GET ANAMAN NAME OF TATA HER GET OF TATE OF TATA HER SECOND OF THE TATA HER SECOND OF T
Ratifications	RATION OF TATTOTED TREESTRY GLIMMORD ROD 3640
คอานทั้งควองวุดคลวงคนิดอาค	ат я я эта ат гэтээээ биялан ялинооод яда эзно
Troopedagederection	O423 CERSPINARY GECCERTS COLORD
	O-FEB GCT XENGRUS LREVIS * RABBERRER FR
	/ * * *
	L henengebudgeb OTIN
<u> </u>	(
าวลาวฎตุกควอาทุคอคาท4 ๆ > คคศุร าออ	
	CYSTEINE
RIT 2 FR R 2 T 2 T 4 T T R R 1 FT FT FT FT FT FT FT FT FT FT FT FT FT	COSS GLC BOVINE* GRGGTGTRAGARANS
	TIM HENDER WERNES TO TIME
ล ราย สุด ควาย วา ปราคล ที่สุว ราช ไ	ярэя финарация за в на така така така така така така така т
	HEPPHILE HELD cont.
18 SO B 52 S4 S6 S8 30 32 34 38 30 40 45	Zi Si Ei ii
	u si +
אמוביבואף איזוביבואף איזוביבואף איזוביבואף איזוביבוא	שונאסאכגר פנפא מ פנפא מ ר

0229\0 UFTENDENT 12 WHITEVEL 0229\12 1HE 2.END DA THE ERRE NEW NEW SELENVINED

ан эээт т ягт тээ т ө а ө э т т ө в я я я э

HETE JYCHONINE HETE TIT

Nucleic Acids Research

TANATIESA SI THEMBELA 0/7040 TANATIESA SI THEMBELA 0/0/700 TANATIESA ZI THEMBELA 0/7000

2 H T

883

994

19.6

THI

T T R 2

1183

9165

494

898

SKINATULD

CYSTEINE cont.

MAR RATX3

8550

**FS50** 

6660

2950

£550

0250

OLSD

LOSO

66+0

**4570** 

_
2
ä
B
10
10
Ą
نِ
유
ĭ
Z

49ZE-6	(1942) MUCT PETOR SER' 10' 257	474 424 25 1134 1516	OSSO M.MAKAJIMA, M.DZEKI, Y.SHIMBA (1)
GADALETA, R.GRILLERANT, A.R.ERBODA, GLAGLIARIELLO, C.SACCONE, E.ERICA	M.HOLTEDP, B.LANAVE, G.FEPE, C.	180r 126, 377-391	OBOT K.FUKADA, J.AMELEBM (1940) J. ROL.
	BESC-JISC 'S 'COM CATEM ASSES	IMPONENT I describe the second	1'0'ADNO (1693) 7'90' 100' 129'
131, A.WORREGA, A.IZADOLGFF (1926)	LLE-BERLANI, S.E. BOWITZ, B.COMU	ADVANCE & MENERAL DES UNE AND	CONTRA CLASS AND ET AL. (1981) HATURE 2 OAD STANDERSON, N.H.L.DEREBLAR, A.R.C.
1113616211111281	77 . 1	**************************************	DT EM .
	7_3 7,7.7.7 7	1 A D 1 A 1 D 1 D 0 1 T 1 T A T A T	DESC THE DROSCHIER YRKUBA *
a a a a a a a a a a a a a a a a a a a	เท่าวควาค เเออ	一   一   一   一   一   一   一   一   -   -	
TTOTTRABILITARBE	-	1 """" by 美国外最级代别对于	OSSA UUG SPOOMBROHYCES CEREV
		Sattataita and Atabant	4 TIME SULF ESSO
3 2 T T 3 A 3 T T A A A A .	. भ्रद्धार १ वर्षे । । । । । । । । । । । । । । । । । । ।	атярэрын талганат	DESS PUE YERST
атттятааттття	TRITION TOO	**************************************	OLTH
		DIE RIDEAU DISTE	מצבי עונה הצויפונינוב אונטער.
<u>ออาวา</u> า คอาวากคออ:	រង្សាំវិសីខិត្ត	38983337818883	oeso ene Erepri
0 B D ⊃ A T A B T T T T B B ⊃	11M 7 9 9 M M	HMMHMMMHMHH	
	eal Piiiie	28493262181888888888888888888888888888888888	1,400.5 6.LU 0+20
ครายสาวลอกระการใควอค	าปุญเวออฤษ รอย	1184611465841	F1 338844 9ND 1050
1			•
			BUIMBTUJÐ
	_		
a a b t t a a a b d t t a a b T	שכשכשנ	NA DANKERRENA	OTIN
		TYTALESTON TO TO TO THE PARTY OF THE PARTY O	# 34140 # 3404 603 6040
_ คอวาปุกกลวอาปุกคอา	<b>┧</b> ႙ 1	า า ๆ คอ	* NEMLH FOR TRACE
f: (			
	11 1		CYSTEINE cont.
	11	i i i	
29 30 35 34 38 38 36 40 45	97 67 77 6 A7 DI	71 81 44 14	
EP LY 65 ZE 3E 65 LE 62	α โฮ <b>ะ ๊อะ ๊เ</b> รีย ทัศเ ้า	R SI PI ZI OI E B C B S & E Z I	
		1 1 1	
HBT2.01THR. 900L.01THR   NST2.011		CHINDREYL STEN   18 STEN	
•			
		•	

A STATE OF THE PARTY OF THE PAR		
ALE-BERLARI, S.G.EGNNITZ, B.CORNIZI, A.NORREGO, A.IZAGGLGFF (1950)  WUCL, AC195 SCJ. G. SG17-5630  P.CARANIUE, C.UE BERGETIO, E.GADALETA, R.GALLERARI, A.RACRODA,  MACEMAP, C.LANANE, G.PEPE, E.GANGLERIELLD, C.SACGONE, E.ERIGA  (1942) MUCL. AC106 RES, 14, 1279-1289  D.G.CLARY, J.R. GGDDARD, B.C.JARITH, C.NR.FRURGN, G.R.VUCSIERRDLNE  D.G.CLARY, J.R. GGDDARD, B.C.JARITH, C.NR.FRURGN, G.R.VUCSIERRDLNE  (1942) MUCL. AC106 RES, 10, 5417-8637	Professional Control   Professional   Professiona	
. T. T. D. G. T. G. T. T. T. T. B. R. F. F. D. D. D. D. D. D. D. D. D. D. D. D. D.	TASTATEMENT A THE TATE A THROWN PAINT OF THE SERVICE OF THE SERVIC	r

44 46 H C E G S K H D 46 60 82 82 63 69 62 64 66 65 67 70 72 74 76 45 67 8 D H J C H J G 8 67 69 74 75

THE STEM | THE LOOP

TANKTIERA EL THENETA ONTREO

돗	
Ĕ	
8	
Ø	
2	
Œ	
20	
.9	
ច	
⋖	
O	
· 6	
==	
3	
Ē	
_	

01.8101. 148, 167-127 WSFEA MMA, D.SGELL, 111.	(1861) WHET YELDS BEST TO SHIIB WEBS 238-586 L'Y'NGHEW(1860) IN:LEGN E'S'S' NOTEN (1861) I'NG E'S'S' NOTEN (1861) I'NG E'S'S'S'S'S'S'S'S'S'S'S'S'S'S'S'S'S'S'S	CG99 S.ANDERSON, M.M.L.DERNOIM, B. I.G.YOUNG (1982) L. NOL. 810L G.A.O.YUNNAG, M.DHIL, H.ISHIKUM. G.A.O.YUNNAG, M.DHIL, H.ISHIKUM. G.A.O.S.O.YUNNAG, M.DHIL, H.ISHIKUM. G.A.O.YUNNAG, M.DHILL, H.ISHIKUM. G.A.O.YUNNAG, M.DHIL, H.IS	260' (22-492 10041' H'M'RWISEUR' D'9"CIFALIDN (1383) 26 812' 11' 4002-8014 10718 818' 23' 8402-414	7373-333 023
	r	n (****** )	*******	
9979974	2111333833	ี่สุด้ว่ด้อดุค ราออ วอ	#####################################	STITTELE SULLICE SUBTILITS
១១១១១១៦:	311133322:	Дири в в в с с с с в в в в	A T T T T T T T T T T T T T T T T T T T	ספסם החל פיכמרוז
			ם נום	SLUTAHIC
		-      · · · · ·   · · · · · · · · · · ·	Ин МИНИКИНИЯ	OTIM
7 7 3 7 7 8 8 4	<u> </u>	ศู <u>ล์วัต้ว</u> อโล อออ เ⊤ค	14 1 2 1 3 2 1 1 1 1 4 8 8 8 1	SHIADE DID 6690
88227984	arara[gaara	वेशीलें वेबिक राय्वे स		0558 기미한 HNRN
этэттва	етттпяя в я в	а́а⊃б⊃а этээятя	8 T 8 T 8 B B B B T R 8 8 F T	PITH PITO ZESO
1131188	2 T T T T R R R 2 G	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	TIBIBOURLE HARMANA L	011M 9500M 900 9660
	h		******	OTTH
1131166	B T T T T A A A A A	वैवैञ्चे जेद रब्ब रा	. 41919994149941	STORES ALLES NORWESTONS (ASSOCIATED CONCORD)
<b>DBDDDT8</b>	атттаааээя	នុក្សិខិខិពុក ខេត ខេ	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	HUDRERT FINGITION BULL COOL
20222199	9111199929	qoedqu qee te	Teese secondina in the second	033380 000 9550
		4 harria (l	*****	CHLORD
1977479	ətttqəəəəq		สุกวรณ์ถาสรอยกูลา	SITIBULE ENGNERS SON ASSO
				SLUTHTINE cont.
		<del></del>		
59 35 40 45 20 <u>26</u> 41 43		BS ES TS A ET A ET BS PS SS TS A ET A ET	St II OLG 9 4 9 S + E Z L	
אמדוב, אודוב אסנ	אונכ. צופא מאזנכ. במ		HER C NOTE JITHOUTH	

NA		
42 1 3 3 3 3 4 1 3 2 3 3 1 4 8 9 3 1 4 9 9 3 4 9		
HARRANA RESERVATE DE LA COMPANSION DE LA	FRI	0180
ย่าคออออศเวาว่ากุกคอว เทื่ออ้อคว	981	5090
	<del>-</del>	
0128210	A R T U J B	
********** *** ***********************		
MH 21 1 BH 1 B 1 3 B 1 4 B B 1 1 B B 1 B 1 B B 1 B 1 B B 1 B 1		
August Au	995	6650
ท่าวคลองที่ออวามุกคลควา บุลคอบมา	893	P890
	רפם	REST
Maranasa sa	998	<b>2550</b>
회유 그 그 그 한 한 대부 다 그 그 작가 다 다 그 그 학교 한 다 그 학교	9 8 8	***
	906	9630 ·
8412313114123114421188888888888888888888	2 3 4	<b>Z99</b> 0
あらココナ8コンドココキャル8コドイ88883フ	1181	6550
TO DE LO DE LE COMPTE C		6330
angananangangangangan ang ang ang ang an	T T A T	8950
aka	1183	1000
	1707	<b>2</b> 990
-3005	BATHRTUJÐ	
	•	
84. P4. E4. 04. 99 89 99 29 09 09 96 bd 76 nc nc nc nc nc nc nc nc nc nc nc nc nc		
	J H B> +>	
A STATE OF THE STA	∏ € 21- S1-	
EXTRES CHEM THE LOOP   THE STEM   INTINCACYL, STEM		

£
क
6
8
ë
Œ
72
ᆢ
9
٠.
.≌
₾

	B BTEM DRITARABA MI EANDERD ANTIARA EL TARRELLA CNATAD	THEOREM DESIRE THE LANGE OF THE WALLS C	
11 11 11 11 11 11 11 11 11 11 11 11 11	Processor and the processor of the proce		
NHWH HANK HERE	****** eq	<b>3 B T</b>	9690
	กลองการกลองกาลออกว่า	993	5680
######################################	188533118831188833	996	0290
S S S S S S S S S S S S S S S S S S S	3 3 3 3 3 1 T G B D T T B D B D D D T T T T T T T T T T	2 9 2	<b>₹250</b>
######################################	#=====================================	. agt	9980
######################################	ก็วววาสาคคอวากุคออล้ว	882	9990
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	18897776871768977	<b>9</b> 9 3	<b>1-9</b> 90
HAMMANAMAN TTTDBDT	# <u></u>	919	6530
9118888	กักคอวาการอวาทุขอวาคำ	887	2990
9 9 9 9 1 9 1	100777788777000777	994	1990
한 다 다 다 그 가 다 ) ###################################	4933331369311699677		
7-22310.	z z z z z z z z z z z z z z z z z z z	4 9 4	0690
		GLUTAMIE ACID COAt.	
94 14 24 04 99 99		1 1 9 3 3 H 9+ ++	
St ET 17 68 78	69 €9 €9 65 <b>€</b> 5 55 €9 €9 € N 1	ัก ผี⊿ี่ ⊑ี่ 8 ไ⁄⊳ี่ 5⊳ั้	
MINIMUNEAL STEM	सदार मा <u>फाट</u> मा सबार मा	HREI DRILKS	

### COMPANY CONTRACTOR OF THE CONTRACTOR (1942)  "FORT SHE TOWN (1952) CHR 1962   STR. CONTRACTOR (1941)  "FER 19, 1273—182  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—254  "FER 19, 2523—255  "F	CF WEIDS NEAT TO' 0446 NEET SO	tet1-ctes
15364 PYTHMUTELHEEROWIN' WYBYNWEFICK (1625) O' BIOF: CHER: 583° 75362-		0630 A.EIGEL, J.CLAN, H.FELDRAMM (1921) MUCL. ACIDS RES. 9 H.FELDRAMM,J.CLAN, H.FFLEDEMREICH(1981) MUCL.ACID9 RES
and the second s	, 2214 ATDC-114C (	e dae adiga mine creati unanti 122 k Máith 1 52317 a GEAS
TA318183TTTTTA3T683883	атта дэтгэд	MANAMANAMA
	) <b>ក</b> ចពុក"១ មែន	######################################
- คอดวิธีอดอนานาสุขยนวิที่สุขตัวสุด หวืออ	) រដ <b>ជ</b> ់រំបំរំងៀង។	OB70 UNC DROSOPHILA HELANO, TCCC PTOT
appadantridabiadrinada 1988	) ១៥៨១១៛១១.	T B T T B D D T BENDA 250MONDAD CORP C 6 6 T B T T B T T B T T B T T B T T B T T B T T B T T B T T B T T B
rantarantinaerganan	вттянаттар.	
весстар веясятст дости с в в в в сторев	. 8 8 K D T 8 D .	CHITCHE THE ENGLITE CCCCCCU
	198131981	OPEN COC ROLL LC C 14 C G G D
Selt smenchinacantitescheng		MENNSHEMMANN DITM
		RRHMANNEM OTIM
	រត្តប្រវត្ត១។	TRITO DE SUPERIORNO PROPERTO DE CERRENTE DE CENTRE DE CONTRA DE CO
คออว มาการรายออก หนึ่นออก รายอ		OSS1 CLC DROSOPHILA MELAND, T C C C"R T R I
аатарын таарын таар		
		GLUTHIC PCID cont.
19 Su B SS S4 S8 S0 GS 34 38 30 40 45		
D'I' GE E SE SE LE EE ZO EZ EZ EZ LE B'EL	A BI PI SI OF E E	. 424587
MOTE DE PARTIC. STEM PATTIC. LOGP PATTIC. LOGP	na karsa	HELES TACHEDITINE
		* ************************************

1	
6	ĺ
ò	į
α	
0	
3	
4	ļ
٤	
4	
Ç	
=	į

TRANTISMA SI THEMMELAN - Q-Q-16-0	TRANSIBAA BI TUBINDILA ONTRAO
4 1 0 2 1 6 0 1 1 1 C 6 0 2 1 1 C 6 0 2 1 0 2 1 2 1	a 1 a Se7u
4TRT3TRT383TTTR85TT3883TR	889 LSZD
T	8 9 1 0ZZ0
1 3 9 2 3 2 7 7 7 8 3 2 7 3 7 8 8 8 9 2 7 1 9 8 9 2 3 2 3 3 3	1999 +040
TO SO STITIES STATES OF ST	1538 6070
TS TE GE OF	1 9 T SU20
TOSOCIATIROTOTIVE STERNING TO SECUL	RDI FOCO
	GLYCINE .
<b>ครัคลอดดาปอรถว</b> วรรคอดราชออาการ	9 7 1 GS80
TRABBASSSSTIABSTTEBASS	⊅ B ⊃ 9690
я тяная адатарданатат тартодт	5 5 1 7050
	tres GIDR SIMMULE
1 K H B Met 24 22 29 29 19 19 19 19 19 10 H N 7 1 N 3 14 10 H N 7 1 N 3 14 10 H N 7 1 N 3 14 10 H N 7 1 N 3 14 10 H N 7 1 N 3 14 10 H N 7 1 N N N N N N N N N N N N N N N N N	9 3 3 5 5 5 b H = 0 8 2 5 5 b
	EXTRR DR

	CSSELLALDENEKER, R. B. GOV RIEKERENAN, R. BOLLINGER, W. BOWANI, E.J. AUSGOLA 179223
'S2-021 Pordecker, C.A.Lazamus, A.Basak, H.EGENIZEL (1981) CELL 23,	
THE TERY WICH SHELLING TO STATE OF WITH COMMITTEE COMMIT	ONGS ETTEMBERT BERANDET VEIDS BERT 11" 2573-2334
PORTES **11900000± (3300) " BIOF" CHEW" 522' 3012-3000 19' 7101-1100	
, N3H3DIELL (SAPE) DEISAN, T. ARURANN, N. 3H3NNT. T. ATDEOY. T. ANELATER.	OA99 6. ANDERSOM, R.H.L.DEGRUILIN, A.R.COGLSON, E.C.EPERDN, F.SANGER,
"HADDOOM" 1'HOEBEKTARO) GEME 13" 33-31 "UM'''TO'KUJEZEKITARO) GEME 13" 33-31	
LEACT, 152, J71-779	
	•
	•
ser elencipricerscincenale res	סיים אראים ובער אונאר, אונאר פון הוא הוא הוא הוא הוא הוא הוא הוא הוא הוא
	CT O CT T T T C T C T T T T T T T T T T
กุล อาการ เลา เลา เลา เลา เลา เลา เลา เลา เลา เลา	ı тадттай атааата таязү ээ∪ ≀гссо
Ratoborationactionering tode	סלצט עכל E.CDLI פכ ה הפרח היו היו היי מי מי מי מי מי מי מי מי מי מי מי מי מ
	**************************************
<u> </u>	OVD4 GCC E.COL1 GC G G G G R R R R G C T C R G T T A
ี ออรอสุคควาย เทียว ควา สุดวัตถายโด เอลิ	Tapatita arabaja elinine elebata en 17 el 17 el 17 el 17 el 17 el 17 el 17 el 17 el 17 el 17 el 17 el 17 el 17
вет принссися встисения та	אסר מרכן מאכן בעוני און איי איי איי איי איי איי איי איי איי אי
	****** MANNERSKENKER
- คอาวทุดควาทาสุดอดวท์สุวคาทุค เอล	тя истятару фтавоов +т32mm зои тото
	OF ACINE
	HERMANNEN OLTH
_ รุฐาน สุวาน การ เลือง กลุ่ง วิจ ล่า	คอาคคอาวิกท์อาวิวิวิริ * #BMIVOS 2LU eeso
BOCT REGRIFCESCETTICACESCE	TO SUCH THE PROPERTY IN THE PR
	OLIM
. <b>รุกว</b> รศูรถอกรากรอยา คุ่อาคคว	ятня фатта∤я тотта жинды эше √ево
	SEUTHALE REID conf.
	THE EL II
En 19 BE TE BE EE EE ES TE BE ES TE BE	A Br of St of Cel ( a a b & S r
מספ עם אלדוב. אלדוב. בזרפון האינוב. בנספי הויונב. בלופו	אנואטשבאר פורו א פורו מ

0389\0 0756MERI 18 988118981 0329\0 0756\0 0756MERI 18 988118981

Nucleic Acids Research

덨

CTARTON MOITERS THE REPEATING UNITS OFLETION MUTARITY OF A 60 NO NOT THE WORLD THE WOR

£
7
ã
9
ğ
α
u
3
C
4
۲
đ
Ö
Ž

577-452 TENTE 366' 423-492	N (1891) 1-A T3 HOBRAGH &- CPTC	ASTAL, E.SACCONE, E.SESSA.	A. HOLTROP, C.LAMAVE, G.PEPE, C.
	CEFF 30, 167-160		O757 P.CANTATORE, C.DE RENEDETTO, G.
CESTF GOTYALD.A.C , DARBERG, U.R.CLAYTOR (1781)		4 ANAMA 45000 PM (5077)	15362-15368
2) HUSELACIDE REE, 11, 4761-8775		(1444) ) IIU ERRE 323'	(ZEY1) MILIMH.G.M .WIBARAI.G.D 8240 MILIMH .W.K .HTRONZUNILIMM.L.M 1240
J.E.DAHLBERG (1943) MUCL. ACIDS	122 17' 4802-4921 2542 11' 4804-4921		10° 441-444
	HOLL, AETDS NES, 13, 2411-	ARA, T.SEXIYA (1982) NUCL. ACIDS RES.	
	PAC DEDECTORS OF AMPLETITUES		19522-6E22
\$10) WREF' WEIDE WEE' B' 1826-1419			UNINSTRUB (CHINDINA, Y AYENIBRI), 9,41581AU
181) CUMB. GEN. 4, 151-158	E-CHOSSKOPF, H.FELDRAM (1)		EE9-529
4121-4451	(1885) MICET VEIDS BEST 10	291' H'RRENLSEF (FAST) EEFF 53'	9751 H.G.KÜECHEL, C.A.LAZARUB, N.RAS
		」 * * * * * * *	OTIM
_ эветцев <b>ээ</b> ттарытта	דם ופומכן:	яяятатыры ттттэтэв	_ NEWTH 30T _ 2640
		<b>并实验的证明的证明的证明</b>	Olim
- трят үк вротуды в тр 🖊	नारता वर	7 8 9 7 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8	* 522UOM 223U 8870
		A C C C C C C C C C C C C C C C C C C C	9500M 200 9640
Tanjannotrijatia	n(Tripala a raa	10 q 1 q 1 d 0 d 0 d 1 d 0 d 1 d 0 d 1	DTIH TOLD SOFT
втязиварттравтти	ครายก		RALDERY RATEHFORDING DOLUMBER 8810
	9 *.9.\$.5]	MANAGARAN .	
a a a a a a a a a a a a a a a a a a a	बारमध्य र व्य	танэттавтраэтыза .	0198 GCC 20805090 P1144050900 P220
	7-7-7-7	AKKANAK MAMA	DTIM
Tanamprobattainatain	ผูวครย คว	n n q T n T 8 n T T 2 2 2 T 2 p	* ALDE JOR 2520
		PHENT NAME OF STREET	סארסאס סבב פחפרפאט פאכורנז 9520
- ความสดดวานาวไทยที่:	ฮ่วอัคลิค รออ ร	194212897818388	פאבנורנג פאבנורנג פאבנורנג פאבנורנג פאבנורנג פאבנורנג פאבנורנג פאבנורנג פאבנורנג פאבנורנג פאבנורנג פאבנורנג פא
	J	AND LOCAL COLUMN CASE	51713899 BRE1903 309 9540
อาาอยุคควายาทุววคคา	ដ្ឋាខ៌ពល)ក	T 2 4 2 T 3 2 2 2 1 2 1 2 2 2 3 2	21 (1706) OKS 10(8 TOB 3250
18538662717386	ATADAR D*TBB	1941413313339	188 JJN +540
1823800331132213	dranan akraa	MANAGEMENT AND AND AND AND AND AND AND AND AND AND	OLIH
gentipalont detti	итзяара тоо		TIDIN STITLENESSE SON CEZO
33014303301430114	4.3070 -03		
1 1	<b>1</b> 1	1 1	.jno> 3H(3Y,28
	i l	i I <u>I</u>	
	1 1		
34 04 by no he 30 on 02 b	<b></b>	94 EL LL	
27 01 195 86 16 26 06 92 13 27 28 30 32 32 45 62 22	2  92 22  8 02 91 21   S2 22 12 11 61 11 9		
EN 14 BE TE BE BE TE	be se be a m a s	F 74 21 VI 0 0 2 0 3 7 6 0 0	
HETZ. STEM POTICILIDE PRITZ. STEMP	אבעוביים אסטרום	HELLS O HELLS TACHONIAN	
	*		

	*******	. 1 _ 1 .	EREE.				
		Misecreze				3 A T	Z6Z0
	<u> </u>	Mexeccess = 1	888188		1	898	9620
	<b>化加州 化水油 医水油 计对应</b>	# ********	R 2 1 1 2 5 1			ват	9640
	PHANKARAKKER		a ta a t t i			298	9920
	AXXXXXX ***	# * * * * * * * * * * * * * * * * * * *	R 3 3 T T 3 3 2			993	\$920
	HAMPSHAMENKA T D G D G D A	E				внт	<b>2540</b>
	**************************************	11020318	я в эттета	3 D E T		1918	9940
	<b>新城市出来来城市的市场市</b>	(	คอวาที่ออลิ			3818	9520
	PARAHAHAHAHAHA Padalahahahaha Padalahahahahahahahahahahahahahahahahahah	85 2 2 3 1 1 T	a a b r T a b a	2 2 2 2		<b># 9 1</b>	<b>&gt;</b> \$20
			ตอวาทุคอว	1 7 2 7		ត <b>។</b> A	ESZ0
		.	ŀ		. Jud	פרגכואב פ	
		<b>_</b>					
92 \$2 52 (	24 04 89 89 34 14 69 49	22 E3 E3 E3 23 E3 E3	15 95 #5 25 25 55 E5 E5	DS BF 0	E G I K H	]	
	MBTE JYDRONING	1 1	400J FT HBT2		HAR GATX3	<b>4</b> 4 27 37	
					7725 00272		
Children reconstant	international			The second of the second of			
a transfer of	والمراجعة والمراجعة والمراجعة	NAS - CALLES - CALLES	سندغاؤت فستوسطيني	ACCUPATION OF THE PARTY OF THE			
					TURNOS	************************	JPW1 700 : 0
			CEFF 39' 19			иЕ, С.ОЕ ВЕНЕDЕТТО, Б.Ф. , С.LAMAVE, Ф.РЕРЕ, С.О	OTATMA3.1 SZCO
	NUCE, ACIDE REE, 11, MIGNT, N.W. WALBERG	H (2871)BNJOAAK.G.L	J.C.LOGNEY,	145	(7195) 1" 810F" CHEN" 3	MESUCATH, N.R. WALLICK	121200.L.A 1270 121200.L.A 1270
EGI39 '1:	IUN (E693) QR34_HAQ,	, כמדכ, פינשאם, אוב,					-1>+> 'Q1
(£\$	) 1. A. BOLGTENNOLNE (1.	nee" II' Soll-Stei 1'V' Awnellinnen' o					3536-3520
Q167-66%1 "1	) אתכרי עכומת מבר: ) אתכרי עכומת מבר:	(O\$91) MDEGIVAC.h ,	OSE2 N.D.HERSHEY			ARUNINSTR. 9, HISHINGAY.Y	EE9-529
	4455-95	* VCIDS MES* 10' 23	1385) HOCE	17 531	I, H.YUEHTZEL (1981) 5E	EL, C.A.LAZARUB, W.BASA	₩ <b>)30%,8.</b> 8. H <b>1</b> 279
	1 T 2 A A T T	gabera	атя	8818191	RTTTTTD# ********************************	HINGN =	320 Z620
-1 -1 -1 -1				· · · · · ·	ATTDDDTDB ***************	* 32UDH * 31IH	
		3			SEBTTGGTG SESSESSESSESSESSESSESSESSESSESSESSESSES	3500M	
	113313	- <del></del>		h	化医洗涤 城區 林枫田町	HILO DECEMBER AND PROPER	
	1138811	-401 ******	_	-	MANAGEMENT AND MANAGE	DROSOPHJLA NELAVO. ************************************	
	9 1 2 2 2 1			F	HHHH WARKHAM	DITH	
	113 4 5 1 3				RTT333T3R	1911 *	
	) T T 2 2 T 8 8	[ * * * * * * * * * * * * * * * * * *			**************************************	פתפרפאט פאטבורנז כארנטאט	
<u>១១</u> ៥៥៦:	3 8 T T 3 3 A A	크림그들마이다	_	- 1 [	STREET BUT DE LE	SITIONUS UNGTONS	
) 9 R R D :	11133813	<b>a q + : a</b> : ∃ : a a	o <sup>x</sup> T a a	o q T A T 5	######################################	OLIM	
	1	-1411		وأبديها بالمارية		CONTRACTOR CONTRACTOR	TON CC/0

YMANTILME SI THERMETA 0/4974

_
2
ğ
æ
용
Ş
Š
응
~

	F`		*		XXX	*6"				7					•		48		-1			
	4	9	9	D T	. g .	45	9	Ţ	2 3	1	1	<b>U</b> 1	3	T	4	9 9	3 t	<u> </u>	킈=	t 9	) <u>(5</u> 1	<b>9</b> 0
	<b>J</b>	1 8	<u>ב</u>	5 1	Ē.	ΨĒ	9	뷥.	Ι:	1	1	8 1	1 3	1	1	D I	, 1	٠	ᆡ	ВT	B 554	<b>9</b> 0
	1	-	#	31 11		<b>*</b>				4					F		k ka					
כ	٦,	) 9 	ኃ.	L 1	9 :	34	9	] 	: כ	1	1	Ø I	כו	1	4	9	9	2	기열	TA	3 HS	80
1	7	9 8	J .	1	b:	1	9	: כ	<b>.</b>	2	L	<b>v</b> 9	3	1	4	9 9	9	7	e le	· 11A	<b>3</b> , 294	<b>0</b> 0
					442	-		•	25	1					-	=		,	~			
	٩.	9	<b>9</b> .	ש	9 (	9	9	۵.	1 3	1	1	U 9	כו	T	4 :	9 9	) T	3	ᆰ	8 8	U 259	80
	-[:		221			:[:				1.				_	. 1				=  .			
•		, D				115	i A	. כ	1 3	4	Ţ	8	בי	1	43	D t	פו	1	3 r	4 8	H FE	10
	of 5	Н	īı	īī	H	il i	ר	7	1 1	]	8	<b>u</b> t	. 7	1	ď	# E	ם		ב ש	8 8		~~
	48	HHH	Ŧ.	**	ENH	7		-			•	•		•	٠,				م ا	0.81	J 694	N L
	3 3	9	נ כ	H	8	1 2	H	<b>5</b> :	3	1	1 (	8	3	1	η,	9 6	9	1	a s	110	3 608	DΑ
	- 1					1				1			-		٦.		_	_	7 -		2 (00	90
	1					l									l					BNIGILSIH		
	- 1																					
	1					1																
	- *	×׫	H#+		CH 9-3										Į.			<b>.</b>				
	f I	H H	H E	H H	urss U t		Ħ .	9 :	) ]		Ι (	9 6		٥.	٤ (	9	;	1 .		9 ម	1 664	۵۵
	f T	H H	H E		ur <del>s</del> s U t	В	Ħ.	9 :	2		т (	9 6	1	٥.	٤ (	9	÷.	1.	1		1 <b>66</b> 4	٥٥
	S I	H H	H E	H	u t	Н	B :	9 :	ב כ		т (	9 6	1	э.		9	5	1.	1	БГУГЛИЕ <001. Э Я	1 662	۵۵
	8 1	H H	#### 5	H	eras E 6	Н	B.	9 :	2		1 (	9 5	1	٠.	£ 9	9	••	1.	1		1 662	۵0
******		•••		•							1 (	9 5	1	э.		9	<b>-</b>	1.			1 <b>5</b> 64	00
9 <u>/</u> +/	Ec	0.	· · · ·	•••	98		f :	9 :		09	9:		99	3 ,	]	25		1 .	1	SLYCINE Cont.	1 <b>5</b> 64	00
******	Ec	0.	· · · ·	•••	98		79				Q:				]	25		)S	200	SLYCINE Cont.		00
9 <u>/</u> +/	22	0. 0. L.2	<b>6</b> 9	99	98	3	<b>&gt;9</b>	 25	19	6	9:	3,25	2	5	ES	25	15	)S ()	200	45 47 B D F H J L N F		۵0
9 <u>/</u> +/	22	0.	<b>6</b> 9	99	98	3	79	 25	19	6	9:	3,25		5	ES	25	15	)S	200	GLYCINE CONT.		0 و
9 <u>/</u> +/	22	0. 0. L.2	<b>6</b> 9	99	98	3	<b>&gt;9</b>	 25	19	6	9:	3,25	2	5	ES	25	15	)S ()	200	45 47 B D F H J L N F		٥٥
9 <u>/</u> +/	13	0. 0. L.2	<b>6</b> 9	99	98	3	<b>&gt;9</b>	 25	19	6	9:	3,25	2	5	ES	25	15	)S ()	200	45 47 B D F H J L N F		40

	G, OARAT. 1, HTIRE-REN!	\$873-6875, 01.239 \$1874-6871, 1239-80138, 121, 1239-825-4268, 11.239 \$1874-86138, 11.239	4590		ELLA, G.MACTWO, A.12A3OLOFF (1981 BUC, G.R.FIMK (1983) J. PIGL. CM	2401-9801				
בי אוננרי עכונם		R.NETZKER, H.B.KOECHEL, K.BAZ		*****						
13 mm 100m - 1011		ACAB. SCI. USA 78, 3423-3427			4791) T2508.5 .T250H R30 RAV.8					
1144 - SAST 1 1491	1 0410000 ( 57300)	\$'\$CHMWWS' 8'0'TOFF1" W'W'319 13\A2-13\A&			MFVHH (1401) CNYN" GEW" 4° TAT-TAY ) (1892) WOCT" VCJUB KEB" 17° 249:					
*/¢7 117943	"TOTA "C (2881) XII	A.J.HOLLINGSWONTH, R.B. HALLI		7144-1	. AUC. HIGL. 156, 663-717					
210 4211		1175-8182		" 1.15MM5.1.1 "	PERKITH' Y'Y'CONTRON' I'C'ENEVGN					
				**********						
		_ /*****	•		Material Aver					
ד ה ה כ כ ה ח ז ה	BITESTES:	הפדד הואפה בדוף		relo z z ele T	HYCES POWER B C T C B C B	DUNI-COOKS ONG ZS80				
	·	777.7.7.9	• • • •	4.2.2.2.312.4	## ######## 	OTIH 5980				
Tagiqiaat	. a T R <sub>1</sub> T a T D 8	ត្សាក្នុង ខេត្ត	. 441	मा उरा यो न म	DISCUSSION STORE OF STREET	119 <del>23356</del> 909 9680				
		<b>-                                      </b>			M	CHUCHO				
_ ja ji ti ti ti ti ti ti ti ti ti ti ti ti ti	่อราโคลอรล	ត្ត[ភូមិស្គីម១រគេខខ	191	R R D D D D T	21800000	3216H 909 +900				
		J., [111111111111111111111111111111111111			ENN'S NAMES	בארטאט 🤆				
TIBBIQUET	อาปลออกเ	ជុំជារីរត់ខំពុង កទខ	190	이 이 그 그 의 비 비	enacius de la case de	tarada eus esso				
		443444			KRRAHERKHHHHHH					
<b>9168</b> 33981	er Heore:	វត់រ៉ង់ដំឡាង ការ៦៦	Tas	มี : ต ับ อีโด ฟ	7378338	1293Y 3U3 S280				
TIBBETBET	ו אכ פ כוז ד פ	בפו שפששום	181	ار بران برای	######################################	TZFOY GUG TZ60 GTIM				
	3 1 A 3 3 3 0 3		100	익 <i>ᅻ</i> .ᅕ.ᅕ.† ┖ 색	0100313	OTIM TZFBY BUB F260				
яятэцввет	וופפפרופ	dalaeed	88838	ดุรรรยกฎ	H	TRE 5U8 6140				
		引 <b>プ</b> マッテッテ フ		7		200 515 4740				
- aaranaaar	81198932	הפדר הואכככוףו	1196	ជាគ្នា ១១១១៧	STILLIS G G C G G T T G	OGOS ENB BUCLETT				
		11 1								
		!		1 1 1	LIDINE	.SIH				
		11 1		1 1 1						
i	Į			1						
		1,5111111111111111111111111111111111111			<b>计算机设计的                                    </b>	OTIN				
_ 38 m 3 T m m 3 3	Trabonra	(संउक्ताब २	13881	ការពារខាត្រា	TYTDIIA *	, BNIADE IIII 6620				
1		1 1		1	- 3 140 P					
	1	ļ l l		1 1	-Jues E	פרגכוא				
Į.		i   I				-				
		<del>  -</del>		<b>┿</b> -						
27 OF 98 96 1	SP 30 35 34	16 20 8 22 24 25	24 SL	EL II						
EP IP GE CE SE	EE }E 62 /2	PS ES 12 A ET	4 ar M	1 SI 01 8 8	13348B7					
	i	14 1		1 1 1						
MƏTZ.DITMA 9001.;	NTIC.STEM , MATEC	R   N312 (I) 9000,	ם ר	HELLS α I	HELS TATEONIAL					

98

ᇁ
Ü
-
ĕ
Ø
•
Œ
Ġ
Ö
ซิ
¥
٩
O
-75
÷
Ω

TANTIGRA EL LEMMELLA CASTO VARILLAR EL TERMELLA GASTO TANTIGRA EL TERMELLA GASTO	DASOLO GLIGHERINI IS ARATINENT O DOSCO.  OLGO O CHIGHERINI IS ARATINENT O DOSCO.  OLGO OLGO OLGO OLGO OLGO OLGO OLGO OLG
AT 1 2 3 3 6 1 1 1 2 6 1 2 7 1 2 1 2 1 2 2 1 2 3 2 1 2 3 2 1 2 3 2 1 2 1	. 150LEUCINE 0901 RGGT 0902 RGGT
124777671222226882424444444444444444444444444444	ядэ север ядэ север
TO CONTROL OF THE CON	日日日 <b>5980</b> 日日日 日日日日 日日日 日日日日
	раво с на 1960 тая 1968 тая
CECA6617168772777777777777777777777777777777	a R 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
94 P4 24 04 99 88 P6 29 D9 95 95 P9 ZS 05 DP 0	44 48 B C E G 1 K M
RESTERN THE REST OF THE PER CAN FROM THE STERN OF THE STE	HAS RAYA B TO LE H JULUM HAS TO LE M JULUM

	ıcı		1, 2 16 ER	W\$'	, .	ND1	134	//E       T	14 538 41 1 (25	12 2-2 2-3 (74 (74	171 172 173 173 173 173 173 173 173 173 173 173	65. 6.0 6.0 6.0 6.0 6.0 6.0 6.0	1131 121 131 141 141	2 4 14 101 101	H* (612)	(0) (0) (0) (0) (0)	125 125 126 126 127 127 127	. 30 A A Ru 3 Mi 3 Mi	1701 1201 1707 1711 1711 1840 1840 1840 1840 1840 1840 1840 18	1181 281 281 1181	/"C C'S 53 } ! 'N	NU EN EN F , A EN	DAB NOV NOV NOV NOV NOV NOV NOV NOV NOV NOV	18, 18, 11,	9 7 1 1 5	661 826	Ď	-	141 36 36	Z-9 Z-9	13 13 13 13 13 13 13 13 13 13 13 13 13 1	. 6	t '	107° 107° 107° 107°	13" 13"	JOR SOR JON JOR JOR	11 10 10 10	(2) (2) (2)	61 61 61 61 61	NO: NO: NO:	172 172 172 178 178	יכית יכית יכית יכית	ψ"(  Ψ"(  Ψ"(  Ψ"(  Δ)	1461 2461 2461 2461 2461 2461	1'4'1 1'4'1 1'4'1 122	, 43 , 43 , 43 , 43	74, RAG RAG RAG RAG RAG	42 41. 14.7 14.7 14.7 14.7 19.0	110 131 131 131	98° 0890 0890 0890 088 203		מן. מין מין מין	219 219 188 011 549	10 10 10 10
_	~ _			ı .				_		<b>1</b> ∷	:				١.	ſ.	٠.	•		i_					_				. 1	ٔ ـ ا		٠	1			٠.													<b>.</b>	_	_			_
			9 :	┪ .						ŀ					-	ł.	•	• • •		ı									1	• • •	• • •		٠,		þ	***		××	**	HER	136					,	1.	<b>3</b> 0:	Hd	112	103		206	O
<u> </u>	T	9	9 9	٩ ٢	4	1	Ħ	9	1	4:	<b>5</b> .	כ נ	3 t	d :	1	9	9	) t	9 9	ㅂ		Τ	1	9 9	3	7	9	9	벙	. ٦	1	3	미	В.	4 5	9 1	. 1	3	9	១	Ħ						ľ	CO	.∃		59		rob	0
																																									3	N	I	) נ	1 ;	17	0	5	I					
				1.		_		_		+					ł	ŀ	• • •		• •										ŀ		• • •	••	-			<del>CK A</del>												C1						
		. <u>.</u> .	] !	4	8	9	1	9 .	Ι.	4:	, <u>, ,</u>	1 H	1 4	i 1	9 '	١.	7.	, E	ָּטָ יָנ						t	1 1	3	Ħ	٩	. <del>.</del> .	Ϊ.	+	9	<b>u</b> .		1 L												NIA LD		9	Πg		869	Đ
Ħ	9	1	ר כ	ď	ㅂ	9	T	9	1.	48	1 5	Jt	, :	) 1	ļ١	1	) (	1 6	1 6						t	; 3	5	Ħ	비	1	Ŧ	1	9	u .	ų t	1 1	R	Ħ	Ħ	t	9							HUW	ПН		19		<b>26</b> 0	0
	9	Ţ	<b>5</b> 1	H	Ħ	9	1	9	1 :	1	1 5	2 4	, 1		1		•	# 6	1 4						t	B	Ħ	5	ų	į.	Ţ	Ţ	9	H .		: ##   T												OT S≥U OT	ON	9	19	1	858	D
Ħ	Ð	Ħ	<b>)</b> 1	ㅂ	H	9	T	9 .	1 3	45	3 5	3 6	9 1	L	ų e	4:	) t	1 6	Ħ	ㅂ						3	T	Ħ	ㅂ	1	T	1	9	<b>u</b> :	(E	3	H	Н	Ħ	1	Ð						, NI	DHA	19		Œ	1	E89	0
Ħ	9	Ħ	<b>3</b> 1	] 6	Ħ	9	T	g .	1 1	մ	j <u>:</u>	9 ម	, ,		Įŧ	:	) t	1 6	ı	Ħ				•		כ	J	b	d	1	1	1 !	9	۲ J	Ī	1	u	ᄖ		1	9				. N	IJ1		EME TO		91	10		2081	D
н	Ġ	ï	J 1	١,	н	8		0				 а м			١.	Ţ.				l H				•		_	_		j			•		<b>.</b>	Į.	) T	KK	1	H.	##	¥		м	771	Ne	ın .		nta TO		-	100		100	n
				1											1	r	• 1	• •	•					•		J	_	•	٩	÷.	÷.	•	7	6 2	١.,	HHE	##	-	ж	in in	7	7	. "					O1	JN.					,
	9	Ţ.	3.1	ㅂ	H	9	T	Ω.	1 1	4:	, 9	H		7 7	ľ	ŀ	} ;	Ġ	H	A						כ	3	Ħ	벽	1.	÷.	Ť.(	P	<b>U</b> 3		HANGE.								=	, 2	37	ND	HI	HD	EIL	19	1	098	)
9	Ħ	7	9 1	)	9	9	T I	9.	T i	r E	) ]	9	1	בו	4	Ų:	t	1	. 9	b		T	1	ġ Ş	)		9	9	ㅂ	1	8	1 !	9	ו כ	ų e	9	T	9	٥	כ	8						3	<b>15</b> N	DН	9	19	9	5 <b>/9</b> 1	Ď
9	9	1	9 3	כו	9	9	T	9 .	1 1	1 9		ם נ	, ,	, ,	١.	Ι.	1 6	9	פו	H		1	1	9 9			1	Ð	ď	ī.			9	נ כ		9						٠.	MH.	12)	: 2	ПІ	ш	250	MI	21	10		0280	٥
				l							_				ł	ľ		_	_	-		_	_	_			_	_	1	_	_		T	-	1		_	_	_		_								•		_			-
				1						1					ĺ	ı													1				Į		Ĺ								420	-	2	МТ	u i	LSI	н					
				L.						1.					L.	L.				ļ 									L				1		L.						_													
			<b>•</b>																		8	Q	Z	V.		۷٤.					L		Ī		ſ						-													
E#	•		66	1	Æ	S	£	EX	8	۴	:	62	i	22	1	F	:	EZ		Ş		Ħ	G	L.	Ħ	1	91	'	4	2	i.	0	니	6 £	1 4	8	S	þ	Ε	Z	L													
И	LS		I LN	Ь	ď	רסנ	د.ا	[1]	W	H	aı	s	1¢	11	Ь	1	ΗΞ	كلا	a					<b>3</b> 00	ָר	Ø			1	ИŒ	ЦŞ	0	1		1	GI (	5 '	И,	æ	NĮ	WJ													
																				H														•																				

_	c
7	Č
- 1	i
	à
- 1	٥
i	ú
- 7	Š
ò	
-	L
4	ı
٦	
	ř
- (	1
ė	ī
7	۹
	1
••	i
ς	Į
7	7
-	
- 3	

r (1691) CEFF 32'	C.A.LAZAAUS, M.EABAK, W.XVXIXEI	ACIDS RES. to. 1407-1424 6733 8.0.KDECHEL.	OPDS 1.LOUGHNET, E.LLMB,J.E.DANLBERS (1942) MUCL.
0.000		******	<del>or merchiss in him</del>
0 T 0 0 0 0 H T H 0		THE REAL PROPERTY.	OSS7 GRU GHOCYSTIS NIBLLONS G G G C T
8913338183	+ 1 <u> </u>	ត្ត ក្រុង ទ រ ំ	18 GENERAL THROCORD THE SEED
<b>AATER DATR D</b>	ヤ ガ T ⊃ A T 可 a A B b p	вазавтэта тат	
<u> </u>	± ച[្ച]១១១៨១១១±១៩១	тав такіртрафітей	CHTUSO HERENESH
ATREE BARTAS	TTSTTBTGTBARA	Tab Darition Tit	DET S GRUNDELL SPERSTLEND SERVING SERVING SERVING WAS AN UNITED TO THE WANTED SERVING THE PROPERTY OF THE PROP
пазазиятия.	1 3 5 1 5 2 1 5 3 5 5 5	TIBB TIBROTOBRITES	<b>・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・</b>
0199966169	מפ מ פ כ מ ד מ כ כ ב ד ד		CALORO ******
# # # # # # # # # # # # # # # # # # #	~ T= ~-= T7.7.7.7.7	H# H#	MARIA CHIN ETHETENU CHICATTE CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
		PARTIES TO THE PERSON OF THE P	DORO CHOLEST C.C.C.
<u> </u>	• • • • • • • • • • • • •		פפר פשה ששכנדרה בתקוורוז פפפר
	r <u>១៦១១គង្គ១១</u> គម្	ттар ттафітіарыті	13 אם פון פון פון פון פון פון פון פון פון פון
атазавятна	ם פע פל פר ב מ כ פ כ ב ג	TT88 TOBETCHBCT 6 TT TRANSPORT	0903 GRU BRCILLES ZULITRES & GG G G C C
			ISOLEUCINE CONT.
			1441 BITT 18 DET
S4 38 38 40 45	20 00 07 07 by		
เข <b>้าข</b> ี่ 22 23 41 43	SE 0E 0S 7S 9S 6S 7S	8 05 81 5t 2t 2t 2t 2t 2	FEZE
M∃TE.SITMA 900J.SITM	M HEITE, STEHN HEITE II		TAZHONIHU
		óm i namen i inale	W.JOUNTHO

D.O.CLARY, J.m.CODDARD, S.C.MARTIN, C.ME. FANRON, D.R.UBLSTEN- MOLER LIPORS) HUEL, OCTOS XES. 10, 6419-6437 MOLER LIANGEN, J.F.GOOLJITLE (1981) MUEL, ACTOS AES. 11, 135-215		ENTRACTO, JR., K.E.GURNLON, C1931) CELL 23, 231-259 ENDOTENAN, SERMER, N.YAMBDA, O.SOELL (1940) CELL 19, 269-495 ENDOTENAN, SERMER, N.YAMBDA, O.SOELL (1940) CELL 19, 269-495 F.E.ÂON (1940) LEGAL AND CONTRACTOR RES. 10, 1771-1730 F.E.ÂON (1940) LEGAL AND CONTRACTOR (1920) J. SIGL.	2540
#GRANDECHEL CLALLER RES. 10, 1277-3219  #GRANDONE, C.DE RENEDETTO, SCHOOLETO, C-SHEGOME, S.SBISA #GRANDONE, C.DE RENEDETTO, SCHOOLETO, C-SHEGOME, A.SBISA #GRANDONE, C.DE RENEDETTO, SCHOOLETO, C-SHEGOME, A.SBISA #GRANDONE, C.DE RENEDETTO, M.KDRONE, A.SBISA #GRANDONE, C.SBISA #GRANDONE, C.DE RENEDETTO, C.SBISA #GRANDONE, C.SBISA #GRAN	CEAD	C.L.) FERLES, F. GEGENHEINER, L1980) HATURE 244, 908-910; L. GAAT, R. KOESER, E.STUTZ, C1980) HATURE 244, 908-910;	064D 064D 0604

45 45 B D E H O 46 20 25 24 28 20 65 84 28 87 24 38 46 47 87 14 48 48 24 25 26 27 24 28

אואמטכאר פונה עב פונה אואמטכאר פונה

P. CUILLERRUT, J.M.MEIL (1762) WUCL. ACIGE RES. 10, 1653-1659 0955/0 ALIBHRENT 19 AMBITAMY

0424/36 AFTER RESIDUE 34 INTERVENTAS SEDUENCE

1996

8118

AHTA

TODR

1994

1998

TODE TDBR

T 9 2 3

1998

COLEUCINE cont.

181

4960

9960

9550

**#5**60

6960

**Z**\$60

LSĖQ 0980

5060

F060 C0G0

_
u
=
4
Ď
7
- 53
=
≖
97
ъ
.=
ບ
~
Э,
£3
<u>.</u> e
_=
$\pi$
೪

	h	1 11411) <u>(2006-2000)                                  </u>
	1 3 8 8 5 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	คอววาอง สูล อออออ รองสภาคา sour acor
81331AAAA1.	тавананана взее ття	אספר נול מידור עום אוניים בינים היא מידור עום אוניים אוניים אוניים אוניים אוניים אוניים אוניים אוניים אוניים א
9 R T D T D B B P D '	1 M R B R T J Z D D P B R D B B T 1 A	1003 CHE BREILLUS SUBTILIS & C.G. 6 D.T. 6 G.G. G.G.
9877878988		· · · · · · · · · · · · · · · · · · ·
		***************************************
araadaaaar.	Tanabaaqhaaann ataa tta	nan tala 1 a a a a a a a a a a a a a a a a a
		rencine
	l.	
8812838183	<u> </u>	CENTRAL SOUTH CONTRACT CONTRAC
##15#8#1#9		CTIM CHARGEN OTIM
		ANTO SET DITO REASSESSED DITO NO DITO 1050
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SESS GRUPATION AND SERVICE OF THE CT C T G T C T C T C T C T C T C T C T
<b>ARTOROPIES</b>	า ทุ⊤ วด 1 ทุ่อุดอัตตุ คล ว	COOP CRUTTUS MORWEGICUS " R G R R T R F C T C T C R
3 3 3 3 3 3 4 1 4 3 1	Talabaras Tala Ta	PER GROUP CALLANT HERE HERE TO COLUMN
333 8 T 1 A A T A D 1	h	CHORD CHOCKE OF EMACES, CC U C C U L C C U L C C C L C C L C C L C C L C C L C C L C C L C C L C C L C C L C C L C C L C C L C L C C L
		7
		ISOLEUCINE cont.
	SE 0E 63 85 45 SS 8 05 81 TI BI	EL LL
E+ 1+ 6E 2E 5E 0E	DE FE ES NS ES ES IS A ET A BT A	M St Dile a 782 + EST
אזוכ.נססף האלוכ,5754	ם נססף ויים אדוב, אודב, או האי	HEITE O NETTE JUDITIONE NO

99 S.ANDEKSON, N.A.L.DEBRUTUM, A.A.COURSON, I.C.EFEROW, F.SANJER.		
ETHEORYGOM EL WE' (1941) INVIONE 360° 422-472		151. USA 80, 3309-3312
CEFF 59* 193-190		GKOA JITAN JOHN (EBRI) BENGER (1983) PROC. NATL, ACAD
SA SILIBIES, B.A.GARE ETTEN, C.T.URIGHT, M.E. MALBERG, D.A.CLAYTON (1781)		C'1' GYEER' B'2' ACTO (11473) WALT' MOTOS BES' II' 2373-255
97 D.R. NOLSTEIN CLAL, C.R R. FALMON, J.A. BODDRAD (1982) GENE 20, 43-69	1002	C.J.GREEN, 8.5.9010 (1963) MUCL. ACIDS RES. 11, 5763-577
NO E-TERRITO' V'EDETORE (1125) HOLF" BEIDZ KEZ" TO' 5092-5939		NDCC" 4CIDS 4EG" (0, 7919-7934
EEFT 32' 312-359		(\$691) HTINE.G.L , MDTJET.G , \$237803.8 .AJJIVCKART.G.T
B.S.CEUISSEN, B.A. TAGBERRAND, G. ZYBRANS, D. ANDRES DV. B.R. B., R. B. (1943)	1 gg 1	C'ENRUON' 1'VREFERDA (1000) 1"POF'BIOF' 110' 155-261
25 9'9'EVENDVO'B'B'8DORDCK!1693] 7'810F'CHEV' 323' 11161-11164		214-289 "961 "TOTA "TOR "F (ZPA1) GHRD1"6"]

<b>跨貨票長貨品資金投票券</b> 在1222.2022.2022.2022.2022.2022.2022.2022	= FEEEFFEE		
4393333355	этяврэттават	3	900 L
42082123333	дга в в этта в э э э	ב פ פ ד ה פ ד ב ה ב ל ב ה ב ב ה ב ב ה ב	1004
R 3 8 3 3 3 7 6 3 7 7 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4	1 1 2 0 D J T 7 5 5 5 5	91 92454444	E001
**********	= =====================================	10 111111 11111111111111111111111111111	SERVI
438373773833;	<b>1</b>	at , roprifabitabeo	roor
	V. #	רבחכואב	
#131118113131	3 2 6 6 6 7 7 7 2 9 6 9 7 7 7 7 9 6 6 9 7 7 7 7 7 7 7 7 7	AT 6918	6660
ринивинийнукатата	20 2000	=	•
**************************************		=  p	<b>4660</b>
	มีวอหลวา ที่ออลอ	=  	9860
412111811213	<u>ส</u> าคคยาว ทุ้ออคอ	я <mark>т янтя</mark>	<b>296</b> 0
<b>53338188863</b>	7 8 8 8 5 7 7 5 5 7 7	1 2 1 2 2 2	0960
C T R C F B C T C T C T C C C C C C C C C C C C C	arragaria arra	a	6560
		isincelicine cont.	
1 1		1000 2012/13/13/1	
9( )4   24   04   129   129   149   28   S4   124   14   168   49   59   159   15	19	44 48 E E E I K H D 48	
M312 JYJHOHIHH H312 FI	n — 900.0 чт ( мэтг чт	HSR ASTX3	

0

102911) PLIEN HERIDDE IL ERLEHAEMING REDRENCE 102310 OFTENENENI ÉZ BUBLISOFA 104011) VELEN HERIDHE IL INLESAEMING REDRENCE

_
7
=
ö
ē
ñ
-
-
. 5
Ų
₫
.9
0
7
~

LABENTZEL (1981) CELL 25,	. 125-239   148-212   159-24439   168-342   168-342   168-342   168-342   168-342   168-342   168-342   168-342   168-342	ECOT 'A "SAN SOTOR	\$170 2168' K'K'CYNEM' N'U'HOFNED (1887) NOCE'	-1212 200'8 6161
		7 22 300		
		· p · · · · · p panel	CHLORO A&AXXXXA	
_ r	aabd 1 jab qa qaa	or n q n o o a o n n T	HUAR G G G G G	1080
<b>511236688113</b> 68		8 6 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	H110 ***********************************	1 6501
		·		0.305
ออราสุรัยคลวรปลเ	อควาสุรายัลิคุครวรออ		DRIEDPHILA MELAND. 6 T C R &	9501
1813138881118		1 1 H 2 H 3 H 3 H 1 H 1	WILD PRESENTED PRESENT	n 9301
	20100321	* + C = 0 - 1 - 2 = 1 - 1 - 2 - 2	M110 M110 MELAND <sup>®</sup> 1 C 1 A A	5501
_ ครราชุกคลรรรมุคย	яна при при в в пред за в при в на в на в на в на в на в на в на в н		GRITTO MENUH GRI	1 <b>F</b> 501
פונוזטפפטונפפטם			JAG ASPENGILLUS AIZUL, OTGGGG AITO N¥ ANASAJ	1 ESO:
		0010003773707	HILD HARRESTELLUS NIXUL, DIBGGG 196 ASPENGILLUS NIXUL, DIBGGG	1 6501
- annitionation	яттапопома втое	TTAGBBT3BTBA	AND REPERBILLUS NIDUL. RTCC 6	n <b>25</b> 01
		hea mace	CAUTHO	
<u>อักววิที่กิดอลาก ที่คล</u>	вой дрозорыя итее.	ក ក ក <b>គ ៨ ១ ៦ ១ ៦ ១</b> ៦ <b>។ គែ</b> ១	HP ENERGIA BEAUTICE & C B B B	1 0901
ออควา (วโอคควา ปุคย	อราวายุรอยคุยเรายอ	วอตุอววอไอน์เ็บ	2 1 1 3 9 12HBY RR:	1 <b>040</b> E
"		KNEW	HENNER PER	
_ออาวา าออกาา <b>ท</b> ุกล	อดวาสวีอีวิตอ ตรออ		9 5 2 3 9 ITID3 73 90f	3 Pror
aattataaaattaa	ветн висесерня	T T R R D D D D D 1 9 B	286 E. G. G. B. B. B. B. B. B. B. B. B. B. B. B. B.	o cror
	30 2 9 9 3 3 3 9 9 3 2 3 3	110000000000000	44 44 44 44 44 44 44 44 44 44 44 44 44	, 4,00
ļ			LEUCINE cont.	
1	11 J	1 1		
			ig=p=q===+	
70 OF RE 96 PE 75 OF		LI SI EL IL		
EP 19 5E ZE SE EE LE	ES CS   ES CS   S A ET A	R Br Fr Sr orleata	3 + 6 2 1	
MATECALISTS ANTICASTEN	12.21TM HBT2 01 902.1	a Hais a Mais	BRINDBCAL 2	
Anna arther grant artifo (64)	13 71740 1 MHTP At COD I	O JMST2 G JMST2	r viacamana	.4,
			• •	.47

•		es2-933	
2052-230E		K.O.ADECHEL, C.A.LAZARUS, H.RABAK, M.KUENTZEL (1981) CELL 23,	ZCOI
A.STEIMRETZ, T.J. GUBBINS, L.BOBORAD (1932) NUCL. ACIDS RES. 16,	0961	127 12° 112-129	
P"1" "KTOOK (1141) HOCF" WEIDE HEE" 6' 1126-1119		W. BRD 1592En. J. L. EREENEEND. G. ZUMPANBET, D. D. P. R. SECT T. R. S. MALLICK (1983)	
G.SACCUE, P.CANTATORE, G.GADALETA, R. SALLERANI, C.LANAUE, 6.9EPE	1026	E'W'0805CD' 7W'' I'B'HVTF1CR (7425) 7" 810F" CHEW' 525' 2592-3552	1920
8'8'KOBIBZERY WODAIDRON (1881) CEFF 52' 521-528		W'T' WERWANN' K'C'ORDEN' T' VRETRON (1492) CEFT 32° 171-152	
N.N.L. DE BRUI (N(1783) NATURE 304, 234-241		EDI 13: 2401-2493	
PHOENZON E1 tf" (1891) NULTURE 350° 125-492		U.R. STAMBETHE, A. VENERGAS, B. L. KRITER (1751) PROC. MATL. ACAD.	8561
I'C'ELERDH' 2'UNDERADH' D'L'HIENFICH (1986) KWINVE SRE' eEG-FF)	1024	N'HVENTING N'OZERI' L'ENINGU (1621) CEFF 52' 326-546	
EC9-SZ7		111-112	
H.G.KOECHEL, C.A.LAZARUB, H.BABAK, N.KUENTZEL (1991) CELL 23,	1023	D'UNERIEN' M'K'CONDEN' N'U'HOFVER (1881) UNEF' VETOR MER' &'	1070

::
3 030r
1 8301
1 9901
n eedt
1024 C
1020 1
1025
T 050r
1 Q+0L
□ PLOT
T OFOF
*

1000/37 ALTER RESIDUE 34 INTERMENING SEQUENCE 1050/37

Nucleic Acids Research

7

1060/0 ALIGNENENT IS ARBITRARY 1061/0 ALIGNENENT IS ARBITRARY 1062/0 ALIGNENENT IS ARBITRARY

_
_
7
~
7
- 22
ų
- 67
•
ĕ
_
W
77
.2
(1
-3
⋖
.⊻
<u>.</u>
⇁
ĭ
_

	*61 *	53¥ <b>5</b> 0	1776	* 7204	12011		****	418 *	1 7 B B T		4-tr												2   13   13   14   15   16   17   17   17   17   17   17   17			
	٠.	230 94	144	I TOTAL		, 44	* 124311	• •	3 40 11 1		8-40		7441													
. 11 .23A 201;	אמער "עד	(\$241	21139	KERNALI	in · a · m	y Tala		EUSH"	9*8*7				1023		61		-		III4	13 106		POI FRU		19 1539 50		0401
120-05	9 '942	38014	N CL	841)	IST I BRI	111	7 · U ·	33113	1012	4 1	7 TWR		POT				DRA	n.	4467	109471		BARKEP	IZ, O.CONOZZI, A.			5761
										ZZS	4-11	24									•	- 300 Bill	1150-2005 '292			
	.11.	a KE3.	YCID	iner"	(EE6	1) 3	TJÓRIK.	31510	1.1.0	, YAS	סיכר	a 1	1 09				QV1(	050	ľ	'BNIB	GINO 1 L	"3 'ZE	HEBBERS' T'ZCHAY			1901
																				h						
88238	m 4 4	э н г		4 6	1 13 1	٦,	<u>ا</u> ۾ ا		4		-		_		, J		H G					**************************************		* 32UOH DTIK	040	SEDL
				1		-1,	<b>ገ</b> ፣ ፡ ፣		1			1 5		10	4	·	9.3	. 71	и,					* 331 IOM	9011	2MD f
98331	פפב	1 13 6	1 1	4 8 9	191	30	d o a	9 g t	d rs			9		9 6	ᆈ	n	ככ	ы	41	- " ما	9 1	1 1 9		NUMER	OMÓ	1094
				<b>}-</b>		-7 '	<b>]</b> • 7• 7		•			-			٦	٠.	7.7	· 📆	. د		H	HENNE	4	FILLER WT	DUI I	7001
96293	195	9 6 3	1	493	1 2 1	<b>d</b> :	d 3 9	9 8 t	ש א	LD.	1 9	9		3 9	ы	9	2 2	9	9 ,	HE	9 1	1 7 1	5 2	HOLL LIVES	980	<b>4801</b>
				<b></b> -			h	• • •				_			٦	-		••	-	**	-	t it WHILL	<del>()</del>			
בפכטם	T 3 £	2 A 3	1.	492	1 B :	그 9	4 3 9	9 9 8	ָ ט ג	LJ.	1 9	9		2 C	ㅂ	פ י	ככ	맥	9 1	1 8 2	9 (	1 I I	9 51496	SUPPLY 1	960	3901
			_	.h		- <b>j</b> .	1:	• • •	1						ŀ	-		۱				i <del>n n a n</del> i		DTIM		
TROOT	3 9 F	9 A T	1 1	46.2	ıāŤ	4	( ) (	3 7 6	3				<b>U</b> .	1 1	벽	9.1	8 2	Ð	<b>a</b> 1			1 1 3				260r
REBOR				J		٦.	Л.		]						.J	٠						HHAM	• • • • • • • • • • • • • • • • • • • •	OTIN		
00239	0 11 5	9 0 1	Ι.	1 - 5		. 4 5	1.	1 1 5	1		•	T 8	0	9 5	4	.1.1	9	9	8 1	1.5.1		T 3	8	THE	960	190L
בככשש	H 9 C	1 H		1 . 9		ıl۰	Į., .					2 0	ш .	<b>.</b>						/C-:	***			MITO #	DL45	E901
			•	1		-1'	<u> ነ</u> ተ።		1		•		ъ.	ں و	٩	-:.'		.7		1		HARES		OT1H	2001	FAOL
парэт	8 9 5	ЯΙ	1 3	d I d	9 1	Д:	: c k	) 1 E	i		1	<b>-</b> 9	н.	Э Н	н	1 1	ня	П	н н	4 H I	9 1	13.	G	TU SHORE	OHO.	290£
		_				٠٦٠	}፣•፣		1		_		٠.		٦.	•		٠٦				NAMES.		DLIW		0000
בננטט	H 9 E	1 11	1:	119	9 1	IJŁ	i o :	1 1 6	•		1	J 9	н :	9 6	н	1.1	4 9	9	8 6			13		פסעורדט	980	180L
**						-∃ `	}		l		_				٦.	•		٠٦				MANA		OTIM		
ובככטט	399	181	1 :	¥⊥9	9 T	IJΕ	ío:	1 1 6	(		ב	J 9	<b>H</b> :	ם כ	H	11	19	9	8 6	E I	1 1	13	# 3 <sup>2</sup>	ZNUJUJIO		090L
						·-j ¯	<b>+</b>	• •	1						٦			-71				****		ELTIM		
TATAT	990	1 4 7	13	(T)	ΑT	ti E	<b>  🕽 t</b>	176	9	ซ.	9	9	1 1	L A	법	9 :	1 6	9	9 1	111	1 1	113	១	T2A3Y		<b>\$208</b>
						'네	· · · ·	• •	l						- 1	•	••••	. 1		****	FERN	HHHHH	×	<b>090.4</b> 0		•
аэтэц	999	1 A 2	1 3	H 9	8 9	<b>F</b>	ו כו	) J t	(5	Ħ J	. 9	9	į.	l H	ᅥ	H 8	Ιŧ	9	9 1	489	1 1	. 3 3	9	HZILH	땑	1901
				l		i.			i						- 1			1		Į.						
1				l											- 1			- 1		1			. faos	ani aya t		
				1			1		ļ						- 1			- 1								
				L		.1.	L		L									- 1		L						
ZP 0>	e or	-	<b>&gt;</b> E	ne.	87	Τ,			7		, ,		- ~~~. - 1		1			-†		T			-			
EP LP GE				ໂຣ້			52 °		. Z	. 05				51		ì.				١, ,	~ ~					
37 00			_	r~ '	- 1	7	PE-		-6	t)	-	0	H	, ,	74	GI		'* '	9 V	4 - 4	5 7	ε 2	•			
Mate.attw	<b>a</b> 00	ועביד	LNH	NE	יזכיז	NH	Na	115 11				07 C	1		- 1	up:	LS O	. 1		So.	e 7/	ZHONT.	LIM			
							. ~2		•		-		• .		'	731	w 4	٠,		. 2471	3 K	١٦١٠	~~ <u>~</u>			

CEFF 38' 187-180		W'EMBSSKORF, MUFELDRAMM (1981) CUMM, GEM, 4, 191-196	520l
M.A.AIBB, A.A.WAN ETTEN, C.T.WRIGHT, N.M.CRABERS, C.A.CLAYTON (1921)	J 0A2	ECS-252 .CI .JOV3.JOn.L (5391) MESJ10.J.A. auau. 4.233051.R.J.MUDAL.n.W	1013
7357-£167		U.A.SRUNN,E.M.FRAGER,A.UAND.A.C.MILSON(1742) J.MOL.KVOL. 18, 225-239	1005
K.L.KDY, N.CEGERE, B.EUCKLAND (1762) MUCL. ACIDS RES. 10.	1014	A*************************************	1001
779-4078		M.A.BROUM.E.A.FRAGER, A.SANG, A.C. WELSON (1982) J.AGL.EVOL, 18, 275-239	1480
D.A. NAKODEKI, N.A. HAAS.K.P. DOLAN, D. GRUNNERGER(1983) HUCL. ACIOS ACS, 11.		MINCE' WCIGE WEE' R' 2011-2039	
8.9ALLI, H.HOFSTETTER, A.L.BIRNSTIEL (1981) HAIURE 254, 626-611	980 L	EDEALANI, S.G.RORITZ, G.CSROZZI, A.NORREGA, A.TZAGOLOFF (1980)	>201
(22)-1129		(1492) 7'810T'CHEW' 198' 2003-2217	
P-O-C-VK1, 0-8-001258MGD-1E (1983) MUCL, ACIDS RES, 11,	C20 t	######################################	1901

	kas:	***	NH H	-		==:		z 0 £																											
E	i s	4	9 6	U .	ם מ	U	명 :	ככ	L	H	Ħ	<b>H</b> :	<b>3</b> 5	3 1	9	9	ΙŢ	ī	<b>5</b>   5	)												Ħ	6	ы	SCOL
	MAN		T 3	HHE	Τ'		-		١.		_				=	==	-	***	티.								* * *					115			
	***	THE	1 J	IJ. H##3	1.	-5:	) : ::	7 T	1-	0	8	Ŋ.	7 1		12	9	9		9  3	,					9	9	A	<b>D</b> 9	3	1	Ţ	) t		1	Þ601
t	2.0	9	7 3	5	12	R	5	3	1	Ħ	ㅂ	อ :	נ כ		9	9	9	1		,			9 9			_		e J	נו	3	5	<b>1</b>	Þ	1	480L
H	3 6	9	13		75	H	<b>5</b> :	5 3	ı	ㅂ	ы	9 :	נכ	ı	9	9	9	1	= =	1							9 1	_	רו	ت	7	) T	;; ¬		8801
	MEMBER	***	***	(HH)	+:	==0		***							•	•			=  -					_	•	_	_		•	_	_		_	-	5001
-	F 2 5		, T	ر <u>ت</u>	4 +	• = •	T :	J 6			1	1 1	LI	. 4	Ŀ	. 9	H.	<b>u</b> 1	비1													Ħ	Ţ	Ħ	590 L
Ħ	1 5	H	Ú	ПЛ	ļ	ť	<b>d</b> :	2	1	J	<b>u</b>	<b>ت</b> ک	9	E	9	9	1	ı	90	ı												Ħ	b	н	Þ801
ㅂ	1 9	U t	, E	H J	Ī	8	b :	כככ	1	5	8	<b>u</b> :	9	1	9	9	==: 1	1	1 .													н	8	н	E901
J	**	###I	***	HONE	8=	E E S	-			_	_		_		••	••	•=•	-	=  =														•	•	COOF
9	2 2 2 2	U (	1 U	####   U		- E	<u>u</u> :	2.3	1	כ	Ħ	8 :	9	1	[9	Q	Ι.	1.	<u>.</u>   ۲													Ħ	Ħ	R	280 r
ㅂ	ΤĐ	Ħ t	A	A T	b	ť	Ħ :	כו	7	כ	<b>u</b>	9 3	9	1	9	Ω	1	ı.	4 2													8	Ħ	Ŗ,	1601
8	I 9	H :	1 4	H I	ы	8	변 :	3	ı	_	<b>H</b> 1	н -	1 9	,	โก	9	-7.	1	1													н	н	ы	0901
	****	KKK	i in lice	MMM	] [				_	_	_	_	-	_		••	<u></u> .	•	٦-					:	:::	::	- = :	:			<b>P</b> 1	: : 1			OONL
-	9 6	88 M		U U	14.	, T	1 3	3	1	9	<b>u</b> (	9 3	1	1	9	9	ᄖ	<b>B</b> (	3 T						۵.		9 t		A	1	٠.	IJ	۲	Ţ	PZ01
Ħ	פֿכ	9 t	ij	2 1	T	כ	1 2	1	1	9	н !	9 2	1 1	1	9	9	ย	9 !	1						_ `		9 6			н	H .		9	1	1901
					ı			- 1																			٠,٠	107		B.I T	בחב	_			
					ĺ			ı											1								4-		-	-11	يا انه	• •			
					L										L				.L.																
		Z		99	١.	9	28	ŀ	9	8	5	99	•	м	7	25	C		90	. 0	W		 K	1		9		3			 H	٩Þ		•	
54 E4	LZ	69		9	59	0	9	19	6	5	45	;	\$\$	-	Ėŝ	•	ıs	61	1	9	N	٦.	٦	•	H	٠.	ⅎ ¯	a	_	8	4)		<b>.</b>	•	
i	BTZ	בער	LION	IW	Ĺ	EN	LS	ᆀ			аX	п	<b>4</b> 1	ŀ		KEN	5	<b>=1</b>						HE	18	ы	TX:	1							
																										_									

ONEACT SANTTENENT SE STATEMENT SE STATEMENT SE STATEMENT SE ONEACT TRANSTERMENT SE STATEMENT SE

_
छ
è
ġ
6
Œ
- 00
õ
딩
₹
·X
<del>-</del>
Ų

SINUE DE INTERVENTAB SEQUENCE SINUE DE INTERVENTAB SECUENCE			0/460T 0/460T
**********	PERESCENCE.	<b>-</b>	
MXXXXXX PXXXxxxxxxxxxxxxxxxxxxxxxxxxxxxx	<u> </u>	al	ISIL
а на визиния жи за осе за да во во во во во во во во во во во во во		T 5 2 A	OSLL
a a a a a a a a a a a a a a a a a a a	์ ปัจจกอวาท์จอออก	‡ тетя	EFLL
A DT D 2 8 T A D T T D	319093119960	פֿפפֿז	<b>OLLL</b> .
1) saarrags 3	J	a	ZOLL
		. 9NI5A7	
***********			
A T B A A A A T A R A D	⊐ุ⊤⊐ ฅ ฅ ⊃ อ ทุ้อ ฮ T T ฅ	<b>8</b> 99 9	eeor
# 3 R R T T 3 3 T 3 T 3 T 3 T 3 T 3 T 3 T		ם דפו כ	860t
4138884	<u> มีกากควอทู่อื่อกับ</u> ก	T BBB .	<b>1601</b>
	<u> </u>	י דובכ כ	3E01
27 E7 17 63 73 23 63 73 34 55 53 7		THE CESIKHO 45	
HEIZ LYZRONING HEIZ 9	ਸ਼ <b>ਬਹਨ</b> । ਜਾ ਅਤਾਣ ਕੀ।	MARI RAYKE	

Zātāk.	782 * NEC * NEC * 124 *	10 10 10	25. 201 201 201	CV0	11 104 102	ינר- ים- יור-	AD,	 191	512 FR( F., 7	i 	724 112 100	35- 35- 11)	(12) (40) (40)		09 6"1 k":	ברש ב'יו פ'יו	110 344 164 111	21. 440 44. 01 R	83: 12: 11: 11:	612 613 70 70 71 71 1111	17. 17. 17. 10.	-E	130 130 114 115 117 118 118 118 118 118 118 118 118 118	A7.	1. におり組むれ	20	tt					<b>'</b> ¥;	18. 18.	*1	0/3 1	מר": מר":	n.t	כדו וז יז	1 286 14-	108° 108° 1087 123	114 (117 (117 (121	75 31 16.0. 18.0. 18.0. 18.5	1011   A.(   A.(	Meir. Meir. Mull	WE WE WE	138V	081- 16 1 89.0 89.0	-7AC 13 MI 1.32,1 1.4()	9KIID 413 4CA9 4CA9 55 63 57 67	2113 OHA. 118. 215. 214. 218.	1	740T
A 8	7 7 7 3 7 3	بعنس عم	Я В	п п	1	1	T T	T		9	9	1	1		E 6	 	9	• •	0 0	8 8	1	Ţ	T T	8 9 9	9	;	1 1 1	. 9	1 1	ы В	֓֞֞֜֜֞֜֜֞֜֜֞֜֜֞֜֜֞֝֜֜֜֝֓֓֞֜֜֜֝֓֓֓֞֜֜֝֓֜֜֝֞֜֜֝֓֓֓֓֜֝֜֜֝֓֓֡֜֝֜֝֓֡֓֜֝֜֜֝֡֜֜֝֡֜֜֝֡֜֜֝֡		) ö	8		1 H H H H H H H H	# U 9 ## U #	**************************************		*** *** *** *** ***	10 第二年 1 年 2 年 2 年 2 年 2 年 2 年 2 年 2 年 2 年 2	4 <b>9E</b> 4EA' 2	104 (33)	3 217: 178: 23: 23:	341 341 75 108	1051 1051 1051	#H31 #H31 1711			n n	9	iorr Brr Brr
A A T	13 33 11	<u> </u>	כ	5 9	9 Y	Ħ	1	1		T A	ы 9	9	1	. 41.4	F	 	9	; ;		ť		b	ı	Ţ	9	3 : 9 !	9 :	) £	1	   	L		9	9	1		1 8 8 8 8 8 8 8	# 7 # C # H # H # H # H # H # H # H # H # H	1 . 1 . 1 . 1 .					Juo:	•	*		LIH LIH LIH LIH LIH	900 900 900	n n	2	360 L 360 L 360 L
€Þ I	(1C.9	۶		£	S	Ε	8	E	1	E	8	2		4		3Z	1	EZ 15		z		В С	E					SI		4	ZI ZI		01	6	- 1	ر د ا						3										٠

3-84DEM3CM ET AL, (1911) MAÍUME 290, 457-465 SELL 26, 167-180	1	29 "1"H'HWH, J.D.HARDING (1963) NOEL, MCTDS REG. [1].	<b>;</b> E7
AZI-IZZZ ALI-IZZZ		25 F.CAMTATOME, C.DE BEMEDETTO, GLEADALERA, M.GALLERANI, B.M.KROOR, B.ARLELLO, CLEACCOME, E.SBISA	217
. E1 .23% BLIDE RESTE (1984) MINCL, ALLDE RES, L1.	9111	D'F'WIFFEM' N'C'WVYLIN (1801) CONN' GEN' 4" 732-742	,.,
374/5706 BKDIH(1873) HYLMYE 304° 534-541 2°NILLIB° E'RILLIB (1843) HYLMYE 584° 28-38		2# 3*8*884115* **15V80#10%\ (1399) 3* 310F* CHEW: 528* 3032-3091 D'EDEFF (1395) MOEFF VCC03 NE3* 10* 2338-2909	:11
(1982) NUCL, ACIDS ACS, 20, AAX1-6419		53 D.DEFRANCO, K.R.BURKE, S.NANASNI, G.N.TEMER, R.C.AILLER, JR., O.DEFRANCO, K.R.BURKE, S.NANASNI, G.N.TEMER, R.C.AILLER, JR.,	277
RAUMENETHAS, ATATA, "ADDRIAM, K. MASHEMMAR, T. MYSHEWAR		\$19 <b>-</b> \$29	
\$623-509		25 M.G.KOECKEL, C.A.LAZARVS, M.BASAK, H.KUEHTZEL (1981) CELL 23,	111
		CITIO	
នុគ្ខក្នុងខ្លួកក្រសួងខ្លួម ក្រុម្មិន្ត្រី ក្រុ	T 2 f	nayın da ala alanın da alanın da alanın da alanın da alanın da alanın da alanın da alanın da alanın da alanın d	LL
8811888711133881783888		#####################################	9.4
	•	G C I D SI C O S I D I D C D T D C D T D C D T D C D T D C D T D C D T D C D T D C D C	••
า ด ว ว ศุกด	39889	ตุอำวัญ อากุคอกา 1 ควั* คอบมหา คมเพชอ <u>ะอสสับ</u> บว ees	LL
Chastartsstrango		PIBIO CLU DRUBANIA POR CONTRA	ıı
		**************************************	
ควาวที่คลาววาวเคอยสอที่สุวอิคอีล เออ	1196	A CUU QHICKEN EHBRYD G G G G G T D ABI T T T B B B B B B B B B B B B B B B B	LL
азтопраттого поветновного тов	2128	וצא מדוו שנוכם פכל בפפלע שובנוכא	LL
		ни инжиниеми	-
- सब्गान्त्र प्रतास्थात विद्या । सब्गान्त स्थापन । सब्गान्त स्थापन । सब्गान्त स्थापन । सब्गान्त स्थापन । सब्गान	TTAF	ואונט איינט איינט איינט פון איינט פון איינט פון פון פון פון פון פון פון פון פון פון	LL
8 8 1 1 9 8 8 1 1 1 1 1 1 2 1 8 8 1 1 9 2 8 8	9 8 1		ււ
		TOTAL	
ा प्रदास स्वास्त्र स्था । जनस्था । जनस्था । जनस्था । जनस्था । जनस्था । जनस्था ।	185	airitidir √air a a a a a a a a a a a a a a a a a a	LL
RADDIRATITIDA DETTA DE RA TES	7192	ובפ נוטו מתמכסירונה אבינאם, פככככפס ודו וכנכה. אאשאאאא אא ויייין אבינאלא	LL
	•	NAMES OF THE STATE	•
า тลว ปุคคา ราวไดย า ค ปุศ ⊃ ค ค ปุค	1 # 5	qітті а  яціці да в в в стіті висті висті висті висті і ві	LL
		LYSING CONE.	
·			
2> 0> BE SE +E ZE DE SZ DZ +Z ZZ E OZ DL	LL SL	EL 11	
En ra es re ar er he es ra es es la a er	A 81 M	1 2 1 0 1 6 8 4 8 8 + 8 2 I	
מספי ווי פוצאן אינוכיפנאן מאדוכינססף אינוכיבאר	э п	HELE TUCKONING	

YAAATIBAA :	EI LHENNETTY 0/6411 EI LHENNETTY 0/9911	. GROSSKOPP, Nufellomenn (1961) DUMM, GEN.	TASS'O RELEMBERT DE RESTRANY 1155/O RELEMBERT DE BETT DE C 4, 131-165 1159/O ALCONEMBET DE MESITERRY
<b>阿米米斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯</b>		******	
49TBR2R4TT1	эт фионе ээ Аң	8 A B A A T	TROB SELL
4 5 T 5 T 5 T 5 T 5 T 5 T 5 T 5 T 5 T 5	2.1		
K <del>naakkaak</del> aa <sub>k</sub> aa <sub>k</sub> aa <sub>k</sub> aa			T 1 2 A 8Er!
d 2 1 G G T D T T D I	ลาปุ่นกายการ	<b>व</b> म	ATTT Sårr
40,144121126	ล ๆ กาด ว อ ต т т คุเ	8 A T D A T	H 64 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
<b>加亚斯安克斯</b> 英斯 英英日本本年日	7 W 7 E C	*****	ABTT 28tr
	555 3 3 8 8 5 2 T 4	3 2 2 T 2. 1	133 66T
d 3 5 5 5 T Y 3 3 A .	) ) ] ] 3 8 8 8 5 5 7 7 1	3 8 8 7 8 2	1999 ZSLL
1000011101	יוו בממפובני	**************************************	
**************************************			1 2 3 5 9 3 5 Tr
g 9 T*g g 2 g 3 J 2 T 3	) <b>าศุ</b> คควาศ[:	) <b>ค</b> อ ค <b>อ</b> ค	TIDA Serr
R 3 1 3 1 1 R T 3 9 A	יו דכ ה אכ דרב ני	1 201	
a d a d d f T T d T d by well white we have a me	≅⋷⋷ <b>न</b> ┝╸		Q 3 3 #2fr
*********	; ១៨ ខេត្ត១។ ជុំខ្	199633	1999 ESIL
คุรา⊒าอลคุาคา	`	рятят	3413 Sen
			FAZINE COUL
	L		
94 94 24 04 99 99 99		: P I K M D VE 20 25	1 1 H 96 bb
SZ EZ LZ E9 Z9 E9		ัเรั <mark>ธ</mark> ฟ้่ ∃ัท ็า ๊ เ ๋ ม ็ ∃่	3
STEN PHINDREN STEN	≳-ਪ⊓ 11 1	MBT2 RT MBMD RNTDG	1

ucleic Acids Research

8101. CHER, 257.	25-435 0.0005CHEL, C.A.LAZARUS, N.BABAK, H.EUEHT 23-633 10.180ARIS, R.B.HARLICE (1963) JL. 10.180ARIS, R.B.HARLICE (1963) JL. 10.180ARIS, R.B.HARLICE (1963) JL. 10.180ARIS, R.B.HARLICE (1963) JL. 10.433	1230 M. RANKALINA, H.FLEMARK 11940) MUCL. RETER RES. 5, 1735-1984 123 M.C. 1230 M.C. 1
	1 1 2 2 1 1 4 1 2 1 2 1 2 1 2 1 2 1 2 1	באד בשת באבערבורוב פפר פפר פפר שפונה פרוב באבער באראא בארא בארא בארא באראא באראא באראא באראא באראא באראא באראא
11881821831	7	1255 CRU REFERENTIUS NIGHT, R R G-R C T A T B C C T A R I C C G G MITO HERPHARMMENT NEWS
	3 18 4 3 1 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
BT B D D D B T R D T B T R D T R P T R D T	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	· · · · · · · · · · · · · · · · · · ·
0 0 1 3 1 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0	3887383888 T88	RESERVE OF THE STATE OF THE SERVER OF THE SE
HETZ., 217MG 900.1, 217WG Ch Th GC 76 26 95 Sh Th BE 86 NE 1	PE ES SS ES S R EL	HOLD U MATE OF E & 5 & 5 & 5 & 5 & 5 & 5 & 5 & 5 & 5 &

		-		-		<b>.</b>	-												252														
	4	1 8	9	H 3	. 9	Ŧ	·	H	<b>5</b> :	1	н	Н	<b>u</b> :	נ כ		9	9	1	1	ᆸ									1	9	H 9	9	65ZL
	1	69	HHK		<del>1 11 11 11</del>	<b>*-</b> -				1						<u></u>	==	••	•	5										_			
	벽	1	9	3:	) T	Ŧ	<u> 1</u>	ī	7	1	K	Ь	<b>U</b> :	ו כ	. 1	۲Đ	9	ㅂ.	9 (	90									1	9	Q \$	5	9521
	H	7	i a	H	TRAR	77	ิด	1	1 -	1.	н	н .	н .	٠,		r.	4	н.		4 -											9 1		9521
	٦	4	HEN	HE	, _ !###	7-:	-	·-·		1-	-	_	٠.		-	١	•	•=		1									•		- 1	•	
	ᄖ	TI	בו	T	9 8	1 1	1	1	<b>8</b> :	Į į	9	t	# S	3 1	. 1	9	1	Ħ	8	<b>4</b> ∓									9	Ħ	al	L	SSZL
		4 <u>7</u> 2 1	H	***	1444	<del>-</del> -	***			١.						<b>}</b>	FF	==:		5.												_	
	-4	<u>ع ر</u>	נו נ			13		5	1 1	1	1		9	<b>)</b> 1	. 1	ſΰ	0	9	0 :	1 7				eller a						0	R 6	3	PSZ.
	뇀	1	ח	1	1 1	3 5	1	8	כ כ	н	법	н :	o :	3 1	В	9	Ð	1	H 1	2			-						1	9	9 t	•	ESZL
	٦,	-	R.	-	-	-				l –	-	_		_	_		-	•=•		7-									_				
	볙	D E	1 11	<b>9</b> 8	) T (	3 2	1	3	ТЭ	>	Ħ	Д :	9.:	3 1	1	9	Н	9	8 I	40									1	9	9 t	5	1251
	J	eza.		ener el 1		7			3 3	١.	ы		۸.	٠.		==	== 9	_'		1.										_	9 9		OLZL
	។	~×.		(KA)		1:	_	_	====	_	Ų				_	. –	251 251	••		17									-	Ð	U 2	,	0101
	ㅂ	1 3				כב	1	3	ם כ	15	Τ	8	9 :	1	1	و ا	9	9	9	d o									1	Ø	9 t	3	1503
	- 1					1				t										1				_					_				
						1																		3	N I	F N C	) I F	1	3	H			
																								3	N 3	F N (	) I F	1	3	H			
		(NJN	養養	**					***															3	N I	FN	110	1 1	-				
	E	O 1	## 2	១ T មក	. T ;		 1	 -	: 1 J	۳	1	Ħ.	1 6	# <b>5</b>	3	9	E	9	A .	1				3	N 3	i n i	11	4 1	-		9 6	1	<b>2611</b>
	- 1	-	**	HHN	- 16		***	·		_				-	Ī	<b></b> -		-		1				9	<b>N</b> 1	E N (	0 1 F	4 1	1	ㅂ	-		
	- 1	5 C WASSING	**	HHN	- 16		***	) )		_	5 T			-	Ī	<b></b> -		9		) 1				3	N I	F N (	0 1 6	4 1	1	ㅂ	១១១		961 L
	- 1	-	**	HHN	- 16		***	·		_				-	Ī	<b></b> -		-		7				9	N 1		0 I F	_	<b>1</b>	8	-		
	- 1	-	**	HHN	- 16		***	·		_				-	Ī	<b></b> -		-		7				3	N I			_	<b>1</b>	8	-		
	- 1	-	**	HHN	- 16		***	·		_				-	Ī	<b></b> -		-		7				3	<b>N</b> 3			_	<b>1</b>	8	-		
 94 tr	9	-	9	9 2 2 Q	_#i	9	1	) )		1	9	<b>U</b> 1	# :		1	9	9	9	<b>u</b> :			· · · · · ·		E	N 1		<i>2</i> 03	<b>3</b> N	<b>1</b>	8	-	1	
87 87 p.	9	3 9 3 9	9	9 2	1	9	1	2		J.	9	5	95		1	9	9	9	<b>u</b> :	₽►	D d N	¥	×r		9	, 31	203 203	<b>3</b> N	n isy	8	9 5	1	
	9 E2	3 9 3 9	9 04	9 2	28 28	9	1	2 2 2	3 3	. J	9	5 4	95	 	1	9	25	9	5 61	₽►		¥ ¬	ץ	I H	9	= .,t.	203 203	<b>3N</b>	n isy	8 9	9 5	1	
	9 E2	3 9 3 9	9 04	9 2	1	9	1	2 2 2	9	. J	9	5 4	95		1	9	25	9	8	₽►		<b>¥</b> ¬	X P	I H	9	, 31	203 203	<b>3N</b>	n ISY T	8 9	9 5	1	

101

Nucleic Actds Research

MANTTIONA SI TEMMENIA DIVESSI

рания праводать продения праводать

1297/0 ALIGNIENT IS ARBITARNI

TBBG 1995

TBBA

888 8 6 6

1989

HETHIONINE cont.

· ADTRITINI-BUINDIHTBH

1323

ZSCL LEEL LOCE

HZZ. ZEZ1

1538

SEZI 1520

ے	
Ö	
ā	
8	
义	
<u>.</u>	
원	
cids	
Acids	
c Acids	
eic Acids	
cleic Acids	

PER ANTIC.STEM ANTIC.LOGP SHITC, STEM

_		L			<b></b> -				••				
, 8	کر ایک م	24 04	. 88 98 60 /0	. <b>79</b>	29 08	95 85 79 S 25 85 2	25 ( 9 (5	05. PI	) B 4	# ;		8 65 24 8 64 34	
	36 64	Į.	MINDNING	l.	12 31	4000 al	H312				EXTRG GRM		
		Marra	IV THEFT PRO		73 341	2001 24	*****						
A STATE OF THE PARTY OF THE PAR									the total				-
	- Anna San San San San San San San San San		Activities and a		Carry.	***************************************							
												•	
											010-400 frc 3331 60	1998, 0.55HAIDI, 9.5GELL (198	2001
						878-878			+	245-E	745 'E1 '538 BGJOV 'T	CTS'EMEEN' BIRCHOFB CTARRY NOC	
,54 SMAH 6		061-176	*************	(2841)	5081 <b>8613</b> 0	.2,0M1X2910.A.A .A.GM1X291K.A.N	1322		,M3OKA,	ē.1 ,	R.COMESON, I.C.EPERON	.a .NUTERSON, M.H.L.GERRUTUN, B.	1297
	125ナーナ!					#' <b>\'\O\$K]'8'</b> @'C # <b>\'\\O\$K]'8</b> '@'C						2"PHERECON (1221) WATHER 250"	
*9/ WSD '	בעכי פכז	JTAR	-SOME CACE	10 13L	LF. 31Eks	5240-5244 8'8' Effenson'		11			2213	Y'?"DEBB' W'Y'AYN ELLER' C'L'N (1192) T'BIOG'CHEN' 328' 2203-	
		ERHOSSON FE	KOZKI" K'BI	1 .A.S .	, MMAr: 223 AZ	# (\$541)11302.0 .4 (\$54131,131).4.	1325		04,8080	T'7 '	SCHWARZ, E.J.GUBBINS	WUCL. ACIDS AES. 10, 7511-7520 A.A. BTEINHETZ, E.T.XREGBERS, Z	1382
١	., L'COUS EI					N.O. 63BXZTTON.H						M .INAIDMIMB.A .DIAX.A .DH3d.H	1360
	١		J	בנד.		lu 699			[5034	اراءا	HECUBERANCES	CUD XENDBOS FUENIS	ESEL
96333										i 1	S R B R J B R . KKHKKKKKKKKK		ZSC1
96233				~~ <b>~</b>	· · · · · · · · ·					i	<b>医医胃溃疡性细胞肿肿性肠</b> 肿		LSÉL
19333					• • • • • • -				- · · - • • •		<b>电光线性阻阻阻性处理</b>	NDS 2374NOOR-CORS URD	1301
בככפט	gpT	₽ ⊃ 1	ַ פּפפר	3 4g	2128	n 198	) J I .	198		! ;		כשה פשכנורות בתפנורונ	LUEL
									ধ	3 1	ATTHI-34	RETHION	
				1							<del>KREKENNN ROM</del>	OTIM	
89333	DRI	ככט	2 2 2 2 2	<u> </u>	Ť 3 a h		A T 1	raq	1389	D 1	BANKAN OKNOMENS POHUTOU	CON BOALME	BES 1
בככפט	2 A T	8 2 3	2999	고시법	T D D R		A T F	9 8 6	T 2 8 R	ם ב	PRESENTATION SERVICES	* MENUR URD	1597
בככפט	JAT	כנט	3 9 9 B	2 T A	1398		RT 7	មេដ	בספר	2 I	8 8 8 8 T 8 A	* 크랑나마에 URC	962¢
99299	281	8 3 1	TT30.	TIP	Tana	E 1199	ا ا	שפו	3138	A T	TDGTDD9		2621
99199				1			1	ו פו	3 T 3 R		TDGTJJA M <del>markarakaa</del>	נאט 1807 נאט לאנונאט	1280
			7	- 77			_	-				froo BNINOIHI <b>SH</b>	
						1		1					
7b dt			+	:-+:					EL LL				
EP 11 5E						8 02 8r	4 8	. <b>"</b> ⊁⊌		6 8	2957621		
Na iciat in			Mare.	ا يا	Marie 6	-200	n a	- [	Naic 4		MAIR LYDHONINH		

D (100h

PHINOMENL STEM D STEM

AMARTEMA 21 THEMMENT 0/2552

457
Rose
cida
Pic A
Ď

) B'IRRIOLE (1881) CEFT 51° 986-500 LEMPORUE* C'U'-E'LEMPORUM* 1-B'CODOMNO (1885) CEME 50° 99-90	ejou.k.o seli edtuae.t est!	100 A.W.GRAY.D.F.(SPENDER11983) FEBS LETTERS 161, 323-327 100 S.SHARY, D.GETRANCO, R.SILDERKLANG, M.M.NOSBACN, T.SCHRIDT, E.KUBLI,	
102 VI2* 10' 1913-913	אואכר" עב	MES, 10, 1095-1076	2.4
* THE CORRAND SICHWARTHE CLMI-RIFFURGN, DIRINGREENHOLRE	866-1462 8643-0,0 6661	129 - VICHEDVA' C'EDUSVES' N'INCT' N'AMENSCHEV (LAUS) MOCC' WCIOS 129 - VICHEDVA' C'EDUSVES' N'INCT' N'AMENSCHEV (LAUS) MOCC' WCIOS	12
EN' 3-C" RENEIKH' D'EGETT (7681) MICE" HCLOR HEE' A"	3,7.0	HOTIMAL C'THHAE BYENG YOURS C'ANNE (GYNIEITS) S'SHCCOME E'BBISH	
D.DEFRANCO, M.STLRERBLANG, M.A.HGEBACH, T.SCHMIDT, E.KUGLI,	1392 2°2HVEL*	ESS .CANTATONE, C.DE SENEDETTD, G.GABALETA, R.GARLERANT, A.N.CAGGN,	EI
EM. F.C.UENSINK, D.SOELL (1981) HUCL. ACIDS RES. 9, 3847-		ess—erb 424 H.g.Korchel, C.H.Larakus, W.Basak, H.Kuremizel (1961) Cell 23,	£1
ASCETISETEGES CCCATARECCAS		<b>新阿利斯林希莱州米特尔里</b>	
	499 29	Mito אונט איא אאוע אונט אונט אונט אונט אונט אונט אונט אונט	îL.
Rabbactabbactaltaba	R T 3 A	PATO ANTILE NUMBER CUST A G T A A G T C A G G T C A G G T C A	i.
18277866776888	2 1 10	See CHURGEGPHILA YAQUBA A C R A R A B A T A R A C T R	
	110	AT 1 A DIG TO A DIS COLOR OF STREET OF SEC.	
8 4 2 5 3 4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5	R 9 8 T 8	эме сицияюсьниця мецямо, яе с я б я б је б б б б б	1
a G C G T G E T G G T C C C R T R R C C C R G	R 5-8 T 2	SEN CTU DROSOPHILD MELANO. R G C R G R G F G G C G C P	-2.
*********		MITO MANARAMENTAL OTIM	
<u> </u>	T 8 8 1 1 A	กลอกอุกปรอง 3 3 3 8 MUVIT236 MUDITINI LFD 086	11
aroodereditabeerdesele	<b>488 T</b>	פפרפרבפוד פפרפרבו	:L
48777744477767		MHKK MARKENNA OTIM	
<u> </u>	8139	CTLA CTL TO SACTORES OF THE UPO SEE	it.
a r a s s s s s s s s s s s s s s s s s	Tar TA	RT CAL GETT B B B B B B B B B B B B B B B B B B	i.
i			
		. Jnos ADTAITINI-BMINDINIEM	
8 52 54 5E 50 35 34 36 38 40 45	OZ 81 Z1 SL	EL LL	
		- L 21 01 6 9 7 8 8 4 E Z I	
METE. STEM PHITC. LOOP PHITC. LOOP	e0071 0	LOSS OF LIGHT STRUMEN	
doe: Stand ( MOTO Stand ) MOTO (I	enn i d	HETZ OF HETZ LYDRONINA	

					444			_=												-		TI.																			
t	Τ.	. :	5	9		נ	[ ]	3	1	a	ם:	9	Ħ	ㅂ	1	<b>3</b> 2	L (	8	9 5	1 1	ㅂ	ᆸ	כ														1	9	8	a	98£1
	×		#	W 163		*	HR.	<b>=</b>		•		1						6:	•	•	•	4																			
ŧ	1	9.	L	۵,	L Ś	1	ננ	3	Ţ	1	3	1 -	A	Н	Ħ	1 :	ι,	45	2 (	1	1	9	1															Ħ	В	8	CBEL
	г		t A					7				١.	н	н	1	н :		٦,		Н	н	н																ㅂ.	ı		3861
,	L					149	ENN		, <u>.</u>	, ÷.	-	1	~	~	-	•		١.			. <u>.</u> .	-	•									•	•	•				_	-	-	
t	1	1 :	) (	Ð.	. :	נינ	נו	9	1	1	3	1 8	B	Ħ	Ð	3 2	L I	9	3 6	H	9	ᆂ	3														1	9	9	Ħ	9861
	H		131	ж	141	(F)	131	62	•		-	1			_	_					•		_															_	_	_	
t	٩.	L :	] !	3 .	L :	] ]	ַ ַ	3	1	1	3 :	30	Ħ	Ą	9	נ כ		1 5	3 2	8		7	2														T	9	a	0	FOET
	l٠	, "			LES!			۱,	ā	1	7	٦,	н	н	9	<b>-</b>		1 9	1	H	=	4	•														3	H :	9	B	0961
-	1	×	H	HH	(M)	H	tw.x		_	-		1	-	~	-		•	٦.	; -		٦.	7	•														_	_			
ŧ	Í.	L:	9	9 :	9	9 5	3 3	g	Ħ	g	2 :	*	Ħ	9	Þ	1 t	5 5	0 5	) ]	1	3	ᆿ	Τ															9 .	1	U	BSEL
	'n		*	241	١.	**	t <del>e</del> s	==			==:	•	_					<u>-</u>		٠.	. =	1																<b>u</b> 1			SSEL
t	1.:	 Си		٠.			בַ נ	7	Ţ		J .	1	J	0	Ð	H 1	١.	Ų:	9	1	. <u>.</u>	7	1													٠		•		U	336.6
	Г			,			ĒН	н	н	1	<b>a</b> :	1 1	_	н	н	3 9	١.	J E	9 6	В	1	1	1															<b>b</b> .	1	Ľ	7SEL
	1	•		-			_	ľ	_	_	•	1-	-	_	_			77	_	•	_	٦	_																		
	1											ı						!				1					. 1 n	103	1	ROT	DI.	TIN	II-	34	IND	CH	13W				
	L											1						1				1																			
	Į.							L				ļ.,						Ļ.																						-	
84 14	2	•	0	2	V2	•	99	1	84	Z	9	þa	•	2	9	S	Þ	5	25	i 1	20		*		1	H		Ж		ī	9		=		3	H	8		•	•	
SL EL		4		ES	•	۷5	1	39		38	LE	4 (	S	2	5	53	,	25	3	١s	8			ď	K		7		r	H	ı	ಕ		Œ	8		CÞ	5	•		
	Į,						HE				LE	,]		~		العا			47		ЧI	ı								est.			<b>—</b>								
	***		,			819.2				343	- 21	Li .		du		51	•	,	~=		91	•																			

1203\0 WITGHNESS IS VEGILIERY.

r
7
Ţ
ď
ď
0
Ξ.
3
4
.2
5
2

еме фиссоруили менека инжини престсретт беб пересытреретере стра	BSFL
TIDETARABLIADER ATARTATION TELEBRATES TO THE TRADE	82Þ1
татот на в в в в в в в в в в в в в в в в в в	CEAT
аатот да в в в в в в в в в в в в в в в в в в	95+1
TIT BY A R A B A D A D A D A D A D A D A D D A D D A D D A D D A D D A D D A D D A D D A D	99*1
от ребельные илил. в сттовор и сторотт вет перестренения илиле в сттовоть и пробраменты в сттовоть по по по по по по по по по по по по по	ナミナル
ENH XENOPLE LARVIS ELEGIANT A DESTINATION OF A DESTINATIO	©S≯t
	75F1
	1571
	20+1
тво од на вестрава и на вестрават и вестравати в в стана едина в при	LOPL
эм Ем Х сы Сы ты на	
Σν 0ν βε 8ε νε 2ε με 6Ζ 22 β2 ν ΖΖ β3 β2 ν ΖΖ β3 β4 Δι β1 ν μ Ζι 01 β β Δ 9 β ν ε Ζ ι	
- The second sec	
האנאסמכאב גזפאן מינוכיבספי מינוכיבספי מינוכיבספי מינוכיבספי מינוכיבספי מינוכיבספי	

7" BIDT' CHEW 1221 Y20-752	
A.C. "ILLER. B. AAARUT, A.SHIIH, D.G. TRILUR, G.M. TENER (1987)	
N'S'YOGIZON' C'B'YZIETT' B'D'GETHNEL' I'C'BIFFHN' B'NBIPZKI'	1424
R.G.GRESSKOFF, H.FELSTWAKH1981) CURR.BEN. 4, 191-194	
R.MOBAYARNI, T.SERI, K.YABINUMA, K.KOILE 119811 GENE 16, 297-307	1429
VCIDS KE8* 11' 8233-1247	
LOOR (CAY); JJ382, B, DARAY, 3, HT IRS-REMNIE, H, CERTA, B, DAR, L, NEJORAD, V	LS+l
FRUC. MATL. ACRD. SC1. USA 75, 190-194	
P. UALEBRUELA, A. VENEDAS, F. VERENERG, R. BISHOP, W. J. GUTTER (1974)	VE+1
POCERE'S'VILLYMDI(JASO) CEFF 16' ARP-STY	

	VNDEHBOM E1 NT" (1881) WAJONE 580' 185-492 978-973	1 (22
	ארפיצמבכאבד' כיטירשלשעתפ' איצשפאצ' איצחפאבבר (1946) בברד זק'	9591
ī	F. MUELLER, S.G.CLANCEUM (1980) CELL 19, 345-353	1423
	E'ESFREN' C'AVHOLENA (1870) NOCE" NCIDE KER' B' 1822-1845	7725
ŀ	CHEW 524 21332-11340 ·	
	.Lait.t (66%) k0213%co.a.t _mam1.G.K _k[TAAK.3.k _#2JJIR.J.G	1571
ι	SIDDIGUS, J.F. Ne. Wildes, B.A. ROEKISGS) WICL. ACIÓS RES. 11, 4279-4329	
	1. SCHEARTZ, RA.KLOTZYT,O.ELSEVIERS, P.J.GALLABHER, M. KREUSKOPF, R.A.O.	1405
1	EAGE-CLOS ,L1 ,23K 2013A.JJUN (5891)ARUXJHRI.H.JHUO.H.AGAAAY.Y	
	STATEMENT BERANDED (1893) MAILTE MOTOS MEST III 2393-2554	1076

MERGORGONA	Moverenttt	p==ek#80;5	
930011	ฏือออวปุวาคควาท	20222	Taba ezbr
A DA A A TA	221RA 8882	T T R D D T	1456 A 6 A
*****	H		-
4248 *****	1110000111	883193	T 2 3 T 73+1
4 3 3 7 7 4	<b>ค</b> อควคววร	818133	1995 33PF
***********	M=,= 2 00 0	*====	
43444	дээргэ твэвэ	12001	8 9 8 9 8 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1
43.999371	3181131888311	ត្នគ ម គ គ គ គ គ គ គ គ គ គ គ គ គ គ គ គ គ គ	TOOA PSP!
NAMES OF STREET	#=== <u></u>		
ADEBUTT.	ที่ อออว์ วี่ วาคอวาที		TOBA CENT
. คืออีอออ	gananatreati	<b>1111</b> 3	1998 St.
**** *********************************	7		
, u u e e e e e	######################################	891919	コロゴゴ パミシャ
4356933.	ทูอคอววาราคอวรท	9 9 7 T 2 J 2	1402 GT 6 T
************	#== ===== <u> </u>		
: כפשפככש	<b>ว่</b> ว รองว่า	9939 <b>9</b>	TOTO POPP
		эміны	<b>BHENAF</b>
94 24 04 99 99	#9 ZB DB WS 9S #9	75 05 86 A U N 7 9	7
		6 1 K M O 48 50 52	3 7 8 8
	1 1		_
M3T2 JYZRONIM	a M312 atr   1002 atr	H3T2 3T   NSFD RATO	3

35.01EHGE	ON INCRYASTINE	ŦΣ	FEBIOIS.	1313V	/E/9511	
ZEONEKCS	1HTERVENING	LE.	REBIONE	RETTER	1125123	

_
छ
ea
9
ž
62
72
2
⋖
.2
<u> </u>
Ü

VANITIEM ET 1	MESNACO 1-14 - G/469 \$	TANATIONERS 22 NATIONERS CALLS.  TANATIONERS 22 NATIONERS CALLS.
401016133161	]	1352 R C C T
Retainatere	<b>3188231121911</b>	1188 rz <i>\$1</i>
######################################		1999 E051
<b>阿奈肯阿<del>尔尔里里</del>斯斯克克</b> • • • • • • • • • • • • • • • • • •		
######################################	4=    기기 : # # # # # # # # # # # # # # # # #	T a a a soet
<b>ต</b> [ยคออาหา[อง тว	. <u>ม</u> ารลดวา บุลอดกฎว	1581 R 5 6 T
		PADLINE
##### ################################	democra	
KHXHAK NAKAKNIPAARARA G J A A A T A J J T J A		n ∂ n ee⊁r
<b>4</b> 0 9 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	म् <b>बर्गन्त म्यास्य विकास</b>	ਸੂਰਸ 8 <b>6</b> ≱।
	<b>6860267333068</b> 7	g a g rapt
F 6 6 7 7 C C 7 6 6 6 6 6 6 6 6 6 6 6 6 6	3178883778832383 **(	1919 99**
7		
		thes SMINDLALMENT (
94 +4 24 54 55 55 55 55 55 55 55 55 55 55 55 55	K H . O +6 20 25 24 26 27 84	I 9 3 3 8 80 60
	18 85 25 95 65 15 64 4 N 7 C	H 4 Q 8 21 SF
MGT2 JYCHONING MGT2:	ati 9 <u>00</u> 0. न⊺ ∤ N∃12 =1 (	NAC RATXS

4		's	11 55 562	173: 144: 146:	E) ( C *( C-E)	111 327 227	TI "H	192 CHEI 21	23 19	8 K 101 Kue Gu,	137- 144 18 1	אַכ טי יביי אַני	189 189 (ES)	м. е ул ул ул ул и, и	( 1) ( 1) ( 1) ( 2)	E	7.00 7.00 86. ASA	אינים אינים אינים אינים	' ''	1 801 1 134 1 3 2 1 1 3 1 1 1 1 1 1 1	THE STATE OF THE S	9-5 319 519 510 510 510	129 114 113 114	t	122 122 120			(11	86 E 1	. 53 . 53	14 \$1 111,011 111,011	45°	JA .	31 04 07	OM *84 *24	30°	6 23 12 146 161	E1 (2-) (4) (1)	. J.	114 114 114 114	252- 8 ,8 6 (8) 6 (8) 6 (8) 6 (8)	.1.: 4 ,1 501; 7 (01;	(094) B "11 B"10 (12) C"12 G "12)	25 3 1 T. 8 8 3 3 6 N	#05" "T (	100°C		381110 VOV30: VOV30: VOTO 10 VOS-21 VOS-21 VOS-21 VOS-21 VOS-21	173 271 272 383 383 383 464 467 464	6671 9671 1771
			,											٠.,	ŕ				ı									ı		٠.				ЖĦ	H N I		H W I		tes	·						011	CH.			
9 t	1 6	Ħ	9	d !	0 5	2 (	ì	1	1	כ	1	1	1	╡'	9년	7 9	3 9	9 6	כ		1	9	5			Ħ	Ħ	ď	<b>u</b> :	ב.	<b>5</b> 5	b	1 5	9	Ħ	T	Ħ	9	Ħ	3						156	J.	99N	i	2521
H					9 6	1 6		. 1	d	6	1	1	3.	1	Ţ	 2 S		9 н	١.			ถ	9			Ł	0	٦	N '	·	 J 9	ıŀ	1 6	**	**		ikk Q	S F	ᄖ	*	٠-,	ו נות	N S	П	319	<b>яз4:</b> Оті		990	ſ	1881
			-	•										7	Ŧ		1	• • •	1			_	_			-	-	7	•••	• •	• • •	1		w=	##	416	×		ij.,	ē										
9 ]	. 4		Ξ.	0	9 9	9 5	) T	1	4	9	9	1	Ħ.	3	벽	J .	} !	9 9	שו		1	9	9	Ţ	1	J	9	ㅂ	٦.	÷.	įδ	4	, 1	[5	Ħ	t Heis	9 1	9	9	כ	5	ורו	TEL	15	511	ПІЭ	1	aau	•	EOSL
9 6	9	כ	회	1 !	9 5	9 5	1	1	1	כ	9	2	1	╡	4.	1 1	3 5	9 1	U		1	g	9			1	9	t	1	3	1 5	9	1								937	9 5	ITI	Œ	바신	OKE	O	990	7	20SL
9 9	1	5	1	8 1	9 6	٠,	3 1	1	,	H	9	·	: כ	<b>1</b>	ď	<b>.</b> .	9 t	5 9	1		1	9	9	1	1	1	9	4	;	ï	 2	J.	1 1						1						<b>7.L</b>	<b>39</b> 5	44	998	:	LOGL
		_				-	_	_			-				]						-	•	_		_	_	_	1	-						_	_	_	_	_	_		3	N			8 6				
	••		4						1			• • •		4	ŀ	•••	• • •		l					٠,				ŀ	• •	•	• • •	ŧ			<b>##</b>				-							011				
1 2	7	9	4	H 1	d t	1 8	9	Ţ	7	ย	כ	9	9	비	4	ָבָ כִּ	l t	1 4	1				Ħ	J	3	ב	4	Ų	Ţ.	Ļ	9	비비	1	9	1	Ħ									<b>₽</b> 3	MIN			E	EEF1
1.1	ב	9		H 1	9 5		. 9	1	5	н	ב.	9	8 (	١,	ď.	ם כ	1 1		ł			н	כ	н	н	1	н	ď	1		2 9	١ŀ٤	1 1		ran J	H			1						_	011.1 3506		888	•	96Þ L
			·Ŧ			_	_	_	7					-1	ጉ	= . :		•	1			_						ŀ	7.	<del>-</del> -		ľ		¥#:		HE	483	W	1	<b>R</b>					-	OTI	Н			
9 1		9	4	H 1	3 6	יו	9	į	귀	Ħ	3	9	<b>5</b>	3	۹.	ַ?	) t	ָּוֹ יָּ	1					Ħ	Ţ	9	<b>H</b> :	۴.	Ļļ	Ļ	פַּכ	å	1	โอ	כ	Ë	Ţ	Ţ	-	9		* 5	ENI	רט	Si		X	<b>UU</b> 9	•	LEPL
ו כ	3	ב	1	B t	d 6	1 15	19	1	٦	범	9	9	H	9 1	Ы.	J F	1 t	1 9	ь		1	9	9		ı	ī	<b>9</b> 1	ч	ב .	ı.	3 9	l	1	٦	9	9	Н	Ξ								ZZIŁ		HH9	(	09 <b>)</b> l
		_	7				•	•		•	_	_		1	1		-	_	1-		_	_	•		_	_		7		_	- :	Т		1	_	_	_					_	<b></b>		<b></b> .		_			
															İ																									* 3		3	MIN	its 1	AFC.	Ner	•			
		•••	t	:	•					-				+	<del>,</del>				<b>}-</b> -									+				t-		┼-						•										
EI-		<b>0</b> ≥									Æ			Þ	_	272		, ZZ	z	Ξ,	02 1			<u>.</u> 4	L 9				ا اح		L OL	la	م ،	١,	g	c		£	z	L										
									ı		_	_		1	Г	•		•	Γ	•	•			_	_	-	•	1	_			٦	_	-	_															
MB1	5	JII	MR	•	400	rt.	31.	INE	, 1	16	112		ш	NE	1	ΗE	115	5 Q	1			ď	30	1 0	I			L	WS.	15	0	J		H	316	;	K.	**	MI	ΗÜ										

1494 M.J.BEBE, R.B.VAN ETTEN, C.I.EKIGNI. T.U.DALGERG, D.A.CLATTON (1951)
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150
CELL 26, 262-150

991

991

991

T. 8 8 R

1998 1994

1998

901

8 9 I

PROLINE cont.

няя аятхэ

86SL

169L

889L

SGSL

E6SL

ZESL

**899**1

<b>Nucleic Acids Research</b>	_
eic Acids I	듄
eic Acids I	器
eic Acids I	8
eic A	E
eic A	Ë
a	ĕ
Ž	
	Ž

																			4871	PC108 WER" 10' P411-9	*130 MIEF*	414
		<b></b>	214-5	126. 66	ופרי	10 . JOH	'r (£1	TOUNG 119	9 ° C							ANUM	EMSI	4°5 1	ATRI.Y	.aguetan.# .AwaxiM3CH	EKLLY' U'	1284 1°2
43:	JM62.7 . 6	06793.3	1 - NO	8 KDO.A	A .	fi. f DAME	J. J. H.	ACERSON, A	1.8	1284									613	ACTOS RES. 10, 6411-6	*130# (Z#	61)
		-	P>-459	1045 3	LUT AT	1 61841		T3 MORREON		Z451						A MUN	ths i	1.8 ,	4181.1	ANDESTAN. X. AMASINEEN	EKIAY' B'	2.1 6921
******				4			991	-LP1 192 T	133		1	121	+-601	17'48	.83	¥ 50	CON	מעובו	(1241)	3,12,1000,1,2,0AL3E	3. G. K. UH.	1245 7*0
CIVATE NO.	77113.4.6	.08341	טיאימש	LINDIA	1.T.C	TTEN.	i MAV.	A.A .8818.		76S1											1005-6	26)
												• 1	H (	3 X E	Q[JY	כדי	ON C	(118)	30K.A.	D.F.A6. H.K.WELSON, 8.	"OKOR" H"	1°f 8551
				61 <b>+7-</b> 13	17 '0	11 .E3A	FOIDS	183) MICE'	(1)												521-441	
	4.89	ainein.	2 , ATA	T.Y "AO	18TAI	A AM	77 I HS1	N.A .AYIES	1.1	1262		7	3K35	1228	THIE	41.6	"WOIL	LLOSI	3,ARIA1	. N. AMUNJOAY . X. INBAYAS		
_																						
	IJ					(	` .I.					- 1	٠.		'I	拼教	HHH	MM	發資資源	Q.I	IM	
A D T T i	ខាខ១១	D T T	. 4 э	9 6 7	1 1	ו ט כן	9 9		t	1 1	8	ㅂ	1 1	1 5	1 6	ᇽᇽ	8 5	9 9	9 4 3		CB 990	1228
	<u> </u>		1:-				. 1					- 1	- •	• •	1	MM	***	***	XXXX			
A R T D i	ជាក១៦	911	· ДЭ	2 R T	시그	TAI	9 9		A 1	1	A A	ㅂ	1 1	1 5	ט ונ	ᄬᄬ	8 5	189	כשפ		이번 되었다.	<b>/85</b> L
	_j					٠٠٠٠	. 1				-	1			1	M.W.	***	-	*******		IH	
82136	2] I 9 9	9 I I	ДЭ	947	3 4	1 6 1	병되		t	1 1	18	뉍	11	19	d la	1 9	H 6	191	CHE		DM 99n	9851
	-1		<b></b>		1		•					7		•	1	THE	-	# MW	HHHHH			444
90939	6 C T [6	ÐЙT	1 2	9 D T	킈圠	TR:	9 1 t	1 19	9		99	ы	1 3	1.6	ıl a	d 1	9.3	1 :	9 9		REG 698	56S1
	~						•   ]		_			7	-,=	. <del>.</del> -	7-	100	-	-	****	-	DG 550	50.5
96801	BITBE	D A T	T 2	9 7 1	J L	189	9 1 E	1 19	9		9 8	ы	1 7	1 9	9	1 1	ดา	-	9 9		RS 339	F691
	-						• -1 -		_			7	:		-	٦.,			CHARA	-	OG 230	<b>PO3P</b>
96939	3 T & 8	8 J T	ДЭ:	9 3 1	ᆲ	T B 5	3 3 6	19	ด		9 9	ы	1.3	T a	6	<sub>'</sub> Г''	6		9 9		EGG R89	EES!
	-			****	-∃7		- 7		-			٦			1-	٠.,	-	***		•	00 231	6631
9697	3 1 9 9	931	<b>11 3</b> 1	9 D I	ᆲᆲ	184	3 4 6	1 19	9		9 9	нł.	1.79	1.0			ดา		9 9		כפפ אם	2651
	-		7		-17	- 7 - 7 - 7	7 7 7		-			٦.	*.*		17	1	-	== -	KEE	DT		COST
RADTE	១១១១	0 1 1	ر د ان	9 4 1	ᆒ	1 14 1	4 6		u i						. ما	J.	~~~	~~ .	כפו			
			7-		77		7		0 1			4	*,÷,	.÷ 0	10					* SIVERLI AUTON		855 L
*40116	1 1 9 9	911	1 7 1	пнп	ᆒ	1 H 4		r	_			J			. I.				付更を書	OT		
	1		7-		44	700	, 510	•	0	1.	ם פ	щ.	1 1	T A		49	8 8	9 t	183	# AGVIJ T	1990 B	ᄯᅑ
	1		ł		13							- [				1						
	ľ		1		11		- 1					ì			1	1				igorīME cont.	ď	
	i		- [									- 1				1						
					$\perp$							- [		•	1	1						
ZÞ 01+	DC GC				IJ							٠.			†·							
		E EE		S_92	严		.22[_	8 OZ (		۷١_			i i		1.	1						
U- 17 GE	1	m th	ÞΕ	66 L	격 1	52 EZ	;	A e!	병	81	L Þ	ᄔ	てし	Οt	6 1	<b>4</b>	8 8	<b>≯</b> €	2 1			
MELE COLLIN	M (565		. ا ، ــ ،		.1.1		!					1			l	1						
AGTS SITN	ו טעט	L.DITM	7 1 HEL	re, all	MD r	HELL	<b>-</b>	æ	ורסו	T.		1)	<b>GIIS</b>	0	i	1 NE	U5 '	NO.	DNIMA			
																			_			

### 48 ## C ## 63 ## 54 ## 55 ## 55 ## 63 ## 64

(1962) MUCL. ACIDS RES. 11, 1594 #-1.8164 FT AL. (1961) MUCL. ACIDS RES. 12, 6412-643  1594 #-1.8164 FT AL. (1961) MATURE 290, 457-463  1594 #-1.8166 FT AL. (1961) MATURE 290, 457-463  1594 #-1.8166 FT AL. (1961) MATURE 290, 457-463  1599 #-1.8166 FT AL. (1961) MATURE 290, 457-463	(557) E.KOJKE.H.KOBAYBMI.X.YAGINUMA,N.TAIRA,  20. 377-165  1352 J.F.H.4080, D.P.Ab. R.K.WILSON, B.A.NDE  1593 J.C.HUJA.D.COTE.E.LUMO.J.E.OALSEBOLY93  1594 J.SEKIYA, R.MISHIZABA, K.MATSUDA, Y.LATY  1595 MUEL. ACIDE RES. 10, 6413-6419  1594 M. A. A. A. A. A. A. A. A. A. A. A. A. A.
2 18 6 17 12 18 18 18 18 18 18 18 18 18 18 18 18 18	

0.45740 M. LOSHERM 15 MEDITARAN 16 MEDITARAN 16 MEDITARAN 16 MEDITARAN 18 MEDITARAN 18 MEDITARAN 18 MEDITARAN 18 MEDITARAN 18 MEDITARAN 19 MENDENT 18 MEDITARAN 19 MENDENT 18 MEDITARAN 19 MENDENT 19 MEDITARAN 19 MENDENT 19 MEDITARAN 19 MENDENT 19 MEDITARAN 19 MENDENT 19 MENDE

				959-93 <b>3</b>			Sec. 20 ( ) 1   1   1   1   1   1   1   1   1   1	SCL. USA 80, 3309-5311	
, 23 J	133 (1841) 132:	TRANT' H'KREST	רשבשעתם" א"ם	שים-בחברשבר בים	ECRE		RADA - JTAN - 2087 (EST)	B.P.KAIME, R.BUPTA, C.R.40EBE (	PQ9 I
	915-406	101 (517 31)	D'EGETT (161	15500 118000 11811 1181 1181 1181 1181 1	Z97 I	SM31133 8434 (*	THAT INC USE TAT TAR	127*159+151 A'W'XBLOKOA'A'K'KEEMSEHKO'V'A'I	****
	E>1-SE: "	. K30 .AXUS	ARTIK (1981)	N°5'' N'5'' N'C''		1//0	FORC IT THE WATER	C.J.GREEN, B.S.WOLD (1983)	ÉDST
180	16-2501 ,225 .!	NAHO.JOIA.C	93FD£L [1450]	21'V "Z1EMC4"0"S	1595	1445	-1976 111 SAN WILLIAM -	C.J.GREEN, B.B.URLD (1983) KUEL	1004 1003
(7. THAT I THE				267-262				(21-121-12)	1071
1 1901411	** ***********************************	. M.FSI GOARRA	1316304.0 .1	R.E.RAKER, A.E18E		BH31137 SH34	OF INCH " O . BULENCE BUTS	V.A.ERYUKOV, V.H. KSENZEMKO, A. U.Z.	2001
	1410-100 0	. 121 20136 . I	1161) T	4.8.FAGE, 8.9.HAL	ospt			ZAV-AR9 *Q/	
134#1#25"d"#	. enecc., J. 48E L61	'G' WHE 17-19-	MI THE SORE	M.C.OGDEN ET AL.O COCO SPATNE HARD.	45.00	.A.S.U.13.01	ATALISED PROC. NATL. ACA	B.P. SAZZAKA, D. PUNKETT, W. H. FICCLA	
•		4 4444	AT AME (060)	14 T3 W3000 3 E	8771		166-566-1651 "1818"7	BULL (DBFE) HOSZZBALL (MBARDT-A	1041
10417			T (****	1		11	MANAGE NAME OF SERVICES	DTIM	
10817	POBIL	<b>3</b> 8813	ជាជាប្រឹម្	<b>4</b>	19	RIBITIDES.	T D R D R D R .		2591
янтэт я				.]			KK <del>rnernken</del>		F33+
		20201	44.5.9.9	da TTD a	7 9	nassina.	<b>ガロエンロンエロ 3</b> 4		Z591.
ា្តមារ ខ្យ	FEETA		ebalia e	n 199			<b>医牙牙利格里斯斯米格里格兰斯</b>	STIN	
		<b></b>	- F		•	사비가 귀려비	រាក្រភពភាគ១ខ	פכון גבוופו	1591
T T T 2 T A	ппорт.	ក្នុង១៦៦	# g > 5 5 6	q R II 9 9	1.0	ele o o de l	11388338	(551	
				1		9 7.2.2.9 7 4	4 + > 6 6 7 8 8	T293Y R2A	19 <del>99</del> t
737378	"ד כב ה ח"	3 6 8 8 8 E	<b>៨៨១១១</b>	q R TT 88	19	de c c e b	ชุค วิศ T วู อ อิ	19:81 190	6 <b>&gt;</b> 81
7 14 1 3 7 14			<b>]</b>	1			HHHHHHHHHHHH	ا دین مصنوب	OFS;
	*10271.	19901	ងា ១ ១ ១ ១ ១	ដុំ៥៦១៥១១	יפ כ	40323191	ם. פככסססססף	1184 <b>706 508070</b> 47 <b>06</b> 893 (	909L
ក្ខភភក្ព	ннявы	1 4 9 3 3 .	- J. J. J. J. J. J. J. J. J. J. J. J. J.			. [	<b>阿里男女长男男男母女生女</b> 皇		
			a		13:	marinana:	<b>ខ្</b> ត្តម្ត <b>១១</b>	21 32 <b>11-1</b> 439	90 <b>8</b> L
919998	813913	: פככל	ричер	4891399			<b>一大大学的大学的大学的大学</b>		
			J 7 * . * . * .	7001305	15:	ねゅうかせゅっ	1899999	CCH BUCIFFIE PRELIFIE	<b>1091</b>
607766	A A D T T 2	19801	ปหอยอา				6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		
			77	7		46.5.5 40 7		EITLER SOTTLE BOD (	E091
<u> ខព្</u> វ១គុន	A B D T T 3	TBRT:	1 H H J D :	1 1 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1681	กุอวอยุอค		Cr Wattama	
			• • • • • • • • • • • • • • • • • • • •			7	FREERRENGERM	* at 33744 A3U 3	209 t
2 1 7 1 6 0	agait:	119923	ははつるてい	811188	101	ศอหาสอง	8 2 2 2 2 2 2	+1 338HT R3U	LOSIL
4		1				77	100000	AY DEGLES COLL	HUSL,
1			l i			1 1		2 E K I N E	
•		1	11	1			J		
	***	L	11	L			· ·		
3F 40 45	9E ≯€ ZS	06 65	3Z 92 ZZ	G 07 0	4. 6.	T			
CIF IT GET 4		LE 62 ZZ	[[b]" <sub>[]</sub>	E OZ SI		.Fttt	1		
		<b>س س</b>	7 r~ ~	~	i er M	니 zr 메드 메	12345B7		
HBT2.JITHA	FAMILIC . L.DOP	HEITS TOTAL	ėj vaus d	4007	n	Hare of	Care alaeman	•	
					_	- 41772 A	HAIR TANK		

<b>医内脏性 医外侧线管膜内线线 (1)</b> 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	pennessa)	1111111111 111111111
atatatantea	1 4 4 8 2 1 1 2 1 2 1 4 2	T113888113881 638
######################################	ฎาคุคคุว า กุล อ ค ว ส ว	BEZ TEGECTCTECCC
東京 <del>日本日本</del> 日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本日本	******	
### ##################################	1	
_garatragaet2	танаэттаанааэ .	33338TTT3888T 058
SECTION OF AN AM	20168112482	פפכונופלככפ נאפו
M##################		**************************************
	11889 1 1 2 3 3 3 3 3 3 3 3	1006 TGCCTCTCC60
8 3 3 7 7 7 7 7 6 3 3 3	ุ่รวดควร ซุ้อออร <b>ศร</b> ววล์ รัก	
Personation of the Community of the Comm		
***********	vz 1111	117 11774
A STATE THE STATE OF THE STATE	1 R R B D T 1 8 D B B B B B B B B B B B B B B B B B B	)
<b>1337133</b> 811163 <b>∃</b>	тря ортибрия для бары	
בבדמובנכנכוכם	ווו כמוחפפריכממארן אין	
		2 E B I N E
	<u> </u>	
	K W D 46 20 25 24 28 29 BD	1 9 3 ) H 8+ ++
27 E4 17 69 79 E8 E8 18		r H ∃ α 8 ZF SF
HETE JYDROKING NETE TI	400J 41   M312 41	HRR RHTX3
		_

1725/12 WEIR VERIDGE 11 INLEWARTHE REDGESCE 1946/12 WEIRE WERIDGE 11 INLEWARTHE REDGESCE

1602/0 EN RETUEND ET.BL. ALLENENENT DEVIATING 1606/37 PUSSIBLE SITE UF INTROM CLEWANSE

Nucleic Acids Research

_
Serc
Rese
ş
ΑĠ
ė.
일

	h	HEER	***	M M M M	-		= =						1		2.0		1												
	44	出来を		医骶骨靴	뭐 -	- T	 ==4:	4	•	t U	ы	Ţ	4	ese Tâ	ы	9	1										1	1 5	B
	되고	7 2	1.	L,L	ī	J 1	۵ :	1	1 t	1 9	3	1	4	9	9	9 5	e										ŧ		. 9
	5 H	### T T	9 J ###)	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	9	ם ס	6 3	2	1 1	u	כ	ï	1	1 [	g	1 :	9										* * :		Ħ
	된근	T B	***;	9 9	42	9 1	כ :	Ι.	ם נ	ם נ	J	1	4	9 9	1	3 5	2		9	9 3	בו	י כ	ן פ	1	1 1	2			1
	σĜ	1 9		-	<u>1</u> 2	9 1	2 :	1	H F	1 4	3	Ţ	T,	9 8	Τ.	) i	6		9	- ' -	, , , , , ,					ייי כל			1
	10	1 1	3 1	# <del>!!!!</del>	13	_ T	1 3	þī	U t	19	٦.	μ,	4	9 9	9	9 6	ט					-				_	ı	. 9	1
	9 j	T T	RMMN T T	L I	9	9 1	H 1	EH	T B	<b>.</b>	ī	J .	4	1 1	ä	5	2										1 ]	פו	1
- 1	ᄖᆲ	Ť 3	1 1	11:	9	9 1	A :	HΗ	) t	H	Ţ	J .	T   5	1 1	Ħ	<b>=</b> :	2											3	
		ב כ	1 1	1	Ţ	3 I	н :	1	8 6	9	כ	1.	ין נ	) [	<b>9</b>	9 E	1		t		A :::			. ц	1	9	 9		
					1			ŀ					l			٠						٠,	uo	3	-20	418	95		

#.D.HMIL [1991] MATURE 291, 444-467 #.V.OLEM.E.E.ANGE,A.ERYEWC,P.U.FIFER,A.MORTHINGTOW,R.B.DUETSS. J.R.REDARL, FREDRAN,F.SHEERERA, CAREL J. INDL. SIGL. J.R.REDARL, F.R.REDARN,F.SHEERERA, CAREL J. INDL. SIGL. J.R.REDARL, F.R. NUMB. D. LIFTON AN, R. R. WILSON (1963) FERSONAL CORMUNICATION FERSONAL C	254-752   ANTENSON ET AL. (1931) NATURE 270, 427-453     1.2.   ANTENSON ET AL. (1931) NATURE 270, 427-453     1.3.   273-732     1.3.   273-732     1.3.   273-732     1.3.   273-732     1.3.   273-732     1.4.   202   202   202     1.4.   202   202     1.5.   202   202     2.5.   2.5.     2.5.   2.5.     2.5.   2.5.     3.   3.   3.   3.     3.   3.   3.
ATA 2 A A A A A A A A A A A A A A A A A	MARIARMAN OTTE
	日日日 1 下フコロロコエロロ「Tag * PallyPTY FLIH*DEOND HOU E88F
กุล ลา การ เลือน วาย ตัว อา ตุล	TESZ VERKEMORUS LAEVIS RRBRARA TEGE CRB PGT (
7 Tag T Tag T a a T a a a a a a 4 1	1987 GCU XENDPUS LAEVIS* GARCTTG PCTGGG CCC
Tarainantiinanan aan aan aa aa aa aa aa aa aa aa aa	HH MENENH HE SD-ITS
	TOTAL CONT.
	TENTH WAY GIVE CEST PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER GEORGE PER
ลดดอง เมื่ออง เคียง คือ เคเื่น อื่อ	
αιριμοκιροισουσομο	BIRT BERRANAN OTH COL
	HILD RAKERBERSHEN
	1858 GELL #MPMU∺ LED 88281
า า กา คุดคาวอาทุาคาคลุคคาย ชุง คาออ	NITO HEFEREILLUE MIDUL. G.G. G. D. D. G. G. T. T. C. C. D. T. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. D. D. G. G. G. G. D. D. G. G. G. G. D. D. G. G. G. G. D. G. G. G. G. G. G. G. G. G. G. G. G. G.
	SERINE cont.
	a- p- v-
	A ST AN ST OF BETARRES!
HBT2.DITMR MTIC.STEM RWTIC.LUDP RWTIC ()	ום ! אפוב ו אפוב אבאסאנואט
	·

	ביי ביי	

K.D.EROWN.E.G.PRRDER.A.MARG.A.C.WILSON!1982) J.NOL.EVOL. 18, 225-239 W.D.ESDAWN.E.G.PRRGER, A.CAMO. A.C. WILSON (1982) J. ROL. W.D.ESDAW. E.G.PRRGER, A.CAMO. A.C. WILSON (1982) J. ROL. EVOL. 18, 225-239 NJJEROW. E.G.PRRGER, A.CAMO. A.C. WILSON (1982) J. AGL. EVOL. 18, 225-239 NJJEROW. E.G.PRRGER, A.CAMO. A.C. WILSON (1982) J. AGL. ECLI 26, 167-180	H.DEMO.R.GEOGRAM.GEOGRAM.C. 8. 1015 102 103 103 103 103 103 103 103 103 103 103	##91 4991 499E 999E
ววคลศุอชรวของโรคอคลีร์ครคอ	S GCU MUNICA TERRESENSIA SERVICE SERVI	
	BATINTO CERTAMMANANAN TIM BATINTO CERTABABIT * SELOM COD E	1 222
> 0 2 7 2 4 4 7 7 5 5 7 3 4 6 6 7 5 6 7 3 4 7 4 7 5 6 7 3 6 7 3 6 7 3 6 7 3 6 7		6/81
******	HERMANNAMEN OLIN	ale r
<u>วาวาว</u> เลยาวอามุลดอกญาค		328 L
1921388128138181	кинденнымин О11И	
	אנום פסגורלט, פטפטראאאאא אונם פ	<u> 1877</u>
าควาทุคศาวอาวาคคอดพุน		⊒ZBL
	HI WHENKER TIN	YES+
า ว ถ า ทุก ค ท ว <b>อ า ว</b> ค ค อ ค ค ท ก		398 L
	MAXXXX MAXXINA OFILINO	
10001661061061		188
rajoja a roja a roja a sa a sa a sa a sa a sa a sa a sa a	CHOTHO	
	1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	(99L
TROTHRETO BIOGRAPH		1991.
******	1 2 1 2 1 2 0 0 0 2 0 2 2 2 2 2 2 2 2 2	. <del></del>
្ត្រ ប្រជាជម្រាជ មានស្រាល់ មានស្រាល់ មានស្រាប់ មានស្រាប់ មានស្រាប់ មានស្រាប់ មានស្រាប់ មានស្រាប់ មានស្រាប់ មានស	אל על אוני און אוי איני איני איני איני איני איני איני	99 L
	ининия при при при при при при при при при при	
_ ค.ร.ว อ ทุว ค.	S GEN MAIXE GE DE BENEEN EST EN COM COM COM COM COM COM COM COM COM COM	991
авартивтреттевритевния тог	СИСОНО ЖИМИНИВИНИЯ	
a na a mara a mara a mara a mara a mara a mara a mara a mara a mara a mara a mara a mara a mara a mara a mara a	т อฤธาราศอฤธยาย ออ 21.1137848 ศษษณฑ เดย №	991
	בפעונה כמוני	
	1 262033	
20 00 25 95 65 25 05 07 07 kg 27 0 07 01		
	ZI BL BL II	
es to set the set the set to lead to set the	A 81 M St Of 68 78 2 5 5 S 1	
רונה מובו שעוביפון שעובירסט שעוביפוא	TO HELS O HELS WOHONING	
ATT (1)	IA LEGIS I LEGIS WINNIEWO	

TRANTION OF THURSDAY 4/8762 TRANTISMA TRANTISMA TRANTISMA TRANTISMA TRANTISMA TRANTISMA TRANTISMA	SI 18303831W 91 18303831W 93 18303831W 93 18303831W	0/6991 0/2991
MANAGAMATERIANS CONTRACTOR OF THE STATE OF T	TTTAR	2691
######################################	TAI	628L
4 3 T 3 T T T 3 B S T A 3 R B T A 3	38	9/9L
427277738878382982782773878232	מכב	
	•	<b>229</b> L
<b>阿外州的祖教 新教</b> 年 以来3日本中 字里写自由 由二	3 T A	9291
**************************************	2 A T	6491
арытталыты арын арын арын арын арын арын арын ары	18181	1889
97711777777	ятат	<b>Z291</b>
diijiidelu maaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa		
ENAMES AND THE PROPERTY OF THE		<b>2991</b>
300000TTTTACTTTACTTTOCTOT	11398	8331
מות ביות ביות ביות ביות ביות ביות ביות בי		2281
וכוח הוח ה ב הב הם הם ההוד ב הב ב ב ב ב ב ב ב ב ב ב ב ב ב ב ב ב ב		<b>599L</b>
	<b>-</b>	ARHI
iti€ cont.	<b>33</b> 5	
34 EX IX E9 29 E9 E9 IO CC 76 E4 E4 E4 E4 E E E E E	SP ++	
H3T2 TYDROWING H3T2 TT STEEN HAIT THE HAIT WAR BATX A	4P SP	
EXIED CON		

SANDANAT IS REPORTED TO BE A C IN A.AIYAJIRAJI, TOKODIA, T. TOKEBE, A.AKKAWAR T. ERZIBOLIYAKI, J. SIGGHEN, 13, 1101-1101

Nucleic Acids Research

TARATILLA SI TRENSELT O VAPALITARES I TRENSELTE O VAPALITARES I TRENSELTE O VAPALITARES O VAPALITARE

ج
20
986
Œ
ğ
ď
eic.
ij
ĩ

7	11 2543-123 14 622-423 17 622-423	12, 33-39 12, 33-39 12, 33-39 12, ACIOS RES, 12, ACIOS RES	1 TONALA, A.LANDY ( ESEN1920) GENE 1 TONALA, LANDY ( 1 TONALA, LAN	######################################	7521 9021 5021 4021 E027	7.8A8(5ER., 73-3867	750 + 721 - 750 - 751 -	71.3128. 8.2.UAN ETTEM. C.1.KR CCLL 34, 367-349 8.AMUENBUN ET PL. (1921) NATURE 8.AMUENBUN ET PL. (1921) 6.L.OMESTEM. W. INC. (1920) 6.L.OMESTEM. W. INC. (1920) 78.FUKADA, G. PLUMKETT. U. H. OCCL.	1 2021 1 2021 1 621 1 6471 2 4471
2 8 8 9 7 8 1 9 2 1 9 2 1 9 2 2 8 1 9 2 2 1 9 2 1 9 2 1 9 2 1 9 2 1 9 2 1 9 1 9	A T B T T A T B T T A T 2 B T A T B T T	2	7, 7, 7, 7, 7	. 199 199 199 199 199 199	ята ята тта	#31380 #31380 #31388	は 日 日 日 日 日 日 日 日 日 日 日 日 日 日 日 日 日 日	1,100,3 USU	1521 9021 9021 8021 8021
T 6 2 T T 6	96 96 36 38 38 38	5 52 23 5 00 92 5 00 92	52 52 52		9t ÞI	Et fr	CBSAES FERE	OTIN * MONTH RELL OTIN	6691 6681

	비	) 6	Ţ	T	1	Ħ	4	9	Ħ	1	1	4 1	Lt	1	j t	1 :	) [	L	6		Ħ		Ξ.	L.															ㅂ	1	. т	
	1	9	H	ㅂ	** 9	الام و	7	Ţ		9	3	<b>.</b>	) ;	) t	j E	3 7	1	LJ	9	9	֓֞֞֞֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓	9	E :	3																	) b	
	Ŀ		**	**	××	_	J		•	•		┫.							ŀ۰		-:	-	7																_	-	_	
	٩.	_	S S	L 181	ر نوب	9 •*:	4	_	== ~	Ţ	] : :	ן נ		) E	: E	9 3		L	5	9	9	9	9	L														T	9	9	A	
1	<b>d</b> [:		·H	2	Ŀ	Ħ	4	7	2	Ø.	1 :	1	t	ו	9	) 3	٠.		9	Ħ	3	9	의 :	3														1	9	9	Ħ	
1	,,,,,		9	יבי כ	T.	.9	Т	1	9 1	9	••·	١,		н					Ī.,	H.	7	7		,																		
	<u></u>		-	£#1	1	1	4	=	_=	==	==	₹	•			_	•	•	þ.		Ē	-	-															*	Ð	3	Ħ	
,	٦.	e We		 *#*	• #4	t P##	2	) 	T :	9	J .	ן נ	. 1	. 6	Ç	כו	1	. 1	9	9		9	9	)														Τ	9	Ŧ	2	
- 1	비 :	9	H	3	1	Ħ	4	9	9 9	ĝ,	1 :	₹1		d	9	כי	1	. 1	9	Ħ	כ	3	3:	1														1	9	Ð	9	
	ł											l											L									_		_		_						
	1						1					L																				ā	М	1	NU	3	a	H 1				
	1		e de la		,	***	Ļ	=				ı						ĺ				_																				
	비	1	3	Ţ	ī	1		٠.	L	1 :	) :	Ţ	1	H	g	J	1	1	9	9	9	9 !	ם פ	1															1	9	ㅂ	
ر	و ل	1	1	1	1	1		3 :	_		-:	h.		ы	9	7		اً.	9	9	G	7 P	기 의 6																			
	*	KHI	H		**	w.		-	-			T	•	_	_	•	-	٦		===		= 2 :	1	1															1	T	1	
E	1 T	1	2	1	1	1	<u> </u>	3 9	9 ]	L	9 =	þv	U	g	۵	Ţ	1	4	9	1	Ħ	<b>&gt;</b> :	₹±																1	Þ	9	
	1						ı																											- 41	<b>10</b> 2	3	IN I	<b>M3</b> 5	į			
	1						ı					•						-																		_						
	Ł-						-}-			÷-						<b>-</b>		-4					٠.																٠.			
: <b>*</b> ∠ 5∠ €∠	~				9		<b>3</b> ⊾	*: 	} €9	25	١B	þ8	1 25	79	ا دی	95	25	٦	_ Z	5,	o S	S Gi	•		٥	. 1	H,	_ :	× ,	. 1		. 5		3	_ :	٠.	. 6	_	4	_	rb	
	1					_		_			-				_			1	_		_	•		4	'	N		•	1		н	•	크		Œ	E	1 .	ZÞ	3	F		
	Ю	LS	ᄮ	ъ	ON	IW	il	Ŀ	131	5	41	ı		ď	Į,	٦,	11	I	H	31	<b>S</b> :	<b>41</b>	l							ķ		t	ПT	ΕX								

121

FIT TRIN BETTE THOSE COLLEGE SERVICES SERVICES SERVICES	\$200-205\$	141° 1009-1045	
AND AND AND AND AND AND AND AND AND AND	"BNO11"H" 3"F" \$521	R.E.MERLANT, C.PENTELLA, G.RAGIND, A.TZABOLUFF (1980) 3, BACT, CYOL-1001	CC41
	•		
		T I ha sessenters OTIM	
<u> </u>	9 T 3 T	ago agy tag trro ta "awiyo a uau d	664 L
aaaaqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqq	втрав	TATA NEW STCCTTG NEW NEW NEW NEW NEW NEW NEW NEW NEW NEW	
Brazhentertereeranzari		DITM	262 L
~~~~~	8288	atra tala farta tala talah kan kan kan kan kan kan kan kan kan kan	9E41
- คุกวร <b>์ฟุลล</b> าองาวุ่าอองวุ่าวคาทุล	888	HILD STATE STATE STATES HERE STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES STATES S	96ZL
20000000000000000000000000000000000000		THE PERSONS STREET	JUL P
	A T. T. T. B.		<b>0</b> 521
- <sub>คือ</sub> ื่ออีฟุลคาอาาปุควอวป <b>ศุวอคฟุ</b> ล	1199 896	USU MAIZE GCCCACTTAGCTC	<b>2521</b>
ออวอ์รูดดาอาราคาอากุควอดอุด		CHURO KARAKKANAKKANA OHOJHO	
	189 191	1. T. T. T. T. T. T. T. T. T. T. T. T. T.	BSZ1
_ รอ ว อ อุ ค ค ร อ อ ร ค ว ว อ ว ค ค ร อ ค อ ค	199 191	FOR SPINATO GCCCTTTARGETC	<b>F</b> 921
яэээтаятеттаээтятатая		MAKE SKERKERE OLIN	/366
	TBA AAS	Ja''à' a' alla alla a a a a a a a a a a a a a	EGZL
_ ผูดอวฐคุดรอก ก น้ำขอา ก นุค ว อ ค ผิค	Tab TTAF	TTD BRTTATATTE.VERGS CEREVANAMEN SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECO	254
1 1 1		HE   C   C   C   C   C   C   C   C   C	23EF
		THREONINE CONT.	
2) 0) BE BE be 20 no 02 02 62 22			
25 34 PE 201 -0-10-10-10-10-10-10-10-10-10-10-10-10-1	8 02 91 2L SL	Et_tt	
	A CT A ST M	ST 01 28	
HETE. STEM MATTE. STEM MATTE. LOOP MATE. STEM	-00710	MERC III MERCHANIAN	

S. ANDERSON F. A. A. S. S. S. S. S. S. S. S. S. S. S. S. S.	1243	(1992) "PBIGHTCHENT S28" 2203-2211 WHY-2DETHERITY E'STREEBERS' STECHARUS' ETTERMBIRS' F'SDECHARO COTHERBELS' E'STREEBERS' STECHARUS' ETTERMBIRS' F'SDECHARO	1521
ALJASTBE A.A.VARR ETTER, C.F.WRIGHT, A.E.MMARRER, D.A.CLENTIDH (1981) CELL 26, 167-160	9441	d-e-mashbant b-e-bubook (1961) of Bloss CREW 257, 1114-1119	1521
G-GOERTZ-H-FELDMANNITAS2) CURA.GEN. 5, 221-225	esci	N'O'ROBERMEN' C'R' CAZANUS, N'ENSAR, M.KUENTZEL (1981) CELL 23,	5571
LIE HANDEL DIRINA, RIKLUILSON, B.A.RDE (1963) NUCL, AC18 RES, 11,	1229	141, 1004-1095 R.E.Berlani, C.Pertella, G.Ragino, A.Tzagoloff (1980) J. Bact.	ECZ1

	Name of Street		eu	-											_																				
	35	9 R	L G		<b>5</b> :	3 1	. i	بطد	1	ב	8	<b>H</b> :	<b>3</b> (	4	J E	) t	1 8	9	a													ŧ	<b>e</b> t	Ħ	6641
_	MHHH	***	int's	i M M				1						Ŀ	ee :			-																	
	7 3 U	99			3.1	<u> </u>	. I .	9				1 :	J .	U	2 C	7 E		- 5	1													•	3 21		2621
	3 B	8 8	83	щ	ו כ	LI	٦.	4		J	1	1 :	5 .	4 1	3 5	) t	4 8	9	1				.~	•••								ŧ	<b>9 8</b>	1 2	9641
	Hatte	HERM	***	==						_		_		ŀ		•	-	EE	1																001
•	1 J 0	99,	NHN					י נ	,N	a	a	. د	L !	ų.	2 t	9 6	1 0	Ė	1														, 0		<b>96</b> 41
	D B	9 8	8 3	Ĭ	<b>&gt;</b> :	<b>,</b> 1	<b>a</b> :	c jc	b	D	t I	<b>b</b> .	1	4 :	9 6	3 t	1 9	1	1													ţ	9	ы	994
	MXXK	* 1	****	NX.				j.		_		_		t:		C	==	==																	4941
		9 3	T S	-	1 1		: C	1 ^	Ħ	Ħ		. د	٠.	۲,	3	) 	. = E		3													1 :	ניי	9	4521
1	פכ	9 6		Ü	ם כ	9	3	4 7	Ħ	Ħ	9 :	. כ	1.	4 9	9 5	:	1	. 9	2													Ţ	9	1	9521
	KXHHH	AN AL	24 (2) 14 (2)	**		***		ీ.				_		ŧ.			**																	ы	F941
	22 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<del>244</del> 7 7	2 0		±===	פנ		1*	Ħ	0		. ر	٠.	۱.	9	, :==	: = = T		17														, 0		PEL
L	2 9	9 9	1 3	ı	Τē	3 1	т.	ᅧᄫ	1	Ħ	9	2 5	3 .	4 5	3 8	j t	1 7	H	Ħ													t	1 t	. #	ESAI
	PRESE				Ξ.			٦.	_	_				: ا			; ) 9		۱.															H	29(1
•	ק ל <b>ו</b>	- ·	0 1	٦			٠.	ጎተ	R	G			• •	٦ ٦	7 2	, -	, 5	•	1													1 0	, ,	U	LASK
	1							1						Ĺ													١,	<b>W</b> D3	1	NI	KED)	ΗŢ			
				- 1				ı						ı																					
	ļ						~	<b>-</b> -				-•-	•••	ֈ.					ļ					+	٠										
		۷_۶		89				þ9		ß.			P5		29		05		₽₩		0	H	_	K	_ 1		9	. 3	' _	Э,	. B.	8>		**	
92 E2	1 4	69	28		<b>59</b>	¢Η	Ļ.	1 '	55	2	5	5	3	F٦	i	15	•	<b>6</b> Þ	l	d	•	í	7			н		3	α	1	I 2	Þ	37		
	NETER		ONI	ш	W	(31 <u>5</u>	5 41	d		ďÜ	07	di	L	Ī	H3	115	4	4	ı						H		Я	TX3	1						

Nucleic Acids Research

TERNASO IN IS MILHER I DE V

_
Ū
ē
8
윤
90
포.
ä
ũ
ē
ฉ

1623/O ALIGNENT IS ARBITRARY SALO ALIGNENT IS ARBITRARY	1927/13 a 15 Eliner 7 dr c
1252/16 N 13 21THER 6 OR 1	7929\2\ VALEH WESIONE 3\ INLEWAEHIMO SEBDEMCE 7929\0 VFIUMBEHI IB VWBILHVUL
1923/0 MLJEMMEUT IN MRRISTARY	SESSION AFTER RESIDUE 37 INTERVENING SESUINCE
4 1 1 2 1 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3	ananana ana sabr
	PEGDETER
	er parter and a 2001
8 エンナンド 8 月 エコンエゴ 1 6 8 8 8 7 1 7	1929 B B B B B B B B B B B B B B B B B B
attosataoacases escent	tern se
MANANA MANANA PEREFERSION DE DIT MA	ອວງລຸ ເລລ <b>ດ</b> ຂອເ
43111833118133111013110	9 A D D T T D D D B B B B F T
7	그 휴 대 대 교
在社会共享的证明。	15251271
สวยวยุลอุศิวคาวปุ่าคลอวาที่อ	2 1 1 2 1 2 PEBr
	889 7 D 2 T 888 T 688 T
arrolf fitting the principle of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property of the property o	255 EP
MANAMANAMAN CONTRACTOR	A D D D D T T T T T T T T T T T T T T T
	prince for the rate
	ABB 8 1 1 8 1 9 1 1081
	иянчотчүят
84 64 64 69 69 69 69 69 65 85 85 66	12 89 4 4 7 7 4 4 9 8 24 54 2 03 84 9 8 1 8 3 1 8 3 2 8 54 54
TE LOOP THE STEM PHINDRICKL STEM	BIR TREE PROPERTY.

*11 *539 ; 65:	14-521 "*\$EE (1493) NACC' VCIO "*\$EY (1493) NACC' VCIO "************************************	MCL. ACIDS RES. 10, 1279-128 WF. ELFILDRAMH (1231) CUBE. (EL AL.1786), CM. TEMBERE R SARING HARB., 173-190 (A. P. P. M. R. C. CILEGH, W. A.) (A. P. P. M. R. C. CILEGH, W. A.) (A. P. M. M. M. M. M. M. M. M. M. M. M. M. M.	1000-2014 N 1876 17 17 17 17 17 17 17 17 17 17 17 17 17	M., M.KUZATZEL (1781) CELL 23, IDX-LYDW, D.L.NIZLER, J.E.DOWELSOW IDCHENISTRY 20, 4015-4021 (1792) J. BIOL. CHEN. 257,	1001 1001 1001 1001 1001 1001 1001 100
1,8138	яваэттэ <u>р</u> я яваэттэ <u>р</u> а	`+	814 8128	日119日日11130日日・	885 US STANDON SOU SOU MITO REBUNEY RIPHOROPOWIL BASIN OTTH
T 2 3 3 8	888311338	ត្រខុត្តប្រធុន	4434	<b>时间外外光规模英条款表示</b>	# SIVERLIS LINEVIS # 8281
	явв <u>эттэ</u> т#	1 A T T T T A A A A A	*N99 261	PYTTERTERMENT AN	, ANTST MUIDSMANECTUM TERM. OTTM
		A	Tãa TRI	A 2 1 2 3 3 1 8 3 2 3 8 8 8 8	1992 CCB XENET
			RIBATI	RIG DE STITE PER PER PER PER PER PER PER PER PER PE	ONCHO * TRN FICH 25381 * TRN FICH
	a*p a 3 3 T 3 T 8			****** ******	1924 ככט בתפרבאט פאטבור 12
	9 A A J T T A B		188 181 188 191	一、	1863 CCH DICTYOSTELIUM DIS
	<b></b> -	A 1 2 1 2 R R H H		11111111111111111111111111111111111111	DTIM TEREY FILL SEA!
99334	188227778			<b>【                                    </b>	ופפו מכש שפשבשפנודוזם אנטחו
1		]]	1 2 2 1 4 0 6		LADJ.3 RDD FOOT
					нертехят
22 40 43 36 40 45	98 PS ZE 06 48 SE 68 PE 5		15 81 71 BF	si ii	
H3T2.SITMA				0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0	
	257M . M2T3	COTTYR   NOTE 40	4007 g	HINDREYL STEM   D STEM	

· · · · ·

Ë
gar
\$
돢
<b>FCI</b>
Š
흥
ž

Leparing Regirace Ma	NTIBSA SI THEMBREAM - 9/0061 NE CE BUNIERE SETTA FELLEPE	Venation of the whole of the ventions of the ventions of the ventions of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vention of the vent
******		
Ceeers	200827088011800880	(111 1111 1111111111111111111111111111
FILECTA	TTTJJTTABDITBBARAD	Taganatarataat 7461
4311341.	paa para a a profest tab	Tabbrantest Roet
43343333333333333333333333333333333333	211231688311888682	TIDABADADIAD SOBI
4224223	วารวฐรคลอวรรออคคลว	113883183183 rost
		TYROSINE
STSSTER	11341 1184381843	9 U B 6621
D T D T T T R F	TTDRT RRD22TT8RFT	
STCTTCT B	11198 A28362868	
		.3003 NHTTIUTTUN EGAS.
	<u> </u>	. 3 no 3 NAHROTRYFIT
84 14 24 04 98 BB	78 28 09 99 99 95 15 25 05 PF D 4	
	83 63 ra 68 ce 22 62 r2 64 9 M	7 F H H O B 24 Sp
MATE JYSHONING	HEITE ATI 9000.1 ATI NESTE ATI	HAND DRITKE

26, 305-31¢ 108 863. 9, 6391-6406 278, 127-143 6, MATL. ACAB-6406	L.NUBSON, J.ARSSI, A.LAHOY (1988) NATURE 29 J.AGGEST, J.EGRALL HADGOR, A.LAMOY(1988) G.M.A.LONNEES, D.J.CURNINGS 11925) HUEL B.A. D. AFGE-AFGENEE, R.BALAK, NATURE E.A. DE ROBERTIE, R.J. GLEDA (1979) NATURE E.A. DE ROBERTIE, R.J. GLEDA (1979) NATURE E.A. SESTIONATION (1979) NATURE F. SESTIONATION (1979) NATURE T. SESTIONATION (1979) NATURE T. SESTIONATION (1979) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NATURE T. SESTIONATION (1978) NA	70° +52° +535	1896 0.1.8788. R.A.VAN ETTEN, C.T.MATONT, N.W.WALBERD, D. 1897 1.00. 1.8788. R.A.VAN ETTEN, C.T.MATONT, N.W.WALBERD, LECL. 26, 187-189  1897 5.AMDERGEM 61 AL. LIVEL) ARIURE 299, 457-465  1897 5.AMDERGEM 61 AL. LORGILLA, A.A. CRULLON, I.C. EFROW, LEGGRA, A.B. LIN, A.B. CRULLON, L.C. ERON, L.C. 156, 425-154  1991 1.000014. S.A.L. LINGLIN, SIGL. 156, 527-154  1991 1.000014. S.A.L. LORGILLA, A.B. CRULLON, L.C. 156, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.B. CRULLON, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, L.C. 150, 176-150  1.0.4001. A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S.A. LORGILLA, A.S. S
a a j r j a a a r a r a r r j r a a a r a r	389811888381 1188	7 4 9 - 9	1981 GUN VERSILLUS NIULL. REBRINK NINKEK MITO TOTOEK EUT VERSINKEK NIULUS NIULUS NIULUS NIULUS REBRINKEK NIULUS NIULUS NI
16101981016 16101981016161 16101888161	7	3 3 8 6 5 7 7 T	1902 GUR E.COLI GENERARMENER RESERVENCE GENERAL REPRESERVENCE EN PRIN GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL GENERAL
		1 1 2 2 2 2 2 1 1	TYROSINE 1901 CURE.COLI GGTGGGG
T3338883TT T3338883TT	32998982299	នក្នុង	TTAAAA WAMAA ADU CEST Masaawaawawaa Otim TTAAAA BAA "SMINDE ADU E267 Masaawaawaawaa
ТЭЭЭАЯЯЯЭТТ	A D D D D D T D D	T P B G G T R C T G C T	TTBRBBR cont. TTBRBBR 4200 420 420 420 ADV ADV ADV ADV ADV ADV ADV
25- DF DE SE FC Z	F 62 75 82 82 12 9 81	G 81 ≯1 S1 O1 8 8	4 9 9 > € Z L
HETE.LINP MATIC.STEN	I HBITZ.SITINȚI MBITZ OLJ 900J	na leasall	, ACHONINA

_
75
- 2
- 25
m
77
**
w
Œ
_
- "
-73
Ų
⋖
_
ω
-=
9
73
$\simeq$
_
7
_

C'ER MOCRALTS'O'ELLARGRACEADES RECET ELS BESET ELS 1850-1915 D'OCCTUBAL, D'AR'HOUTERELANDITER (1892) MEDET UTS 1950-1916 W'A'H'F'OCE WOMEN (1892) WOLDER 2005-1916-571	TARY CARLES AND TARGET TAY TARABLE TAY TO THE TAY TO THE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABBE TAY TARABLE TAY TARABLE TAY TARABLE TAY TARABBE TAY TARABBE TARABBE TAY TARABBE TARABBE TAY TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE TARABBE T
А. 260955¥ДРF, Н. FELDMANN (1913) НИСІ. АСТВЗ РЕЗ, 11, 1-Г. Н. 19009. О.Я. 176, R. К. 41812ВВА, В. А. 161-196 1977—2004.	L 1-14 GEALS, A. SECRETARY, S. S. S. S. S. S. S. S. S. S. S. S. S.
	A SILOG FLD CONTRACTOR OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE
8 8 7 3 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	AT A ST A ST A ST A ST A ST A ST A ST A
детотянят задве поврене по де в	ээн ар ээн ар ан ан ан ан ан ан ан ан ан ан ан ан ан
	TTTBREEDITTBE TTTBE "PELINKY PLINE SHEF
1 D D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D M D D D M D D D M D D D M D D M D D D D M D D D D D D D D D D D D D D D D D D D D	TITER RELIGIOUS SALT DE L'AND SALT TRE D'ANDE PRE 2007
RATDIRRATETIASATITISER TRAINING TRAINING  19 P D T D D D D D D D D D D D D D D D D D	
S D D D T A A A T D T A D D D D D D D D D	
TTDJTA TAT BT B T B B B B B B B B B B B B B	1963 GLIR XENDRUS LEGVIS CCTTCGRTR GCTCR GCT
аттэпппттт папп т з э э э п п т т т д а	אל איצא דו איצא א איצא א איצא א איצא א איצא א איצא א איצא א איצא א איצא א איצא א איצא א איצא א איצא א איצא א א
	Juga Enisonal
20 00 95 BC 05 ZE 05 97 BZ 07 ZZ 8 0Z 91	
LOOP O STEM FINITIC.STEM RNITE.LOOP RNITE.STEM FO	HACKENFALL SIEM 18 18 14 18 D
1025 (1	PHEMOTEUR STEM   10 STEM   11 L

565
£641
7441
1462
7841
SEAT
4541

[1482] MAICE, ACIDS RES, 10, 3279-1237;	
N. HALLINGP, C. LANNOE, G. PEPE, C. DURGLIGATELLO, C. SACCONE, E. 1918A	
P.CANTATORE, C.OE BENEDETTO. B.GADALETA, R.BALLERANS, A.7. ZAUDN,	1822
2799-2799 Millioli (1982) 1. Birkellick (1982) 1. Biol. Chem. 257.	
QZATI-9/ATI "FC?	3701
T.A.SEL, LEGEL, LEGEL HAND AND REAL PARKELA. B. SHELLER ST. J. SELL. CHER.	
FCT-CVI 'AI 7737 INDEED WOODWARD LOVE ENTRYPOLICE	

1957/19 WIEWEREN IS WRITHARY
1957/0 WIEWEREN IS ANSTHARY
1957/0 WIEWEREN IS ANSTHARY
1957/0 WIEWEREN IS ANSTHARY
1957/19 WIEWEREN IS GEOUGHUE
1957/19 WIEWEREN IS GEOUGHUE
1957/19 WIEWEREN IS GEOUGHUE
1957/19 WIEWEREN IS GEOUGHUE

TTDBBDTBDTBD

TITDIBDIIDA

TYROGINE cont.

MAIN MAINS

5 9 B

8 9 H

병 그 법..

911

AIR

819

898

1996

TBBG

6681

ZEEL

9661

9561

1882

996L

CCC L

1822

PSG1

ESEL

1925

אואסאכאר פופא

1766/0 ALIGNENT IS AREITRANT 1974/0 ALIGNENT IS AREITRANT 1974/0 ALIGNENT IS AREITRANT 1974/0 ALIGNENT IS AREITRANT

q 9 q 9 g 9 g 7 c g g c c c c c c c c g g g g g

Hate at

20

_
Ę
æ
ese
=
to
סד
Aci
Ġ.

VCC1 (0		1				-7-7-
[A57:90	\$0-004-62 9251220	•			•	
69%	#MITIED# 5					
8 8						
Acic					•	
eic.	ADITION S	TAN TO REAL TRANSPORT TO SERVICE	MIGHARIT IS ARITAN (G.LA.TS INSAYABBYA &		E. THRESTELL, A. 12A60LOFF (1926) J. FIOL. CHEN. 225.	2027/Q IN 8°
25	1	<b>.</b>				
_		HERRESHERS DE LE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE SELECTION DE S	# TTT000188	a ⊃ T T 2 a ⊃ 8 i	5 191	A 1802
		HEAR MARKANA	11AaT 338A	a o t t a a o t i	•	
		48444444444444444444444444444444444444	патавотев Иставате Првати "А	F	1	R BS0S
į		######################################	199933318		33	
:		A D T D T D D I	эватт эв	A T T 2 R A 2 T T	1- 199	
	Í	RESE BENEAUSER	73383788	A D Y T B T B B R		
	1	4216883 ** **********************************		9 1 1 9 9 9 1 P	T TAB	H LS0Z
		RESERVENCE OF THE SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECOND SECON		a draga da a draga da draga	193	
					עמנוא E	S 500S
	87 P.	ET 17 E8 T8 38 38	+9 28 08 05 59 €8 18 65 29	95 ¥5 25 05 5 95 ¥5 25 05	9 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
		HATACHERY, STEM	Mare an 900	DJ TT   NETE TI	мяя вятха	

R.C.MILLER, B.RALFUT, B.R.TAPLOR, D.A.TEMER (1982) J. PIOL. CHER. 257, 670-675 (1962) MIEL. 257, 670-675 (1962) MIEL. A.C. D. SELP-667 (1962) MIEL. A.C. SELP-667 (1962) MIEL. A.C. SELP-667 (1962) MIEL. A.C. SELP-667 (1963) MIEL. A.C. SELP-667 (1963) MIEL. A.C. SELP-667 (1963) MIEL. A.C. SELP-667 (1963) M.C. SELS MER. L. A. MERLEE C. (1961) DERE 14, 357-307 (1963) M.C. SELEN MER. L. A. MERLEE C. (1961) DERE 14, 357-307 (1963) M. M.C. SELEL A. M. M.C. SELEN MER. M. M.C. SELEN MER. M. M.C. SELEN MER. M. M.C. SELEN MER. M. M.C. SELEN MER. M. M.C. SELEN MER. M. M.C. SELEN MER. M. M. M. M.C. SELEN MER. MER. M. M. M. M.C. SELEN MER. M. M. M.C. SELEN MER. M. M. M.C. SELEN MER. M. M. M. M.C. SELEN MER. M. M.C. SELEN MER. M. M. M.C. SELEN MER. M. M. M. M. M. M. M. M. M. M. M. M. M.	2035 C031-29-205 REE. 8. L426-1442 L0.E.DOMELSON (1980) NUEL. AC185 D11. 2055 C11. AC185 D11. AC185 C11. AC185
The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	parameter and account on
Ranjahan trabata taba	SOUT UNG BUSLEND GROCILIS GG G G G T A T G C T C T C T C T C T C T C T C T C T
ออาออเอวคอาทุววควาเอาอิคยุน เยย	
naga and an and an and and and an an an an an an an an an an an an an	DIEN CENT TO A TO TO A TO THE DIEN CONT
аянаття заття в этти д зая я н	MARKANAMAA SITU
	2058 LINC INDISOPHILA YOURR CARTTIA PARA ELECTTRATE AND 8205
даарына тарыры тары тары	SUSA SHE ZHOSOPHILA MELAND, GITTCE GIGING 161 PGT 6
a a a t T a a a t t a a a a a a a a a a	PER SERVICE OF THE PERSON AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND PROPERTY AND P
	Second Tip and Tarana Canada Second
ี กุลอาคาการาการการสาราชุรอดสุด รออิ	אודם הפיפורנוב אומער, אה פה האוד הפרוב ה בוד ה ביום אודם ביום אודם ביום אודם ביום אודם ביום ביום ה
RED HIRECHTICGITITACACHCERR	MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MANUAL MA
	a traditionalite and a record
Randana Albant Transcard Tran	9 7 1 0 M 1 7 1 G/D 1 0 7 1 1 4 0 5
	15031 INI 050Z
вее явлетстестествев	2003 URC BRILLIS SUBTILLIS G G G G G T T A G C T C G
	онттис
7b Dt	
2) 0) 15 95 15 25 05 9Z 8Z 7Z 7Z 8 0Z 91.	L SI EL LL
as he as so he as he as he	A 81 P1 S1 O1 6 8 5 8 8 5 7
עסטף מאדוב, אודוב, בונטף מאדוב מ אסטר אודוב עו	סר מ אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס אוויס
	PRIS G ( PRIS MARGINING
	• (

8 9 1 8 8 8 8 9 1 9 9 9 9 9 9 9 9 9 9 9	1 6 9 C 6 1 1 6 9 C 6 1 1 6 2 6 1 2 6 2 6 1	- 7	R 188 388		2062 6PC SP119CH  2063 6PC 108ACCO  2069 UAC 108ACCO  2069 UAC 108ACCO  MITO  MITO  MITO  MITO  2065 UAC 80UNE **  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO  MITO
NTIC.STEK SS 47 43 AD 42	TE SE SE	7		Hate II Hate A Sheri	. אחבוזאו≝ בסחני.

ALL-8186, R.A.VAR EITEN, CLT-MRIGHT, ALULMACBERG. D.A.CLAYTUN (1921) CCLL 28, 167-180 S.ANDERSON, R.A.L.GENRUILM, A.R.COULÇON, I.C.EPEROM, F.SANGER. J.G.YDUNG (1982) J. GOL. SIOL, 156, 642-77)	4 DEWL A.KASALI Z. LIMINIZALI G TIME CARDINA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . OF ALA . O	790 Z

	N-26 M	XX	EX#	**	HH.	Mar in	•••			7					F	-	* = =	# F ?		•																
•	Ę.	Ţ	[ ]	_	U.	Ţά	_ H	9	1 (	4		1 1	H	ב	4	1	b	) ]	L	3													Ħ	9	Ħ	S038
•	Ð	Į:	1	_	8	Ü	U	9	1 1	1		8 3	)	U	2	1	Ħ.	)	1	1													b	9	t	9602
•	1	) :	) D	9	₩.	H H	1	9	] : ==:	į τ	9 1	9	)	1	7	9	9	3 6	Ţ	כ												Ţ	9	9	đ	₩90Z
ŧ	HÆH T	) : ***	C (	I,	H H	1	<b>U</b>	9		כוב	9 (	1 9	)	Ţ	ヿ	9	<b>U</b> :	) j	. H	ב												L	9	Ħ	Ħ	S023
t	1	<b>&gt;</b> :	בו	1	A 1	4	Ħ	9	1 :	į I	9 1	19	)	1	4	9	<b>u</b> :	) 1	เย	כ												T	9	Ħ	U	2062
																												•	ţuo	3	3H:	ישרו	١			
87 67 87 47	22 L	02	69	99	95	59	8	:9	19		9	<b>Z</b> S	95	S	g		5	0.8	6>	P>	9	N	И	 >	۳.	ī	9	 :	9 0	ò	e t	, S	) 5	 	- •	
	HEL	5 7	ノコ	JON	IHC	ł	HΞ	25	ΉL	]	•	00	ן א	1	1	H	319	; 4	u l							HAR	H3	11X	3							

2046/36 AFIER RESIDUE 16 OR 37 INTERVENIAMS SEGUENCE 2046/0 ALIGNMENT 15 ARGITARRY

TRANTIES SI INSTRUCTA OVATOR

30K 3RD 3S	INTERVEATING			0/960Z 9E/790Z	

THRATIGMA BI INGCHRIJA 6/9901

	j	ee:		£364	149 ) I	## H	H 90	 H	4 a	0 C C	es H			1	1 t	1 3	1	ſï	- e e	, 3	T 1	1,														t	9	Ħ	6	202
	ŀ	##		*1	HE	**	**	==: H	H		E			H	- ·	_	9	<u>-</u>	- =; H	 3	 L 1	]														E	9	Ħ	8	Súa
	ŀ	**	K K	*	H	##	**	2 C C		ก -				_	9 :	 1	1	9	9	. <u>.</u> .	E==	]_														1 €	9	н		80Z
	*	ĸ×		***		**	**		==		-	וַ	ถ	н	9 :	1 1	. 1	9		- <u>-</u> -	1 1	5														TE	В	8	ε	:90Z
	ď	H)Ł	HX:	HK!		## H		:==		7 . 9 .		]_	9	н	η -	1		9	**																	1 5	) H	ㅂ	Z	<b>508</b>
	٦	•	•				1	•				] -	_	•		_		-	_	-	_											ţu	<b>6</b> 3	3	רנא	<del>ህ</del> ስ				
94 44	ţ	 Z	٥.		99		88	٠	9	ZS	 1	     D9		75	85		+9	-	 2\$		15	89		0			 K		1	9		3		- <b>-</b>	<b>н</b>	91		 44		
SZ E		1.		<b>13</b>		<b>Z</b> 8		<b>5</b> 9	•		١Đ				s	99	1	ES		LS	61		Ą		N	٦	ı	r	١		£		0	a	2	Þ	SÞ	'		
	١.						4					1		-	~~	- 14		ı			-11	1							UNIT	• н	ИIX									

	92		٠.			u	.1.	ш.	ч.	. = .	- <del>1</del>	_5			_	_	_	-		L					] -																				
	F S	1	י כ	1	ב כ	병	Έ	ъ.	Ħ	9	1	4			ㅂ	כ	כ	Н	9	ľ	t	1 :	٠.	1 1	1																	8	3 6	ı	96Ò
	<b>∦</b> ₩	**1	*** **	*** C	(94) 5	HEN H	1	: :: : :::::::::::::::::::::::::::::::	T.	9	֡֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֓֡֓֓֓֓֡֓֡֓	-	1	9	Ħ	9	כ	1	. 1		9	) :	3 (	R 7	c																1	9 9	) H	ı	₩80
	**	***	13H	***	H	e <del>na</del> H	"	: a : 1	e e q	9	••• 1	겈	ב	9	н	9	2	1	. 1	,	. t	, = : j :		1 t	3 >																T	9 t	<b>.</b>	)	E90
	•	**!	ä	(K		- EX-M E1	٠,	-	 H	9	- k	3	7	- 9	Н	- -	7	1	1		i e	1 2	3 m i		١,																1	9 t		ı	280
	٦	_	•	_	•	٠	٦	•		_	-	٦	_	_	Ĭ	_	_		_	1					}_											٠,	up	5	3	ZĮT					
																				١					1															•					
	+-					- <b>-</b>	-		. <u>-</u> -											}.					<del> </del> -				 W						 9							 >	 44		
9/ \$/ E		. ( 14			19 2		15	;9	9		29 	ıΒ	D9 E	35	96		85		15	Ŀ	29 :	Ļ	Q! 3	<u>و</u>		Ą	0	N	-	٦	K	r	•	н	•			_	8			51			
	M3	Į5	v		ION	ı[H	d		M3	915	5 :	إير			ď	00	7	J.L:		l	WE	315	5 .	41									보유	8 (	l Kt	ΧΞ	ł								

2042 J.-F.BRIAT, m.cana, S.LOISEAUK, R.IMCHE(1952) NUCL. actos RES. 10, 6805-6275 2096 A.L.BISS, A.R. Unic. Bios. 156, 482-717

2043 A.TGROOH, E.SHINDZAKI, m.susididae (1961) NUCL. actos RES, 9, 5399- CELL 24, 167-140

2044 H.DEND, A.KATO, K.SHINDZAKI, m.susididae (1982) 2099- CELL 24, 167-140

2045 S.A.MOEKSBA, A.R.L.COMESON, F.SANGER, F.SANGERSPA, A.R.L.COMESON, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER, F.SANGER,

TTOR

100

661

199

d007 (

1.

HELS OF

MENT STEM

Nucleic Acids Research

אוזביבופא אאזזביבופא אוזביבופא אוזביבופא מו

" SQUOR TRU NITO URC BOVINE " TIN

CHLORO 1980 1 280 090119

OCCUPACION CONTROL

HOWNIAS ONS

WHLINE cont.

2023 960Z

\$002

2083

**2002** 

# **EXHIBIT E**



# Compilation of tRNA sequences and sequences of tRNA genes

Mathias Sprinzl\*1, Konstantin S. Vassilenko<sup>2</sup>

<sup>1</sup> Laboratorium für Biochemie, Universität Bayreuth, 95440 Bayreuth, Germany and <sup>2</sup> Institute of Protein Research, Russian Academy of Sciences, 142290 Puschchino, Moscow Region, Russia

\*To whom correspondence should be addressed

Tel.: +49 921 552420

Fax: +49 921 552432

email:

mathias.sprinzl@uni-bayreuth.de;

kvassil@vega.protres.ru

#### INTRODUCTION

The new compilation of tRNA Sequences and Sequences of tRNA genes contains in addition to 3279 sequences of the last edition from 1998 (1) the completely new Genomic tRNA Compilation including the sequences of tRNA genes from complete genomes published up to January 2002. The current Database consists of three parts:

- 1. Compilation of tRNA Genes (MS Excel® file, ZIPed)
- 2. Compilation of tRNA Sequences (MS Excel® file, ZIPed)
- 3. Genomic tRNA Compilation (MS Excel® file, ZIPed)

# Compilation of tRNA Genes,

is a summary of the sequences of tRNA genes published in the literature and databases up to the end of 1998. It contains tRNA genes of all organisms and organels, but is not updated since January 1999. This table contains about 500 sequences of cytoplasmic tRNA genes that are not included in the Genomic tRNA Database. Most of the tRNA gene entries in this table have references of the publications in which the sequence was communicated.

Compilation of tRNA Sequences,

is a summary of tRNA sequences, including modified bases and references of the publications. The references are restricted to the first publication of the complete sequence unless additional information (e.g. base modification, corrections, etc.) was later obtained. In such cases additional references were added. This compilation is updated up to January 2002. The table contains the known tRNA sequences of all organisms including organells. This is the continuation of the original tRNA compilation first published in 1978.

# Genomic tRNA Compilation,

is a new addition to the Database. This is the most complete compilation of the sequences of cytoplasmic tRNA genes derived from complete genome sequences included into DNA databases. Since sequences of tRNA genes originated from cellular organelles frequently can not be processed to the general cloverleaf scheme, they were not included in the Genomic tRNA Compilation. There are specialised databases dealing with these sequences (see links below).

Current Genomic tRNA Compilation consists of about 3700 tRNA gene sequences from 63 organisms covering archaea, bacteria, higher and lower eukarya. The database includes the tRNA genes sequences collected in GtRDB (2) as well as those from the additional complete genomes found in DNA databases. If the genomes of the different strains of the same organism were sequenced, the corresponding tRNA genes were added to the database independently.

# PRESENTATION OF SEQUENCES

# Compilation of tRNA Genes and Compilation of tRNA Sequences

In order to facilitate a computer analysis an alignment of sequences is used which is most compatible with the tRNA phylogeny and known three-dimensional structures of tRNA (3, 4). The corresponding numbering system is shown in Figure 1. Positions in particular sequence which are not filled (gaps in the generalised structure) are indicated by a dash. All nucleotide insertions are commented and denoted by underlining at the place of insertion.

This compilations use a one-letter code for all nucleotides including modified ones. For standard nucleotides, adenosine, cytidine, guanosine, thymidine and uridine the usual abbreviations, A, C, G, T and U, respectively, are used. To designate modified nucleotides, the other ASCII signs are employed (see table "Intro" in the corresponding MS Excel<sup>®</sup> file). Terminology and structure of the modified nucleosides occurring in tRNAs were used according to (5) and (6).

Sequences are presented as MS Excel<sup>®</sup> files. Each sequence in the compilation occupies two consecutive rows. The first row begins with the unique six-position identification code of the sequence ('D' or 'R' for DNA or RNA, respectively; a one-letter code for the amino acid, X for methionine-initiator, Z for selenocysteine; the three-digit code specifying the organism and one digit for isoacceptor number). After this, the sequence of the anticodon is given, followed by the abbreviated name and the kingdom of organism, and the sequence (99 standard positions). The second line begins with the sign '+' and contains the information about base-pairing (double helical regions only, tertiary interactions are not annotated). Nucleotides involved in Watson-Crick pairs are marked with '=', the GU pairs are indicated with the sign '\*'.

The database is organised as an MS Excel® workbook. All the information collected are split into different indexed tables according to the type of data (specificity, sequence, organism, etc.) and the descriptions of certain genes are summarised in the main worksheet that includes the relations between the data tables. The information can be obtained by filling the query form that allows to enter the simple search criteria and to select the type of data to be displayed. The result of search is presented as a table containing the description of the genes found. This includes unique id, amino acid specificity, anticodon sequence, organism name and taxonomy, strain, original database source, position of the gene in genome, literature reference, sequence, basepairing and additional comments. Sequences are aligned in the same way as it was described above for the tRNA compilations.

In addition to the plain text table one can explore the result of search by presenting the sequences in a cloverleaf form (Figure 1). It is possible to scroll the found sequences one by one or to select directly the sequence of interest from the result table. The presentation supports colour code for different structural features in the canonical cloverleaf model.

Simple statistical information on the occurrences of certain bases at given positions and the preferences in basepairing also can be obtained on a special data sheet.

#### **Useful links:**

The RNA Modification Database <a href="http://medlib.med.utah.edu/RNAmods">http://medlib.med.utah.edu/RNAmods</a>

A database for plant mitochondrial tRNA genes and molecules <a href="http://bio-www.ba.cnr.it:8000/BioWWW/#PLMItRNA">http://bio-www.ba.cnr.it:8000/BioWWW/#PLMItRNA</a>

Compilation of mammaliam mitochondrial tRNA genes <a href="http://mamit-trna.u-strasbg.fr">http://mamit-trna.u-strasbg.fr</a>

GtRDB: The Genomic tRNA Database <a href="http://rna.wustl.edu/tRNAdb">http://rna.wustl.edu/tRNAdb</a>

## **ACKNOWLEDGEMENT**

This project was supported by Fonds der Chemischen Industrie and Universität Bayreuth. We are gratefull for advise, cooperation and help with data collection to Todd Michael Johnson Lowe, Genetics, Stanford University, California, Dr. Carlos Hoyo-Vadillo, Departamento de Farmacologia y Toxicologia, Cinvestav, Mexico City, Mexico, Yvonne Baberowski, Mark Dürr and Bernhard Thielen, Universität Bayreuth.

#### REFERENCES

- 1. Sprinzl M., Horn C., Brown M., Ioudovitch A. and Steinberg S. (1998) Nucl. Acids Res. 26, 148-153.
- 2. Lowe, T.M. & Eddy, S.R. (1997) Nucl. Acids Res. 25, 955-964.
- 3. Transfer-RNA: Structure, properties and recognition, P.R. Schimmmel, D. Söll, J.N. Abelson Eds., 1979, Cold Spring Harbor Laboratory, p.518-519.
- 4. Steinberg S.V. and Kisselev L.L. (1992) Biochimie 74, 337-351.
- 5. Limbach P.A., Crain P.F. and McCloskey, J.A. (1994) Nucl. Acids Res. 22, 2183-2196.
- 6. Crain P.F. and McCloskey J.A. (1997) Nucl. Acids Res. 25, 126-127.

## tRNA database searching engine

Internet service that allows to find records in the database according to multiple search criteria. Complicated sequence-based queries can be formed (Updated for the data in Compilation of tRNA Genes and Compilation of tRNA Sequences up to the end of 1998).

## tRNA-Editor

Researchers who wish to perform an advanced search for tRNA sequences according to several criteria, e.g. anticodon, amino acid specificity, modified nucleoside, or wish to print the requested sequences in the cloverleaf form can <u>download</u> appropriate Windows 3.1 based software as a 900kB ZIPed file (Updated for the data in Compilation of tRNA Genes and Compilation of tRNA Sequences up to the end of 1998).

Copyright © 1993 by the Genetics Society of America

# A Rare tRNA-Arg(CCU) That Regulates Ty1 Element Ribosomal Frameshifting Is Essential for Ty1 Retrotransposition in Saccharomyces cerevisiae

Koichi Kawakami,\* Suchira Pande,† Brenda Faiola,‡ Daniel P. Moore,§ Jef D. Boeke,§ Philip J. Farabaugh,† Jeffrey N. Strathern,‡ Yoshikazu Nakamura\* and David J. Garfinkel‡

\*Department of Tumor Biology, The Institute of Medical Science, University of Tokyo, Tokyo 108, Japan, †Department of Biological Sciences, University of Maryland-Baltimore County, Catonsville, Maryland 21228, ‡Laboratory of Eukaryotic Gene Expression, NCI-Frederick Cancer Research and Development Center, ABL-Basic Research Program, Frederick, Maryland 21701-1201, and †Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Manuscript received February 24, 1993 Accepted for publication June 10, 1993

#### **ABSTRACT**

Translation of the yeast retrotransposon Ty1 TYA1(gag)-TYB1(pol) gene occurs by a +1 ribosomal frameshifting event at the sequence CUU AGG C. Because overexpression of a low abundance tRNA-Arg(CCU) encoded by the HSX1 gene resulted in a reduction in Ty1 frameshifting, it was suggested that a translational pause at the AGG-Arg codon is required for optimum frameshifting. The present work shows that the absence of tRNA-Arg(CCU) affects Ty1 transposition, translational frameshifting, and accumulation of mature TYB1 proteins. Transposition of genetically tagged Ty1 elements decreases at least 50-fold and translational frameshifting increases 3-17-fold in cells lacking tRNA-Arg(CCU). Accumulation of Ty1-integrase and Ty1-reverse transcriptase/ribonuclease H is defective in an hsx1 mutant. The defect in Ty1 transposition is complemented by the wild-type HSX1 gene or a mutant tRNA-Arg(UCU) gene containing a C for T substitution in the first position of the anticodon. Overexpression of TYA1 stimulates Ty1 transposition 50-fold above wild-type levels when the level of transposition is compared in isogenic hsx1 and HSX1 strains. Thus, the HSX1 gene determines the ratio of the TYA1 to TYA1-TYB1 precursors required for protein processing or stability, and keeps expression of TYB1 a rate-limiting step in the retrotransposition cycle.

THE Saccharomyces cerevisiae retrotransposon Tyl is a mobile genetic element that replicates via an RNA intermediate (reviewed by BOEKE and SAND-MEYER 1991; GARFINKEL 1992). The transposition cycle of Ty1 elements resembles several important steps in the replication of retroviruses. Tyl protein maturation by Ty1-protease (PR) and reverse transcription take place within Ty1 virus-like particles (Ty1-VLPs), which appear to be absolutely required for the transposition process. The Ty1 genome contains two genes, TYA1 and TYB1, which correspond to the gag and pol genes of retroviruses, respectively (CLARE and FARABAUGH 1985). As with certain retroviral pol genes (reviewed by HATFIELD et al. 1992), expression of TYB1 requires programmed ribosomal frameshifting (CLARE, BELCOURT and FARABAUGH 1988). Ribosomal frameshifting solves two problems encountered in the life cycle of a retrovirus or retrotransposon. First, since catalytic Pol proteins, such as reverse transcriptase/ribonuclease H (RT/RH) and integrase (IN), are usually found in much lower amounts than the structural Gag proteins, requiring a frameshift event for pol expression is an effective strategy of gene regulation. Second, since Pol proteins function within a particle, creating a Gag-Pol fusion

protein by frameshifting delivers Pol proteins to the correct compartment.

The TYA1-TYB1 fusion protein is synthesized by a +1 frameshifting event in the TYA1 sequence CUU AGG C (BELCOURT and FARABAUGH 1990). Ribosomal pausing at a rare AGG-arginine codon and slippage of a leucyl-tRNA from CUU to UUA are required for frameshifting. A single-copy tRNA-Arg(CCU) gene that recognizes the AGG codon is located on chromosome X (GAFNER, DE ROBERTIS and PHILIPPSEN 1983). BELCOURT and FARABAUGH (1990) have shown that overexpression of the tRNA-Arg(CCU) gene reduces Ty1 frameshifting. Ty1 transposition is also reduced when the level of the tRNA-Arg(CCU) is increased (XU and BOEKE 1990). These results suggest that the low abundance of tRNA-Arg(CCU) promotes frameshifting. Recently, we have identified this tRNA gene as the HSX1 gene involved in the heat shock response (KAWAKAMI et al. 1992). Even though there is only one copy of the HSX1 gene (GAFNER, DE ROBERTIS and PHILIPPSEN 1983), an hsx1 disruption mutant is viable. Apparently, the AGG codons normally decoded by the single-copy HSX1 gene are decoded by another tRNA [probably by the near-cognate tRNA-Arg(UCU)

TABLE 1
Yeast strains

Strain	Genotype	Plasmid	Source or reference
DMy51	MATα ura3-167 his3Δ200 leu2Δ trp1Δ1 GAL	pGTy1A-Bneo (pD109)	This work
DMy94	MATa ura 3-52 his 3\(\Delta\)200 lys2 trp 1-289 GAL	. ,	This work
JC287	Matα ura3-167 his 3Δ200 leu2GB Ty1-146::lacZ Ty1mhis 3A1-263 GAL		M. J. Curcio
JC344	MATα ura3-167 his3Δ200 leu2GB Ty1-146::lacZ Ty1mhis3A1-270 GAL		M. J. Curcio
KK156	JC287: hsx1::LEU2		This work
KK157	JC344; hsx1::LEU2		This work
KK240	MATa ura3 his3 leu2 trp1 hsx1::111S3		This work
KK242	MATa ura3 his3 leu2 trp1		This work
KD198-16A	MATa his4Δ5 ura3 arg11 GAL		K. J. DURBIN
DG1301	JC344	pGAL1-lacZ	This work
DG1302	JC344	pGTy1-H3neo	This work
DG1305	KK157	pGALI-lacZ	This work
DG1306	KK157	pGTy1-H3neo	This work
DG1333	JC344	pGTy1-H3neo::Sacl-1702	This work
DG1334	KK157	pGTy1-H3neo::SacI-1702	This work
DG1344	JC344	pGTyAlneo(PGK1 ter.)	This work
DG1347	KK157	pGTyAlneo(PGK1 ter.)	This work

gene]. In this paper, we describe the effects of an hsx1 disruption mutant on Ty1 frameshifting, transposition and protein processing.

#### MATERIALS AND METHODS

Yeast strains, plasmids, general genetic methods and media: The strains used for the Ty1 transposition assays are listed in Table 1. Strains KK240 (MATa ura3 his3 leu2 trp1 hsx1::H1S3) and KK242 (MATa ura3 his3 leu2 trp1) were used to test Ty1 frameshifting. These strains were derived from an hsx1::H1S3/HSX1 diploid strain (KAWAKAMI et al. 1992).

The plasmids pMB38-9merWT and pMB38-9merFusion contain the frameshift heptamer fused to Escherichia coli lacZ gene in the +1 TYB1 reading frame and the 0 TYA1 reading frame, respectively (BELCOURT and FARABAUGH 1990). The plasmid pMB38-9merFusion(w/o AGG) contains the AGG-less 0 reading frame [GAT CCG CTG ACA CTT GGC CAT GAG GTA C (the frameshift region is highlighted)] fused to lacZ. The plasmid pKK67 was constructed by cloning the 230 base-pair (bp) wild-type HSX1 DNA, amplified by polymerase chain reaction (PCR) (SAIKI et al. 1985) into the URA3-based centromere-plasmid YCp50 (Rose, et al. 1987). The plasmid pKK68 carrying the mutant hsx1(MluI\*) gene was constructed by digestion of the plasmid pKK67 with MluI, fill-in synthesis with Klenow DNA polymerase, and ligation to a SalI linker. The hsx1::HIS3 and hsx1::LEU2 disruption alleles were constructed by modifying the same MluI restriction site and ligation to a ClaI fragment containing the HIS3 gene, or an MluI-ClaI fragment containing the LEU2 gene (kindly provided by P. ROGAN). The plasmid pKK69 was constructed by cloning the PCR-amplified 112-bp wild-type SUP201-0 gene (THI-REOS, PENN and GREER 1984; MORISHITA and UNO 1991) into the URA3-based centromere-plasmid pRS316 (SIKORSKI and HIETER 1989). The plasmid pKK71 carrying the SUP201-0-1(CCU) gene was constructed by digestion of plasmid pKK69 with MluI and BamHI and ligation to a 63-bp synthetic double-stranded DNA containing the C for T substitution at 3' base of the anticodon. The EcoRI-BamHI DNA fragments containing the mutant and wild-type tRNA genes were prepared from plasmids pKK67, pKK68, pKK69 and pKK71, and subcloned into the TRP1-based centromere-plasmid pRS314 (SIKORSKI and HIETER 1989). These subcloning procedures generated plasmids pKK73 (derived from plasmid pKK67), pKK74 (from pKK68), pKK75 (from pKK69), and pKK76 (from pKK71). The plasmid pGTy1A-Bneo (also known as plasmid pD109), with the Tyl frameshift correctly removed (BELCOURT and FARABAUGH 1990), was constructed from a transposition-competent pGTy1-H3/Ty1-912 hybrid plasmid by oligonucleotide-bridge mutagenesis (MANDECKI 1986). The frameshift mutation and tRNA sequences were confirmed by chain-terminating DNA sequencing (SANGER, NICKLEN and COULSON 1977) using Sequenase 2.0 (U.S. Biochemical Corp.). The plasmid pGTyAIneo (PGK ter.), kindly provided by P. ROGAN, was constructed by replacing almost all of the pGTy1-H3 TYB1 gene (from a BglII site located at position 1702 to the end of the element) with the bacterial neo gene and the PGK1 transcriptional terminator. Standard techniques were used for all molecular cloning procedures (SAMBROOK, FRITSCH and Maniatis 1989).

The hsx1::HIS3 and hsx1::LEU2 disruption mutants were constructed by single-step gene disruption (ROTHSTEIN 1991). Plasmids were introduced into cells using the transformation procedure of ITO et al. (1983). All yeast media and standard genetic techniques were those described by ROSE, WINSTON and HIETER (1990).

Transposition assays: TyImhis 3Al and TyImade2Al transposition assays were performed as described previously (CURCIO and GARFINKEL 1991, 1992), and will be presented briefly here. For detecting spontaneous TyImhis 3Al transposition events, liquid cultures were inoculated at low densities (about 2 × 10<sup>3</sup> cells/ml) and grown to saturation at 20° in YPD or in SC-ura (glucose). A portion of each culture was spread on SC-his or SC-his-ura (glucose) plates and incubated at 30°. The cultures were titered on YPD or SC-ura (glucose) plates. For detecting chromosomal TyImhis 3Al transposition events in the presence of a pGTyI helper plasmid, cells were grown on SC-ura (glacose) plates for 7 days at 20°, or an overnight SC-ura (glucose) liquid culture was diluted 50-fold into SC-ura (galactose) liquid medium and incubated with aeration for

3 days at 20°. Tylmhis3AI transposition events were detected as His\* papillae by replica plating cells from the SCura (galactose) to SC-his-ura (glucose) plates, followed by incubation at 30° for 3 days. To determine the number of Tylmhis3Al or Tylmade2Al transposition events in galactose-grown liquid cultures, the cells were concentrated, spread on several SC-his-ura (glucose) or SC-ade-ura (glucose) plates, and incubated at 30° for 3-5 days. Cells were titered on SC-ura (glucose) plates. Tylneo and TylA-Bneo transposition events were detected as described previously (BOEKE, Xu and Fink 1988; Curcio, Sanders and Garfin-KEL 1988) with the following minor modifications. Diploid strains were constructed by mating strains KD198-16A with strains DG1302 or DG1306, or by mating strains DMy51 and DMy92 (Table 1). The resulting diploids were induced for Tyl transposition on SC-ura (galactose) plates as described above. After segregation of the pGTy Ineo plasmid from the strains, the level of resistance to the antibiotic G418 (Gibco) was determined by growth on YPD plates containing a final G418 concentration of 500 µg per ml (for diploids derived from mating strain KD198-16A with strains G1302 or DG1306) or 75 µg per ml (for diploid derived from mating strain DMy51 with DMy94).

Tyl RNA levels and Tylmhis3AI splicing efficiency: We isolated total RNA from hsx1 and hsx1::LEU2 strains by established procedures (CURCIO, SANDERS and GARFINKEL 1988; Rose, Winston and Hieter 1990). Northern analysis was used to analyze Ty I RNA levels (Curcio, Sanders and GARFINKEL 1988; CURCIO and GARFINKEL 1992), and reverse transcription-PCR (RT-PCR) was used to estimate Tylmhis3AI RNA splicing efficiency (WANG, DOYLE and MARK 1989). The total amount of RNA transferred to hybridization membranes was estimated by staining with NAQ-STAIN, a reversible fluorescein-based stain developed by Integration Separation Systems. Transcripts from the PYK1 and ACT1 genes were used as internal loading standards. RNA sequences that span the region where the artificial intron (AI) was inserted in HIS3 (Curcio and GARFINKEL 1991) were amplified using the HIS3-specific oligonucleotide primers CTCCACGCGCCAGTAGGGCC (for DNA amplification) and ATGACAGAGCAGAAAGC CC (for reverse transcription and DNA amplification). The amplified products were separated by agarose gel electrophoresis through a 2% NuSieve/1% SeaKem (FMC Bioproducts) gel, stained with ethidium bromide, and photographed. The resulting negatives were scanned using an LKB Ultroscan XL enhanced laser densitometer. Relative splicing efficiencies were estimated by the amount of the amplified products. The splicing efficiency is defined as the amount of 334-bp spliced product over the amount of spliced plus 438-bp unspliced products.

Immunoblot analysis: Total yeast protein isolation, polyacrylamide gel electrophoresis, protein transfer, and antibody reactions were performed as described previously (Youngren et al. 1988; Garfinkel et al. 1991). Antibodies were added in at least 10-fold excess, as determined by titration experiments. Ty1-VLP antibodies were previously shown to react with TYA1 and TYA1-TYB1 precursor proteins, but not with TYB1 proteins (ADAMS et al. 1987; Youngren et al. 1988; Garfinkel et al. 1991). Tyl-VLP antibodies did not show a dramatic difference in avidity for TYAI vs. TYAI-TYBI precursor proteins, as determined by titration experiments (A.-M. HEDGE and D. J. GARFIN-KEL, unpublished results). Ty1-VLPs were isolated by the method of Eichinger and Boeke (1988), except the final continuous sucrose gradient was omitted. Equal amounts of protein (approximately 20 µg per lane) were loaded onto SDS-8% polyacrylamide gels. Protein concentrations were verified by staining gels run in parallel with Coomassie blue. Cross-reactivity of immunoblotted proteins with antisera that recognize the mature proteins p54-TYA1 (Ty1-VLP antiserum; ADAMS et al. 1987; YOUNGREN et al. 1988), p90-Ty1-IN (B2 antiserum; YOUNGREN et al. 1988), p60-Ty1-RT/RH (B8 antiserum; GARFINKEL et al. 1991), and their respective precursor proteins were detected using the ECL chemiluminescent detection system (Amersham).

Ty1 frameshifting efficiency:  $\beta$ -Galactosidase assays and the efficiency of Ty1 frameshifting were determined as described previously (Belcourt and Farabaugh 1990). Briefly, six transformants of each plasmid were each assayed in triplicate for  $\beta$ -galactosidase activity. The frameshifting efficiency is measured by determining the ratio of  $\beta$ -galactosidase activity produced from the construct requiring a +1 frameshift to express lacZ (pMB38-9merWT) to that of a construct in which the upstream and downstream genes are fused in frame [pMB38-9merFusion and pMB38-9merFusion(w/oAGG)].

The efficiency of Ty1-H3 frameshifting was also estimated from immunoblot analysis. Strains DG1333 (pGTy1-H3neo::Sac1-1702, HSX1) and DG1334 (pGTy1-H3neo::Sac1-1702, hsx1::LEU2) were constructed by transforming the plasmid pGTy1-H3neo::Sac1-1702, which contains a Ty1-PR mutation (Youngren et al. 1988), into strains JC344 and KK157, respectively (Table 1). Total protein isolated from galactose-grown cultures of strains DG1333 and DG1334 was analyzed by immunoblotting using Ty1-VLP antiserum. To determine the ratio of p58-TYA1 to p190-TYA1-TYB1 protein, exposures of the resulting blots were scanned using a laser densitometer. The efficiency of Ty1 frameshifting equals the amount of p190-TYA1-TYB1 protein divided by the total amount of p58-TYA1 plus p190-TYA1-TYB1 protein.

#### **RESULTS**

Tyl transposition is inhibited in an hsxl disruption mutant: We determined whether a disruption mutation of HSX1 affects Ty1 transposition using two assays that monitor transposition of chromosomal elements marked with the his3AI retrotransposition indicator gene (Curcio and Garfinkel 1991), as well as by monitoring the transposition of plasmid-borne pGTy Ineo and pGTy Imade2AI elements (BOEKE et al. 1985; BOEKE, XU and FINK 1988; M. J. CURCIO and D. J. GARFINKEL, unpublished results). The his 3AI gene is a yeast HIS3 gene interrupted by an artificial intron (AI) in the antisense orientation. The his 3AI sequences are inserted in a Ty1 element at a unique restriction site located between the TYB1 gene and the downstream long terminal repeat, such that the intron is on the sense strand of the Ty1 element. Placement of marker genes at this position of a Tyl element does not severely inhibit transposition. Since splicing and retrotransposition of the marked Ty RNA gives rise to His<sup>+</sup> cells, the relative efficiency of Ty/mhis3AI transposition can be monitored by plating cells on media lacking histidine. An ade2AI retrotransposition indicator gene has also been developed (M. J. Curcio and D. J. Garfinkel, unpublished

First, the relative efficiency of Ty1mhis3AI trans-

TABLE 2
TyImhis3Al transposition in an hsxI disruption mutant

Genotype	Ty1mhis3A1	His* colonies/ total cells (×10*)	Relative transposition efficiency
HSX1	TyImhis3Al-263	25/1.6 46/1.6 40/1.8 36/1.9 30/1.9	2.0 × 10 <sup>-6</sup>
hsx1::LEU2	TyImhis3AI-263	0/2.3 0/2.3 1/2.2 2/2.2 0/2.1	2.7 × 10 <sup>-8</sup>
HSX1	Ty I mhis 3AI-270	28/1.6 34/1.6 22/1.4 32/1.4 36/1.6	2.0 × 10 <sup>-6</sup>
hsx1::LEU2	Ty1mhis3Al-270	3/1.7 0/2.3 0/2.4 0/2.1 1/1.8	3.8 × 10 <sup>-8</sup>

The Ty1mhis3AI-263 element is present in HSX1 strain JC287 and hsx1::LEU2 strain KK156. The Ty1mhis3AI-270 element is present in HSX1 strain JC344 and hsx1::LEU2 strain KK157. Each measurement represents the results of one of five independent cultures. The relative transposition efficiency is the mean fraction of total colonies that are His\*. To estimate the efficiency of Ty1 transposition, the relative transposition efficiency should be multiplied by a factor of 8, to account for the splicing efficiency of the Ty1mhis3AI transcript, and by a factor of 11, to account for the effect of introducing the his3AI marker gene into a Ty1 element (Curcio and Garfinkel 1991).

position in isogenic HSX1 and hsx1::LEU2 strains containing single marked chromosomal elements Tylmhis3Al-263 or Tylmhis3Al-270 was determined (Table 2). These unspliced Ty1mhis3AI elements were identified after galactose-induction of a strain containing plasmid pGTy1-H3mhis3AI, and are present at different chromosomal locations (CURCIO and GARFINKEL 1991). There was a 53- or 74-fold decrease in the efficiency of TyImhis3AI-263 or Ty/mhis3AI-270 transposition, respectively, as monitored by the number of His<sup>+</sup> colonies in a hsx1::LEU2 mutant background. The transposition defect in the hsx1::LEU2 mutant KK157 was complemented by a low copy number plasmid carrying the wild-type HSX1 gene (pKK67), but not by a plasmid carrying a mutant hsx1(M1uI\*) gene (pKK68) (Table 3).

The second transposition assay depends upon the ability of a pGTy1 helper plasmid to stimulate transposition of a genomic Ty1mhis3AI element in trans (Curcio and Garfinkel 1992). Expression of the pGTy1-H3 helper plasmid increases the frequency of genomic Ty1mhis3AI transposition about 100-fold (Curcio and Garfinkel 1992; M. J. Curcio and D.

TABLE 3

Tylmhis3AI-270 transposition in hsx1 mutant KK157 containing plasmid copies of tRNA genes

Plasmid (genotype)	His <sup>+</sup> colonies/ total colonies (×10 <sup>6</sup> )	Relative transposition efficiency
pKK67 ( <i>HSX1</i> )	17/5.3 58/2.3 16/3.6 18/5.3 23/4.1	6.4 × 10 <sup>-6</sup>
pKK68 [ <i>hsx1(MluI*</i> )]	0/4.5 0/4.6 0/4.4 0/2.3 0/4.5	<4.9 × 10 <sup>-6</sup>
p <b>KK6</b> 9 [ <i>SUP201-0(UCU</i> )]	0/5.7 0/6.5 0/5.2 0/5.6 0/5.9	<3.5 × 10 <sup>-8</sup>
pKK71 [ <i>SUP201-0-1(CCU</i> )]	4/7.5 3/5.6 7/5.3 11/5.9 8/6.1	1.1 × 10 <sup>-6</sup>

The TyImhis JAI-270 element is present in the hsxI::LEU2 strain KK157. The designated plasmids were introduced into strain KK157 and single transformants were chosen for further analysis. Refer to Table 2 for more information.

J. GARFINKEL, unpublished results). The pGTy1-H3neo helper plasmid (BOEKE, Xu and FINK 1988) or the control plasmid pGAL1-lacZ (BOEKE et al. 1985) were introduced into isogenic strains JC344 (HSX1) and KK157 (hsx1::LEU2) that also contain the chromosomal Ty1mhis3AI-270 element. Ty1 transposition was induced by growing the cells on SC-ura (galactose) plates and spliced Ty1mHIS3 transposition events were detected by replica plating onto SC-hisura (glucose) plates (Figure 1). The HSX1 strain DG1301 (containing the pGAL1-lacZ control plasmid) gave rise to a few transposition events, while the HSX1 strain DG1302 (containing the pGTy1-H3neo helper plasmid) gave rise to hundreds of transposition events. In contrast, no Ty1mHIS3 transposition events were present in the hsx1::LEU2 strains DG1305 and DG1306, even though strain DG1306 contains a pGTy1-H3neo helper plasmid that was induced for transposition. Since the hsx1::LEU2 mutation is recessive (Table 3), we showed that the pGTy1-H3neo helper plasmid is transposition-competent by testing pGTy1-H3neo transposition in an hsx1::LEU2/HSX1 diploid strain (Table 4).

Several controls were performed to determine whether the hsx1 mutation directly affected the Ty transposition process or whether the hsx1 mutation affected RNA splicing or Ty RNA levels. The splicing efficiency of the Ty1mhis3AI-270 transcript varied

DG1301: pGAL-lacZ HSX1 DG1305: pGAL-lacZ hsx1::LEU2

DG1302: pGTy1-H3neo HSX1

DG1306: pGTy1-H3neo hsx1::LEU2 FIGURE 1,—Ty/mhis3A1-270 transposition in an hax1 mutant background, Strains DG1301, DG1302, DG1305 and DG1306 contain the genomic Ty/mhis3A1-270 element. The relevant plasmids and status of the HSX1 gene are shown alongside the strains. These strains were tested for transposition by growing cells on SC-ura (galactose) plates for 7 days at 20°, replica plating to SC-his-ura (glucose), and incubating the replicas for 3 days at 30°.

TABLE 4
Tylneo transposition in hsxl/HSX1 diploid strains

Relevant genotypes	Relative transposition efficiency (%) <sup>b</sup>	
HSX1/HSX1	42 (15/36)	
hsx1::LEU2/HSX1	47 (16/84)	

<sup>a</sup> Homozygous HSX1/HSX1 diploids were obtained by mating strains DG1302 and KD198-16A. Heterozygous hxx1::LEU2/HSX1 diploids were obtained by mating strains DG1306 and KD198-16A.

In this transposition test, the transposition efficiency is the number of G418', Ura plasmid segregants divided by the total number of Ura plasmid segregants.

from 12 to 20% in both HSX1 or hsx1::LEU2 strains as determined by RT-PCR. These splicing efficiencies agree with previous results where it was shown that about 12% of the Ty1mhis3AI transposition events had lost the AI by splicing (Curcio and Garfinkel 1991). However, the overall Ty1 and Ty1mhis3AI-270 RNA levels were between 2- and 8-fold lower in an hsx1::LEU2 mutant background when compared with ACT1, PYK1 RNA or rRNA levels, although these differences were not completely reproducible.

To determine whether this moderate decrease in the level of Ty RNA could account for the more than 50-fold reduction in Ty 1 transposition, we assayed the level of pGTy1-H3made2AI retrotransposition (M. J. CURCIO and D. J. GARFINKEL, unpublished results) in an hsx1::LEU2 mutant. In collateral experiments, the level of pGTy1 expression in an hsx1::LEU2 mutant was determined by immunoblotting (see below). The efficiency of Tylmade2AI transposition was reduced almost 70-fold in an hsx1::LEU2 mutant background, while the level of GAL1-promoted Ty1 proteins remained unchanged in the mutant (Figure 2), A similar decrease in transposition was also observed when an HSX1 strain containing a pGTy1A-Bneo plasmid with a mutation that corrects the frameshift was galactoseinduced. Taken together, these results suggest that neither inhibition of splicing nor the lower concentration of chromosomal Ty1 or Ty1mhis3Al RNA can completely account for the reduction of Ty1 trans-




FIGURE 2:—Immunoblot analysis of Ty1 proteins from an hsx1 mutant background. Strains DG1302 (HSXI, pGTy1-H3neo; lane 1), DG1301 (HSX1, pGAL-lacZ; lane 2), DG1306 (hsx1::LEU2, pGTy1-H3neo; lane 3), DG1305 (hsx1::LEU2, pGAL-lacZ; lane 4), DG1333 (HSXI, pGTyI-H3neo::Sacl-1702; lane 5), and DG1334 (hsx1::LEU2, pGTy1-H3neo::Sac1-1702, lane 6) were induced for transposition by growth in SC-ura (galactose) medium and total protein was isolated for immunoblot analysis. Proteins were separated by electrophoresis on an SDS-8% polyacrylamide gel, transferred to a nitrocellulose membrane, and cross-reacted with B2 and VLP antisera. The B2 antiserum detects p90-Ty1-IN and its precursors. The VLP antiserum detects p54 and p58, which are VLP structural proteins derived from TYA1, as well as p190-TYA1-TYB1. The minor bands observed between p90-Ty1-IN and p140-TYB1 are probably caused by cellular proteolysis because they are present in immunoblots prepared from a Ty PR mutant (S. D. YOUNGREN and D. J. GARFINKEL, unpublished results). Tyl protein size estimates (in kilodaltons) are indicated.

position in an hsx1::LEU2 mutant. Previous analyses have shown that increased expression of tRNA-Arg(CCU) (HSX1) negatively regulates Ty1 transposition (Xu and BOEKE 1990). Our results indicate that the HSX1 gene is required for transposition of Ty1 elements.

Mature TYB1 proteins do not accumulate in an hsx1 disruption mutant: To further investigate the inhibition of Ty1 transposition by hsx1::LEU2, we compared the levels and processing of Ty1-encoded proteins in isogenic HSX1 and hsx1 disruption strains (Figure 2). Total protein was isolated from strains DG1302 (HSX1, pGTy1-H3neo; lane 1), DG1301 (hsx1, pGAL1-lacZ; lane 2), DG1306 (hsx1::LEU2, pGTy1-H3neo; lane 3), and DG1305 (hsx1::LEU2, pGAL1-lac2; lane 4) that were induced with galactose. The proteins were separated on SDS-polyacrylamide gels and immunoblotted. The resulting filters were reacted with B2 antiserum, which reacts with the fulllength 190-kilodalton (kD) TYA1-TYB1 precursor protein, the 160-kD and 140-kD processing intermediates, and mature 90-kD Ty1-IN (GARFINKEL et al. 1991) or Ty1-VLP antiserum, which reacts with the 58-kD TYA1 precursor protein and the mature 54kD TYA1 product (ADAMS et al. 1987; MULLER et al. 1987; YOUNGREN et al. 1988). Wild-type protein patterns were observed when the HSX1 strain DG1302 was analyzed with B2 or Ty1-VLP antiserum (lane 1), or with an antiserum (B8) that detects p60-Ty1-RT/ RH (B. FAIOLA and D. J. GARFINKEL, data not shown). As expected, strains DG1301 (lane 2) and DG1305 (lane 4) containing the heterologous expression plasmid pGAL-lacZ had very low levels of Tyl proteins (GARFINKEL et al. 1985; CURCIO and GARFINKEL 1992).

The hsx1::LEU2 strain DG1305 (Figure 2, lane 3) displayed a different protein pattern when reacted with B2 and Ty1-VLP antisera. Essentially wild-type levels of the 190-kD TYA1-TYB1 precursor protein and 160-kD processing intermediate were detected using B2 antiserum. However, very little of the 140kD precursor or 90-kD IN protein was detected. Similar results were obtained when an antiserum (B8) that detects RT/RH was used: the 190-kD and 160-kD TYB1 precursor proteins were present at wild-type levels, but the 140-kD precursor and the 60-kD Ty1 RT/RH protein were barely detectable (B. FAIOLA and D. J. GARFINKEL, data not shown). When TYA1 proteins were analyzed with Ty1-VLP antiserum, normal levels of mature p54-TYA1 protein were observed in an hsx1 mutant, but very little full-length p58-TYA1 precursor was detected even after extended exposure of the filter. Furthermore, similar protein patterns were observed when partially purified Ty1-VLPs were reacted with B2, B8, or Ty1-VLP antisera (B. FAIOLA and D. J. GARFINKEL, data not shown). These results suggest that the transposition defect observed in hsx1 mutants is related to aberrant protein processing.

Ty1 frameshifting increases in an hsx1 disruption mutant: We tested whether the observed transposition defect in the hsx1 mutant resulted from abnormal

TABLE 5
Translational frameshifting in an hsx1 mutant

Relevant genotype	Frameshift site	β-Galactosidase units	Frameshifting efficiency (%)
HSX1	9merWT	2400	
	9merFusion	6800	35
	9merFusion(w/o AGG)	8900	27
hsx1::HIS3	9m34WT	5100	
	9merFusion	5600	91
	9merFusion(w/o AGG)	6100	84

Strains KK242 (HSXI) and KK240 (hsxI::HIS3) were transformed with plasmids pMB-9merWT, pMB38-9merFusion, and pMB38-9merFusion(w/o AGG).  $\beta$ -Galactosidase activities are the averages from six independent transformants. The frameshift efficiency is defined as the  $\beta$ -galactosidase activity of the 9merFusion or the 9merFusion (w/o AGG) (Bellcourt and Farabaugh 1990).

TABLE 6
Translational frameshifting in an hsx1 mutant KK240 containing plasmid copies of tRNA genes

Plasmid genotype	Frameshifting efficiency (%)
pKK73 (HSX1)	35
pKK74 [hsx1(MluI*)]	98
pKK75 [SUP201-0(UCU)]	90
pKK76 [SUP201-0-1(CCU)]	65

Plasmids were introduced into strain KK240 (hsx1::HIS3) by transformation. Refer to Table 5 for experimental details.

frameshifting using two different frameshifting assays. In the first assay, the HSX1 strain KK242 and hsx1::HIS3 mutant strain KK240 were transformed with pMB38-9merFusion and pMB38-9merWT plasmids in which the 0 (TYA1) and +1 (TYA1-TYB1) reading frames and lacZ are fused, respectively (Table 5). β-Galactosidase activity was determined from at least six different transformants of each plasmid and Tyl frameshifting efficiencies were calculated as described (see MATERIALS AND METHODS; BELCOURT and FARABAUGH 1990). A frameshifting efficiency of 35% was obtained in an HSX1 background, which is comparable to published values (BELCOURT and FARA-BAUGH 1990). In contrast, the hsx1::HIS3 disruption resulted in 91% frameshifting. The frameshifting efficiency was restored to 35% by a low copy number plasmid carrying the wild-type HSX1 gene (pKK73; Table 6).

We also determined the Ty1 frameshifting efficiency by quantitating the ratio of the unprocessed p58-TYA1 precursor to the p190-TYA1-TYB1 precursor in HSX1 and hsx1::LEU2 strains DG1333 and DG1334, respectively (Figure 2, lanes 5 and 6). To insure that unprocessed precursor proteins accumulated during the galactose induction, strains DG1333 and DG1334 contained a pGTy1-H3 plasmid with a well characterized Ty1-PR mutation, pGTy1-

H3neo::SacI-1702 (YOUNGREN et al. 1988; GARFINKEL et al. 1991; CURCIO and GARFINKEL 1992). Proteins were analyzed by immunoblotting using TyI-VLP antiserum, which recognizes TYA1 proteins and the 190-kD TYA1-TYB1 precursor protein (ADAMS et al. 1987; MULLER et al. 1987; YOUNGREN et al. 1988), and frameshifting efficiencies were calculated by densitometry (see MATERIALS AND METHODS).

The HSX1 strain DG1333 (Figure 2, lane 5) showed the pattern of unprocessed 58-kDa and 190-kDa proteins expected from a Tyl-PR mutant (ADAMS et al. 1987; MULLER et al. 1987; YOUNGREN et al. 1988). A frameshifting efficiency of about 3% was obtained from densitometric scans of various exposures of the immunoblot. In contrast, the hsx1::LEU2 strain DG1334 (Figure 2, lane 6) had much more of the 190-kD TYA1-TYB1 precursor and slightly less of the 58-kD TYA1 precursor than the HSX1 parent strain DG1333 (Figure 2, lane 5). The hsx1::LEU2 disruption mutant had a frameshifting efficiency of about 50%, which is about 17-fold higher than in an HSX1 background. The overall level of Ty1 protein also appeared to be similar in the HSX1 or hsx1 mutant backgrounds. These results suggest that the absence of tRNA-Arg(CCU) enhances ribosomal pausing at AGG and slippage of the leucyl-tRNA from CUU to UUA. Furthermore, the regulation of frameshifting by the HSX1 gene is essential for Ty1 transposition. The reduction in transposition in an hsx1 mutant may be caused by a defect in protein processing that results from an aberrant stoichiometry of Ty proteins.

The capacity to translate an AGG codon does not limit  $\beta$ -galactosidase synthesis in an hsx1 mutant: The lacZ fusion gene in the pMB38-9merFusion plasmid has only one AGG codon and it is located at the fusion site (Belcourt and Farabaugh 1990). That AGG codon is missing in the pMB38-9merFusion(w/ oAGG) lacZ fusion gene. Therefore, the effect of a single AGG codon on  $\beta$ -galactosidase synthesis was determined in an hsx1::HIS3 mutant. Interestingly, βgalactosidase activities in the hsx1::HIS3 mutant or the HSX1 parental strain harboring the pMB38-9merFusion and the pMB38-9merFusion(w/oAGG) plasmids were similar (Table 5). These results suggest that the capacity to translate the AGG codon does not limit \beta-galactosidase synthesis in an hsx1 mutant. However, we do not know how the AGG is translated in an hsx1 mutant. Since haploid cells contain more than eight tRNA-Arg(UCU) genes (BECKMANN, JOHNSON and ABELSON 1977), it is possible that tRNA-Arg(UCU) decodes AGG codons by near-cognate recognition when tRNA-Arg(CCU) is absent (YOKOYAMA et al. 1985).

Complementation of hsx1 by a tRNA suppressor SUP201-0-1(CCU): Although tRNA-Arg(UCU) may decode AGG codons, excess tRNA-Arg(UCU) does

not inhibit frameshifting (BELCOURT and FARABAUGH 1990). This may be because of sequence or structural differences between tRNA-Arg(UCU) and tRNA-Arg(CCU) (Figure 3). Alternatively, the information needed to regulate Ty1 frameshifting may reside within the anticodon. To determine if the CCU anticodon is sufficient to regulate Ty1 transposition (Table 3) and frameshifting (Table 6), we constructed a low-copy-number plasmid carrying a mutant tRNA-Arg gene that has a CCU instead of a UCU anticodon. The SUP201-0-1(CCU) anticodon mutation was introduced into the SUP201-0 tRNA-Arg(UCU) gene (THI-REOS, PENN and GREER 1984; MORISHITA and UNO 1991), by oligonucleotide mutagenesis (refer to MA-TERIALS AND METHODS). Functionally active tRNAs were synthesized from these plasmids because a plasmid carrying the same 112-bp segment of DNA with a SUP201 nonsense suppressor complemented the cyr1-2 UGA allele (Morishita and Uno 1991; K. KAWAKAMI and Y. NAKAMURA, unpublished results).

To determine if SUP201-0-1(CCU) could suppress the transposition defect imposed by an hsx1 mutation, strain KK157 containing Ty1mhis3AI-270 and hsx1::LEU2 was transformed with the suppressor plasmid pKK71 [SUP201-0-1(CCU)] or the parental plasmid pKK69 [SUP201-0(UCU)]. The level of Ty1 transposition was partially restored when the pKK71 [SUP201-0-1(CCU)] plasmid was present in the hsx1::LEU2 mutant (Table 3). This result suggests that the CCU anticodon can regulate transposition.

An hsx1::HIS3 mutant strain KK240 harboring plasmids pMB38-9merWT or pMB38-9merFusion was transformed with plasmids pKK75 [SUP201-0(UCU)] and pKK76 [SUP201-0-1(CCU)] and frameshifting efficiencies were analyzed in these transformants (Table 6). The SUP201-0-1(CCU) mutant tRNA resulted in an intermediate level of frameshifting. Interestingly, frameshifting in the pKK76 [SUP201-0-1(CCU)] transformant was higher (65%) than in the pKK73 [HSX1; tRNA-Arg(CCU)] transformant (35%). This result is consistent with the lower level of transposition of the pKK71 [SUP201-0-1(CCU)] transformant (1.1 × 10<sup>-6</sup>) when compared to the pKK67 [HSX1; tRNA-Arg(CCU)] transformant (6.4  $\times$  10<sup>-6</sup>; Table 3). Therefore, although SUP201-0-1(CCU) can partially regulate Ty transposition and frameshifting, it does not work as well as tRNA-Arg(CCU) encoded by HSX1. Other aspects of SUP201-0-1(CCU) expression or structure may prevent full complementation of the hsx1 mutation. These results also suggest that base pairing at the third position of the second codon in the frameshift heptamer is essential for regulating Ty1 transposition and frameshifting.

Increasing TYA1 expression restores Ty1 transposition in an hsx1 mutant: Our results indicate that more of TYA1-TYB1 fusion protein is translated in

SUP201-0 GCUCGCGUGGCGUAAUGGCAACGCGUCUGACUUCUAAUCAGAAGAUUAUGGGGUGCGACCCCCAUCGUGAGUG

HSX1 GUUCCGUUGGCGUAAUGGUA<u>ACGCGU</u>CUCCCUCCUAAGGAGAAGACUGCGGGGUUCGAGUCCCGUACGGAACG

MI UI




FIGURE 3.—Comparison of SUP201-0 and HSX1. Nucleotide sequences of the SUP201-0 and HSX1 tRNAs are shown. Identical nucleotides are indicated by asterisks. Anticodons are in bold lettering. The clover leaf structure of the SUP201-0 and HSX1 genes, and the SUP201-0-1(CCU) mutation are also shown.

the hsx1 disruption mutant, and that this altered stoichiometry of TYA1 to TYA1-TYB1 precursor proteins may inhibit Ty1 transposition. Therefore, providing more TYA1 protein should restore TyI transposition in an hsx1 mutant background. To test this idea, the efficiency of TyI transposition was determined with strains DG1344 (HSX1) and DG1347 (hsx1::LEU2) containing the helper plasmid pGTy-Alneo (PGK1 ter.), and strains DG1301 (HSX1) and DG1305 (hsx1::LEU2) containing the heterologous expression plasmid pGAL-lacZ. The helper plasmid pGTyAlneo (PGK1 ter.) contains a complete TYAl gene, about 25 codons of N-terminal TYB1 sequence, the neo marker gene, and a transcriptional terminator from the PGK1 gene in place of the downstream long terminal repeat. Liquid cultures of strains DG1301, DG1305, DG1344 and DG1347 were galactose-induced and transpositions of the chromosomal Ty1mhis3AI-270 element were selected on SC-his-ura (glucose) medium (Table 7). Although expression of the helper plasmid pGTyAlneo (PGK1 ter.) did not markedly affect Ty1 transposition in an HSX1 strain, expression of TYA1 stimulated Ty1 transposition 50fold more in an hsx1 strain than in an HSX1 strain. In addition, galactose-induction of pGTyA1neo (PGK ter.) did not affect the level of full-length Ty1 RNA in an HSX1 or hsx1 disruption strain (B. FAIOLA and D. J. GARFINKEL, data not shown). As expected, the level of the TyAlneo (PGK ter.) transcript was the same in the HSX1 and hsx1::LEU2 mutant strains. These results indicate that expression of pGTyAlneo

TABLE 7

Effect of pGTyAIneo(PGKI ter.) expression on TyImhis3A1270 transposition in an hsx1 mutant

Strain	Relevant genotype	Relative transposition efficiency
DG1301	HSX1, pGAL1-lacZ	1.3 × 10 <sup>-7</sup>
DG1344	HSX1, pGTyAlneo(PGK1 ter.)	$4.8 \times 10^{-7}$
DG1305	hsx1::LEU2, pGAL1-lacZ	<3.7 × 10 <sup>-9</sup>
DG1347	hsx1::LEU2, pGTyAIneo(PGK1 ter.)	$2.4 \times 10^{-5}$

These strains contain the genomic TyImhis3AI-270 element. Relative transposition efficiencies were determined from liquid cultures grown in SC-ura (galactose) as described in MATERIALS AND METHODS. The relative transposition efficiency is the number of His<sup>+</sup>, Ura<sup>+</sup> colonies divided by the number of Ura<sup>+</sup> colonies. Each measurement represents the mean of four cultures. The total number of colony-forming units was similar within each set of cultures. Refer to Table 2 for more information.

(PGK1 ter.) stimulates Ty1 transposition in an hsx1 mutant background by restoring the proper stoichiometry of TYA1 to TYA1-TYB1 precursor proteins.

#### DISCUSSION

Our study reveals that the HSX1 gene is necessary for TyI transposition because elimination of this gene causes a significant transposition defect. Our work also shows that TyI translational frameshifting increases dramatically in an hsxI disruption mutant. The hsxI mutant defects in frameshifting and TyI transposition are completely complemented by the wild-type HSXI gene and partially complemented by the

mutant SUP201-0-1(CCU) gene, while no complementation occurs with the SUP201-0(UCU) gene (Tables 3 and 6). Therefore, at least some of the information required for Ty1 frameshifting is provided by the CCU anticodon. The partial complementation activity of the mutant SUP201-0-1 tRNA-Arg(CCU) suggests two possibilities. First, SUP201-0-1(CCU) may be expressed at a lower level than HSX1, thus directly affecting the level of tRNA-Arg(CCU) available for frameshifting. Second, SUP201-0-1(CCU) may not recognize the AGG codon within the context of the frameshift heptamer as well as HSX1, since the SUP201-0-1 and HSX1 tRNA genes differ by 20 nucleotide changes (Figure 3). RAFTERY and YARUS (1987) have shown that the structure of the proximal anticodon stem affects efficiency of a tRNA suppressor of E. coli and suggested that it is a part of the extended anticodon. The 2-bp difference in the anticodon stem between SUP201-0-1 and the HSX1 tRNAs may result in the altered AGG codon recognition activity of the SUP201-0-1 tRNA.

Both -1 and +1 frameshifting mechanisms used by a variety of RNA viruses, retroviruses, and retrotransposons apparently require a translational pause for optimum efficiency (reviewed by Hatfield et al. 1992). For example, the translational pause in retroviral -1 frameshifting is created by a pseudoknot located a few nucleotides downstream of the frameshift, whereas Ty1 +1 frameshifting uses a the rare tRNA-Arg(CCU). Our results are consistent with the +1 frameshifting model proposed by Belcourt and Far-ABAUGH (1990). According to this model, the increase in +1 frameshifting results from a longer translational pause in an hsx1 mutant created by the absence of tRNA-Arg(CCU). The longer translational pause regulates translation of TYB1-pol by allowing more time for the tRNA-Leu to slip from the 0-frame CUU codon in TYA1 to the +1-frame UUA codon in TYB1.

Two different approaches were used to estimate the increase in frameshifting that occurs in an hsx1 disruption mutant. First, frameshifting was measured using the minimal heptamer sequence with lac2 as a reporter gene (Belcourt and Farabaugh 1990). The absence of tRNA-Arg(CCU) increased frameshifting as measured by β-galactosidase activity about 3-fold. Second, frameshifting was measured by immunoblotting using Ty1-VLP antiserum and a Ty1-PR mutant defective in protein processing. The increase in frameshifting at the CUU-AGG-C sequence leads to accumulation of slightly less p54-TYA1 protein and much more p190-TYA1-TYB1 fusion protein. Using this assay, frameshifting increased about 17-fold in an hsx1 background.

We estimate that Ty I frameshifting occurs at about a 3% efficiency in an HSXI background by immunoblotting. In other words, 3% of ribosomes translating

the TYA1-gag open reading frame undergo a +1 frameshift and continue translating the TYB1-pol open reading frame. It is somewhat surprising that the Ty1 frameshifting efficiency of 3% is about 5-10-fold lower than that obtained by lacZ fusion analysis. It is possible that we have underestimated the Ty1 frameshifting efficiency obtained from immunoblotting because of an inability to detect the p190-TYA1-TYB1 precursor protein. However, control experiments suggest that p58-TYA1 and p190-TYA1-TYB1 are transferred at about the same rate under the immunoblotting conditions used in this study, bind to Ty1-VLP antiserum with comparable affinities, and have similar turnover rates (A.-M. HEDGE and D. J. GARFINKEL, unpublished results; Curcio and Garfinkel 1992). There may also be differences in translation rates of lacZ in yeast, or in the placement of the frameshift heptamer relative to the start of translation that contribute to this apparent discrepancy (P. J. FARABAUGH, unpublished results).

The Ty1 frameshifting efficiency of 3% obtained by immunoblot analysis is comparable to the efficiencies obtained from several viral systems that utilize different mechanisms for translation of the pol gene. Retroviruses that utilize programmed ribosomal frameshifting or read-through suppression undergo translational suppression at an efficiency of about 5% (reviewed by HATFIELD et al. 1992). Yeast Ty3 retrotransposons have a +1 frameshifting efficiency of about 4%, even though these elements use a different frameshifting site (KIRCHNER, SANDMEYER and FOR-REST 1992) and mechanism than Ty1 or Ty2 elements (P. J. FARABAUGH, unpublished results). In addition, the yeast L-A double-stranded RNA virus undergoes -1 frameshifting to express its pol gene at an efficiency of about 2% (DINMAN, ICHO and WICKNER 1991). Even though the molecular mechanisms underlying these expression strategies are quite different, a certain ratio of "structural" (Gag) proteins to "catalytic" (Gag-Pol) proteins may be a general requirement for formation of a transposition/replication-competent particle.

Immunoblot analysis suggested that a processing defect of the TYA1-TYB1 fusion protein is related to the lower level of Ty1 transposition in an hsx1 disruption mutant. The protein cleavages required to form p54-TYA1 and the p160 processing intermediate still occur, while the proteolytic cleavage required to convert the p160 processing intermediate to p23-PR and the p140 processing intermediate apparently do not (Figure 4). Since formation of p140-TYB1 is defective, it follows that low amounts of mature IN and RT/RH are detected in an hsx1::LEU2 mutant. Perhaps Ty1-PR is not completely activated when more of the TYA1-TYB1 fusion protein is produced. Alternatively, normal amounts of p140, IN and RT/RH




FIGURE 4.—Scheme for TYB1 protein processing in an hsx1 mutant (modified from GARFINKEL et al. 1991), p190-TYA1-TYB1, the 190-kD product of the gag-TYA1 and pol-TYB1 genes, is cleaved near the frameshift region (the vertical line separating TYA1 and TYB1). This proteolytic cleavage releases p160-TYB1, which is normally cleaved to form Ty1-PR (23 kD) and p140-TYB1. Cleavage of p140-TYB1 produces IN (90 kD) and RT/RH (60 kD). The dotted lines indicate that p160 and p23 may be encoded by both TYA1 and TYB1. The arrows show that neither the p140-TYB1 percursor nor mature p90-Ty1-IN and p60-Ty1-RT/RH accumulate in an hsx1 mutant. Also shown is the p58-TYA1 precursor and p54 processed product, which are the major structural components of Ty1-VLPs. In an hsx1 mutant, we detect p54-TYA1 but not the p58-TYA1 precursor.

may be synthesized, but are rapidly degraded because of an hsx1-dependent defect in Ty1-VLP assembly.

To prove that aberrant protein stoichiometry is the major reason for the block in Ty1 transposition in an hsx1 disruption mutant, we showed that a pGTy1 plasmid expressing just the TYAI gene not only restores Tyl transposition in an hsxl::LEU2 mutant, but stimulates transposition to a level 50-fold higher than is observed in an HSX1 strain. We also showed that overexpression of TYA1 does not alter the level of Tyl RNA in an hsxl mutant. These results suggest that overexpression of TYA1 enhances the utilization of Tyl RNA as a transposition template by rebalancing the level of TYA1 and TYA1-TYB1 proteins required to make transposition-competent Ty1-VLPs in an hsx1 mutant, even though the absolute level of Tyl RNA is somewhat lower in the hsxl mutant. Furthermore, since GAL1-promoted Ty1 transposition decreases about 70-fold without a concomitant decrease in GAL1-promoted Ty1 protein levels in an hsx1 disruption mutant, whatever effect the hsx1 mutation has on Tyl RNA levels is limited to chromosomal Tyl elements. These results suggest that the hsx1 mutation may affect chromosomal Ty1 RNA accumulation, but we have not investigated this idea further.

The stimulation of Ty transposition that occurs in an hsx1 mutant when TYA1 is overexpressed supports and extends previous biochemical and genetic studies that identified the availability of Ty1-PR, which is

encoded by TYB1, as a rate-limiting step in the Ty1 retrotransposition cycle (CURCIO and GARFINKEL 1992). Since more TYA1-TYB1 precursor protein is made in an hsx1 mutant, the availability of TYA1 protein becomes rate-limiting under these conditions. Therefore, a specific ratio of TYA1 to TYA1-TYB1 precursor proteins is required to form fully processed Ty1 proteins and functional Ty1-VLPs.

Several retrovirus, retrotransposon and endogenous viral mutants in which gag and pol have been artificially fused are defective in particle formation,

replication and infectivity. For example, fusion of gag and pol genes blocks production of infectious Moloney murine leukemia virus (FELSENSTEIN and GOFF 1988) and human immunodeficiency virus (PARK and MOR-ROW 1992). In Moloney murine leukemia virus, the Gag-Pol precursor protein is produced, but neither protein processing nor particle formation occurs. In human immunodeficiency virus, the Gag-Pol protein is produced and processed, but particles do not form. A protein processing and transposition defect similar to the one created in an hsx1 mutant is observed when TYA1 and TYB1 are fused by deleting one base at the frameshift site of a pGTy1 plasmid and transposition is galactose-induced in an HSX1 strain. Preliminary experiments suggest that Ty1-VLPs are formed in an hsx1 mutant (B. FAIOLA and D. J. GARFINKEL, unpublished results) or when just the TYA1-TYB1 fusion protein is expressed (J. D. BOEKE and D. J. GARFINKEL, unpublished results). Recently, a Ty3 GAG3-POL3 fusion mutant has been analyzed for defects in transposition and Ty3-VLP formation using a pGTy3 expression system (KIRCHNER, SANDMEYER and FOR-REST 1992). The fusion mutant is transposition-defective, but can be rescued by coexpression of GAG3 or just the capsid domain of GAG3. Protein processing of GAG3 capsid protein and Ty3-IN is altered in the mutants, as is individual Ty3 protein and Ty3-VLP yield. Optimal ribosomal frameshifting and the proper

In summary, our work has identified an essential role for HSXI in TyI frameshifting and transposition. This is one of a small but growing collection of cellular genes required for TyI transposition that act post-transcriptionally (reviewed by BOEKE and CHAPMAN 1991; GARFINKEL 1992). The additional defects of an

Gag to Gag-Pol protein ratio are also required for L-

A virus propagation in yeast (DINMAN and WICKNER

1992). Therefore, Ty1 and Ty3 elements seem to be

unique in that some particle assembly can take place

when excess Gag-Pol precursor protein is synthesized (KIRCHNER, SANDMEYER and FORREST 1992) when

only Gag protein is synthesized (ADAMS et al. 1987;

Burns et al. 1992), or when PR-dependent protein

processing is blocked (ADAMS et al. 1987; MULLER et

al. 1987; Youngren et al. 1988; KIRCHNER and SAND-

MEYER 1993).

hsx1 disruption mutant (KAWAKAMI et al. 1992) may allow us to select second-site suppressors that restore Ty1 transposition without affecting Ty1 frameshifting mediated by tRNA-Arg. These suppressors may identify additional cellular genes involved in Ty1 frameshifting or Ty1-VLP assembly.

We thank M. J. CURCIO, K. J. DURBIN, Y. MATSUI, T. MORISHITA and P. ROGAN for plasmids and strains. We thank S. BROWN, D. COURT, M. J. CURCIO and A. REIN for their helpful comments and J. HOPKINS for preparing the manuscript. This work was supported in part by The Ministry of Education, Science and Culture, Japan (K.K. and Y.N.); U.S. Public Health Service grants GM 29480 (S.P. and P.J.F.) and GM 36481 (D.P.M. and J.D.B.); and the National Cancer Institute under contract N01-CO-74101 with ABL (B.F., D.J.G., and J.N.S.). The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

#### LITERATURE CITED

- ADAMS, S. E., J. MELLOR, K. GULL, R. B. KIM, M. F. TUTTE, S. M. KINGSMAN and A. J. KINGSMAN, 1987 The functions and relationships of Ty-VLP proteins in yeast reflect those of mammalian retroviral proteins. Cell 49: 111-119.
- BECKMANN, J. S., P. F. JOHNSON and J. ABELSON, 1977 Cloning of yeast transfer RNA genes in *Escherichia coli*. Science 196: 205– 208.
- BELCOURT, M. F., and P. J. FARABAUGH, 1990 Ribosomal frameshifting in the yeast retrotransposon Ty: tRNAs induce slippage on a 7 nucleotide minimal site. Cell 62: 339-352.
- BOEKE, J. D., and K. B. CHAPMAN, 1991 Retrotransposition mechanisms. Curr. Opin. Cell Biol. 3: 502-507.
- BOEKE, J. D., D. J. GARFINKEL, C. A. STYLES and G. R. FINK, 1985 Ty elements transpose through an RNA intermediate. Cell 40: 491-500.
- BOEKE, J. D., and S. B. SANDMEYER, 1991 Yeast transposable elements, pp. 193-262 in *The Molecular and Cellular Biology of the Yeast Saccharomyces: Genome Dynamics, Protein Synthesis, and Energetics*, Vol. 1, edited by J. R. BROACH, J. R. PRINGLE and E. W. JONES. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- BOEKE, J. D., H. Xu and G. R. FINK, 1988 A general method for the chromosomal amplification of genes in yeast. Science 239: 280-282.
- Burns, N. R., H. R. Saibil, N. S. White, J. F. Pardon, P. A. Timmins, S. Mark, H. Richardson, B. M. Richards, S. E. Adams, S. M. Kingsman and A. J. Kingsman, 1992 Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles. EMBO J. 11: 1155-1164.
- CLARE, J. J., M. BELCOURT and P. J. FARABAUGH, 1988 Efficient translational frameshifting occurs within a conserved sequence of the overlap between the two genes of a yeast Ty I transposon. Proc. Natl. Acad. Sci. USA 85: 6816–6820.
- CLARE, J. J., and P. J. FARABAUGH, 1985 Nucleotide sequence of a yeast Ty element: Evidence for an unusual mechanism of gene expression. Proc. Natl. Acad. Sci. USA 82: 2829-2833.
- CURCIO, M. J., and D. J. GARFINKEL, 1991 Single-step selection for Ty1 element retrotransposition. Proc. Natl. Acad. Sci. USA 88: 936-940.
- CURCIO, M. J., and D. J. GARFINKEL, 1992 Posttranslational control of Ty1 retrotransposition occurs at the level of protein processing. Mol. Cell. Biol. 12: 2813–2825.
- Curcio, M. J., N. J. Sanders and D. J. Garfinkel,

- 1988 Transcriptional competence and transcription of endogenous Ty elements in Saccharomyces cerevisiae: Implications for regulation of transposition. Mol. Cell. Biol. 8: 3571-3581.
- DINMAN, J. D., T. ICHO and R. B. WICKNER, 1991 A -1 ribosomal frameshift in a double-stranded RNA virus of yeast forms a gag-pol fusion protein. Proc. Natl. Acad. Sci. USA 88: 174-178
- DINMAN, J. D., and R. B. WICKNER, 1992 Ribosomal frameshifting efficiency and gag/gag-pol ratio are critical for yeast M<sub>1</sub> double-stranded RNA virus replication. J. Virol. 66: 3669-3676.
- EICHINGER, D. J., and J. D. BOEKE, 1988 The DNA intermediate in yeast Ty1 element transposition copurifies with virus-like particles: cell-free Ty1 transposition. Cell 54: 955–966.
- FELSENSTEIN, K., and S. GOFF, 1988 Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J. Virol. 62: 2179-2182.
- GAFNER, J., E. M. DE ROBERTIS and P. PHILIPPSEN, 1983 δ sequences in the 5' non-coding region of yeast tRNA genes. EMBO J. 2: 583-591.
- GARFINKEL, D. J., 1992 Retroelements in microorganisms, pp. 107-158 in *The Retroviridae*, Vol. 1, edited by J. A. Levy. Plenum Press, New York.
- GARFINKEL, D. J., J. D. BOEKE and G. R. FINK, 1985 Ty element transposition: reverse transcription and virus-like particles. Cell 42: 507-517.
- GARFINKEL, D. J., A.-M. HEDGE, S. D. YOUNGREN and T. D. COPELAND, 1991 Proteolytic processing of pol-TYB proteins from the yeast retrotransposon Ty1. J. Virol. 65: 4573-4581.
- HATFIELD, D. L., J. G. LEVIN, A. REIN and S. OROSZLAN, 1992 Translational suppression in retroviral gene expression. Adv. Virus Res. 41: 198-239.
- ITO, H., Y. FUKUDA, K. MURATA and A. KIMURA, 1983 Transformation of intact yeast cells treated with alkali cations. J. Bacteriol. 153: 163-168.
- KAWAKAMI, K., B. K. SHAFER, D. J. GARFINKEL, J. N. STRATHERN and Y. NAKAMURA, 1992 Ty element-induced temperature-sensitive mutations of *Saccharomyces cerevisiae*. Genetics 131: 821-832.
- KIRCHNER, J., and S. B. SANDMEYER, 1993 Proteolytic processing of Ty3 proteins is required for transposition. J. Virol. 67: 19–28.
- KIRCHNER, J., S. B. SANDMEYER and D. B. FORREST, 1992 Transposition of a Ty3 GAG3-POL3 fusion mutant is limited by availability of capsid protein. J. Virol. 66: 6081– 6092.
- MANDECKI, W., 1986 Oligonucleotide-directed double-strand break repair in plasmids of *Escherichia coli*: a method for site-specific mutagenesis. Proc. Natl. Acad. Sci. USA 83: 7177-7181.
- MORISHITA, T., and I. Uno, 1991 Genetic and molecular analyses of the SUP201 gene: a tRNA-Arg nonsense suppressor of yeast cyr1-2. J. Bacteriol. 173: 2406-2408.
- MULLER, F., K.-H. BRUHL, K. FREIDEL, K. V. KOWALLIK and M. CIRIACY, 1987 Processing of Ty proteins and formation of Ty virus-like particles in Saccharomyces cerevisiae. Mol. Gen. Genet. 207: 421-429.
- PARK, J., and C. D. MORROW, 1992 Overexpression of the gagpol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J. Virol. 65: 5111-5117.
- RAFTERY, L. A., and M. YARUS, 1987 Systematic alterations in the anticodon arm make tRNA-Glu-Su-ochre a more efficient suppressor. EMBO J. 6: 1499-1506.
- Rose, M. D., F. Winston, and P. Hieter, 1990 Laboratory Course Manual for Methods in Yeast Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- Rose, M. D., P. Novick, J. H. Thomas, D. Botstein and G. R.

- FINK, 1987 A Saccharomyces cerevisiae genomic plasmid bank based on a centromere-containing shuttle vector. Gene 60: 237-243.
- ROTHSTEIN, R., 1991 Targeting, disruption, replacement, and allele rescue: Integrative DNA transformation in yeast. Methods Enzymol. 194: 281-301.
- SAIKI, R., S. SHARF, F. FALOONA, K. B. MULLIS, G. T. HORN, H. A. ERLICH and N. ARNHEIM, 1985 Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230: 1350–1354.
- SAMBROOK, J., E. F. FRITSCH and T. MANIATIS, 1989 Molecular Cloning, Ed. 2. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- SANGER, F., S. NICKLEN and A. R. COULSON, 1977 DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74: 5463-5467.
- SIKORSKI, R. S., and P. HIETER, 1989 A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122: 19-27.

- THIREOS, G., M. D. PENN and H. GREER, 1984 5'-Untranslated sequences are required for the translational control of a yeast regulatory gene. Proc. Natl. Acad. Sci. USA 81: 5096-5100.
- WANG, A. M., M. V. DOYLE and D. F. MARK, 1989 Quantitation of mRNA by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86: 9717-9721.
- Xu, H., and J. D. Boeke, 1990 Host genes that influence transposition in yeast: The abundance of a rare tRNA regulates Ty I transposition frequency. Proc. Natl. Acad. Sci. USA 87: 8360-8364.
- YOKOYAMA, S., T. WATANABE, K. MURAO, H. ISHIKURA, Z. YAMAIZUMI, S. NISHIMURA and T. MIYAZAWA, 1985 Molecular mechanism of codon recognition by tRNA species with modified uridine in the first position of the anticodon. Proc. Natl. Acad. Sci. USA 82: 4905–4909.
- YOUNGREN, S. D., J. D. BOEKE, N. J. SANDERS and D. J. GARFINKEL, 1988 Functional organization of the retrotransposon Ty from Saccharomyces cerevisiae. Mol. Cell. Biol. 8: 1421-1431.

Communicating editor: A. G. HINNEBUSCH

#### **EXHIBIT G**





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

J Bacteriol, February 1998, p. 840-845, Vol. 180, No. 4 0021-9193/98/\$04.00+0

Copyright © 1998, American Society for Microbiology. All rights reserved.

# tRNA<sup>Arg</sup> (fimU) and Expression of SEF14 and SEF21 in Salmonella enteritidis

S. C. Clouthier, 1,2 S. K. Collinson, A. P. White, P. A. Banser, and W. W. Kay<sup>1,2,\*</sup>

Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia V8W 3P6, <sup>1</sup> and Microtek International Ltd., Saanichton, British Columbia V8X 3X1, <sup>2</sup> Canada

Received 21 August 1997/Accepted 16 December 1997

#### Abstract of this Article

- Reprint (PDF) Version of this Article
- Similar articles found in: JB Online
- PubMed
  PubMed Citation
- This Article has been cited by: other online articles
- Search Medline for articles by: Clouthier, S. C. | Kay, W. W.
- Alert me when: new articles cite this article
- Download to Citation Manager
- Books from ASM Press

#### **▶** ABSTRACT

A Tn10 insertion affecting SEF14 fimbrial synthesis in Salmonella enteritidis was located 13 bp upstream of a gene designated fimU. The 77-bp DNA sequence of fimU from S. enteritidis was identical to that of fimU encoding tRNA Arg (UCU) from Salmonella typhimurium and 96% identical to that of the Escherichia coli argU homolog. Furthermore, the open reading frame adjacent to and overlapping the 3' end of fimU was similar to the prophage

- ▲ Top
- Abstract
- **▼** Introduction
- ▼ Materials & Methods
- **▼** Results
- **▼** Discussion
- References

DLP12 integrase gene. The fimU-encoded transcript comigrated with total cellular tRNA and was predicted to form a tRNA-like cloverleaf structure containing the arginine anticodon UCU. Thus, fimU encoded a tRNA arg specific for the rare codon AGA. fimU mapped to the SEF21 fim operon located 15 C's from the sef14 gene cluster. Although fimU was located within the SEF21 fim gene cluster, the fimU Tn10 insertion mutant of S. enteritidis was found to be defective in SEF14 as well as SEF21 (type 1) fimbria production. SEF17 and SEF18 fimbria production was not affected. Complementation of this mutant with plasmid-borne fimU restored normal production of the fimbrins SefA and FimA as well as their respective fimbriae SEF14 and SEF21. This is the first description of tRNA simultaneously controlling the production of two distinct fimbriae.

## INTRODUCTION

Regulation of fimbria biosynthesis in bacteria is multifactorial and complex. In *Escherichia coli*, the expression of type 1 fimbriae is transcriptionally regulated in part by an inversion-dependent, phase-variable mechanism that

- ▲ Top
- A Abstract
  - Introduction
- ▼ Materials & Methods

involves two site-specific recombinases (17, 24, 27) and a tRNA<sup>Leu</sup> molecule (32). tRNA<sup>Leu</sup>, specific for the rare leucine codon UUG, stimulates type 1 fimbria synthesis by influencing the switch from phase off to phase on (35). Recently, type 1 fimbria expression in *Salmonella typhimurium* has been

**▼** Results

**▼** Discussion

References

shown to be regulated by mechanisms that are different from those controlling type 1 fimbria expression in E. coli (41). However, a common regulatory theme does exist in that a tRNA, specific for the rare arginine codons AGA and AGG, is required (40). Swenson et al. (40) suggest that the amount of tRNA<sup>Arg</sup> (UCU) available in S. typhimurium may influence the expression of three genes encoding regulatory proteins of the *fim* gene cluster, since in each of these genes there is a high frequency of rare AGA codons recognized by tRNA<sup>Arg</sup> (UCU).

Salmonella enteritidis 27655-3b produces at least four fimbrial types: SEF17 (10), SEF18 (6), SEF21 (type 1 fimbriae) (30), and SEF14 (7, 14). Although little is known about how the expression of the operons is regulated, SEF21 and SEF14 fimbriae are produced under similar environmental conditions (5, 12). Thus, the question arises as to whether or not their expression is coregulated. In a previous study, a Tn10 insertion mutant, S. enteritidis 3b-122, was generated which no longer produced SEF14 fimbriae and carried the transposon outside of sefA, the structural gene for these fimbriae (14). Further characterization of 3b-122 in this study indicated that this mutant was also defective in type 1 fimbria (SEF21) production, suggesting that the Tn10 interrupted a gene whose product coregulated the expression of both SEF14 and SEF21 fimbriae. The results of this study show for the first time that the production of two fimbriae is coregulated by the same tRNA.

#### MATERIALS AND METHODS

Bacterial strains, plasmids, media, and growth conditions. S. enteritidis 27655-3b, originally isolated from human feces, was provided by T. Wadstrom (University of Lund, Lund, Sweden). S. enteritidis 27655-3b-122, a Tn10 insertion mutant of the parent strain, was constructed by Feutrier et al. (14). E. coli DH5α and S. enteritidis 3b-122 were used as hosts for pSFA (11), pLU/TA 4-1, and pGEM-T1. To create pLU/TA 4-1, PCR-amplified finely was cloned into pGEM-T (Propage Comp.) a TA closing a training and the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the parents of the p

- ▲ Top
- ▲ Abstract
- ▲ Introduction
- Materials & Methods
- **▼** Results
- **▼** Discussion
- **▼** References

fimU was cloned into pGEM-T (Promega Corp.), a TA cloning vector containing 3'-terminal thymidines. To create pGEM-T1, the 3'-overhanging thymidines of pGEM-T were filled in with dATP and T4 DNA polymerase prior to ligation (38).

Bacteria were grown at 37°C with shaking in Luria-Bertani (LB) broth (36) supplemented with ampicillin to a final concentration of 250  $\mu$ g/ml except where noted. To analyze the production of fimbriae by *S. enteritidis*, the cells were grown in various liquid media under different growth conditions (Table 1). Cultures grown in LB broth and terrific broth (TFB) (38) were transferred to ice 24 h after inoculation, whereas cultures grown in colonization factor antigen (CFA) medium (13) and T broth (10) were transferred to ice 48 h after inoculation. All the cultures were standardized to an optical density at 630 nm (OD<sub>630</sub>) of 1.

**View this table:** S. enteritidis 3b and S. enteritidis 3b-122 [in this window]

[in a new window]

Subcloning Tn10 from *S. enteritidis* 27655 3b-122. *S. enteritidis* 3b-122 chromosomal DNA was isolated by the method of Alm et al. (1), purified by CsCl centrifugation (38), and digested with *Hin*dIII. To subclone the Tn10-containing chromosomal DNA fragment, size fractionated *Hin*dIII fragments (2 to 3 and 3 to 5 kb) were purified from an agarose gel with Sephaglas (Pharmacia Biotech), ligated to *Hin*dIII-digested and -dephosphorylated cloning vector pTZ19R, and then introduced into *E. coli* DH5α by transformation (38). A total of 2,880 colonies grown on Hybond N<sup>+</sup> membranes (Amersham) were screened by hybridization to the oligonucleotide probe Tn10 IS10L+R (5' GCAGAATTGGTAAAGAGA 3'). This probe, complementary to the sequence located 134 bp inside the insertion sequence of Tn10, was used to identify Tn10-containing clones. The probe, end labelled with [γ-32P]ATP, was hybridized to the membranes at 45°C in prehybridization buffer (38) containing 200 μg of herring sperm DNA (Sigma)/ml. Following hybridization, the membranes were washed in 0.2× SSC buffer (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate) containing 0.1% sodium dodecyl sulfate (SDS) at 45°C, and the results were recorded by autoradiography on Kodak BioMax film.

**DNA sequencing and computer analyses.** The Tn10-positive clones and the three fimU PCR products amplified with primers located outside the fimU gene were sequenced with Sequenase version 2 (United States Biochemicals). The custom oligonucleotide primer Tn10IS10L+R was synthesized on a PCR-MATE EP model 391 DNA synthesizer (Applied Biosystems Inc.). The DNA sequences obtained were analyzed with DNA Strider 1.1 (26). Similarity searches of the National Center for Biotechnology Information (NCBI) databases were conducted with the program BLASTN (2).

PCR amplification of fimU. Custom oligonucleotide primers fimULT (TAATAGCGATACGCAGAATTCAAAAATATCCTACACGGCAGG) and fimULB (CAGATATGCTCACCTAAGCTTTAATCATTTAACGGAACACGG) were designed based on the S. typhimurium chromosomal DNA sequence flanking fimU and were synthesized by Gibco BRL. fimU was PCR amplified from a previously prepared cosmid clone, pPB523 (12), with fimULT and fimULB. To facilitate the cloning of the amplified product, the primers were designed to contain an EcoRI site and a HindIII site, respectively (underlined). Amplification was carried out in a 100-µl reaction volume containing 10 µl of pPB523 (0.01 µg/ml), 25 pmol of each primer, the four deoxynucleotide triphosphates (Boehringer Mannheim) at 0.5 mM each, and 2 U of Taq DNA polymerase (Boehringer Mannheim) in reaction buffer consisting of 50 mM Tris-HCl (pH 8.5), 20 mM KCl, 2.5 mM MgCl<sub>2</sub>, and 0.5 mg of bovine serum albumin/ml. The Taq enzyme was added after an initial 3-min denaturation step at 95°C (4). Thermocycling was performed in a PTC-100TM Programmable Thermal Controller (MJ Research Inc.) as follows: 1 cycle of 75°C, 1 min; 50°C, 2 min; 74°C, 2 min and 30 cycles of 95°C, 1 min; 50°C, 1 min; 74°C, 2 min, followed by an 8-min elongation at 74°C.

**Subcloning PCR-amplified** *fimU*. PCR-amplified *fimU* was purified from a 1% agarose gel with Sephaglas, ligated to pGEM-T according to the manufacturer's instructions (Promega Corp.), and then

transformed into E. coli DH5a (38).

Mapping of fimU on genomic restriction maps of Salmonella and E. coli strains. The fimU gene was mapped as previously described for the four fimbrin genes sefA, agfA, fimA, and sefD (8). The fimU probe, prepared by running EcoRI- and HindIII-digested pLU/TA 4-1 on a 1% agarose gel and purifying the fragment with Sephaglas, was labelled with  $[\alpha^{32}P]dATP$  (Pharmacia Biotech) by nick translation. The radiolabelled fimU probe was hybridized to nitrocellulose blots containing XbaI- and BlnI-digested E. coli, S. typhimurium, and S. enteritidis genomic DNA separated by pulsed field gel electrophoresis (blots were provided by K. Sanderson and S.-L. Liu; see reference 8).

RNA extraction and Northern blot analysis. Total RNA was prepared from *S. enteritidis* 3b, 3b-122, 3b-122 pGEM-T1, and 3b-122 pLU/TA 4-1 grown statically in LB or CFA broth at 37°C for 45 h by a modification of the procedure of McCormick et al. (28) as described in Clouthier et al. (7). For *fimU* transcript analysis, the RNA was separated on a 10% polyacrylamide gel containing 8 M urea and transferred onto Hybond N<sup>+</sup> membranes (Amersham) with transfer buffer (0.025 M phosphate buffer [pH 6.5]) and an LKB Pharmacia semidry blotting apparatus. For *sefA* transcript analysis, the electrophoretic separation of total cellular RNA and its subsequent transfer to Hybond N<sup>+</sup> membranes (Amersham) were performed as described in Fourney et al. (15). The *fimU*- and *sefA*-specific probes used for Northern blot analysis were gel purified from *Eco*RI and *Hind*III digests of pLU/TA 4-1 and pSFA, respectively, with Sephaglas. The probes were labelled with [α<sup>32</sup>P]dATP (Pharmacia Biotech) by nick translation and hybridized to the blots at 65°C for 18 h in the presence of 200 μg of herring sperm DNA (Sigma)/ml. The membranes were washed at high stringency (0.2× SSC buffer-0.1% SDS, 65°C), and the results were recorded on Kodak BioMax or X-Omat AR5 film.

**SDS-PAGE** and Western blot analysis. Whole-cell lysates of *S. enteritidis* 3b or clones of this strain were screened for the presence of four fimbrial types. SEF14, 18, and 21 were solubilized from whole cells with SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer supplemented with 0.2 M glycine (pH 2, 100°C, 10 min), whereas SEF17 fimbriae were solubilized from whole cells with formic acid according to the method of Collinson et al. (9, 10). A portion of each culture (1  $OD_{630}$  unit) was resuspended in 200  $\mu$ l of sample buffer, and 10  $\mu$ l (0.01  $OD_{630}$  unit) was loaded per lane. Proteins in these samples were separated by SDS-PAGE, electrophoretically transferred to nitrocellulose, and screened with rabbit polyclonal anti-SEF14 (7), SEF17 (10), SEF18 (6), or SEF21 immune serum (30). Immunoreactive proteins were detected with goat anti-rabbit immunoglobulin G-alkaline phosphatase conjugates (Cedarlane) and visualized with 5-bromo-4-chloro-3-indolylphosphate and Nitro Blue Tetrazolium (Sigma).

**Electron microscopy.** SEF14 and SEF21 fimbriae on *S. enteritidis* 3b, 3b-122, 3b-122 pGEM-T1, and 3b-122 pLU/TA 4-1 were immunogold labelled with SEF14- or SEF21-specific rabbit polyclonal immune sera followed by incubation with protein A-15-nm-diameter gold particles (Cedarlane). Negative staining was performed as described previously (10).

Nucleotide sequence accession number. The nucleotide sequence reported herein for fimU has been submitted to GenBank and has been given the accession number <u>AF013136</u>.


### RESULTS

**Fimbria production in** *S. enteritidis* **3b-122.** Production of SEF14, -17, -18, and -21 fimbriae by the *S. enteritidis* Tn10 mutant 3b-122 grown under various growth conditions was assessed by Western blotting with fimbria-specific antisera, and the results were compared to those obtained with the wild-type strain *S. enteritidis* 3b. The Tn10 mutation in 3b-122 had a pronounced effect on SEF14 and SEF21 production but little or no effect on

- ▲ Top
- ▲ Abstract
- ▲ Introduction
- ▲ Materials & Methods
- Results
- **▼** Discussion
- **▼** References

SEF17 and SEF18 production (Table 1). As previously reported, SEF14 fimbriae were not expressed by 3b-122 grown in static CFA broth at 37°C (Table 1). Further characterization in this study, however, showed that 3b-122 lost SEF14 expression under all the growth conditions in which 3b was SEF14 positive (Table 1). In addition to the SEF14-negative phenotype, 3b-122 was also defective for type 1 fimbria (SEF21) production. The wild-type strain produced FimA under all growth conditions tested, whereas 3b-122 only produced FimA in CFA broth cultures. Thus, the result of the Tn10 insertion was the complete loss of SEF14 expression under all growth conditions and selective loss of SEF21 expression under certain growth conditions. The altered production of SEF14 and SEF21 fimbriae in the Tn10 insertion mutant relative to the wild-type expression patterns suggested that the transposon insertion interrupted a gene whose product was required for both SEF14 and SEF21 fimbria expression.

Identification of the Tn10 insertion site in S. enteritidis 3b-122. To determine the Tn10 insertion site, HindIII fragments of 3b-122 chromosomal DNA were subcloned into pTZ19. Clones containing Tn10 were identified with the probe IS10L+R, which hybridized within the insertion sequence located at either end of the transposon (Fig. 1A). Of the 17 Tn10-positive clones identified, 3 were subjected to DNA sequence analysis. Comparison of the 3b-122 DNA sequence flanking Tn10 to sequences listed in the NCBI databases revealed that the sequence was 99% identical to that of the region located between fimW and fimU of the S. typhimurium type 1 fimbrial gene cluster. Thus, on the basis of DNA sequence comparison, Tn10 was inserted 13 bp upstream of the predicted start site of the gene, which will hereafter be referred to as fimU (Fig. 1A and B).




View larger version (19K): [in this window] [in a new window]

FIG. 1. Location of Tn10 on the S. enteritidis 3b-122 chromosome and identification of the genes flanking the Tn10 insertion in S. enteritidis 3b. (A) Schematic diagram of S. enteritidis (S.e.) 3b-122 chromosomal DNA (black line) showing the Tn10 insert and the strategy used to obtain the chromosomal DNA sequence adjacent to one side of this insert. A 3-kb HindIII fragment comprising 3b-122 chromosomal DNA fused to one end of Tn10 was identified by hybridization with the Tn10 oligonucleotide IS10L+R. IS10L+R was also used as a sequencing primer to obtain 240 bp of DNA sequence from the subcloned HindIII fragment. (B) Schematic diagram of the S. typhimurium (S.t.) chromosome (black line) between fimW and fimU of the type I fimbrial gene cluster that was homologous to the 240 bp of S. enteritidis 3b-122 DNA sequence. Two 42-bp oligonucleotide primers, fimULT and fimULB (horizontal

arrows), were made based on the *S. typhimurium* sequence previously deposited in GenBank (L19338) by Swenson and Clegg (39). (C) Segment of the *S. enteritidis* 3b chromosome (black line) amplified by PCR with the primers *fimU*LT and *fimU*LB. This amplified DNA segment was subcloned and sequenced (Fig. 2) to identify the DNA flanking the Tn10 insert. The Tn10 insertion point (vertical arrow) was determined to be between the -10 region and the start of the *fimU* gene. The presence of *fimW*, *fimU*, and the -35 region on the 3b chromosome is also noted.

**DNA sequence analysis of fimU subcloned from S. enteritidis 3b.** By using primers fimULT and fimULB designed from the sequence flanking the fimU gene in S. typhimurium, a 490-bp fragment was PCR amplified from the cosmid clone pPB523-G containing 35 kb of S. enteritidis 3b DNA (Fig. 1B). The fimU PCR product was subcloned into vector pGEM-T (Fig. 1B). Nucleotide sequence analysis of three clones revealed a potential promoter, but a putative translated protein could not be detected by open reading frame analysis. Comparison of the DNA sequence downstream of the potential promoter to sequences listed in the NCBI databases showed that the sequence was identical to that of fimU of S. typhimurium (Fig. 1C and 2B) and 96% similar to that of argU/dnaY of E. coli (Fig. 2A). These genes encode arginine-specific tRNAs that recognize the rare AGA codon. The nucleotide sequence of fimU from S. enteritidis 3b contained 4 inverted repeats, which were predicted to fold the sequence into the characteristic tRNA-like cloverleaf structure (Fig. 2B) with UCU in the expected tRNA anticodon position. Together, these data suggested that fimU from S. enteritidis 3b encoded an arginine-specific tRNA.




View larger version (22K): [in this window] [in a new window]

FIG. 2. Sequence comparison of fimU from S. enteritidis 3b (S.e.) with fimU of S. typhimurium (S.t.) and argU of E. coli (E.c.) as well as the predicted fimU RNA secondary structure. (A) Alignment of S. enteritidis fimU DNA sequence with both the S. typhimurium fimU (39) and E. coli (31) argU gene sequences. Symbols: •, DNA sequence identity; –, gaps introduced to maximize homology; \*, bases constituting the -35 and -10 boxes; \$\frac{1}{2}\$, bases constituting the anticodon; \$\frac{1}{2}\$, position of the Tn10 insertion on the S. enteritidis 3b-122 chromosome. The DNA sequence corresponding to the proposed mature  $tRNA^{Arg}$  (UCU) is underlined. (B) Diagram of the proposed secondary structure for  $tRNA^{Arg}$  (UCU) from S. enteritidis 3b. The anticodon bases are underlined.

Analysis of the nucleotide sequence downstream of *fimU* revealed an open reading frame oriented in the opposite direction such that the 3' ends of the two genes overlapped. The predicted amino acid sequence was 88% similar to that of the prophage DLP12 integrase of *E. coli*. The sequence further downstream of *fimU* displayed 60 to 88% similarities to those encoding transposases of the IS3 family of insertion elements.

Mapping fimU on the S. enteritidis 3b genome. Like fimA, fimU was localized to chromosomal XbaI and BlnI fragments in the 98.5- to 13.0-C's region of the chromosome in both Salmonella serovars. By using a series of S. typhimurium and S. enteritidis Tn10 mutants the fimU gene was more precisely mapped to between purE884::Tn10 at 12.6 C's and the first XbaI restriction site at 13.6 C's in S. enteritidis or 13.0 C's in S. typhimurium. Thus, fimU mapped to the same region shown previously to contain the fimA gene in the fim gene cluster.


Analysis of fimU transcription. To determine if the fimU transcript was the same size as tRNA, a fimU-specific probe was hybridized to a blot containing total RNA isolated from S. enteritidis 3b, 3b-122, 3b-122 pGEM-T1, or 3b-122 pLU/TA 4-1 grown under conditions optimal for type 1 fimbria (SEF21) production in S. enteritidis 3b (static LB broth, 48 h, 37°C). The fimU-specific probe hybridized to a transcript that was present in total RNA from 3b and 3b-122 pLU/TA 4-1 (Fig. 3). The fimU transcript was consistently difficult to detect on Northern blots of 3b RNA even with excessive amounts of RNA loaded on the gels (25 µg [Fig. 3, lanes 1 to 4] and 50 µg [Fig. 3, lanes 5 to 8]) and extended exposure of the blots to X-ray film. Although the transcript was not found in RNA prepared from 3b-122, trace levels were evident in 3b-122 carrying the vector pGEM-T (Fig. 3), but the transcript was even more difficult to detect than its counterpart in 3b. The transcript detected with the fimU-specific probe comigrated with tRNA, suggesting that the product of fimU from S. enteritidis was indeed a tRNA molecule.



View larger version (29K): [in this window] [in a new window]

FIG. 3. Northern blot analysis of tRNA<sup>Arg</sup> (UCU) production in *S. enteritidis* 3b strains. A *fimU*-specific probe was hybridized to PAGE-separated total RNA from *S. enteritidis* 3b (lanes 1 and 5), 3b-122 (lanes 2 and 6), 3b-122 pGEM-T1 (lanes 3 and 7), or 3b-122 pLU/TA 4-1 (lanes 4 and 8). Lanes 1 to 4 contain 25 μg of RNA, and lanes 5 to 8 contain 50 μg of RNA.

Complementation of fimbrin expression and fimbria assembly in 3b-122. Fimbria expression was examined in *S. enteritidis* 3b, 3b-122, 3b-122 pGEM-T1, and 3b-122 LU/TA 4-1 grown under conditions that promoted production of both SEF14 and SEF21 by the wild-type strain (static CFA broth, 48 h, 37°C). Western blot analysis of whole-cell lysates using SEF14- or SEF21-specific antisera showed that complementation of the insertion mutation in 3b-122 with pLU/TA 4-1 restored SEF14 and SEF21 fimbria expression (Fig. 4). Thus *fimU* affected the production of two fimbrins encoded by genes located on two different gene clusters.




View larger version (49K): [in this window] [in a new window]

FIG. 4. Complementation analysis of *S. enteritidis* 3b-122 Tn 10 mutant with the fim U-containing recombinant plasmid pLU/TA 4-1. Whole-cell extracts were analyzed by Western blotting to determine the presence of SefA (21 kDa) and FimA (14 kDa) fimbrin proteins in *S. enteritidis* 3b (lane 1), 3b-122 (lane 2), 3b-122 pGEM-T1 (lane 3), and 3b-122 pLU/TA 4-1 (lane 4). Numbers at right indicate positions of SefA (21) and FimA (14).

Assembly of SEF14 and SEF21 fimbriae on the cell surface of S. enteritidis 3b, 3b-122, 3b-122 pGEM-T1, or 3b-122 pLU/TA 4-1 was determined by immunogold labelling and electron microscopy performed on cells grown in static CFA broth for 48 h at 37°C. The wild-type strain, S. enteritidis 3b, expressed both SefA and FimA and assembled the respective subunits into SEF14 and SEF21 fimbriae (Table 2). Similar analyses of 3b-122 and 3b-122 pGEM-T1 showed that SEF14 was not produced and that SEF21 fimbriae on the cell surfaces of these two strains were rarely detected (Table 2), a result consistent with the Western blot data (Fig. 4). In contrast, SEF14 and SEF21 fimbriae were evident on the surface of 3b-122 pLU/TA 4-1 (Fig. 5) at levels equal to or greater than that on 3b. Thus, expression of SefA and FimA fimbrins and assembly of their respective fimbriae were restored by complementation of the Tn10 fimU mutation in 3b-122 with a wild-type copy of the fimU gene on pLU/TA 4-1. Cells producing SEF17 were readily seen without immunolabelling on all the grids prepared for electron microscopy (Table 2).

[in this window] antifimbrial sera [in a new window]


TABLE 2. Detection of assembled SEF14 and SEF21 fimbriae in various View this table: S. enteritidis strains by immunoelectron microscopy with specific



View larger version (90K): [in this window] [in a new window]

FIG. 5. Analysis of SEF14 and SEF21 fimbria assembly in S. enteritidis 3b-122 pLU/TA 4-1 by immunogold electron microscopy. S. enteritidis 3b-122 pLU/TA 4-1 was labeled with protein A-gold and negatively stained following incubation with immune serum generated to SEF14 (A) or SEF21 (B). Arrows indicate individual immunogold-labeled SEF14 and SEF21 fimbriae in panel A and B insets. respectively. The average diameter of the gold particles was 15 nm. Bar, 0.5 μm (electron micrograph) or 50 nm (inset).

Analysis of sefA transcription. The effect of tRNAArg (UCU) on sefA transcript production was analyzed by hybridizing a sefA-specific probe to a blot containing total cellular RNA isolated from S. enteritidis 3b, 3b-122, 3b-122 pGEM-T1, or 3b-122 LU/TA 4-1 grown under conditions optimal for SEF14 production in 3b (static CFA broth, 48 h, 37°C). The sefA-specific probe hybridized to a 660base transcript that was present in RNA from 3b and 3b-122 pLU/TA 4-1 but absent from RNA from 3b-122 and 3b-122 pGEM-T1 (Fig. 6). The strains expressing the sefA transcript corresponded to those carrying a functional fimU gene, suggesting that fimU was required for expression of sefA.



View larger version (36K): [in this window] [in a new window]

FIG. 6. Northern blot analysis of sefA transcription in S. enteritidis 3b strains. A sefA-specific probe was hybridized to 10 µg of total RNA from S. enteritidis 3b (lane 1), 3b-122 (lane 2), 3b-122 pGEM-T1 (lane 3), or 3b-122 LU/TA 4-1 (lane 4).

#### DISCUSSION

fimU, located in the fim (sef21) operon of S. enteritidis 3b, encodes an arginine-specific tRNA that is required for expression of not only SEF21 fimbriae (type 1) but also SEF14 fimbriae. The product of fimU in 3b is a tRNA, since Northern blot analysis of RNA from 3b and 3b-122 pLU/TA 4-1 demonstrates that the fimU transcript comigrates on polyacrylamide gels with tRNA. Furthermore, the 77-nucleotide sequence of the fimU gene of 3b is identical to that a fig. 11.

- ▲ Top
- ▲ Abstract
- ▲ Introduction
- ▲ Materials & Methods
- ▲ Results
- Discussion
- ▼ References

identical to that of fimU of S. typhimurium (39) and shares extensive homology with that of argU encoding  $tRNA^{Arg}$  (UCU) from E. coli (18). The fimU-encoded transcript from 3b can be folded into a typical tRNA cloverleaf structure containing the 3'-terminal sequence CCA as well as the invariant or semivariant nucleotides common to tRNA molecules (19, 34). Finally, the DNA sequence 5' to the fimU gene contains features common to the promoters of tRNA operons including the consensus E. coli -10 and -35 promoter elements (16, 21) and a G+C-rich discriminator sequence (16, 42, 43). The regulatory mechanisms controlling fimU expression are unknown. Recently, however, the integration and excision of plasmids, phage, and pathogenicity islands into and out of the chromosomes at tRNA loci have been shown to affect tRNA gene expression (20, 33). As shown with the E. coli tRNA gene argU (25), the open reading frame adjacent to and overlapping fimU is a homolog of the integrase gene (int) from the defective lambdoid prophage DLP12. Integration of prophage DLP12 at this site prevents cotranscription of the int gene with fimU, which may contribute to the regulation of fimU expression in S. enteritidis 3b.

The influence of tRNA<sup>Arg</sup> (UCU) encoded by *fimU* on SEF14 and SEF21 fimbria production is evident in the Tn10 insertion mutant S. enteritidis 3b-122. The transposon, inserted between the predicted promoter and the 5' end of the mature *fimU* transcript, disrupts transcription of *fimU* and thus tRNA<sup>Arg</sup> (UCU) production. This mutation results in the loss of SefA production and selective loss of FimA production, i.e., the subunits of SEF14 and SEF21 (type 1) fimbriae, respectively. Thus, in S. enteritidis 3b, tRNA<sup>Arg</sup> (UCU) is required for SEF14 production and enhances type 1 fimbria (SEF21) production. In E. coli, cross-talk has also been reported to occur between adhesin gene clusters (29), and tRNA molecules have been shown to play a key role in global regulatory cascades (20). However, this is the first study to show that a tRNA-specific locus found on one fimbrial operon influences the production of two fimbrins whose operons are separated by 15 C's on the chromosome.

tRNA<sup>Arg</sup> (UCU) encoded by *fimU* is required for transcription of *sefA*, the gene encoding the subunit of SEF14 fimbriae in *S. enteritidis* 3b. The regulatory mechanism is unknown, but a direct correlation between the abundance of tRNAs and the occurrence of the respective codons in protein genes (22, 23) has been suggested to control the translation of genes containing rare codons (3, 37). Since AGA, the codon recognized by the tRNA<sup>Arg</sup> (UCU) species encoded by *fimU*, is one of the least-used codons for arginine, then perhaps the limited availability of charged tRNAs for this minor codon controls the level of translation of the *sefA* transcript or of a transcript whose protein product is involved in the regulation

of sefA transcription. sefA contains neither of the rare arginine codons AGA or AGG recognized by  $tRNA^{Arg}$  (UCU), indicating that fimU expression would not have a direct effect on the translation of sefA mRNA. However, sefE, the gene encoding the putative AraC-like transcriptional activator of the sef14 gene cluster, contains 13 arginine codons, including 9 AGA codons and 1 AGG codon (5). Perhaps the  $tRNA^{Arg}$  (UCU) encoded by fimU regulates translation of sefE, which would in turn affect transcription of sefA and the downstream genes.

With the exception of the gene *fimA* encoding the subunit of SEF21 fimbriae (12), the remainder of the *sef21* gene cluster has not been characterized in *S. enteritidis* 3b. Thus, the mechanism for regulation of type 1 fimbria synthesis by *fimU* remains to be determined. However, type 1 fimbria (SEF21) production is optimal when *S. enteritidis* 3b is grown at 37°C in a static broth culture but suboptimal when the cells are grown at lower temperatures (21 to 30°C) in shaking broth culture or on solid medium (12). Similarly, expression of SEF14 fimbriae by *S. enteritidis* 3b is environmentally controlled by temperature, medium composition, and aeration, and is optimal at 37°C in static, aerobic CFA broth (5). Thus, the coregulation of SefA and FimA fimbrin production by *fimU*-encoded tRNA<sup>Arg</sup> (UCU) results in the corresponding fimbriae being expressed under similar environmental conditions, which may give the bacteria a competitive advantage for survival.

## ACKNOWLEDGMENTS

This project was supported by operating grants to W.W.K. provided by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Bacterial Diseases Network. S.C.C. was the recipient of an Industrial Postdoctoral Fellowship from NSERC, and A.P.W. was the recipient of a Graduate Research Engineering and Technology Award scholarship from the Science Council of British Columbia and a Graduate Research scholarship from NSERC.

We thank S. Lee for helpful discussions on tRNA.

#### FOOTNOTES

\* Corresponding author. Mailing address: Department of Biochemistry and Microbiology, University of Victoria, Victoria, B.C. V8W 3P6, Canada. Phone: (250) 721 7078. Fax: (250) 721 8882. E-mail: <a href="https://wkay@uvic.ca">wkay@uvic.ca</a>.

#### REFERENCES

- ▲ Top
- ▲ Abstract
- Introduction
- Materials & Methods
- Results
- ▲ Discussion
- · References

- genes among isolates of Campylobacter coli and Campylobacter jejuni. J. Bacteriol. 175:3051-3057 [Abstract].
- 2. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410[Medline].
- 3. Chen, G.-F., and M. Inouye. 1994. Role of the AGA/AGG codons, the rarest codons in global gene expression in *Escherichia coli*. Genes Dev. 8:2641-2652[Abstract].
- 4. Chou, Q., M. Russell, D. E. Birch, J. Raymond, and W. Bloch. 1992. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplification. Nucleic Acids Res. 20:1717-1723[Abstract].
- 5. Clouthier, S. C. 1995. Ph.D. thesis. University of Victoria, Victoria, Canada.
- 6. Clouthier, S. C., S. K. Collinson, and W. W. Kay. 1994. Unique fimbriae-like structures encoded by *sefD* of the SEF14 fimbrial gene cluster of *Salmonella enteritidis*. Mol. Microbiol. 12:893-903 [Medline].
- 7. Clouthier, S. C., K.-H. Müller, J. L. Doran, S. K. Collinson, and W. W. Kay. 1993. Characterization of three fimbrial genes, sefABC, of Salmonella enteritidis. J. Bacteriol. 175:2523-2533[Abstract].
- 8. Collinson, S. K., S.-L. Liu, S. C. Clouthier, P. A. Banser, J. L. Doran, K. E. Sanderson, and W. W. Kay. 1996. The location of four fimbrin-encoding genes, agfA, fimA, sefA, and sefD, on the Salmonella enteritidis and/or S. typhimurium XbaI-BlnI genomic restriction maps. Gene 169:75-80 [Medline].
- 9. Collinson, S. K., P. C. Doig, J. L. Doran, S. C. Clouthier, T. J. Trust, and W. W. Kay. 1993. Thin aggregative fimbriae mediate binding of *Salmonella enteritidis* to fibronectin. J. Bacteriol. 175:12-18[Abstract].
- 10. Collinson, S. K., L. Emödy, K.-H. Müller, T. J. Trust, and W. W. Kay. 1991. Purification and characterization of thin, aggregative fimbriae from *Salmonella enteritidis*. J. Bacteriol. 173:4773-4781[Medline].
- 11. Doran, J. L., S. K. Collinson, S. C. Clouthier, T. A. Cebula, W. H. Koch, J. Burian, P. A. Banser, E. C. D. Todd, and W. W. Kay. 1996. Diagnostic potential of sefA DNA probes to Salmonella enteritidis and certain other O-serogroup D1 Salmonella serovars. Mol. Cell. Probes 10:233-246[Medline].
- 12. Doran, J. L., S. K. Collinson, C. M. Kay, P. A. Banser, J. Burian, C. K. Munro, S. H. Lee, J. M. Somers, E. C. D. Todd, and W. W. Kay. 1994. fimA and tct based DNA diagnostics for Salmonella. Mol. Cell. Probes 8:291-310[Medline].
- 13. Evans, D. G., D. J. Evans, Jr., and W. Tjoa. 1977. Hemagglutination of human group A erythrocytes by enterotoxigenic *Escherichia coli* isolated from adults with diarrhea: correlation with colonization factor. Infect. Immun. 18:330-337[Medline].
- 14. Feutrier, J., W. W. Kay, and T. J. Trust. 1986. Purification and characterization of fimbriae from Salmonella enteritidis. J. Bacteriol. 168:221-227[Medline].
- 15. Fourney, R. M., J. Miyakoshi, R. S. Kay III, and M. C. Paterson. 1992. Northern blotting: efficient RNA staining and transfer. Focus 10:5-7.
- 16. Fournier, M. J., and H. Ozeki. 1985. Structure and organization of the transfer ribonucleic acid genes of *Escherichia coli* K-12. Microbiol. Rev. 49:379-397.
- 17. Gally, D. L., J. Leathart, and I. C. Blomfield. 1996. Interaction of FimB and FimE with the *fim* switch that controls the phase variation of type 1 fimbriae in *Escherichia coli* K-12. Mol. Microbiol. 21:725-738[Medline].
- 18. Garcia, G. M., P. K. Mar, D. A. Mullin, J. R. Walker, and N. E. Prather. 1986. The *E. coli dnaY* gene encodes an arginine transfer RNA. Cell 45:453-459[Medline].

- Gauss, D. H., and M. Sprinzl. 1983. Compilation of tRNA sequences. Nucleic Acids Res. 11:1-53
  [Medline].
  - 20. Hacker, J., G. Blum-Oehler, I. Mühldorfer, and H. Tschäpe. 1997. Pathogenicity islands of virulent bacteria: structure, function and impact on microbial evolution. Mol. Microbiol. 23:1089-1097[Medline].
  - 21. Hawley, D. K., and W. R. McClure. 1983. Compilation and analysis of *Escherichia coli* promoter DNA sequences. Nucleic Acids Res. 11:2237-2255[Abstract].
  - 22. **Ikemura, T.** 1981. Correlation between the abundance of *Escherichia coli* transfer RNAs and the occurrence of the respective codons in its protein genes: a proposal for synonymous codon choice that is optimal for the *E. coli* translational system. J. Mol. Biol. **151:**389-409[Medline].
  - 23. **Ikemura**, **T.** 1981. Correlation between the abundance of *Escherichia coli* transfer RNAs and the occurrence of the respective codons in its protein genes. J. Mol. Biol. **146:1-21**[Medline].
  - 24. **Klemm, P.** 1986. Two regulatory *fim* genes, *fimB* and *fimE*, control the phase variation of type 1 fimbriae in *Escherichia coli*. EMBO J. 5:1389-1393[Abstract].
  - 25. Lindsey, D. F., D. A. Mullin, and J. R. Walker. 1989. Characterization of the cryptic lambdoid prophage DLP12 of *Escherichia coli* and overlap of the DLP12 integrase gene with the tRNA gene argU. J. Bacteriol. 171:6197-6205[Medline].
  - 26. Marck, C. 1988. "DNA Strider": a "C" program for the fast analysis of DNA and protein sequences on the Apple Macintosh family of computers. Nucleic Acids Res. 16:1829-1836[Abstract].
  - 27. McClain, M. S., I. C. Blomfield, and B. I. Eisenstein. 1991. Roles of *fimB* and *fimE* in site-specific DNA inversion associated with phase variation of type 1 fimbriae in *Escherichia coli*. J. Bacteriol. 173:5308-5314[Medline].
  - 28. McCormick, J. R., J. M. Zengel, and L. Lindahl. 1991. Intermediates in the degradation of mRNA from the lactose operon of *Escherichia coli*. Nucleic Acids Res. 19:2767-2776[Abstract].
  - 29. Morschhauser, J., V. Vetter, L. Emody, and J. Hacker. 1994. Adhesin regulatory genes within large, unstable DNA regions of pathogenic *Escherichia coli*: cross-talk between different adhesin gene clusters. Mol. Microbiol. 11:555-566[Medline].
  - 30. Müller, K.-H., S. K. Collinson, T. J. Trust, and W. W. Kay. 1991. Type 1 fimbriae of Salmonella enteritidis. J. Bacteriol. 173:4765-4772[Medline].
  - 31. Mullin, D. A., G. M. Garcia, and J. R. Walker. 1984. An E. coli DNA fragment 118 base pairs in length provides dnaY<sup>+</sup> complementing activity. Cell 37:669-674[Medline].
  - 32. Newman, J. V., R. L. Burghoff, L. Pallesen, K. A. Krogfelt, C. S. Kristensen, D. C. Laux, and P. S. Cohen. 1994. Stimulation of *Escherichia coli* F-18Col<sup>-</sup> type-1 fimbriae synthesis by *leuX*. FEMS Microbiol. Lett. 122:281-287[Medline].
  - 33. Reiter, W.-D., P. Palm, and S. Yeats. 1989. Transfer RNA genes frequently serve as integration sites for prokaryotic genetic elements. Nucleic Acids Res. 17:1907-1914[Abstract].
  - 34. Rich, A., and U. L. RajBhandary. 1976. Transfer RNA: molecular structure, sequence, and properties. Annu. Rev. Biochem. 45:805-860[Medline].
  - 35. Ritter, A., D. L. Gally, P. B. Olsen, U. Dobrindt, A. Friedrich, P. Klemm, and J. Hacker. 1997. The Pai-associated *leuX* specific tRNA<sup>Leu</sup> affects type 1 fimbriation in pathogenic *Escherichia coli* by control of FimB recombinase expression. Mol. Microbiol. 25:871-882[Medline].
- 36. Rosner, J. L. 1972. Formation, induction and curing of bacteriophage P1 lysogens. Virology 48:679[Medline].
- 37. Saier, M. H., Jr. 1995. Differential codon usage: a safeguard against inappropriate expression of specialized genes? FEBS Lett. 362:1-4[Medline].
- 38. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. . Molecular cloning: a laboratory manual,

2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

- 39. Swenson, D. L., and S. Clegg. 1994. Salmonella fimbriae, p. 105-113. In P. Klemm (ed.), Fimbriae: adhesion, biogenesis, genetics and vaccines. CRC Press, London, United Kingdom.
- Swenson, D. L., K.-J. Kim, E. W. Six, and S. Clegg. 1994. The gene *fimU* affects expression of Salmonella typhimurium type 1 fimbriae and is related to the Escherichia coli tRNA gene argU. Mol. Gen. Genet. 244:216-218[Medline].
  - 41. Swenson, D. L., and S. Clegg. 1992. Identification of ancillary fim genes affecting fimA expression in Salmonella typhimurium. J. Bacteriol. 174:7697-7704[Abstract].
  - 42. **Travers, A. A.** 1984. Conserved features of coordinately regulated *E. coli* promoters. Nucleic Acids Res. 12:2605-2618[Abstract].
  - 43. **Travers**, A. A. 1980. Promoter sequence for stringent control of bacterial ribonucleic acid synthesis. J. Bacteriol. 141:973-976[Medline].

J Bacteriol, February 1998, p. 840-845, Vol. 180, No. 4 0021-9193/98/\$04.00+0

Copyright © 1998, American Society for Microbiology. All rights reserved.

## This article has been cited by other articles:

- Edwards, R. A., Matlock, B. C., Heffernan, B. J., Maloy, S. R. (2001). Genomic analysis and growth-phase-dependent regulation of the SEF14 fimbriae of Salmonella enterica serovar Enteritidis. *Microbiology* 147: 2705-2715
  [Abstract] [Full Text]
- Tinker, J. K., Hancox, L. S., Clegg, S. (2001). FimW Is a Negative Regulator Affecting Type 1 Fimbrial Expression in Salmonella enterica Serovar Typhimurium. *J. Bacteriol*. 183: 435-442 [Abstract] [Full Text]
- Tinker, J. K., Clegg, S. (2000). Characterization of FimY as a Coactivator of Type 1 Fimbrial Expression in Salmonella enterica Serovar Typhimurium. *Infect. Immun.* 68: 3305-3313 [Abstract] [Full Text]
- Julio, S. M., Heithoff, D. M., Mahan, M. J. (2000). ssrA (tmRNA) Plays a Role in Salmonella enterica Serovar Typhimurium Pathogenesis. J. Bacteriol. 182: 1558-1563 [Abstract] [Full Text]

Abstract of this Article

- Reprint (PDF) Version of this Article
- Similar articles found in:

JB Online PubMed

- ▶ PubMed Citation
- This Article has been cited by:
- Search Medline for articles by: Clouthier, S. C. | Kay, W. W.
- Alert me when:

new articles cite this article

- Download to Citation Manager
- ▶ Books from ASM Press

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Appl. Environ. Microbiol.

Infect. Immun.
J. Virol.

Eukaryot. Cell

Mol. Cell. Biol.

Microbiol. Mol. Biol. Rev.

**ALL ASM JOURNALS**